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          ABSTRACT 
MIGRATION STIMULATING FACTOR, THE SEARCH FOR INHIBITORS 
 
The oncofetal protein Migration Stimulating Factor (MSF) is a truncated isoform of 
human fibronectin which exhibits numerous bioactivities that are pertinent to cancer 
progression. The MSF protein (70kDa) has potent motogenic activity, with only 
femtomolar concentrations required to produce half-maximal. The proteolytic 
degradation of MSF generates the functionally equivalent 43kDa Gel-BD domain and 
21kDa IGD peptide.  The screening of conditioned medium (CM) for bioactivity 
revealed two sources of MSF-inhibitory (MSF-I) activity; the spontaneously 
immortalised human keratinocyte cell line (HaCaT) and endothelial cells (ENDO 742) 
specifically when exhibiting a cobblestone phenotype.  
The CM from the HaCaT keratinocyte line was fractionated by both molecular weight 
and ionic charge, followed by sequence analysis which identified the inhibitor as 
Neutrophil Gelatinase Associated Lipocalin (NGAL). Both recombinant and cell-
produced NGAL neutralise the motogenic activity of MSF. This novel bioactivity for 
NGAL is not dependent on its iron transportation capability or direct binding to MSF. 
HaCaT cells also secrete MSF; the bioactivity of which is masked by the co-expression 
of NGAL.  
The relative expression levels of the pro- and anti-motogenic factors, MSF and NGAL, 
were assessed using an in vitro model for human skin carcinogenesis, the HaCaT –ras 
clones. The shift in tumorigenic potential from benign to metastatic was characterised 
by a decrease in NGAL and an increase in MSF expression, indicating their potential 
role in tumour progression. 
The protein responsible for the MSF inhibitory activity is cell- type specific; NGAL is 
not expressed by endothelial cells in vitro. MSF stimulates the generation of sprouting 
endothelial cells from a cobblestone monolayer and acts a survival factor for 
spontaneously sprouting cells within a 3D matrix. NGAL does not selectively the target 
sprouting phenotype of endothelial cells, but induces apoptosis in all endothelial cells. 
Fractionation of endothelial CM revealed that both sprouting and cobblestone cells 
express bioactive MSF and a MSF-I. Endothelial MSF-I was located in fractions of MW 
70kDa, 40kDa and ≤25kDa; further investigation is required to identify the protein 
responsible.  
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        Chapter 1: Literature Review  
 
1.1 THE HALLMARKS OF CANCER 
 
The progressive transformation of normal cells into highly malignant derivatives is 
considered to be a multistep process. Evidence was gained from the analysis of human 
cancers, which revealed that the lesions could represent intermediate steps in a process 
through which cells evolve progressively from normalcy via a series of malignant states 
into invasive cancers; with each step the cell acquires a specific growth advantage 
(Foulds, 1954, Nowell, 1976). Furthermore, several types of pre-malignant lesions, such 
as dysplasia and hyperplasia, have been detected prior to the emergence of fully 
malignant invasive tumours (Yokota, 2000). Transgenic models of tumourigenesis have 
also frequently conferred that a series of rate limiting steps is involved in cancer 
progression (Bergers et al., 1998). These discoveries have formed the basis of the 
clinical and pathological methods for cancer staging.  
The final stage of cancer progression is the formation of secondary tumours at a distant 
site, a process termed metastasis. It is these distant metastases that are responsible for 
the majority of cancer-related deaths (Yokota, 2000). 80% of all first relapses of breast 
cancer patients are due to secondary tumours alone or concurrent with loco-regional 
area (Citron et al., 2003). The five year survival rate of ductal carcinoma in situ post-
surgery is 95% compared to only 15% for stage IV breast cancer (that is with systemic 
metastases) despite the administration of every available therapeutic treatment (Bastid, 
2012). Undeniably, the most important clinical prognostic factor is the presence of 
distant metastases. Therefore, research efforts have focused on how a cancer cell 
accomplishes this journey to invade and ultimately colonise.  
Neoplastic disease is considerably diverse, with over a hundred human cancers 
identified. Yet, in 2000, Hanahan and Weinberg proposed that this vast catalogue of 
cancer cell genotypes is achieved by the acquisition of six essential alterations in cell 
physiology. That is, as a normal cell progressively evolves to a neoplastic state, they 
acquire a succession of these hallmark capabilities. The six hallmarks of cancer are: 
self-sufficiency in proliferative signals, insensitivity to growth suppressors, resistance to 
programmed cell death (apoptosis), a limitless replicative potential, induction of 
angiogenesis and activation of invasion and metastasis (Table1.2). Hanahan and 
Weinberg have subsequently added two new emerging hallmarks; the capability to 
deregulate cellular metabolism and to resist immune defence mechanisms (2011).  
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Table 1.1: The Hallmarks of Cancer. Originally proposed in 2000 by Hanahan and 
Weinberg. (Hanahan and Weinberg, 2000, 2011). 
Hallmarks of Cancer Potential Mechanisms 
Sustaining proliferative 
signalling  
 Autocrine proliferative stimulation 
 Cancer cell stimulation of cells in tumour-associated stroma, 
which respond by expressing various growth factors. 
 Elevated level of receptor proteins, resulting in cells 
becoming hyper-responsive to a limited source of growth 
factor  
 Structural changes in receptor molecules facilitate ligand-
independent stimulation. 
 Constitutive activation of signalling pathways downstream of 
receptors. 
 Defective negative feedback mechanisms. 
Resisting cell death  Loss of TP53 tumour suppressor function. 
 Increased expression of anti-apoptotic regulators (Bcl-2, Bcl-
xL). 
 Increased expression of survival factors (Igf1/2). 
 Down-regulation of pro-apoptotic factors (Bax, Bim, Puma). 
 Adaptation of autophagic program.  
 Release of pro-tumoural factors by necrotic cell death of 
cancer cells.  
Evading growth 
suppressors 
 Inactivation of tumour suppressor genes (RB  and TP53). 
 Loss of contact mediated growth suppression (NF2 gene/ 
Merlin, LKB1). 
Activating invasion and 
metastasis 
 Down-regulation or mutational inactivation of the cell to cell 
adhesion molecule, E-cadherin. 
 Expression of epithelial –mesenchymal transition (EMT) 
inducing transcription factors (Snail, Slug, Twist, Zeb1/2). 
 Cancer cell activation of stromal cells to promote local 
invasion.  
 Tissue-specific colonisation programs.  
Enabling replicative 
immortality 
 Maintenance of telomeric DNA. 
 Transient telomere deficiency.  
Inducing angiogenesis  Activation of angiogenic switch. 
 Imbalance of angiogenesis inducers (VEGF-A, FGF) and 
inhibitors (TSP-1). 
 Oncogene (Ras, Myc) upregulation of angiogenic factors 
expression.  
 Pro- angiogenic contribution by the innate immune system 
(macrophages, neutrophils, mast cells, myeloid progenitors).  
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1.2 AN INTRODUCTION TO MIGRATION STIMULATING FACTOR  
 
Migration Stimulating Factor (MSF) was the first truncated isoform of human 
fibronectin to be described (Schor et al., 2003). Discovery was led by experimental in 
vitro observations of the disparity in migratory potential between adult and foetal 
fibroblasts (Schor et al., 1985). Isolated from foetal skin fibroblast conditioned medium, 
MSF was shown to be responsible for the foetal cell’s ability to migrate into a 3D 
matrix of native type I collagen gel by a substantially greater extent than their healthy 
adult counterparts (Schor et al., 1988, Grey et al., 1989). However, although the adult 
fibroblasts do not express MSF themselves, they react to its presence when exposed to 
foetal fibroblast conditioned medium, with increased motogenic activity equivalent to 
that of foetal cells. The responsiveness of adult fibroblasts to MSF is integral to the 
sensitive 3D collagen gel migration bioassay, which has become pivotal in assessing 
MSF expression by numerous cell lines in vitro and its subsequent purification from 
bioactive conditioned medium (Schor et al., 1988 and 1989). 
MSF was cloned from a foetal fibroblast cDNA library and shown to be a product of 
variant alternative splicing (Schor et al., 2001, 2003). The 2.1Kb MSF message is 
generated from the fibronectin gene by read-through of intron 12, which separates exon 
III-1a and III-1b, followed by premature intra-intronic cleavage and polyadenylation. 
Consequently, due to this post-transcriptional foreshortening, the MSF message is 
identical to the 5’end of fibronectin, up to and including exon III-1a, followed by a 30bp 
intron-derived in frame coding sequence and a 165bp 3’UTR. Therefore, the 70kDa 
MSF protein is identical to the N- terminus of fibronectin and terminates in a MSF-
unique (intron coded) 10 amino acid sequence, which is not present in any full length 
fibronectin. (EMBL accession number AJ535086-NCBI/Pub Med)  (Schor et al., 2003, 
Kay et al., 2005, Jones et al., 2007). 
In addition to the 2.1Kb MSF transcript, subsequent studies using Northern Blot 
analysis with an MSF-specific probe identified an additional 5.9Kb MSF mRNA. 
Unlike the 2.1Kb MSF mRNA which is specific to foetal fibroblasts, the 5.9Kb version 
is present in all cultured fibroblasts. Both MSF mRNA species share an identical coding 
region, however they differ in the length of the remaining intron- derived 3’ – 
untranslated region (UTR) and their ability to be transported from the nucleus. MSF 
expression therefore appears to be regulated by a multistep process; initially a 5.9Kb 
mRNA is transcribed and sequestered within the nucleus, cleavage of its 3’UTR 
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produces a truncated 2.1Kb version which is permitted export to the cytoplasm and 
subsequently translated. Control of this cleavage event is perhaps a potential novel 
mechanism for the therapeutic control of gene expression. Transforming Growth Factor 
beta 1 (TGFβ1) has been shown to increase 3’UTR cleavage of the 5.9Kb mRNA and 
has been suggested as a mechanism for increasing MSF expression during tumour 
progression. Adult fibroblasts transfected with constructs expressing dominant-negative 
p53 mutants exhibited altered MSF mRNA and protein secretion, implying that tumour 
promoting factors may induce MSF as part of their oncogenic repertoire. (Kay et al., 
2005). Due to the presence of an AU rich instability element in the 3’UTR MSF has an 
extremely short half-life (Schor et al., 2003). 
Approximately 20 distinct full length isoforms of human fibronectin have been 
identified (molecular mass approximately 250kDa) (Kornblihtt, 1996). These full length 
forms are generated by alternative splicing of the fibronectin primary gene transcript 
resulting in either the retention or deletion of the type III exons EDA and EDB; in 
addition to further splicing in the down-stream IIICS region (Hynes 1990). MSF is a 
truncated isoform of fibronectin and was the first to be described in humans. Zebrafish 
also produce a truncated form of fibronectin; Fn2, a C terminus 70kDa isoform which 
terminates in a unique 20 amino acid sequence (Zhao et al., 2001). Other truncated 
fibronectin isoforms have been detected in goldfish, trout, mice and humans (Liu et al., 
2003). 
Fibronectin (Fn) is a modular extracellular matrix glycoprotein (Type I, Type II and 
Type III) consisting of various proteolysis- resistant functional domains, named on the 
basis of their binding affinities for other matrix macromolecules (fibrin, collagen and 
proteoglycans) and members of the integrin family. Cell adhesion is often described as 
the principle function of fibronectin but the ability of its domains to form different 
structures results in fibronectin having numerous cryptic activities, including the 
mediation of cellular interactions within the ECM with important roles in cell migration, 
growth and differentiation (Hynes, 1990). Obviously, MSF shares a similar modular 
structure to the fibronectin N-terminus (Figure 1.1).  
A potent motogenic factor, MSF has the ability to stimulate the migration of fibroblast, 
epithelial and endothelial cells. The motogenic bioactivity of MSF is mediated by the 
IGD amino acid motif (iso-gly-asp) bioactive sequence located within its gelatin 
binding domain (GBD) (Schor et al., 1996) (Figure 1.2). GBD is a highly conserved 
feature of the fibronectin type I module; MSF contains four such motifs in Fn1 modules 
3, 5, 7 and 9. Antibody neutralisation experiments have shown that MSF-stimulated 
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migration is completely inhibited by an anti-GBD monoclonal antibody whilst 
unaffected by antibodies raised to other FN functional domains. In vitro mutagenesis 
experiments revealed that only Fn1 modules 7 and 9 are bioactive in serum free 
conditions, whilst modules 3 and 5 require presence of serum or vitronectin to be 
motogenic. The IGD sequences appear to act in a manner which induces Focal 
Adhesion Kinase (FAK) phosphorylation (Schor et al., 1993, 1994, 1996, 2003. Ellis et 
al., 2010).  
The development of a recombinant MSF protein has progressed the understanding of 
the motogenic activity of MSF. The recombinant protein, which is identical to MSF 
purified from foetal fibroblast conditioned medium, possesses half maximal activity at 
fetomolar concentrations with activity characterised by a bell shaped dose response 
curve. Similarly its activity is neutralised by anti-GBD antibodies (Schor et al., 2003). 
Recombinant MSF and GBD experiments led to the discovery that the fibroblast 
motogenic response is strictly matrix dependent, being only manifest by cells that are 
adherent to native but not denatured type I collagen (Schor, 2001). It has been suggested 
that the matrix dependence of MSF may provide a means of controlling cellular 
responsive to MSF during pathological processes characterised by matrix remodelling 
i.e cancer.  
Consequently, MSF and GBD are considered to be functionally equivalent. That is, two 
independent mechanisms create a factor whose end point is to produce the same 
motogenic activity. MSF is the genetically produced truncated isoform of fibronectin, 
whilst GBD is generated by the proteolytic degradation of matrix fibronectin. The 
obvious advantage of a genetically generated MSF is having the controlled production 
of a single bioactive factor without the necessity of proteolysis producing a mixture of 
Fn fragments that express a complex array of cryptic bioactivities, some of which 
maybe actually be inhibitory (Schor et al., 2003). Described “neo-activities” attributed 
to proteolysis generated Fn fragments include inhibition of cell proliferation (Muir and 
Manthorpe, 1992), adipocyte differentiation (Fukai et al., 1993) and stimulation of  
monocyte migration (Clark et al., 1988). 
Furthermore to its motogenic bioactivity, MSF also possesses the ability to stimulate 
matrix remodelling via proteolytic activity and hyaluronic acid biosynthesis, and 
angiogenesis (Schor et al., 1988, 1989, 1990. Kay et al., 2005. Ellis et al., 1992. Houard 
et al., 2005). Yet, all of MSF’s bioactivities appear to have a causal link to its 
motogenic activity (Table 1.2).  
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Concentrations of MSF which induce cell migration also produce a parallel stimulation 
in the synthesis of high molecular weight hyaluronic acid (HA) (Ellis et al., 1992). The 
response of adult fibroblasts to MSF appears to be mediated by HA synthesis. Co-
incubating MSF with Streptococcal hyaluronidase prevented the stimulation of adult 
fibroblasts to migrate. In addition, the application of HA to adult fibroblast stimulates 
their migration (Schor et al., 1989). Foetal fibroblasts, which have a greater migratory 
potential, have been shown to produce significantly more HA than their adult 
counterparts; both hyaluronidase and MSF function- neutralising antibodies have the 
ability to diminish their migration activity (Chen et al., 1989, Aljorani, 2012). 
Site-directed mutagenesis determined that the zinc-binding motif, HEEGH, located in 
module I-8, is responsible for MSF’s fibronectin proteinase activity. The substitution of 
the two histidine residues of HEEGH for phenylalanine resulted in the complete loss of 
both motogenic and proteinase bioactivity. Approximately 65% of MSF’s motogenic 
activity has been shown to be dependent on its proteinase activity, via either 
extracellular matrix digestion or by the processing of cell surface molecules. The 
invasive potential of several adenocarcinoma cell lines appears to relate to their MSF 
expression levels (Houard et al., 2005). Perhaps by modulating the matrix composition 
MSF is creating a permissive microenvironment which promotes cells to adopt a more 
invasive phenotype, subsequently promoting cancer progression (Schor et al., 2003). 
Both in vivo and in vitro assays have shown the ability of MSF to elicit an angiogenic 
response. In the chick yolk sac assay an application of MSF induced blood vessel 
formation within a 24 hour period; acting in a bell-shaped dose response over a broad 
concentration range, 0.5-500ng/MCG (unpublished data, Schor and Schor, 2010). 
Collagenous graft matrices containing MSF subcutaneously implanted into rats and pigs 
induce endothelial cell and fibroblast infiltration into the graft matrix, which 
subsequently leads to the establishment of a significantly greater number of blood 
vessels when compared to the controls (Schor and Schor, 2010).  
In a reflection of the in vivo situation, cultured endothelial cells have the ability to adopt 
different phenotypes. The resting or cobblestone phenotype is characterised by a 
homogenous monolayer of contact-inhibited polygonal cells considered to be 
morphologically similar to the endothelial lining of the blood vessel wall in vivo.  The 
second phenotype appears in post-confluent cultures, when the resting cells undergo a 
transition into a distinctive elongated fibroblastoid morphology and begin to grow 
underneath the intact cobblestone monolayer, eventually forming an interactive 
network; described as displaying a sprouting phenotype they reflect endothelial cells in 
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vivo undergoing an angiogenic response (Folkmann and Haundenschild 1979 and 1980, 
Makarski 1982, Schor et al., 1983). MSF has been shown to induce endothelial 
activation in vitro; homogenous cobblestone endothelial cells are stimulated to adopt the 
sprouting phenotype (Schor and Schor, 2010). Unlike MSF stimulation of fibroblast 
migration, which only requires the two IGD motifs present in Fn type I modules 1-7 and 
1-9, endothelial migration requires all four IGD motifs (1-3, 1-5, 1-7, 1-9) to be 
bioactive (Schor and Schor, 2010). 
The expression pattern and effective bioactivities of MSF, in vitro and in vivo, all of  
which are pertinent to cancer progression and wound healing, led to its description as a  
potent soluble oncofetal regulatory molecule. Using both the 3D collagen gel migration 
bioassay  and immunohistochemistry with MSF specific antibodies (raised against its 
unique c-terminal decapeptide) it has been shown that during foetal development MSF 
is expressed by keratinocytes, fibroblasts and vascular endothelial cells but is generally 
not expressed in the equivalent healthy adult cells. However, it is transiently re-
expressed during acute wound healing and persistently re-expressed by both tumour and 
stromal cells in various common human cancers, including breast, lung, colorectal, oral, 
prostate and oesophageal. (Unpublished data. Schor et al., 2003, 2005, Jones et al., 
2007). 
 
Table 1.2: The Bioactivities of MSF. The numerous actions of MSF target a variety of 
cell types and the resulting effects are relevant to the progression of cancer (Schor et al., 
1988, 1989, 1990, 1996, 2003; Kay et al., 2005, Ellis et al., 1992, Houard et al., 2005). 
BIOACTIVITY TARGET EFFECT 
Endothelial cell activation Endothelial cells           Angiogenesis. 
Hyaluronic acid synthesis Fibroblasts 
Matrix remodelling. 
Cellular migration 
Motogenesis 
Fibroblasts 
Endothelial cells 
Epithelial cells 
Cellular migration 
Invasion. 
Metastasis 
Proteolysis 
Fibroblasts 
Extracellular Matrix 
Matrix remodelling. 
Processing of cell surface 
molecules. 
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Figure 1.1: A comparison of the modular structures of fibronectin and MSF. 
Consisting of the functional domains: Hep-1/Fib1 (NH2-terminal low-affinity binding to 
heparin and fibrin), Gel-BD (binding to gelatin/collagen), Cell-BD (RGD-mediated 
binding to integrins), Hep-2 (high affinity heparin binding), Fib2 (COOH-terminal 
fibrin binding site). Each functional domain is composed of three possible homology 
modules (types I, type II and type III). Alternative splicing of the fibronectin primary 
gene transcript at the sites EDA, EDB and IIICS produce various “full-length” isoforms 
of fibronectin. MSF contains two domains also present in the N-terminus of fibronectin 
and the first part of the third domain; the truncation takes place in the first type III 
repeat. Image courtesy of Dr S. Jones (Schor and Schor, 2001; Ellis et al., 2010) 
 
 
 
MSF 
MLRGPGPGLLLLAVQCLGTAVPSTGASKSKRQAQQMVQPQSPVAVSQSKPGCYDNGKHY
QINQQWERTYLGNALVCTCYGGSRGFNCESKPEAEETCFDKYTGNTYRVGDTYERPKDS
MIWDCTCIGAGRGRISCTIANRCHEGGQSYKIGDTWRRPHETGGYMLECVCLGNGKGEW
TCKPIAEKCFDHAAGTSYVVGETWEKPYQGWMMVDCTCLGEGSGRITCTSRNRCNDQDT
RTSYRIGDTWRKKDNRGNLLQCICTGNGRGEWKCERHTSVQTTSSGSGPFTDVRAAVYQ
PQPHPQPPPYGHCVTDSGVVYSVGMQWLKTQGNKQMLCTCLGNGVSCQETAVTQTYGGN
SNGEPCVLPFTYNGRTFYSCTTEGRQDGHLWCSTTSNYEQDQKYSFCTDHTVLVQTRGG
NSNGALCHFPFLYNNHNYTDCTSEGRRDNMKWCGTTQNYDADQKFGFCPMAAHEEICTT
NEGVMYRIGDQWDKQHDMGHMMRCTCVGNGRGEWTCIAYSQLRDQCIVDDITYNVNDTF
HKRHEEGHMLNCTCFGQGRGRWKCDPVDQCQDSETGTFYQIGDSWEKYVHGVRYQCYCY
GRGIGEWHCQPLQTYPSSSGPVEVFITETPSQPNSHPIQWNAPQPSHISKYILRWRPVS
IPPRNLGY 
 
Figure 1.2: The protein sequence of MSF. The IGD and HEEGH amino acid motifs 
are highlighted. The protein sequence was confirmed by mass spectrometry. Image 
courtesy of Dr S. Jones (Schor and Schor, 2001; Ellis et al., 2010)  
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1.3  MSF AND CANCER PROGRESSION 
 
MSF is present in more than 80% of common human tumours. Its diverse functionality 
has led to the postulation that MSF is a driver of cancer progression (Table 1.2) (Schor 
and Schor, 2010). As previously discussed, MSF exhibits number of potent 
bioactivities, including the stimulation of cell migration/ invasion, matrix remodelling 
and angiogenesis, which are all pertinent to cancer evolution (Kay et al., 2005, Hu et al 
2009, Schor and Schor 2010) (Table 1.1). The importance of MSF in cancer progression 
is made all the more relevant when paralleling its bioactivities with Hanahan and 
Weinberg’s description of the essential alterations in cell physiology required for cancer 
development (Hanahan and Weinberg, 2000 and 2011).  
Recent research has shown how MSF contributes to achieving these hallmarks of 
cancer; thereby, rendering MSF as a potential novel tumour biomarker and prognostic 
indicator (Schor and Schor, 2010).Detectable quantities of serum MSF have been 
measured in more than 90% of breast cancer patients, compared to only 10-15% of the 
healthy age matched controls (Picardo et al., 1991). Evidence suggests that this 
systemic expression of MSF may continue, even after resection of the primary tumour 
and without reoccurrence of the disease; implying that the level of serum MSF does not 
relate to tumour burden (Aljorani et al., 2011).  In situ hybridisation experiments, using 
a MSF specific antisense riboprobe, detected weak MSF expression in a small 
percentage of ductal epithelial cells and interlobular fibroblasts in normal tissue whilst 
in the breast tumours strong expression was detected in carcinoma cells, stromal 
fibroblasts and some blood vessels. Initial ex vivo observations have suggested a poorer 
prognosis associated with an elevated MSF expression in breast tumours. As in breast 
cancer, MSF is over-expressed in both epithelial and stromal cells of malignant salivary 
gland tumours (Aljorani et al., 2011). 
Cell migration and invasion into tissue matrices is essential for cancer cell metastasis. 
MSF is a potent stimulator of cell migration/ invasion; responsible for the increased 
migratory activity of fetal fibroblasts, as compared to their adult counterparts (Schor et 
al., 1988, Grey et al., 1989). The generation of an hTERT-immortalised fibroblast cell 
line overexpressing MSF conferred a greater migratory potential than the vector-alone 
control fibroblasts. However, the overexpression of MSF also resulted in a change of 
phenotype to that of a cancer-associated fibroblast. The MSF fibroblasts were 
characterised by myofibroblast differentiation with the expression of markers including 
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smooth muscle-specific proteins and two small GTPase proteins, Rac1 and Cdc42. In 
addition, they appeared to be functioning as a chemo-attractant stimulating cancer cell 
migration. Finally, MSF overexpression led to the increased production of TGFβ, which 
is upregulated in most tumours and acknowledged to play a vital role in cancer 
progression (Carito et al., 2012).  
The effect of MSF on invasiveness was also examined by upregulating MSF in the 
human bronchial-alveolar carcinoma cell line, A549 (Deng et al., 2013). The migration 
and invasion of A549 cells increased substantially after MSF upregulation, although the 
proliferation rate remained unchanged. As there was no detected increase in MMP-2 
and MMP-9 expression, it was suggested that MSF may promote cell migration and 
invasion by enhancing amoeboid invasion, in the absence of proteolytic ECM 
breakdown (Deng et al., 2013).  
A further study investigating the effect a tobacco carcinogen, benzo(a)pryene, had on 
A549 cell gene expression levels, revealed the induction of changes in expression levels 
of numerous genes related to the epithelial to mesenchymal transition (EMT) process 
(Yoshino et al., 2007). EMT is considered an essential process in tumour progression. 
Of these EMT related genes, MSF was the most up regulated; suggesting that MSF may 
influence the transformation of tumour cells and may also promote EMT in lung 
epithelium (Yoshino et al., 2007). A subsequent examination of MSF expression in non-
small cell lung cancer (NSLC) discovered that MSF was overexpressed in both tumour 
cells and a variety of tumour-associated stromal cells including fibroblasts, 
microvascular endothelial cells and macrophage dust cells. Indicating that MSF is over 
expressed during tumour occurrence and progression, and maybe a potential biomarker 
of NSLC (Deng et al., 2013) 
Critical to a role for MSF in cancer progression is considered to be its ability to create a 
more permissive tumour microenvironment by remodelling via its proteolytic 
bioactivity and synthesis of HA (Schor et al., 2003). However, MSF has also been 
shown to metabolically remodel the tumour microenvironment by reprogramming 
cancer-associated fibroblasts toward glycolytic metabolism which results in the 
generation of a catabolic tumour microenvironment that actively “fuels” anabolic 
tumour growth (Carito et al., 2012). MSF overexpressing fibroblasts activate the 
inflammation-associated transcription factor NFκB, which controls the autophagic 
process, resulting in the generation of elevated L-lactate production and a decrease in 
mitochondrial activity, thereby directing a shift toward glycolytic metabolism. 
Glycolytic fibroblasts are thought to increase tumour growth by providing high-energy 
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nutrients (L-lactate) to epithelial cancer cells; MSF overexpressing fibroblasts increased 
tumour growth by up to four fold (Carito et al., 2012). 
Another, consequence of MSF overexpression was the activation of the Akt pathway, 
which may protect the cells against apoptosis due to the transcription of pro-survival 
genes. It was suggested that Akt activation by MSF in stromal fibroblasts may lead to 
activation of protein synthesis, as a compensatory mechanism to prevent apoptotic cell 
death in cells undergoing constitutive autophagy/ mitophagy (Carito et al., 2012).  
Tumour-associated macrophages (TAMs), have recently become recognised as having a 
crucial role in the development of a tumour microenvironment; directly affecting 
neoplastic cell growth, stimulating angiogenesis and extracellular remodelling (Solinas 
et al., 2010). MSF has been shown to be expressed by TAMs in vitro; being associated 
with the M2 polarisation of macrophages thereby contributing to the macrophage –
mediated promotion of cancer cell invasion and metastasis. Experiments performed 
using MSF-containing supernatants of tumour-conditioned macrophages showed that 
due to its Gel-BD, MSF had a strong chemotactic activity for monocytes and tumour 
cells; suggesting an autocrine regulatory loop for leukocyte recruitment in addition to  
paracrine effects on the tumour cells (Solinas et al., 2010). 
The induction of angiogenesis is a key step in cancer progression (Folkman, 1971). The 
establishment of tumour vasculature is essential to enable tumour growth and metastasis 
(Mauriz and Gonzalez-Gallego, 2008). As discussed, MSF is known to induce an 
angiogenic response in both in vitro and in vivo models. Exposure of endothelial cells in 
vitro to MSF results in endothelial activation as manifested by the adoption of a 
sprouting cell phenotype. Whilst in vivo rat and pig models and the chick yolk sac assay 
have shown MSF elicit the induction of an angiogenic response, over a board 
concentration range (unpublished data, Schor et al., 1983, Schor and Schor, 2010).  
The subsequent discovery that endothelial cells present within tumours express MSF 
implied a role of MSF in tumour-related angiogenesis (Schor et al., 2003, Kay et al., 
2005. Experiments performed by Hu et al (2009) have revealed that the in vivo bio-
distribution of a labelled anti-MSF antibody (1D2 monoclonal antibody) was selectively 
concentrated in tumour blood vessels in a mouse model of xenograft oesophageal 
carcinoma and the inhibition of MSF bioactivity resulted in a 70% reduction in tumour 
growth. Thus, implying MSF could be a target for anti-angiogenic treatment of 
oesophageal cancer (Hu et al., 2009).  
MSF has been described as a pleiotropic effector, capable of eliciting multiple responses 
from various target cell types (Schor and Schor, 2010). A critical functional role of this 
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oncofetal protein appears to be as a driver of cancer progression. MSF bioactivities are 
consistent with Hanahan and Weinberg’s hallmarks of cancer progression; the ability to 
activate migration/ invasion of both stromal and tumour cells, the creation of a 
permissive tumour microenvironment, the induction of angiogenesis and the 
deregulation of cell metabolism. Additional evidence is the significant association 
between elevated MSF expression and poor survival in patients with breast and oral 
cancer (Schor and Schor, 2010). 
A mechanism of control of MSF bioactivities is therefore essential. It is already known 
that MSF expression is controlled by an mRNA cleavage event within the nucleus, but it 
is not known whether there is a mechanism to regulate the bioactivity of the actual MSF 
protein. Only fetomolar concentrations of MSF are required to produce half-maximal 
motogenic activity, plus there is the potential of a prolonged cellular response due to 
MSF degradation releasing active IGD domains (Ellis et al., 2010). Therefore, 
considering the consequences of unrestricted MSF bioactivity, the co-secretion of a 
functional inhibitor appears plausible. It is the aim of this project to identify potential 
MSF inhibitors and to determine their role in the regulation of MSF bioactivity. Special 
emphasis is made to MSF’s association to cancer progression and its pro-angiogenic 
activity; investigating the possible anti-angiogenic activity of potential MSF inhibitors, 
as targeting MSF in tumours may have a therapeutic potential. 
Therefore, the subsequent literature review will discuss two of hallmarks of cancer 
which correlate to the bioactivities of MSF; firstly, how cancer cells acquire migratory 
and invasive capabilities through the process of epithelial-mesenchymal transition and 
secondly, the process of tumour angiogenesis. In addition, since it is the aim of this 
project to identify potential MSF inhibitors special emphasis is made to the 
development of anti- angiogenic therapies. 
 
 
. 
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Chapter 1: Literature Review  
 
THE EPITHELIAL- MESENCHYMAL TRANSITION  
       IN CANCER PROGRESSION                                                               
 
1.4  Introduction. 
The term metastasis was first coined in 1829 by Jean Claude Recaimer and is now 
defined as “the transfer of disease from one organ or part to another not directly 
connected to it” (Dorland, 1965).  Tumour metastasis is itself a multistage process 
during which malignant cells disseminate from the primary tumour to distant organs. 
Metastasis is the primary clinical challenge as it is unpredictable in onset and it 
exponentially increases the clinical impact on the host; resulting in ineffective treatment 
and poor patient prognosis. The majority of cancer patients die from their disease as a 
result of metastasis (Talmadge and Fidler, 2010, Thiery et al., 2009, Bastid, 2012). 
Research was focused on how epithelial-derived cancers accomplish the complex 
process of metastasis and similarities to the developmental programs of cell migration 
and invasion were observed (Table 1.3). During embryonic development, epithelial cells 
are considered to be highly plastic, possessing the ability to switch back and forth 
between an epithelial and mesenchymal phenotype via the processes of epithelial-
mesenchymal transition (EMT) and the reverse, mesenchymal-epithelial transition 
(MET). These processes play crucial roles in the formation of the body plan and in the 
differentiation of multiple tissues and organs (Thiery et al., 2009).  In the adult, EMT is 
also essential in both physiological and pathological processes such as wound healing 
and organ fibrosis, respectively (Zeisberg and Neilson, 2013). 
In metastatic dissemination, the essential first step is local invasion. Due to similarities 
with embryonic morphogenesis, EMT and epithelial plasticity were hypothesised to 
contribute to tumour progression (Theiry, 2002). Thereby, implying that during 
tumourogenesis, embryonic developmental pathways are reactivated inappropriately, 
enabling epithelial cancer cells to acquire the abilities to invade, to resist apoptosis and 
to disseminate; attributes that facilitate metastatic spread (Micalizzi et al., 2010). 
Numerous in vitro experiments and xenografted and transgenic models have 
demonstrated that epithelial carcinoma cells can acquire a mesenchymal phenotype; 
confirming that induction of EMT confers tumour cells with invasive and metastatic 
abilities. This multifaceted EMT program can be activated transiently or consistently, 
14 
 
and to differing extents by carcinoma cells during the course of invasion and metastasis. 
Certain tumour cells will retain many epithelial traits while acquiring some 
mesenchymal ones; others will shed all traces of their epithelial origin and become fully 
mesenchymal (Kalluri and Weinberg, 2013). 
However, a contradiction to this hypothesis was raised when an examination of 
secondary metastatic colonies revealed that the majority of cells resembled, at the 
histopathological level, the primary tumour from which they originated rather than the 
mesenchymal phenotype attributed to a metastasising carcinoma cells (Tarin et al., 
2005, Bastid, 2012). This prompted the suggestion that during secondary tumour 
formation the metastasising cancer cells have the ability resume an epithelial phenotype 
via a reversal the EMT process; the mesenchyme to epithelial transition (MET) 
(Zeisberg et al, 2005). Subsequently, the new microenvironment of the metastatic 
colony was proposed to provoke the disseminated cells to undergo MET due to an 
absence of the heterotypic signals they experienced in the primary tumour which were 
responsible for inducing EMT in the first place (Thiery, 2002, Bissell et al., 2002). This 
therefore proposes that both EMT and MET are pivotal for cancer progression. EMT as 
the mechanism to allow tumour cells to invade and spread to distant sites and MET to 
enable the subsequent colonisation process (Kalluri and Weinberg, 2013). 
The type of invasiveness involving EMT has been termed “mesenchymal”. In addition, 
two other distinct modes of invasion have been identified and implicated in cancer cell 
invasion (Friedl and Wolf, 2008, 2010). “Collective invasion/ migration” is a vital 
cellular process especially during mammary gland branching morphogenesis, intestinal 
epithelial differentiation and wound healing (Micalizzi et al., 2010). Squamous cell 
carcinomas adopt collective invasion; nodules of cancer cells have been observed 
advancing en masse into adjacent tissues. Since these cancers are rarely metastatic this 
type of invasion appears to lack the functional properties to facilitate metastasis 
(Hanahan and Weinberg 2011). “Amoeboid invasion” involves individual cells gaining 
morphological plasticity and rather than forming a migratory path themselves, they take 
advantage of existing spaces in the ECM and slip through (Madsen and Sahai, 2010, 
Sabeh et al., 2009). 
The process of EMT has been classified into three different subtypes according to 
functional consequences and biological context (Zeisberg and Neilson, 2009). Type I 
EMT occurs during implantation, embryogenesis and organ development. Type II EMT 
is usually associated with an inflammatory response and occurs during wound healing, 
tissue regeneration and organ fibrosis. Type III is the oncogenic EMT which provides a 
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mechanism for tumour cells to leave the primary tumour and invade into the local tissue 
and blood vessels, thereby increasing their metastatic potential. The three classes of 
EMT represent distinct biological processes, however they appear to share a common 
set of genetic and biochemical components that appear to facilitate these outwardly 
diverse phenotypic programs (Kalluri and Weinberg, 2009).  
 
1.4i The Process of EMT 
 
Epithelial cells have many distinguishing features including apical- basal polarity and 
close connection to neighbouring cells established by adherens junctions, desmosomes 
and tight junctions. Layers of epithelial cells communicate via gap junctional complexes 
and are separated from adjacent tissues by a basal lamina. These features convey the 
ability to function as barriers or absorption surfaces. In contrast, mesenchymal or 
stromal cells are loosely organised in the 3D extracellular matrix and form connective 
tissues adjacent to epithelia (Thiery et al., 2009). During development a highly 
coordinated and specific series of events define the transition between epithelial cells 
and mesenchymal cells. Yet, during oncogenic EMT this series of steps is less clear and 
is specific to individual cancer pathologies. However, overall the basic steps are similar 
(Table1.4).  
Firstly, epithelial connections to neighbouring cells disintegrate with the loss of 
epithelial cell surface proteins such as E-cadherin and the gain of mesenchymal 
markers, like N-cadherin. The tight junctions between the epithelial cells are dissolved 
thereby losing apical-basal polarity; this allows the interaction of apical and basolateral 
membrane components and the acquisition of a front-rear polarisation. Adheren and gap 
junctions disassemble. The activation of proteolytic enzymes, such as matrix 
metalloproteinases, degrade the underlying basement membrane and cell-matrix 
adhesion is altered. Remodelling of the cytoskeleton occurs with the peripheral actin 
cytoskeleton replaced by stress fibers and vimentin replacing cytokeratin intermediate 
filaments. The cell changes from a polygonal/ epithelial shape to a spindly/ fibroblastic 
morphology. Finally, devoid of any cell-cell contacts the cell disengages from the 
primary tumour, acquiring the ability to invade and move into the surrounding ECM.  
Subsequently, the cell can enter the circulation with the potential to reach new 
metastatic sites (Iwatsuki et al., 2010, Micalizzi et al., 2010, Hanahan and Weinberg 
2011).  
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Table 1.3: A list of the seminal papers which have increased the understanding of EMT and the cancer progression.  
Date Author(s) Paper Title Journal Contents 
1968 E.D. Hay Organisation and fine structure of 
epithelium and mesenchyme in the 
developing chick embryo. 
Epithelial-
mesenchymal 
Interactions. 
Williams & Wilkins, 
31-55. 
Defined the process of EMT and MET using the chick primitive streak as 
a model. Proposed that epithelial cells can undergo phenotypic changes 
that reflect their transformation to mesenchymal cells. 
1982 G. Greenburg, 
E.D. Hay. 
Epithelia suspended in collagen gels 
can lose polarity and express 
characteristics of migrating 
mesenchymal cells. 
Journal of Cell 
Biology, 95 (1), 333-
339. 
The first characterisation of the EMT process. Revealed the profound 
effect environmental conditions have on epithelial phenotype, cell shape 
and apical-basal polarity.  
1985 M. Stoker, 
M. Perryman. 
An epithelial scatter factor released by 
embryo fibroblasts. 
Journal of Cell 
Science, 77, 209-223. 
Described the induction of EMT in MDCK cells when exposed to 
medium conditioned by human embryo fibroblasts. The presence of a 
scattering factor appeared to initiate separation and mobilisation of the 
epithelial cells. 
1987 M. Stoker, 
E. Gherardi, 
M. Perryman, 
J. Gray. 
Scatter factor is a fibroblast-derived 
modulator of epithelial cell mobility. 
Nature, 327, 239-242. Described Scatter Factor as a paracrine effector of epithelial-
mesenchymal interaction. Released by embryonic fibroblasts with the 
ability to cause disruption of epithelial cell to cell junctions, increase local 
cell motility and scattering of contiguous sheets of cells. Proposed an 
involvement with epithelial migration during embryogenesis and wound 
healing.  
1999 R. Maestro, 
A.P. Dei Tos, 
Y. Hamamori, 
S. Krasnokutsky,  
V. Sartoreeli,  
L. Kedes,  
C. Doglioni,  
D.H. Beach,  
G. J. Hannon. 
Twist is a potential oncogene that 
inhibits apoptosis. 
Genes & 
Development, 13, 
2207-2217. 
cDNA functional screen identified two related bHLH family members, 
Twist and Dermo 1, which could counteract the proapoptotic effects of 
myc oncogene. Twist shown to inhibit oncogene and p53-mediated 
apoptosis. Proposed Twist had numerous roles in the formation of 
rhabdomyosarcomas, arresting terminal differentiation, inhibiting 
apoptosis and interfering with the p53 tumour-suppressor pathway.  
2000 A. Cano,  
M.A. Perez-Moreno,  
I. Rodrigo,  
A. Locascio,  
M.J. Blancos, 
The transcription factor Snail controls 
epithelial-mesenchymal transitions by 
repressing E-cadherin expression.  
Nature Cell Biology, 
2, 76-83. 
Snail shown to be a strong repressor of transcription of the E-Cadherin 
gene. Snail expression by epithelial cells results in fibroblastoid 
phenotypic and acquirement of tumorigenic and invasive properties. Snail 
suggested as a marker of malignancy since the Snail protein is present in 
invasive mouse and human carcinoma cell lines and tumours which have 
17 
 
M.G del Barrios,  
F. Portillo, 
M. Angela Nietos 
lost E-Cadherin expression.  Described how the same molecules trigger 
epithelial-mesenchymal transitions during both embryonic development 
and tumour progression. 
2000 E. Batlle,  
E. Sancho,  
C. Franci, D. 
Dominguez,  
M. Monfar, 
 J. Baulida,  
A. Garcia de 
Herreros. 
The transcription factor Snail is a 
repressor of E-Cadherin gene 
expression in epithelial tumour cells. 
Nature Cell Biology, 
2, 84-89. 
Expressed by fibroblasts and some E-cadherin- negative epithelial tumour 
cell lines, the transcription factor Snail was shown to repress transcription 
of E-cadherin by binding to three E-boxes present in the human E-
cadherin promoter. Expression of the E-cadherin gene can be restored by 
the inhibition of Snail function. 
2002 J.P. Thiery Epithelial- mesenchymal transitions in 
tumour progression.  
Nature Reviews 
Cancer, 2 (6), 442-
454. 
First comprehensive review of epithelial-mesenchymal transitions and the 
role in progression of carcinoma towards dedifferentiated and more 
malignant states.  
2002 A. Inoue,  
M.G. Seidel,   
W.Wu,  
S. Kamizono,  
A.A. Feraando, et al. 
Slug, a highly conserved zinc finger 
transcriptional repressor, protects 
hematopoietic progenitor cells from 
radiation-induced apoptosis in vivo.  
Cancer Cell, 2 (4), 
279-288. 
The zinc finger transcriptional repressor, Slug, was shown to act as an 
antiapoptotic factor by promoting the survival of hematopoietic 
progenitors which have undergone DNA damage. Implicated Slug in a 
novel survival pathway. 
2004 J. Yang,   
S.A. Mani,  
J.L. Donaher,  
S. Ramaswamy, 
 
Twist, a master regulator of 
morphogenesis, plays an essential role 
in tumour metastasis.  
Cell, 117, 927-939. Using a murine breast tumour model, the transcription factor Twist, a 
master regulator of embryonic morphogenesis, was shown to contribute to 
metastasis by promoting an epithelial- mesenchymal transition. High 
levels of Twist expression in human breast cancer correlated with highly 
invasive lobular carcinoma which is associated with loss of E-cadherin 
expression.  
2004 M. Kajita,  
K.N. McClinic,  
P.A. Wade. 
Aberrant expression of the 
transcription factors Snail and Slug 
alters the response to genotoxic stress. 
Molecular and 
Cellular Biology, 24 
(17), 7559-7566. 
Investigated the effects of aberrant expression of Snail and Slug 
transcriptional repressors in human cancer cells; which resulted in 
changes in cell morphology, loss of cell-cell contacts and acquirement of 
invasive growth properties. Snail and Slug implicated as promoters of 
tumorigenesis by an increased resistance to apoptosis.  
2005 D. Tarin. The fallacy of epithelial mesenchymal 
transition in neoplasia. 
Cancer Research, 65 
(14), 5996-6000. 
Investigated the validity of the proposal that EMT is active during 
embryonic development, wound healing, carcinogenesis and tumour 
metastasis. Concluding that in vivo there was no conclusive proof of a 
conversion of epithelial cells into mesenchymal cell lineages. 
2005 W-S. Wu,  
S. Heinrichs, 
Slug antagonises p53-mediated 
apoptosis of hematopoietic progenitors 
Cell, 123 (4), 641-
653. 
Showed that upon irradiation, the transcriptional repressor, Slug is 
transcriptionally induced by the tumour suppressor p53. This results in the 
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D.Xu,  
S.P. Garrison,  
G.P. Zambetti,  
J.M. Adams,  
A.T. Look. 
by repressing puma. damaged cell being protected from apoptosis by directly repressing p53-
mediated transcription of puma, a key BH3-only antagonist of the 
antiapoptotic Bcl-2 proteins.  
2006 K.L. Knutson,  
H. Lu,  
B. Stone,  
J.M. Reiman,  
M.D. Behrens,  
Immunoediting of Cancers may lead to 
epithelial to mesenchymal transition. 
Journal of 
Immunology, 177 (3), 
1526-1533. 
Revealed that immunoedited tumour cells undergo EMT characterised by 
an up-regulation of invasion factors and increased invasive potential. The 
immunoedited tumour cells are able evade immune surveillance.  
2006 C.L. Chaffer,  
J.P. Brennan, 
J.L. Slavin,  
T. Blick,  
E.W. Thompson,  
E.D. Williams. 
Mesenchymal-to- epithelial transition 
facilitates bladder cancer metastasis: 
role of fibroblast growth factor 
receptor-2. 
Cancer Research, 66 
(23), 11271-11278. 
The bladder carcinoma TSU-Pr1 (T24) progression series of cell lines 
which display increasing metastatic potential was used to investigate role 
played by mesenchymal to epithelial transition metastasis (MET). 
Overexpression of fibroblast growth factor receptors shown to reverse 
MET. 
2006 S. Spaderna,  
O. Schmalhofer,  
F.Hlubek,  
G. Berx, 
A. Eger,  
S. Merkel,  
A. Jung,  
T. Kirchner, 
T. Brabletz. 
A transient, EMT-linked loss of 
basement membranes indicates 
metastasis and poor survival in 
colorectal cancer.  
Gastroenterology, 
131 (3), 830-840. 
Investigated the clinical relevance of basement membrane (BM) turnover 
in the progression of malignant colorectal cancer; discovering a transient 
loss of the BM at the invasive font of the tumour which correlates with 
increased distant metastasis and decreased patient survival. The invasion-
associated loss of BM appears to be due to a reduction in synthesis 
associated with EMT. The zinc-finger enhancer protein 1 (ZEB1) 
identified as the crucial transcriptional repressor of BM components in 
colorectal cancer.  
2007 H. Peinado, 
D. Olmeda, 
A.Cano. 
Snail, ZEb and bHLH factors in tumour 
progression: an alliance against the 
epithelial phenotype? 
Nature Reviews 
Cancer, 7 (6), 415-
428. 
A review of the involvement of transcription factors Snail, ZEB and basic 
helix-loop-helix (bHLH) in the repression of E-cadherin and the induction 
of EMT. 
2008 A.J. Trimboli,  
K. Fukino,  
A. de Bruin.,  
G. Wei,  
L. Shen, et al. 
Direct evidence for epithelial- 
mesenchymal transitions in breast 
cancer. 
Cancer Research, 68 
(3), 937-945. 
Oncogene-driven mouse mammary tumour models and cell-fate mapping 
strategies provide direct evidence of EMT occurring in vivo in breast 
cancer. Although rare, the incidence of EMT in invasive human breast 
carcinomas is associated with an amplification of MYC. 
2008 S.A. Mani,  
W. Guo, 
M-J. Liao,  
The epithelial-mesenchymal transition 
generates cells with properties of stem 
cells. 
Cell, 133, 704-715. Described a direct connection between EMT and the gain of epithelial 
stem cell properties. The induction of EMT in immortalised human 
mammary epithelial cells resulted in the acquirement of mesenchymal 
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E. N. Eaton,  
A. Ayyanan, et al. 
characteristics and the expression of stem cell markers.  
2008 S. Ansieau,  
J. Bastid,  
A. Doreau,  
A-P. Morel, 
B.P. Bouchet, 
C. Thomas,  
F. Fauvet,  
I. Puisieux,  
C. Doglioni, et al.  
Induction of EMT by Twist proteins as 
a collateral effect of tumour-promoting 
inactivation of premature senescence. 
Cancer Cell, 14, 79-
89. 
The major regulators of embryogenesis, Twist1 and Twist2, shown to be 
overexpressed in a large variety of human cancers. The Twist proteins are 
described as the early drivers of tumorigenesis as they completely 
revoked oncogene-induced senescence by inhibiting the key regulators of 
the p53 and Rb-dependent pathways.  
Describe complete EMT requiring collaboration between the Twist 
proteins and activated motogenic oncoproteins, such as Ras or ErbB2. 
2008 A-P. Morel, 
M. Lievre,  
C. Thomas, 
G. Hinkal, 
S. Ansieau,  
A. Puisieux. 
Generation of breast cancer stem cells 
through epithelial-mesenchymal 
transition. 
PLos ONE, 3 (8), 
e2888. 
A human mammary tumour progression model (HMEC) demonstrated 
that cells possessing both stem and tumorigenic characteristics of “cancer 
stem cells” can be generated from non-tumorigenic mammary epithelial 
cells via the activation of the Ras/MAPK pathway. The process is 
accelerated by EMT induction.  
2008 M-H. Yang,  
M-Z Wu,  
S-H. Chiou, 
P-M. Chen, 
S-Y. Chang,  
C-J. Liu,  
S-C. Teng,  
K-J. Wu. 
Direct regulation of Twist by HIF-1α 
promotes metastasis. 
Nature Cell Biology, 
10 (3), 295-305. 
Show that hypoxia or over-expression of hypoxia-inducible factor-1α 
(HIF-1α) promotes EMT and metastasis. Twist expression is regulated by 
HIF-1α through direct binding to the hypoxia-response element (HRE) in 
the Twist proximal promoter. EMT and metastatic phenotypes can be 
reversed in HIF-1α overexpressing or hypoxic cells by the siRNA –
mediated repression of Twist.  
2009 J. P. Thiery,  
H. Acloque, 
R.Y.J. Huang, 
M. A. Nieto. 
Epithelial-mesenchymal transitions in 
development and disease. 
Cell, 139, 871-890. Comprehensive review of EMT involvement in embryonic development, 
tissue homeostasis, wound healing, fibrosis and cancer progression. 
Special focus on EMT and tumour progression and the impact on drug 
resistance. 
2009 M. Santisteban,  
J.M. Remain, 
M.K.Asideu, 
M.D. Behrens, 
A. Nassar, et al. 
Immune-induced epithelial to 
mesenchymal transition in vivo 
generates breast cancer stem cells. 
Cancer Research, 69 
(70, 2887-2895. 
Described how in breast cancer EMT can be induced by CD8 T cells with 
the resulting tumours displaying characteristics of breast cancer stem 
cells. Questions the hierarchal cancer stem cell hypothesis.  
2011 C-J. Chang,  
C-H. Chao,  
p53 regulates epithelial-mesenchymal 
transition and stem cell properties 
Nature Cell Biology, 
13 (3), 317-323. 
Reveal a role for p53 in regulating EMT-MET and differentiation 
plasticity. By directly binding to the microRNA miR-200c promoter p53 
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W. Xia,  
J-Y. Yang,  
C-W Li,  
W-H. Yu,  
S. K. Rehman, 
J.L. Hsu, 
H-H. Lee, 
M. Liu, et al. 
through modulating miRNAs. transcriptional activates the miR-200c. In mammary epithelial cells the 
loss of p53 expression results in a decrease in miR-200c expression with 
an activation of the EMT process and an increase in the number of 
mammary stem cells. This is exhibited by an increase in expression of 
EMT and stem cell phenotype markers and subsequent development of a 
group of high grade breast tumours.  
2012 A. Bonnomet,  
L. Syne, 
A. Brysse,  
E. Feyereisen,  
E.W. Thompson, 
A. Noel,  
J-M. Foidart, 
P. Birembaut, 
M. Polette, 
C. Gilles. 
A dynamic in vivo model of epithelial- 
to –mesenchymal transitions in 
circulating tumour cells and metastases 
of breast cancer. 
Oncogene, 31, 3741-
3753. 
Describe the transient and reversible nature of EMT in vivo that 
accompany metastatic spread. In primary tumours EMT affords the 
tumour cells a greater ability to intravasate and generates circulating 
tumour cells. Post extravasation in the secondary organ(s) MET occurs to 
facilitate metastatic growth. Developed an animal model with 
transplantable human breast tumour cells which showed the spontaneous 
nature of EMT and allowed the metastatic process to be followed. The 
dynamic expression of vimentin, a marker of EMT, was assessed 
throughout, along with the expression of epithelial (E-cadherin, ZO-3, 
JAM-A) and mesenchymal (Snail, Slug, fibroblast-specific protein-1) 
specific molecules. 
 
Table1.4: The process of epithelial to mesenchymal transition. 
1. Loss of Apical-Basal Polarity. 
The dissolution of tight junctions, allow apical and basal membrane proteins intermix 
Disassembly of adherens and gap junctions. 
2. Loss of Epithelial Cell to Cell Connections. 
Epithelial specific integrins and cell surface proteins, such as E-cadherin, are switched to 
mesenchymal specific integrins and N-cadherin.  
3. Remodelling of Cytoskeleton. 
Stress fibres replace the peripheral actin cytoskeleton and accumulate at cell protrusions.  
Vimentin replaces cytokeratin intermediate filaments.  
4. Degradation of Basement Membrane. 
5. Cell Invasion. 
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1.4ii The Molecular Mechanisms Involved in EMT. 
 
Four fundamental regulatory networks are thought to drive EMT in cancer cells. EMT is 
thought to be initiated when the balance of these networks is disturbed and the 
subsequent level of EMT achieved is defined by how far the balance is tipped in one 
direction or the other (DeCraene and Berx, 2013). The regulatory networks are so 
closely interconnected that an alteration of one network will result in knock-on effects 
on the others. The most extensively studied network is that built around the nuclear 
transcription factors Snail, Zeb and Twist families. The three other networks are the 
expression of small non-coding RNAs, differential splicing and translational and post-
translational control (which affect protein stabilisation and localisation) (DeCraene and 
Berx, 2013). Many of the factors were first identified by developmental genetics and 
relate to migratory processes during embryogenesis.  
The loss of E-cadherin expression is a fundamental event in EMT and is a marker for 
poor prognosis in various human cancers (colorectal, breast and gastric) (Table1.5). E-
cadherin is a calcium dependent transmembrane glycoprotein expressed by the majority 
of epithelial tissues. It exerts a role as repressor of tumour progression by forming tight 
junctions connecting adjacent epithelial cells and therefore is a key suppressor of cell 
motility, invasion and metastatic dissemination (Peinado et al., 2004).  
Normally, E-Cadherin is regulated at both mRNA and protein levels by several 
processes including translational or transcriptional events, protein degradation and 
altered subcellular distribution (Yang and Weinberg, 2008). Many human cancers are 
characterised by the functional loss of E-cadherin due the expression of a defective 
protein, this may be the consequence of a gene mutation, abnormal post-translational 
modification (phosphorylation or glycosylation) or increased proteolysis (Tiwari et al., 
2012). At the transcriptional level E-cadherin gene expression can be silenced due to 
promoter hypermethylation. E-cadherin was one of the first genes with promoter 
hypermethylation identified at very high frequencies in human cancer (van Roy and 
Berx, 2008, Tiwari et al., 2012). 
E-cadherin regulation also occurs by transcriptional repression. Transcriptional 
repressors of E-cadherin such as zinc finger proteins (Zeb1, Zeb2), basic helix-loop-
helix protein (Twist) and the snail family of zinc finger proteins (Snail, Slug) are all 
associated with EMT (Iwatsuki et al., 2010). These transcription factors can be 
classified into two groups; those which bind to and repress the activity of the E-cadherin 
promoter (Snail, Zeb, E47, KLF8) and those which repress E-cadherin transcription 
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directly (Twist, Goosecoid, E2.2, FoxC2) (Yang and Weinberg, 2008, Thiery et al., 
2009). Various signal pathways such as TGFβ, Wnt cascade, and PI3K/AKT axis are 
connected with these transcriptional repressors of E-Cadherin (Iwatsuki et al., 2010).  
The level of EMT achieved by the cancer cells is primarily dependent on the potency of 
EMT-inducing transcription factors which are the triggering cellular reprogramming.  
The power of these factors relies not only on direct repression of E-cadherin but also on 
the simultaneous repression of several other factors which facilitate the general 
dedifferentiation programme (De Craene and Berx, 2013). Snail1 and Zeb1 can 
determine the loss of cell polarity since the three protein complexes are involved in 
maintaining the apical-basal polarity in epithelial cells (Par, Crumbs and Scribble) can 
each be regulated by the Snail1 and Zeb1 (Thiery et al., 2009). Snail and Zeb also 
induce the expression of matrix metalloproteinases which degrade the basement 
membrane, thereby assisting invasion. Conversely, MMP3 promotes EMT by increasing 
the cellular levels of reactive oxygen species, which in turn induces Snail1 expression 
(Radisky et al., 2005). 
MicroRNAs (miRNAs) are small non-coding RNA molecules that suppress gene 
expression by interacting with the 3’ untranslated regions (3’UTRs) of target mRNAs 
and have been linked to EMT and cancer. The miR-200 family and miR-205 have the 
ability to inhibit the E-cadherin transcriptional repressors, Zeb1 and Zeb2. Conversely, 
Zeb1 and Zeb2 repress the expression of the miR-200 gene cluster (Burk et al., 2008). It 
has recently been revealed that p53 activates miR-200c through direct binding to its 
promoter. The loss of p53 in mammary epithelial cells correlates with a decreased 
expression of miR-200c and an increase in EMT markers with the subsequent 
development of a cohort of high grade breast tumours (Chang et al., 2011). In metastatic 
breast cancer miR-10b is overexpressed due to up-regulation by Twist and is associated 
with invasiveness and metastatic potential (Ma et al., 2007).  
It is well acknowledged that TGFβ prompts numerous responses in cancer progression 
including angiogenesis, immune suppression and anti-apoptosis (Derynck et al., 2001).  
TGFβ, the ubiquitously expressed cytokine, is also an important inducer of EMT. 
During development TGFβ is required for heart development and palatogenesis 
(Micalizzi et al., 2010).  In vitro experiments have shown that exposure to TGFβ results 
in dramatic consequences; loss of apical-basal polarity, down-regulation of cell-cell 
adhesions and expression of mesenchymal markers such as vimentin (Micalizzi et al., 
2010). Studies have revealed that TGFβ induces EMT programs via numerous signal 
pathways, including Smad 2 and Smad 3, integrin, Notch and Wnt (Iwatsuki et al., 
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2010). TGFβ has been implicated in the loss of cell polarity during EMT by adopting 
two approaches. The more established pathway is by the induction of Snail and Zeb 
expression. However, TGFβ can also initiate the downregulation of Par3 expression and 
the Par6-mediated degradation of RhoA resulting in the local alteration of actin 
cytoskeleton (Theiry et al., 2009). 
Many developmental studies have presented evidence that in the embryo, neighbouring 
cells are involved in triggering the expression of EMT-inducing transcription factors in 
cells destined to pass though EMT (Micalizzi et al., 2010). There is also increasing 
evidence that tumour–associated stromal cells appear to be inducing cancer cells to 
undergo EMT. EMT occurring in carcinomas in vivo, is often located at the invasive 
margins of the tumour, implying that these cancer cells are subjected to a specific 
microenvironmental stimuli which is distinct from those exposed to cancer cells located 
in the core of the tumour (Hlubeck et al., 2007, Hanahan and Weinberg, 2011). While 
cancer cells that have disseminated from the primary tumour to metastatic sites no 
longer experience these tumour associated –stromal originated EMT-inducing signals 
and thus the absence of signals may cause the carcinoma cells to revert via MET to their 
non-invasive epithelial phenotype. This would explain why many new tumour colonies 
exhibit histopathology similar to the primary tumour (Hugo et al., 2007). 
 
Table1.5: A list of epithelial and mesenchymal markers.  
Epithelial Markers Mesenchymal Markers 
E-cadherin                      
Cadherin-16                   
Cadherin-6B                   
VE-cadherin                    
Claudin 1                         
Connexin 43                   
Crumbs3                         
Cytokeratin         
Entactin       
Dig1 
HNF-1β 
Integrin α3 
Laminins α3, α5, α6 
miR200 family 
Mucin-1 
Nephrin 
Occludins 
PTEN 
Zona occludens-1 
α-SMA 
Β-catenin 
CyclinD1 
Fibroblast specific protein -1 
(FSP-1) 
Fibronectin 
Forkhead box C2 
Goosecoid 
N-cadherin 
Snail1 
Snail2 
SIP1 
Syndecan-1 
Twist 
Vitronectin 
Vimentin 
Zeb1 
 
24 
 
1.4iii The Controversy of EMT  
 
The clinical relevance of EMT during human cancer progression has been contentious. 
Although in vitro studies are numerous and well documented, there has been a distinct 
lack of direct and conclusive evidence of complete EMT in clinical samples (DeCraene 
and Berx, 2013). The importance of EMT has been difficult to prove since the changes 
are often transient and occur in a small population of cancer cells. Developmental EMT 
is characterised by sequential step-wise process under the tight control of morphogenic 
signals. However, oncogenic EMT is particularly difficult to predict due to the genetic 
instability of the tumour cells coupled with the abnormal local tumour environment 
(Micalizzi et al., 2010). 
It is especially challenging, in vivo to make the morphologic distinction between 
carcinoma cells undergoing EMT and neighbouring stromal cells, since they will appear 
as mesenchymal-like cells (Bastid, 2012). However, the advancement of in vivo imaging 
has helped gain evidence of EMT in cancer progression (Wyckoff et al., 2007). In 2007, 
Prall described cords or small aggregates of tumour cells extending and detaching from 
the primary tumour mass into the local stroma. This process of tumour budding is 
commonly observed and the tumour cells have been shown to have down-regulated E-
Cadherin (Iwatsuki et al., 2010). Xenograft experiments and genetically modified 
mouse cancer models have supported these clinical observations.          
Assessing the gain or loss of markers is also considered to be subjective since many 
cancers, due to presence of genetically unstable cells, express both epithelial and 
mesenchymal markers (Talmadge and Fidler, 2010). Yet, there are numerous recorded 
examples of carcinoma cells at the invasive front of tumours expressing an EMT profile 
(Table1.6). In colon carcinoma, EMT has been observed in single migratory cells at the 
invasive front; cells lose E-cadherin expression, the Wnt pathway is deregulated and a 
there is a selective loss of the basement membrane (Brabletz et al., 2001). In addition 
the expression of EMT inducers, including the transcription factors Snail 1 and 2 have 
been shown to significantly correlate with poor prognosis and disease relapse in breast, 
colorectal and ovarian cancer (Thiery et al., 2009). Many EMT markers are now used to 
predict patient prognosis (Iwatsuki et al., 2010) (Table1.5). 
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Table 1.6: Evidence of epithelial- mesenchymal transition taking place during human cancer progression. 
Cancer Type Evidence of EMT Reference 
Cervical 
Carcinoma 
 Compared to primary tumours, lymph node micrometastases of cervical 
cancer display an increased expression of EMT-related genes.  
 SNAIL 1 expression correlates with EMT and invasiveness.  
 The invasive front of cervical tumours characterised by Vimentin expression 
and loss of E-cadherin. 
Hagemann et al., 2007. 
 
Lee et al., 2008 
Hsu et al., 2007 
Colorectal 
carcinoma (CRC) 
 Snail 2 expression shown to be an independent prognostic parameter for poor 
survival. 
 Invasive front of CRC characterised by selective loss of basement membrane 
and deregulation of Wnt pathway.  
 The epithelial and stromal signalling pathway profiles are more similar to each 
other in CRC than in the normal colon. 
Shioiri et al., 2006. 
 
Brabletz et al., 2001. 
 
Sheehan et al., 2008 
Cutaneous 
malignant 
melanoma (CMM) 
 A subset of EMT genes associated with cell adhesion, cell motility, migration 
and ECM interaction are differentially expressed in CMM with metastasis as 
compared to samples without metastasis.  
Alonso et al., 2007. 
Breast Carcinoma  Histological grade of breast tumours have been related to expression profiles 
of EMT.  
 EMT-signalling pathways of TGFβ and Wnt shown to regulate EMT 
programs. TGFβ signalling induces EMT and metastasis of breast cancer cells 
to bone via Smad4. 
 Homeobox gene HOXB7 which induces EMT in MCF10A cells is 
overexpressed in primary and metastatic breast cancer tissues and cell lines.  
Teschendorff et al., 2007. 
 
 
Deckers et al., 2006. 
 
Wu et al., 2006. 
Head and neck 
carcinoma 
 EMT-related genes identified in high risk  squamous cell carcinoma  Chung et al., 2004,  
Chung et al., 2006 
Hepatocellular 
carcinoma (HCC) 
 Snail1 and Zeb2 expression, induced by TGFβ, increases invasion of HCC 
cells due to an upregulation of metalloproteinase expression.  
 The sensitivity of HCC cell lines to EGFR-targeted therapies (erlotinib, 
Miyoshi et al., 2004 
 
Fuchs et al., 2008. 
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gefitinib, cetuximab) has been associated to EMT.  
 Snail1 and Twist overexpression in HCC samples correlated with a worse 
prognosis. 
 
Yang et al., 2009 
Ovarian Carcinoma  Snail1 expression correlates with lower survival rate. Blechschmidt et al., 2008. 
Pancreatic 
Carcinoma 
 EMT in pancreatic carcinoma cells can be induced by TGFβ and EGF family 
member HB-EGF.  
 Snail1 and Snail 2 expression reported in 78% and 50% of pancreatic 
carcinoma tissues, respectively.  
Bardeesy et al., 2006,  
Jungert et al., 2007. 
Hotz et al., 2007. 
Papillary Thyroid 
Carcinoma (PTC) 
 The invasive front of PTC tumours shown to have an expression profile 
consistent with EMT; characterised by limited expression of genes related to 
cell adhesion while over expression of integrin and TGFβ pathway 
components, including Snail 1 and 2 genes.  
Vasko et al., 2007, 
Hardy et al., 2007 
Prostate Carcinoma  Zeb1 expression correlates to a high Gleason score in prostate carcinoma 
tissues.  
 The EMT process to switch from E to N-cadherin was shown to be an 
independent prognostic factor for treatment failure, metastasis, reoccurrence 
and overall survival.  
Graham et al., 2008. 
 
Gravadal et al., 2007. 
Uterine Carcinoma  Zeb1 expression correlated with EMT and invasive potential. Spoelstra et al., 2006. 
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1.4iv The Additional Consequences of EMT  
 
EMT induction in cancer cells has also been linked to an acquisition of various 
additional capabilities that are also highly relevant to cancer progression.  The nature 
and strength of the EMT induction apparently determines the magnitude of these cancer 
progression associated capabilities (Tiwari et al 2012). 
When a cancer cell disengages from the tumour mass and enters the circulation, the lack 
of cellular adhesion can induce a type of apoptosis called anoikis. However, cancer cells 
that have undergone EMT appear to have acquired resistance to cell death. TGFβ has 
been implicated in enabling cancer cell survival by activating the E-cadherin repressors 
Snail and Twist which are known to confer resistance to cell death (Thiery et al., 2009). 
Several weeks exposure of breast tumour derived NMuMG cells to TGFβ has been 
shown to generate cells which display a sustained EMT and have the ability to escape 
apoptosis (Gal et al., 2008). Furthermore, in neuroblastomas Twist antagonises Myc-
mediated pro-apoptotsis (Puisieux et al., 2006). 
E-cadherin repressors also seem to protect the EMT-induced carcinoma cells from 
undergoing oncogene induced premature senescence. Twist 1 and 2 confer resistance to 
senescence induced by oncogenes by inhibiting p16/inka and p21/cip (Ansieau et al., 
2008). It has also been reported that Zeb1 protects mouse embryonic fibroblasts from 
senescence (Liu et al., 2008). These findings would therefore suggest that the process of 
EMT not only yields cancer cells possessing an invasive and metastatic phenotype but 
also ensures their survival by suppressing two safeguard mechanisms against cancer 
progression: premature senescence and apoptosis (Thiery et al., 2009). 
EMT also appears to allow carcinoma cells to evade the immune defence mechanism. 
Cells undergoing EMT gain the expression of a number of cytokines and secreted 
factors that inhibit immune responses (Tiwari et al., 2012). By undergoing EMT, Neu-
driven tumours appear to elude immune surveillance (Knutson et al., 2006). EMT 
inducer, Snail 1 expression is associated with the activation of immunosuppressive 
cytokines, regulatory T cells, cytotoxic T lymphocytes resistance and the generation of 
impaired dendritic cells (Kudo-Saito et al., 2009, Thiery et al., 2009). Interestingly, 
immunosuppressive agents used to reduce host rejection after organ transplantation, 
such as cyclosporine, also induce epithelial de-differentiation.  These agents induce the 
production of TGFβ which serves to stimulate and maintain partial EMT (Tiwari et al., 
2012). 
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Carcinoma cells undergoing EMT have been reported to develop a resistance to 
chemotherapy. Conversely, anticancer agents and radiotherapy can actually induce 
EMT by creating a “stress” environment within the tumour, characterised by hypoxia. 
Continual exposure of colon and ovarian carcinoma cell lines to oxaliplatin and 
paclitaxel, respectively, lead to the development of resistance whilst the cells exhibit a 
mesenchymal phenotype and express several EMT markers (Yang et al., 2006, 
Kajiyama et al., 2007). Having undergone EMT the cell lines MCF7 and MDA-MB-434 
are reported to have elevated Twist expression and resistance to Paclitaxel (Cheng et al., 
2007). 
EMT is considered to be accountable for the relapses that befall patients who had 
initially presented with tumours highly sensitive to treatment. EMT derived multi- drug 
resistance permits rapid progression of the tumour (Iwatsuki et al., 2010). However, the 
restoration of chemotherapeutic sensitivity has been shown by the forced expression of 
miR-200C, a negative regulator of EMT (Cochrane et al., 2009). Multidrug resistance in 
breast cancer cells can be partially reversed by depletion of Twist (Li et al., 2009).  
Cancer stem cells (CSC) have been recently identified in breast, colon and pancreatic 
cancer. This minority population of cancer cells have the ability to self-renew and give 
rise to differentiated tumour cells. Evidence suggests that cells that undergo EMT 
acquire stem cell-like properties (Morel et al., 2008). HMLE cells, an immortalised 
human mammary epithelial cells induced to undergo EMT by ectopic expression of 
Twist or Snail have been shown to have up-regulated mesenchymal markers (N-
cadherin, vimentin, fibronectin) as well as exhibiting many characteristics of CSC; a 
CD44 
high
/ CD24
low 
phenotype, the ability to self-renewal and the capacity to form 
mammopsheres (Mani et al., 2008, Iwatsuki et al., 2010). The human mammary tumour 
progression model (HMEC) has been used to demonstrate that activation of the 
Ras/MAPK pathway can generate CSC from non-tumourigenic mammary epithelial 
cells; a process which is accelerated by EMT induction. These findings imply that EMT 
may play a role in cancer stem cell development. 
 
1.4v Therapies Targeting EMT. 
 
A consequence of reducing EMT could be the decrease in the occurrence of anticancer 
drug resistance and subsequent improved efficacy to conventional chemotherapy. The 
development of anti-EMT targeted therapy is problematic as the inducers of the EMT 
process are transcription factors and thus difficult to target. The new techniques of RNA 
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interference and microRNA have been adopted. The silencing of Snail by shRNA 
reversed EMT and reduced tumour growth, in vivo (Olmeda et al., 2007). As discussed 
previously, miR-200C has been shown to reverse EMT instigated chemotherapy 
resistance (Cochrane et al., 2009). However, further development is required in order to 
increase reagent stability, improve efficiency of cell targeting and intracellular delivery. 
In addition, agents originally developed as inhibitors to cell proliferation and/or 
angiogenesis, such as small-molecule inhibitors or antibodies directed against EGFR, 
IGFR, PDGFR, cMET and TGFβR, may prove to also interfere with the EMT process 
(Chu et al., 2008). 
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Chapter 1: Literature Review  
 
ANGIOGENESIS AND ANTI-ANGIOGENIC THERAPY  
 
1.5  Introduction 
 
During embryogenesis the first system to develop and reach a functional state is the 
cardiovascular system (Chung and Ferrara, 2011), highlighting the essential role the 
vasculature has in embryonic development. Vasculature development is controlled by 
genetic and epigenetic mechanisms, molecular cues and cell behaviour both temporally 
and spatially (Adams and Alitalo, 2007). A functional vasculature is fundamental for 
tissue growth; ensuring a continuous and consistent supply of the essentials for life, 
oxygen and nutrients, whilst removing harmful bi-products. It is also crucial in the 
maintenance of homeostasis, transport of endocrine hormones and the immune 
response. 
Although, the vasculature was initially described in the 17
th
 century, only the last 40 
years has seen an intensification of interest by researchers. Numerous experimental 
procedures, in vivo and in vitro, have been specifically developed to increase our 
understanding of how blood vessels are formed from endothelial and mural cells. 
Copious publications have provided valuable insights into the key mechanisms and 
molecular factors which control blood vessel growth; a process which is termed 
angiogenesis (in adults). It is now appreciated that the strict regulation of angiogenesis 
is due to dynamic balance between pro-angiogenic and anti-angiogenic factors. A 
consequence of an imbalance in expression of these factors is either uncontrolled or 
inadequate angiogenesis. 
Deficiencies in the process of angiogenesis are associated with an ever growing list of 
disorders (over 70 at present); often described as a “disease common denominator”. The 
most reported illnesses for which angiogenesis is aberrantly switched on is cancer, 
ocular and inflammatory disorders, but many additional conditions are affected such as 
obesity, asthma, diabetes, cirrhosis, multiple sclerosis, endometriosis, AIDS and 
autoimmune disease (Mauriz and  Ganzolez-Gallego, 2008). Conditions characterised 
by insufficient angiogenesis include ischaemic heart disease, preeclampsia, stroke and 
non-healing wounds (Carmeliet, 2005). (Table 1.7a). It is predicted that worldwide over 
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500 million people would benefit from angiogenic therapeutic strategies (Carmeliet and 
Jain, 2011, Herbert and Stainer, 2011) (Table1.7b). 
A seminal publication in 1971, by Judah Folkman linked the progression of cancer to 
the ability of a tumour to express pro-angiogenic factors which stimulated the formation 
of its own vasculature. The establishment of an efficient blood supply is essential for 
tumour growth and subsequent expansion via metastatic spread through the circulation 
to other sites. A tumours acquisition of an angiogenic phenotype occurs early in 
development and is a rate-limiting step of tumour progression (Hanahan et al., 1996) 
Subsequently, Folkman proposed that the inhibition of tumour blood vessel formation 
would be an effective and but selective way to treat cancer (Folkman, 1971). Although, 
Folkman was initially derided for his theory anti-angiogenic therapy has now become a 
hothouse of research bringing together scientists, oncologists, chemists and the 
pharmaceutical industry (Table 1.8).  
 
 
Table 1.7a: A list of conditions regularly described as having a faulty angiogenic 
switch. 
 
Excessive Angiogenesis Insufficient Angiogenesis 
Age-related macular regeneration Chronic non-healing wounds 
Cancer Coronary artery disease 
Diabetic blindness Preeclampsia 
Psoriasis Stroke 
Rheumatoid arthritis  
 
Table 1.7b: A list of diseases which could be treated with anti-angiogenic therapy. 
 
Disease 
Cancer 
Atherosclerotic plaques 
Benign prostatic hypertrophy 
Crohn’s Disease 
Diabetic retinopathy 
Endometriosis 
Psoriasis 
Rheumatoid arthritis 
Uterine fibroids 
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Table 1.8: A list of the seminal papers which have increased our understanding of angiogenesis and the therapeutic potential of anti-
angiogenic therapies. 
 
Date Author(s) Paper Title Journal Contents 
1907 E. Goldman. The growth of malignant disease in 
man and the lower animals with 
special reference to the vascular 
system.  
Lancet, ii, 1236-1240. First description of tumour vasculature. 
1932 E.R. Clark, 
E.L. Clark 
Observations on living blood vessels 
as seen in a transparent chamber 
inserted into the rabbit ear. 
American Journal of 
Anatomy, 49, 441-447 
Placed glass chambers in the rabbit ear  in order to draw the 
branching patterns of blood vessels that entered the wound. Their 
work established the field of vascular biology. 
1939 A.G. Ide,  
N.H. Baker,  
S.L. Warren 
Vascularisation of the Brown Pearce 
rabbit epithelioma transplant as seen 
in the transparent ear chamber. 
American Journal of 
Roentgenology, 42, 891-
899 
Observed that tumour growth was accompanied by infiltration of 
newly formed blood vessels in a rabbit tumour model. 
1945 G.H. Algire, 
H.W.Chalkey, 
F.Y. Legallais, 
H.D. Park 
Vascular reactions of normal and 
malignant tumours in vivo. Vascular 
reactions of mice to wounds and to 
normal and neoplastic transplants. 
Journal of National 
Cancer Institute, 6, 73-85 
Description of blood vessels migrating towards tumours in wound 
chambers. First demonstration that tumours actively attract new 
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1.5i Tumour Angiogenesis 
 
New blood vessels can be formed either spontaneously via vasculogenesis or from pre-
existing vasculature by the process of angiogenesis or intussusception. Blood vessel 
formation can also be classified according to whether the vessels are formed during 
embryogenesis, (vasculogenesis), during a physiological process (regulated / normal 
angiogenesis) or during a disease process (pathological or dysregulated angiogenesis) 
(Herbert and Stainer, 2011, Claesson-Welsh, 2012).  
Embryonic vasculogenesis refers to the formation of primitive vessels within both the 
embryo and its amniotic membranes. Newly formed angioblasts aggregate into a 
primitive vascular plexus which then undergoes a complex remodelling process 
resulting in the formation of a functional vasculature (Chung and Ferrara, 2011). 
Intussusception is when a pre-existing vessels splits creating two vessels (Burri et al., 
2004). 
Normal angiogenesis is a strictly controlled event. In the adult, most pre-existing 
vasculature is considered to be in a quiescent state with angiogenesis only normally 
occurring during the female reproductive cycle, bone morphogenesis and wound healing 
and repair (Carmeliet, 2003). However, the endothelial cells still retain the ability to 
respond to an angiogenic stimulus, such as an injury or hypoxia (Carmeliet, 2005). It is 
the retained responsiveness of endothelial cells which is hijacked during pathological 
angiogenesis. 
The process of angiogenesis consists of a highly coordinated series of linked, sequential 
steps. Endothelial cells undergo an ordered series of events, which include activation, 
proliferation, migration, alignment, tube formation, branching and anastomosis (Mauriz 
and Gonzalez- Gallego, 2008) (Table 1.9). Under normal physiological conditions 
angiogenesis is controlled by the balance in production of pro- angiogenic and anti- 
angiogenic factors; at present over 30 have been identified (Table 1.10). Pathological 
angiogenesis shares many processes with physiological angiogenesis, however the 
major difference is that pathological angiogenesis does not reach resolution upon 
establishment of vascular perfusion. The angiogenic cascade is persistent and 
unresolved, driven by the pathological condition (Chung & Ferrara, 2010). 
As Folkman described, pathological angiogenesis occurs in tumours whereby an 
avascular tumour converts to an angiogenic phenotype (Hanahan & Folkman, 1996). 
This has been termed as the “angiogenic switch” and represents a distinct step in the 
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multistep pathogenesis of cancer (Hanahan et al., 1996, Hanahan and Weinberg 2000). 
Tumour angiogenesis is fuelled by the relentless uncontrolled production of angiogenic 
stimulators, in excess of inhibitors, which tips the balance in favour of hyperactive 
vessel growth (DeBock et al., 2011). The establishment of tumour vasculature is 
essential to enable tumour growth and metastasis (Mauriz and Gonzalez- Gallego, 
2008). 
The trigger for tumour angiogenesis appears to be tumour size (Folkman, 1973, 1990). 
Similar to what occurs during embryogenesis; the tumour grows to a size beyond which 
the passive diffusion of oxygen, nutrients, and metabolic waste is ineffectual. The 
hypoxic environment created within the tumour appears to, in addition to oncogenic 
events (glucose deprivation, oxidative and mechanical stress), be responsible for 
promoting angiogenesis (Dayan et al., 2008, Longo et al., 2002). The heterodimeric 
transcription factors, hypoxic inducible factors (HIFs) initiate the process by inducing 
the expression of pro-angiogenic mediators, especially VEGF-A. HIFs are composed of 
two subunits, α and β. It is the α subunit which is regulated by oxygen levels, which 
under normal conditions are present at low levels due to regulation by the tumour 
suppressor von Hippel-Lindau (VHL) (Longo et al., 2002, Chung & Ferrara, 2011). 
Mutations in VHL have been described in renal cell carcinoma, increasing the stability 
of HIF-1α and thereby promoting angiogenesis (Pugh & Ratcliffe, 2003). It would 
appear that the pro-angiogenic phenotype of a tumour is due to a combination of 
oncogene activation and loss of tumour suppressor function, preceding the activation of 
growth factor signalling (Liao & Johnson, 2007). It is these mutations which enable 
angiogenesis to give the tumour a selective development advantage. 
Vascular endothelial growth factor A (VEGFA) overexpression appears to be crucial in 
most tumour angiogenesis. Many tumour cells overexpress VEGFA and its major 
receptor, VEGFR-2, is highly expressed by endothelial cells engaged in tumour 
angiogenesis (Kerbel, 2008). VEGFA levels are also enhanced by secretion by tumour 
stromal cells such as fibroblasts, monocytes and platelets (Kut et al., 2007). VEGFA is 
the prototypic member of a gene family that also includes VEGFB, VEGFC, VEGFD 
and placenta growth factor (PIGF) (Ferrrara, 2004). Numerous effects have been 
attributed to VEGF signalling including endothelial migration, proliferation, survival 
and gene expression. It affects vascular permeability by inducing pores and 
fenestrations in the endothelium. VEGF is also responsible for the recruitment of bone-
marrow derived progenitor endothelial cells and can induce their differentiation; the 
differentiation of haemopoietic lineages and dendritic cells can be influenced by VEGF 
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(McMahon, 2000). FGF, PDGF and PIGF have also been implicated in angiogenesis. 
(Table1.11). 
Tumour angiogenesis is perpetuated by the recruitment of other cell types to add to the 
relentless production of pro-angiogenic factors. Tumour associated fibroblasts (TAFs) 
secrete proangiogenic factors such as VEGF and FGF and aid in the recruitment of 
bone-marrow derived endothelial progenitors by release of stromal-cell-derived factor-
1α (SDF-1α) (Chung & Ferrara, 2011, Orimo et al., 2005). The recruitment of mature 
myeloid cells, such as neutrophils, has been reported in various cancers including 
gastric, colon and bronchioalevolar carcinoma and correlates with a poor prognosis 
(Tazzyman, 2009). They are attracted to the tumour by the production of G-CSF and 
CXCL chemokines (CXCL8 and CXCL6), which bind to and activate their CXCR1 and 
CXCR2 receptors. Neutrophils are responsible for the majority of MMPs present within 
the tumour (Coussens et al., 2000). The MMPs mediate the release of proangiogenic 
factors from the surrounding ECM (Pahler et al., 2008).  
As in physiological angiogenesis, immune cells are recruited due to release of tumour 
derived chemoattractants (PIGF, VEGF, CSF-1) including monocytes, dendritic cells 
and lymphocytes. The extent of macrophage infiltration into a tumour has been shown 
to correlate with increased vascular density and poor prognosis (Bingle et al., 2002). 
Macrophage recruitment appears to amplify angiogeneisis due to cooperation with 
tumour cells in mediating HIF-1α transcription of proangiogenic factors VEGF-A, 
bFGF, and CXCL8 (Chung and Ferrara, 2011). 
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Table 1.9: The key steps in angiogenesis.  
 
 
1. Production of pro-angiogenic factors, by either injured tissues or tumour, diffuse 
into nearby tissues. VEGF is the most common of at least 6 pro-angiogenic 
proteins (PDGF, bFGF). 
2. Specific receptors on endothelial cells of pre-existing vessels bind the pro-
angiogenic factors stimulating an intracellular signalling process. 
3. Intracellular signalling activates the endothelial cells into the production of new 
molecules and enzymes.  
4.  Degradative enzymes, such as MMPs, dissolve tiny holes in the blood vessel’s 
basement membrane.  
5. Endothelial cell proliferation.  
6. Directional migration of the endothelial cells towards the injured tissue or 
tumour. Adhesion molecules, integrins (αvβ3, αvβ5) serve as grappling hooks to 
help pull the sprouting new blood vessel sprout forward 
7. ECM remodelling by MMPs. Tissue in front of the sprouting vessel tip is 
dissolved to accommodate the extending vessels whilst tissue is remolded 
around it. 
8. Tube formation. Sprouting endothelial cells roll up to form the characteristic 
blood vessel tube structure. 
9. Loop formation. Blood vessel tubes connect to form blood vessel loops that are 
capable of circulating blood. 
10. Vascular stabilisation and maturation. Vessels are covered by pericytes which 
provide perivascular support. 
11. Blood flow begins. 
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Table 1.10: Regulators of Angiogenesis 
Angiogenic Stimulators Angiogenic Inhibitors 
Angiogenin Angioarrestin 
Angiopoietin-1 (Ang-1) Angiostatin (plasminogen fragment) 
Del-1 Angiopoietin-2 (Ang-2) 
Epidermal growth factor Antiangiogenic antithrombin III 
Endothelial growth factor (EGF) Cartilage-derived inhibitor (CDI) 
Fibroblast Growth Factors: acidic (aFGF) 
and basic (bFGF) 
CD59 complement fragment 
Follistatin Endostatin ( collagen XVIII fragment) 
Granulocyte colony-stimulating factor 
(G-CSF) 
Fibronectin fragment  
Hepatocyte growth factor (HGF)/ Scatter 
factor (SF) 
Gro-beta 
Interleukin-8 (IL-8/ CXCL8) heparinases 
Leptin Heparin hexasaccharide fragment 
Midkine Human chorionic gonadotropin (hCG) 
Placental growth factor (PIGF) Interferon alpha/ beta/ gamma 
Platelet-derived endothelial cell growth 
factor (PD-ECGF) 
Interleukin-12 
Platelet- derived growth factor-BB 
(PDGF-BB) 
Kringle 5 (plasminogen fragment) 
Pleiotrophin Metalloproteinase inhibitors (TIMPS) 
Progranulin 2- Methoxyestradiol 
Proliferin Placental ribonuclease inhibitor 
Transforming growth factor- alpha (TGF-
α) 
Plasminogen activator inhibitor 
Transforming growth factor- beta (TGF-
β) 
Platelet factor-4 
Tumour necrosis factor- alpha (TNF-α) Prolactin 16kD fragment 
Vascular endothelial growth factor 
Family (VEGFA/B/C/D)/ Vascular 
permeability factor (VPF) 
Proliferin- related protein (PRP) 
 Retinoids 
 Tetrahydrocortisol-S 
 Thrombospondin-1 (TSP-1) 
 Tissue inhibitor of metalloproteinase 
(TIMP) 1, 2, 3 
 Transforming growth factor –beta (TGF-
β) 
 Vasculostatin 
 Vasostatin (calreticulin fragment) 
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Table 1.11: Key pro-angiogenic growth factors 
 
Factor Ligands Receptors Signalling Pathways Effects 
Vascular Endothelial 
Growth Factor 
(VEGF)/  
Vascular Permeability 
Factor (VPF) 
5 structurally related:  
VEGFA, VEGFB, 
VEGFC, VEGFD and 
Placental growth factor 
(PIGF) 
3 related receptor tyrosine 
kinases composed of a 
extracellular domain with seven 
Ig-like folds and a short kinase 
insert: 
VEGFR1- binds VEGFA,    
                 VEGFB, PIGF 
               - expressed in    
                 monocytes,  
                 macrophages 
VEGFR2- binds VEGFA,  
                  VEGFC, VEGFD  
               - expressed vasculature  
                 endothelial cells 
VEGFR3- binds VEGFC,  
                  VEGFD 
                - expressed lymphatic  
                  endothelial cells 
 
VEGF co-receptors: 
Heparin sulphate proteoglycans/ 
heparin 
Neuropilins 
Integrins 
 
Ras- mitogen activated 
protein kinase (MAPK), 
Phosphoinositol-3-kinase 
(PI3K), 
Phospholipase C (PLC), 
Rho-GTPase 
Endothelial migration, 
proliferation, survival 
and gene expression, 
vascular permeability, 
ECM degradation. 
 
 
 
Normal expression: 
Embryonic development, 
wound healing, female 
reproductive cycle, after 
exercise. 
Fibroblast Growth 
Factor (FGF) 
FGF family comprises 22 
proteins (FGF1-23). 
4 receptor tyrosine kinases 
composed of three extracellular 
Ras- mitogen activated 
protein kinase (MAPK), 
Endothelial cell 
proliferation, migration 
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7 sub families based on 
sequence comparisons. 
Ig-like loops, a transmembrane 
domain and a split tyrosine 
kinase domain 
 
FGF co- receptors: 
Heparin sulphate proteoglycans/ 
heparin 
Neuropilins 
 
Extracellular Signal-
regulated kinase (ERKs), 
Src,  
p38 MAPKs,  
Phospholipase-C-Gamma 
(PLC-gamma), Protein 
Kinase-C (PKC-C), Jun 
N-terminal kinase (JNK). 
and production of 
proteases. 
 
Normal expression: 
Wound healing, 
especially tissue 
remodelling. Embryonic 
development. 
Platelet- derived 
Growth Factor 
(PDGF) 
5 dimeric isoforms, 
assembled from 
polypeptide chains denoted 
A, B, C and D: 
PDGF-AA, PDGF-BB, 
PDGF-AB,  
PDGF-CC, PDGF-DD 
(only A and B forms 
secreted as active forms) 
2 structurally highly related 
receptor tyrosine kinases, with 5 
extracellular Ig-like loops and a 
split tyrosine kinase domain. 
Both expressed on mesenchymal 
cells 
PDGFRa  
PDGFRb 
 
PDGF co-receptors: 
Heparin sulphate proteoglycans/ 
heparin 
Integrins 
Ras- mitogen activated 
protein kinase (MAPK), 
Phospholipase-C-Gamma 
(PLC-gamma), Protein 
Kinase-C (PKC-C), 
Phosphoinositol-3-kinase 
(PI3K), 
Pericyte coverage of 
endothelial cells- vessel 
maturation. Interstitial 
pressure regulation. 
 
 
 
Normal expression: 
Wound healing, regulates 
interstitial pressure. 
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1.5ii Tumour Vasculature 
 
Tumours are similar to normal tissues in regards to requiring a proficient blood supply 
to deliver oxygen and nutrients, whilst removing harmful bi-products. Early researchers, 
pre-1960, presumed that a tumour simply received its blood supply from the dilation of 
neighbouring pre-existing vessels. Subsequently, it was discovered that a tumour 
requires development of its own vasculature if it is to grow beyond 1-2mm in size 
(Folkman, 1973).  
Normal vasculature is characterised by a distinct hierarchical organisation (arteries, 
capillaries and veins) which ensures tissues are efficiently perfused with a continual 
flow of blood (Herbert and Stainer, 2011). The endothelial cells form an uninterrupted 
lining of the vessels, with tight junctions between individual cells. Endothelial cells also 
deposit a basement membrane composed of fibronectin, collagen IV, laminins and 
heparan sulphate proteoglycans (Sottile, 2004). Specialised mesenchymal cells, 
pericytes, surround and support the vessels.  Thus, vessel permeability is highly 
regulated creating a healthy tissue environment. However, in tumours the uncontrolled 
and persistent release of pro-angiogenic factors results in an imbalance, with the 
angiogenic switch turned in favour of hyperactive vessel growth. Consequently tumour 
vasculature is abnormal in both structure and function (Wu and Li, 2008, Claesson- 
Welsh, 2012) (Table1.12).  
Tumour vessels are routinely described as mal-shaped, irregular and disorganised with a 
tortuous architecture. The normal organisation does not exist, although attempts have 
been made to classify the vessels (Eberhard et al., 2000, Hanahan and Weinberg, 2000) 
(Table1.13).  The vessels are highly dysfunctional, exhibiting spatiotemporal 
heterogeneity. The irregular shape of endothelial cells results in a loss of the normal 
vessel lining; tumour endothelial cells will stack on top of each other causing 
protrusions which obstruct blood flow through the vessel (DeBock et al., 2011). 
Connections between endothelial cells are often loose due to wider junctions and lack of 
perivascular support owing to coverage by fewer and abnormal pericytes (Mauriz and 
Gonzalez-Gallego, 2008). Gaps also form in the endothelium where the endothelial cells 
have either died or migrated away. This results in poor inconsistent blood flow and a 
leaky endothelium. 
Many of the abnormalities including tortuosity, fragility, lack of pericytes and 
propensity for bleeding and exudation are attributed to an abundant expression of 
VEGFA (Nagy et al., 2207). A consequence of a leaky endothelium and poor 
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inconsistent blood flow is a rise in interstitial pressure (Claesson-Welsh, 2012). A 
unique, feature of tumour vasculature is the de-differentiation program of tumour cells 
called vasculogenic mimicry; whereby the tumour cells actually line the blood vessels 
instead of endothelial cells (Hendrix et al., 2003).  
Tumour angiogenesis is frequently described as non-productive due the resultant 
vasculature being dysfunctional. The lack of adequate perfusion of the tumour creates 
an adverse hypoxic and acidic environment which promotes a pro-malignant 
programming of the tumour cells, leading to disease progression (Rapisarda and 
Melillo, 2009, Lunt et al., 2009, DeBock et al., 2011). This also affects the efficiency of 
how anti-tumoural chemo-therapeutics can be administered. Metastasis is aided by the 
leaky vessels; allowing tumour cells to escape into the blood stream and subsequent 
distribution throughout the body where they can seed forming secondary tumours.  
Therefore, the tumour vasculature promotes tumour invasiveness, dissemination and 
overall malignancy (DeBock et al., 2011). 
 
Table 1.12: The differences between normal and tumour vasculature. 
 
 
 
 
 
 
 
 
• Disorganised 
• Undefined vessels 
• Unevenly distributed 
• Tortuous routes 
• Obstructed and/ or restricted flow 
• Dilated 
• Highly permeable 
• Premature and lack pericytes 
• Lack basement membrane 
• Well organised 
• Defined arterioles and venules 
• Non - dilated 
• Non - permeable 
• Mature and coated with pericytes. 
• Low interstitial pressure 
• Complete basement membrane 
• Normal rate of blood flow. 
Tumour Vasculature Normal Vasculature 
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Table 1.13: The classification of tumour vasculature. 
 
Name Features 
Capillaries Similar to normal capillaries. 
Feeder Arteries (FA) Greatly enlarged, tortuous pericyte coated 
vessels that supply the complex of tumour 
blood vessels. 
Draining Veins (DV) Enlarged and tortuous vessels that drain 
blood away from tumour. 
Mother Vessel (MV) Greatly enlarged, tortuous, thin walled, 
immature in regards to pericyte coating, 
hyperpermeable. 
Glomeruloid Microvascular 
Proliferations (GMP) 
Tangles of tiny vessels immersed in a 
complex mixture of irregularly ordered 
pericytes and extensive multilayered 
basement membrane. 
Vascular Malformations (MV) Large vessels with irregular coating of 
pericytes. 
 
 
 
1.5iii The First Generation of Anti- Angiogenic Agents 
 
It has been over 40 years since Folkman first published the theory of stopping tumour 
growth and metastasis by a therapy aimed at interfering with tumour angiogenesis. Anti-
angiogenic therapy has since been described as having the potential to become the 
“fourth modality for cancer treatment”, joining surgery, chemotherapy and radiotherapy 
(Abdollahi et al., 2005). Over 60 anti-angiogenic agents have been evaluated in the 
clinical trial process. In 2004 the first FDA approval was given to a drug solely 
developed as an angiogenesis inhibitor; Bevacizumab (Avastin, Genentech) for the 
treatment of advanced colorectal cancer. The process of the discovery and development 
of any new drug is a long, costly, complicated process. Success is preceded by many 
failures.  
In order to develop anti-angiogenic treatments specific assays were required to identify 
and characterise potential agents. After purification, preliminary evaluation of an angio-
suppressive effect is performed using in vitro assays of cultured endothelial cells on a 
gelatinised surface; testing the pharmacodynamics effects of the agent on endothelial 
growth, proliferation, migration, invasiveness and tube formation. Human capillary 
endothelial cells are considered to be more representative of tumour endothelia than 
cells extracted from the larger blood vessels (Folkman et al., 1979, Longo et al., 2002).  
The nest stage is to define the agents’ pharmacokinetic parameters, for example mode of 
administration and dosing strategy. Numerous in vivo angiogenesis assays allow the 
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direct effect of the agent to be tested. Matrigel assays are the simplest, where the agent’s 
response to specific angiogenic stimuli can be quantified histologically. Chick 
chorioallantoic membrane (CAM) is a semi-quantative assay whereby tumours are 
implanted onto the CAM and the agent is assessed by its ability to inhibit the growth of 
capillaries (Auerbach et al., 1974). Corneal neovascularistaion assay permits to the 
direct visualisation of the agents’ effect on both new vessels and pre-existing 
vasculature in cornea of experimental animals. Orthotopically transplanted human 
tumours in nude mice is routinely the model of choice, as not only can the agents effect 
on inhibiting neovascularisation on tumour growth be measured but the systemic impact 
can be monitored via serum and urine testing (Longo et al., 2002).  
After vigorous testing, an application is then made to undertake human clinical trials. 
The three phases of trails are designed to provide the highest level of confidence in the 
validity of the results. The initial Phase I human testing, is performed on a small group 
of healthy volunteers upon which the drugs’ safety and dosing range is evaluated: 
pharmacokinetics factors assessed include absorption, metabolism and elimination of 
the agent whilst pharmacodynamic tests screen for side effects. Phase II evaluates the 
effectiveness of the agent in a small group of patients (100-500) with the disease / 
condition under study; optimising dosage and treatment schedules, assessing short-term 
effects and the drugs’ mechanism of action. Phase III is the longest and most expensive, 
often involving multi-centre, global contributors. A large group of patients (1000-5000) 
are tested in order to generate statistically significant data about safety, efficacy and the 
overall benefit/risk relationship of the agent. Patients are randomly assigned to either 
receive the test drug or standard treatment. Finally, the FDA reviews all the data 
collected, determining if the agent has any clinical benefit and whether to approve it for 
treatment. The whole process from initial discovery to FDA approval can take up to 
15years and cost millions (Longo et al., 2002, DiMasi et al., 2003). 
Compared to conventional therapy, anti-angiogenic treatments were considered to have 
many advantages. Homogenous and diploid the endothelial cells were seen as 
genetically stable uniform target, where spontaneous mutations were thought to rarely 
occur (Rak and Kerbel, 1996). Unlike the heterogenetic tumour cells which displayed 
high genetic instability and mutation rates; characteristics which promote the selection 
subpopulations with acquired resistance to anti- tumoural drugs.  By nature of their 
active proliferation and migratory activity the tumour endothelial cells could be 
selectively targeted, as opposed to the quiescent normal endothelia (Longo et al., 2002). 
Also, endothelial cells are easily accessible via the blood; allowing systemic 
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administration of drugs thereby avoiding the difficulties of low penetration experienced 
with anti-tumoral drugs in solid tumours. In addition, a tumour’s vasculature will 
support the growth of numerous and various different populations of tumour cells, by 
targeting the vasculature it would subsequently affect the survival of many tumour cells 
(Mauriz et al., 2005, Mauriz-Gonzalez-Gallego, 2008). Finally, some anti-angiogenic 
drugs also have synergistic effects when combined with cytotoxic drugs and radiation 
therapy (Kakeji and Teicher, 1997). 
There are many ways in which anti- angiogenic agents can be classified and at present 
there is not a universally agreed approach. For ease of discussion the first generation of 
anti- angiogenic agents, which were developed to specifically target the tumour 
vasculature endothelium, will be reviewed first. Tumour endothelial inhibitors fall into 
three categories; firstly those  which target the endothelial cells directly by stopping 
proliferation, secondly those which block the ability of endothelial cells to migrate 
through inhibiting MMPs and adhesion molecules and finally those which  inhibit the 
angiogenic signalling cascade by interfering with either angiogenic factors or their 
receptors. In a subsequent section, the next generation of anti-angiogenic treatments will 
be discussed.  
 
Blocking the Endothelial Cells Directly. 
According to the angiogenic switch hypothesis, tumours secrete both stimulators and 
inhibitors of angiogenesis and it is the altered balance of production which results in an 
excess of stimulators compared to inhibitors. Hence, tumours express an angiogenic 
phenotype. Two of the most researched endogenous angiogenic inhibitors were 
discovered in Folkman’s laboratory by his colleague Michael O’Reilly: angiostatin 
(1994) and endostatin (1997). Other endogenous inhibitors include angiogenin (Fett et 
al., 1985), thrombospondin-1 (Nicosia and Tuszynski, 1994), interferons (Dinney et al., 
1998), platelet factor-4 (Nicosia et al., 1994) and 16kDa prolactin (Hanahan and 
Folkman, 1996). 
Originally isolated from tumour bearing mice, Angiostatin is a 38kDa amino-terminal 
fragment of plasminogen which is produced in the tumour stroma (O’Reilly, 1997).  
Angiostatin inhibits endothelial proliferation by down-regulating the protein level of 
cyclin-dependent kinase 5 (cdk5), a cdk absent in quiescent cells but induced by pro-
angiogenic factors. It can also act by upregulating of the mRNA level of FasL and 
reducing the level of c-Flip which activates the extrinsic apoptotic pathway (Mauriz and 
Gonzalez-Gallego, 2008). Other effects include inhibiting endothelial cell migration, 
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tube formation and vessel network formation and primary metastasis in mouse models 
(Miriam et al., 2004). Elevated angiostatin levels have been observed in the serum, 
urine and ascites fluid of cancer patients (Cao et al., 2000, Yokoyama et al., 2000).  
Endostatin was isolated from a hemangioendothelioma cell line and is a naturally 
occurring 20kDa C terminal fragment derived from type XVIII collagen. It is a member 
of multiplexin family which are characterised by multiple triple-helix domains and 
interruptions (Abdollahi et al., 2005). Of the endogenous angiogenesis inhibitors, 
Endostatin has the broadest anti-cancer spectrum; targeting angiogenesis regulatory 
gene on more than 12% of the human genome (Folkman, 2006). It interferes with 
endothelial proliferation by numerous mechanisms; reducing mRNA level of several 
proliferative genes including MAPK1, MAPK2 or c-myc, disturbing the survival/death 
balance by inhibiting the anti-apoptotic signal induced by the P13K/PKB pathway and 
alternatively activating pro-apoptotic pathways through induction ofcaspase-9 by 
reducing the level of anti-apoptotic proteins Bcl-2, Bcl-XL and Bad (Mauriz and 
Gonzalez-Gallego, 2008). 
Using recombinant proteins, the efficacy of angiostatin and endostatin has been 
demonstrated in many animal model studies, on a wide selection of solid tumour types 
(O’Reilly et al., 1997). However, this has not translated to clinical trials. A notable 
feature of the Endostatin Phase I trials was the complete absence of drug-related toxic 
effects,  but unfortunately  there was  limited efficacy in humans compared to the mice 
models; there was a 50 fold difference in proliferation rates between tumour tissue and 
normal endothelium in mice whilst human studies indicated only a 10 fold difference 
(Rubin, 1998). Although requiring prolonged administration, a similar result was gained 
using Angiostatin (Dell’Eva et al., 2002). Lack of acquired resistance was also a feature 
of mouse models studies (Boehm et al., 1997). However, problems with purity, 
stability, storage and handling plus the lack of critical folding of the recombinant 
protein(s) appeared to be responsible for the lack of clinical success (Marshall 2002).  
However, Chinese researchers developed a novel recombinant form of endostatin, 
Endostar, expressed and purified in E.Coli with an additional nine amino-acid sequence 
added to the N- terminal which forms a six-histidine tag (Ling et al., 2007). In 2005, the 
Chinese FDA approved Endostar for treatment of Non-small-cell lung cancer (NSCLC); 
further trails in lung, breast, pancreas and colorectal cancer are being undertaken 
(cancertherapychina.com). The use of gene therapy also has the potential to produce the 
either/both angiostatin and endostatin, at high concentrations for a prolonged period in a 
specific area (Dell’Eva et al., 2002). 
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The inhibition of endothelial cell proliferation was the first experimental strategy for the 
screening of new anti-angiogenic drugs. The first angiogenic inhibitor to be clinically 
tested was Fumagillin (although initially described as antimicrobial agent). Isolated 
from the mould Aspergillus fumigatus Fresenius it has a potent endothelial cytostatic 
activity by inhibiting the enzymatic activity of methionine aminopeptidase-2 (MetAP-2) 
(Lien et al., 2004). Unfortunately severe side effects impeded progress but in 
collaboration with Takeda Chem Industries, Folkman developed fumagillin analogues 
as a novel class of anti-proliferative agents (Folkman, 1990). TNP-470 was reported to 
be fifty times more potent than fumagillin and was the first MetAP-2 inhibitor to enter 
clinical trials. TNP-470 inhibits angiogenesis due to endothelial cell cycle arrest late in 
G1 phase, it may also induce p53 pathway, thereby stimulating the production of cyclin-
dependent kinas e inhibitor p21 (Mauriz et al., 2007). Although, initially promising 
results in early Phase I/II studies, with tumour growth slowed in patients with metastatic 
cancer, the clinical testing was terminated due to dose-limiting toxicities and a poor 
clinical pharmacokinetic profile. The small size of the TNP-470 molecules was 
considered to be a reason for the neurotoxic effects. New analogues with a better 
toxicity profile, PP1-2458 (Praecis Pharma/ Glaxo Smith Kline), are now in Phase I 
trials (Bernier et al., 2005, Cooper et al., 2006, Lefkore et al., 2007). 
 
Blocking  Endothelial Cell Migration. 
MMP enzymes are one of the first products manufactured by growing endothelial cells. 
MMPs are a family of zinc-dependent neutral endopeptidases that proteolytically 
degrade various components of the ECM (Hidalgo et al., 2001). The family is 
subdivided according to their primary structure and substrate specificity; collagenases, 
gelatinases, matrilysins, membrane type MMP and stromelysins. The numerous MMPs 
exhibit several roles which enhance angiogenesis including releasing angiogenic factors 
bound to ECM, generating pro-migratory ECM component fragments, pericyte 
detachment of angiogenic vessels and the cleavage of endothelial cell- cell adhesions 
promoting endothelial cell migration (Rundhaug, 2005). MMPs are also essential in 
allowing tumour cells to gain access to the circulation via basement membrane 
breakdown thereby facilitating metastasis. Numerous studies have reported increased 
expression of MMPs in tumours. For example MMP-1 is overexpressed in breast, 
colorectal, gastric, ovarian and oesophageal cancers whilst MMP-2 is overexpressed in 
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melanoma and sarcoma metastatic models (Mauriz and Gonzalez-Gallego, 2008, 
Hofmann et al., 2000).  
TIMPs are endogenous MMP inhibitors which have anti-angiogenic activities. TIMPs 
1-4 have been shown to inhibit VEGF- induced endothelial migration as well as cell 
proliferation and tube formation (Jiang et al., 2002). Numerous synthetic MMP 
inhibitors have been developed; showing promising anti- angiogenic activity in vitro 
and in vivo pre-clinical models but so far having limited success in clinical trials (BMS-
275291, Marimastat, Tanomastat). The inhibitors are able to target numerous MMPs 
which may explain the reported adverse side effects. (Li et al., 2010) more specific 
inhibitors are in development; pre-clinical trials include monoclonal antibodies to MT1-
MMP and recombinant PEX domain to inhibit proMMP2 activation (Galvez et al., 
2001, Pfeifer et al., 2000). 
Endothelial cell migration is also dependent on integrins; cell adhesion molecules which 
allow endothelial cells to adhere to ECM proteins, such as vitronectin (Auerbach, 1994). 
Integrins are cell surface glycoproteins that are formed by α and β subunits. Angiogenic 
endothelial cells express different integrins compared to quiescent cells. αvβ3 and  αvβ5 
integrins are upregulated on the surface of activated endothelial cells. The fibronectin 
receptor α5β1 integrin is also selectively expressed (Erdreich-Epstein et al., 2000, Kim 
et al., 2000, Dunehoo et al., 2006). In various animal models, antagonists of αvβ3 such 
as the LM609 antibody have caused a decrease in angiogenesis and induced tumour 
regression. They appear to trigger apoptosis within the activated vessels (Brooks et al., 
1994). Vitaxin (Applied Molecular Evolution), a humanised version of LM609, also 
appears to induce apoptosis in newly generated endothelial cells and has undergone a 
promising Phase I study (Gutheil et al., 2000). 
 
Blocking the Angiogenic Signalling Cascade. 
Numerous proteins and molecules have been classified as being stimulators of 
angiogenesis but none have proven as essential as the VEGF family. The VEGF family 
(originally identified as vascular permeability factor (VPF)) consists of five structurally 
related ligands VEGFA, VEGFB, VEGFC, VEGFD and Placental growth factor 
(PIGF); which functionally differ in their ECM binding capacity (Ferrara, 1989). 
Secreted as a cysteine knot glycoprotein, VEGF is transcriptionally activated in 
epithelial, mesenchymal and tumour cells in response to hypoxia (Nieves et al., 2009). 
VEGF isoforms bind to principally two main receptor kinases (RTKs); VEGFR1 (Flt-1) 
and VEGFR2 (Flk-1) located on neighbouring endothelial cells. The VEGF receptors 
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display a similar organisation of an extracellular ligand binding domain, a 
juxtamembrane domain, a spilt tyrosine kinase domain and a C-terminal tail (Claesson-
Welsh, 2012).  The activation of VEGF receptors by VEGF-specific binding leads to 
homo-or hetero dimerisation of the receptor proteins thereby initiating a number of 
signalling pathways including Ras-mitogen activated protein kinase (MAPK), 
phosphoinositol-3-kinase (PI3K) and phospholipase C (PLC) gamma which promote 
endothelial migration, proliferation, permeability, ECM degradation, survival and gene 
expression. (Table1.11). 
VEGFA is often described as the master regulator of angiogenesis. Although not 
considered as a cancer biomarker, it is the most frequently expressed pro-angiogenic 
factor in the tumour microenvironment (Claesson-Welsh, 2012). Elevated expression 
levels of VEGF receptors are also common in tumour vasculature; a rat glioma model of 
tumour angiogenesis has been reported to have increased numbers of VEGFR1 and 
VEGFR2 (Plate et al., 1993). VEGF deletion and neutralisation studies in tumorigenic 
mice suggested that VEGF signalling was not required in the adult (Gerber et al., 1999, 
Kuo et al., 2001); apart from during wound healing responses, female reproductive 
cycle and following exercise (Maharaj and D’Amore, 2007). Thus targeting of VEGF 
and/or its receptors became a prime objective, as it was thought such treatments would 
spare healthy tissues from non-specific damage. Strategies to inhibit the VEGF 
signalling cascade are monoclonal antibodies against the VEGF protein or its receptors, 
VEGFR tyrosine kinase inhibitors (TKRIs), VEGF-R targeted ribozymes and VEGF 
decoy receptors. 
Monoclonal antibodies have the potential to modulate signalling pathways by either 
interacting with the growth factor thereby stopping binding to its receptor or directly 
with receptors themselves to prevent ligand binding. Initially, lack of suitable 
production methods hampered progress but the development of large-scale bioreactors 
helped to improve both the quality and quantity of the recombinant antibodies. Another, 
advancement was the humanisation of antibodies as previously antibodies were usually 
of murine origin. The insertion of human sequences to the antibody resulted in a longer-
life and less immunogenicity. 
In 1993 Kim et al., showed that a neutralising antibody against mouse VEGF (A.4.6.1) 
inhibited tumour growth and angiogenesis in mouse models. The positive results 
obtained led to the development of a humanised version of this antibody, bevcaizumab 
(Avastin, Genetech), which is considered to be one of the most successful compounds 
within the anti-angiogenic therapy field. The monoclonal antibody has the ability to 
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neutralise biologically active forms of VEGF which interact with VEGFR1 and 
VEGFR2 thereby repressing endothelial cell mitogenic activity and vascular 
permeability (Brekken et al., 2000). In 2004, bevacizumab was the first Food and Drug 
Administration (FDA) and European Medicines Agency (EMA) approved anti-
angiogenic treatment for cancer and subsequently experienced numerous successes in 
clinical trials in combination with chemotherapy (Hurwitz, 2004). Bevacizumab 
combined with specific chemotherapeutic agents was shown to improve patient survival 
time and have been FDA approved for the treatment of metastatic colorectal cancer, 
non-small cell lung cancer, metastatic breast cancer, renal cell carcinoma and 
glioblastoma multiforme (Kesisis et al., 2007, Norden et al., 2008, Ferrara, 2010). 
(Table 1.14). 
DC101, a rat anti-mouse Flk-1 monoclonal antibody against the extracellular domain of 
VEGFR2 blocked tumour growth in a variety of xenograft models, as well as hepatic 
metastasis derived from colon cancer (Bruns et al., 2000). A fully humanised version, 
ramucirumab (IMC-1121B, ImClone Systems) was developed, which has been shown 
in preclinical and animal models, to inhibit VEGF-induced VEGFR2 activation thereby 
inhibiting VEGF-stimulated cellular migration and proliferation. Ramucirumab is 
currently being investigated in multiple clinical trials involving a variety of tumour 
types (Spratilin, 2011). Tanibrumab (TTAC-0001, PharmAbcine) another anti-VEGFR2 
monoclonal antibody is undergoing preclinical assessment (Lee, 2011). Inhibition of 
VEGFR2 is a promising anti-angiogenic target since VEGFR2 expression has been 
shown to be up-regulated several fold in tumour vascular endothelial cells (Plate et al., 
1994, Spratillin, 2011). 
Over time, the tumour environment varies considerably leading to fluctuations in the 
levels of angiogenic factors thereby making drug dosing and optimum neutralisation of 
VEGF difficult. However, researchers believed the number of VEGF receptors in 
tumour endothelial cells was relatively low making them more easily saturable, as less 
antagonist molecules would be required in order to block all the receptors (Mauriz and 
Gonzalez- Gallego, 2008). Receptor tyrosine kinase inhibitors (RTKIs) block the 
intracellular activation of growth factor receptor signalling by competitive inhibition of 
ATP binding to the tyrosine domain and are smaller molecules compared to the large 
antibodies used to target growth factors. They are considered adept to suppress tumour 
growth as monotherapy because of an ability to inhibit multiple targets; VEGFR, 
PDGFR, EGFR, cKit, MAPK and other kinase pathways. The most advanced broad 
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spectrum tyrosine kinase inhibitors are Sunitinib (Sutent, Pfizer), Sorafenib (Nexavar, 
Bayer) and Pazopanib (Votrient, GSK). 
Sunitinib (sunitnib malate, SU11248, Sutent, Pfizer) is an orally bioavailable, oxindole, 
multi-targeted tyrosine kinase inhibitor of numerous receptors including VEGFR1-3, 
PDGFR α and β (Mauriz and Gonzalez- Gallego, 2008). Sunitnib was approved first for 
the treatment of metastatic or unresectable gastro-intestinal tumours in 2006. In 2009, 
NICE guidance led it to be the first line drug treatment for patients with advanced / 
metastatic renal cell carcinoma and in 2011 it was approved by the FDA for treatment 
of advanced refractory pancreatic neuroendocrine tumours. Currently, numerous 
Sunitinib trials are in progress for various cancers with and without the addition of 
chemotherapeutic agents (National Cancer Institute).  
The originality of Sorafenib (Nexavar/ Bayer) is its ability to simultaneously target the 
Raf/Mek/Erk pathways by inhibiting Raf kinase, PDGFR, VEGFR-2 and VEGFR-3 and 
c-Kit (Flaherty, 2007). In 2006 it was FDA and EU approved for the treatment of 
advanced refractory clear-cell renal- cell carcinoma, having been shown to increase 
progression free survival by approximately 3 months. Pazopanib (GW786034, GSK) is 
an orally available, inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR and c-kit 
(Mauriz and Gonzalez- Gallego, 2008). 
Another method of targeting receptor tyrosine kinases is the use of decoy receptors. 
Also described as a VEGF trap, the decoy receptors bind to VEGF thereby preventing it 
from binding to the native cell receptors therefore stopping any signalling cascade 
(Holash et al., 2002). The most established VEGF Trap is known as Afibercept or 
Zaltrap (Regeneron Pharmaceuticals/ Sanofi-Aventis); a fully human soluble VEGF 
receptor fusion protein with the ability to bind to VEGF-A, VEGF-B and PIGF more 
tightly than native receptors and any anti-angiogenic monoclonal antibody therapies 
(Konner and Dupont, 2004). Afibercept is a recombinant protein comprised of portions 
of the extracellular domain of human VEGFR-1 and VEGFR-2 fused to the constant 
region (Fc) of human IgG1.  It is currently awaiting results of a regulatory review 
having undergone a Phase III trial for the treatment of refractory, metastatic colorectal 
cancer (Konner and Dupont, 2004). In 2011 Afibercept was approved by the United 
States FDA as an anti-angiogenic treatment for wet macular degeneration (Stewart et 
al., 2012). 
Compared to the other anti-angiogenic drugs, ribozyme drugs use an entirely different 
mechanism to elicit an anti-angiogenic response. Instead of a obstructing the activity of 
the target protein, ribozyme drugs actually destroy the mRNA therefore stopping the 
54 
 
target protein from being synthesised in the first place. A ribozyme is a catalytic RNA 
molecule which has the capability to cut other RNA molecules into fragments, thereby 
by preventing translation into protein. Angiozyme (RPI.4610) (Ribozyme 
pharmaceuticals) was developed to recognise the conserved region of human, mouse 
and rat VEGFR-1 mRNA; one of the most important VEGF receptors. Angiozyme 
treatment has been shown in mouse models to have anti-angiogenic, anti-tumour and 
anti-metastatic activity (Weng and Usman, 2001). Phase I and II trials have been 
conducted as a mono-therapy and in conjunction with chemotherapy (Bergsland, 2004). 
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Table 1.14: Anti-VEGF Agents. FDA approved Bevacizumab (Genentech,Avastin) Treatments (Additional data from National Cancer 
Institute). Bevacizumab treatment combined with standard chemotherapeutic agents. 
 
Cancer type Chemotherapeutic  
Agent  
FDA 
Approval 
Trial Number Median Progression 
Free Survival  
(months) 
Side- effects 
Colorectal cancer 
(metastatic) 
5’fluorouracil/ 
irinotecan 
2004 ----- 3-4  GIT perforation, impaired wound 
healing, hypertension, fatigue, 
thrombosis, diarrhoea, infection, 
headaches. 
Non-small cell lung 
cancer 
(advanced, 
recurrent, 
metastatic) 
paclitaxel/ 
carboplatin 
2006 E4599 2  Neutropenia, fatigue, hypertension, 
infection, thrombosis/embolism, 
hypernatremia, proteinuria, GIT 
perforation 
Breast Cancer 
(metastatic) 
paclitaxel/ 
docetaxel 
2008 
Revoked 
2011 
Study 7/ E2100 No evidence for 
extended life or 
quality of life. 
Sensory neuropathy, hypertension, 
fatigue, infection, vomiting, diarrhoea, 
bone pain, headache, proteinuria, 
cerebrovascular ischemia 
Glioblastoma 
multiforme 
(recurrent) 
+/- Irinotecan 2009 AVF3708g/ NCI 
06-C-0064E 
3.9 - 4.2  Infection, fatigue, headaches, 
hypertension, epistaxis, diarrhoea 
Renal Cell 
Carcinoma 
(metastatic) 
Interferon α 2009 B017705 5  Hypertension, haemorrhage, thrombosis, 
proteinuria. 
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1.5iv Toxicity of Anti-angiogenic Therapy 
 
It was maybe a naive of the first researchers to underestimate the systemic effects anti-
angiogenic therapy would have. Initially, they believed that targeting angiogenesis 
would result in a selective and specific attack on the tumour vasculature since normal 
blood vessels were considered to be in a quiescent state. Normal angiogenesis was 
reported to only occur during the reproductive cycle, pregnancy and in response to 
injury during wound healing (Chung and Ferrara, 2011). In addition, first generation 
anti- angiogenic drugs were supposedly developed to inhibit only one pathway. 
However, the side effects reported in experimental models and clinical trials reinforce 
angiogenesis as a multifactorial process which is, through its diverse signalling 
pathways, associated with numerous processes including the regulation of blood 
pressure, coagulation cascade and immune system (Mauriz and Gonzalez-Gallego, 
2008). The role angiogenic factors have in vessel maintenance was also misjudged; 
VEGF functions in established vessels to promote endothelial cell survival and induce 
capillary fenestrations (Inai et al., 2004). In the adult, VEGFR2 phosphorylation occurs 
in many tissues suggesting that even in a supposed quiescent vasculature VEGF 
signalling is still required (Maharaj et al., 2006). 
Determining optimal dosing of anti-angiogenic drugs at biologically active levels has 
also been problematic. Initially the concept of “the more the better” was applied, with 
many drugs administered at fixed doses irrespective of body weight (Mauriz and 
Gonzalez-Gallego, 2008). In addition, treatment strategies often involve anti-angiogenic 
therapy in conjunction with traditional chemo- or radiotherapy, which have toxicity 
issues of their own. The reported toxicity of anti-angiogenic therapy, from both 
experimental models and clinical trials and an increased understanding of angiogenic 
signalling (VEGF especially) has subsequently led to a more cautious approach and 
reassessment of long-term treatment. Pregnant women and children are considered 
unsuitable for anti-VEGF treatment due to its numerous roles during development 
(Mitchell and Bryan, 2010). 
Reported side effects frequently include hypertension, proteinuria, thrombosis, impaired 
wound healing, bowel and nasal perforations and leuokencephaolpathy (Table 1.15). 
Although rarely life threatening and clinically manageable, their occurrence may require 
either an altered dosing strategy, a treatment “holiday” or in severe cases a cessation of 
therapy. In general, the clinical benefits of anti-angiogenic therapy are considered to 
out-weigh the adverse side effects (Mitchell and Bryan, 2010). 
57 
 
The most common side effect, experienced by 16-35% of all patients, is hypertension.  
Anti-hypertensive drugs are effective in resolving in the problem; the majority of 
patients on bevacizumab therapy will require anti- hypertensive medication in order to 
achieve a normal blood pressure (Ranpura et al., 2010). The anti-VEGF therapies 
appear to affect the renin-angiotensin system and subsequently aldosterone release; 
which regulate pressure via electrolyte (Na/ K) and blood volume balance and through 
modulation of nitric oxide regulated arterial smooth muscle relaxation and vasodilation 
(Mitchell and Bryan, 2010). A reduction in angiotensin receptor activity has been 
reported during VEGF inhibition (Sane et al., 2004). Complications with kidney 
function, including proteinuria, thrombotic microangiopathy and renal microangiopathic 
haemolytic anaemia are also considered to be a consequence VEGF inhibition. VEGF 
has a direct effect on kidney function; VEGF signalling is required for repair of 
glomerular vessels and control glomerular permeability (Eremina et al., 2007, Zhu et 
al., 2007). 
Reversible posterior leukoencephalopathy (RPLS), an oedema of posterior areas of the 
cerebral hemispheres, is also associated with anti-VEGF therapy. The specific cause is 
not known but an increase in vascular permeability of the blood- brain barrier is a 
possibility (Shord et al., 2009). The discovery that VEGF receptors are not singularly 
specific to endothelial cells has called into question the belief that anti-angiogenic 
therapy would exclusively target tumour vasculature. Expression of VEGF receptors 
have been reported in numerous non-endothelial cells including chondrocytes, 
keratinocytes, retinal neurons, dental odontoblasts, and skeletal myocytes (Mitchell and 
Bryan, 2010). 
In general, cancer patients have an increased risk of thrombotic events because the 
tumour itself promotes blood coagulation due to cytokine release and fibrinolytic 
activity. However, the inability of endothelial repair to occur normally during anti-
angiogenic therapy augments healing deficiencies and blood clotting problems. If 
unrepaired damage to the endothelium results in the exposure of the basement 
membrane, the subsequent release of tissue factor activates the coagulation cascade 
which promotes thrombogenic activity (Zangari et al., 2009).  Complications can result 
in deep vein thrombosis and pulmonary embolism.  
Healing and tissue regeneration deficiencies are a direct result of angiogenic inhibition 
causing numerous complications including disturbed wound closure, bruising, 
mucocutaneous bleeding, haemorrhages, bowel and nasal septum perforations (Mitchell 
and Bryan, 2010). Anti-angiogenic therapy is often stopped prior to and post-surgery. 
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Between 3.4-13% of colorectal cancer patients receiving bevacizumab treatment have 
experienced post-surgery wound healing problems (Scappaticci et al, 2005). 
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Table1.15: A list of common side effects associated with anti-angiogenic therapy.  
   Many of these side effects can be correlated to the role of VEGF. 
 
Side Effect Clinical Manifestation Cause(s) 
 
Hypertension High blood pressure.  Interference with renin-angiotensin-aldosterone system which regulates blood 
pressure through alterations in electrolyte and fluid balance (Khakoo et al. 
2008). 
 Modulation of nitric oxide regulated arterial smooth muscle relaxation and 
vasodilation (Hood et al. 1998) 
Kidney dysfunction 
 
Proteinuria. 
Swelling. 
Thrombotic microangiopathy. 
Renal microangiopathic haemolytic 
anaemia. 
 Interference with kidney filtration processes due to alteration in the integrity 
of glomerular vascular endothelium. 
 Impaired repair to damaged glomerular vessels. 
 Modulation of glomerular permeability (Zhu et al. 2007). 
Thrombotic events 
 
Deep vein thrombosis. 
Pulmonary embolism. 
Mesenteric venous thrombosis. 
Axillary venous thrombosis. 
 Impaired endothelial repair and regeneration. 
 Exposure of sub-endothelial collagen, due to endothelial damage, stimulates 
the release of tissue factor which activates the coagulation cascade. (Zangari 
et al 2009). 
 Tumour cells promote thrombotic events through procoagulation activity, 
fibrinolytic activity and cytokine release (Mitchell and Bryan 2010). 
Impaired wound 
healing 
 
Wound closure failure (especially 
after surgery). 
Bruising. 
Mucocutaneuous bleeding. 
Haemorrhages. 
Bowel perforation. 
Nasal spectrum perforation. 
 Disruption of normal angiogenic process which is essential for normal wound 
healing and tissue regeneration (Hapani et al. 2009, Shord et al. 2009). 
Hypothyroidism Fatigue 
Hair loss 
 Reduced vascularity of the thyroid (Faivre et al 2006) 
 Autoimmune hypothyroidism (Mauriz and Gonzalez-Gallego 2008). 
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Anaemia 
Personality changes 
Depression 
Reversible Posterior 
Leukoencephalopathy 
(RPLS) 
Oedema in the white matter of 
posterior regions of the cerebral 
hemispheres. 
 Exact mechanism unknown. Possibly due to increased vascular permeability 
of the blood- brain barrier (Shord et al 2009, Maharaj et al 2008). 
Epidermal Toxicity Hair loss 
Hair depigmentation 
Acral erythema 
 Epidermal cell apoptosis (Mauriz and Gonzalez-Gallego 2008). 
 
61 
 
1.5v Anti-angiogenic Resistance 
 
Anti- angiogenic therapy does increase progression free survival but unfortunately fails 
to produce an enduring clinical response in patients. Transient disease stabilisation, with 
possible tumour regression, is often followed by tumour revascularisation and 
subsequent tumour resurgence, frequently at an accelerated pace. Generally patient 
survival is minimally increased. Many tumours appear capable of developing a 
complete resistance to the anti-angiogenic drugs (Mitchell, 2010). 
Several mechanisms have been ascribed to explain the refractoriness to anti-angiogenic 
treatment. Frequent explanations are attributed to the heterogeneity and plasticity of 
cancer cells whilst first generation anti-angiogenic therapeutics have a limited capacity 
as they were developed to target a specific angiogenic factor or pathway.  During 
tumour progression cancer cells can undergo a number of mutations and chromosomal 
arrangements which may result in the emergence of a tumour clone which either 
increases expression of the same or other pro-angiogenic factor(s) thereby making the 
anti-angiogenic treatment ineffective. Tumours are proficient in their ability to activate 
alternative pro-angiogenic signalling pathways (Ferrara, 2010).  In mice VEGF 
inhibition reportedly upregulates VEGF, PIGF, ANG-1 and FGF (Casanovas et al., 
2005). Colorectal and renal cancer patients undergoing anti-VEGF therapy have shown 
increased expression in VEGF and PIGF (Mitchell and Bryan, 2010). Infiltrating 
fibroblasts, immune cells (macrophages), and stem cells (bone-marrow-derived cells) 
will also contribute to the release of alternative compensatory pro-angiogenic factors.  
Endothelial cells were considered an ideal therapeutic target as they were thought to be 
genomically stable and therefore would not develop a resistance to anti-angiogenic 
therapy (Carmeliet et al., 2005, Wu & Li, 2008). However, many differences have now 
been described between endothelial cells from normal tissues and those associated with 
tumours. In vitro, tumour endothelial cells have an altered morphology and fail to 
senesce, exhibiting cytogenetic abnormalities. Aneuploidy is shown to increase with 
long term culture (Hida et al., 2008). Normal endothelial cells do not express epidermal 
growth factor receptors (EGFR), however in cancers that express EGF such as prostate, 
EGFR are found on tumour endothelial cells (Yazici et al., 2005). The tumour 
microenvironment may indeed promote the endothelial cells genetic instability, de-
differentiation and even cell fusion with tumour cells (Mitchell and Bryan, 2010).    
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Also, angiogenesis is not the only mechanism that can be adopted to create blood 
vessels. Vasculogenesis and vascular mimicry have been described in tumours. Bone 
marrow derived endothelial cell progenitors (EPCs) can be recruited by the tumour to 
form endothelial cells and subsequently form an endothelium (Nolan et al., 2007). In 
addition EPCs can secrete numerous pro-angiogenic factors (VEGF, ANG-1, ANG-2, 
SDF-1); thereby circumventing single target anti-angiogenic drugs and aiding blood 
vessel formation (Wu and Li, 2008, Mitchell and Bryan, 2010). Vascular mimicry, 
whereby tumour cells imitate endothelial cells and form vessels, will be completely 
unaffected by anti-angiogenic therapies that specifically target endothelial cells (Zhang 
et al., 2007). Once again, the failure of treatment appears to be the limitations of a 
single anti-angiogenic agent (for example anti-VEGF) to inhibit the numerous possible, 
often over-lapping mechanisms by which the vasculature can be formed.  
The aim of anti- angiogenic therapy is the regression of tumour vasculature which in 
itself can contribute to the development of resistance. Successful inhibition of tumour 
angiogenesis, limiting the already restricted blood supply in the tumour will enhance the 
hypoxic tumour microenvironment. Such an adverse environment promotes malignant 
progression of tumour cells and survival of pro-angiogenic inflammatory cells 
(Carmeliet, 2005, Rapisarda and Melillo, 2009, Weis and Cheresh, 2011).  Hypoxia 
inducible factor-1 alpha (HIF-1α) is known to advance the genetic instability of tumour 
cells, either by binding to hypoxia responsive elements or displacing the Myc 
oncoprotein transcription factor, with the resultant up regulation of genes associated 
with cell survival and disease progression (To et al., 2005). Furthermore, a regressed 
tumour vasculature will result in the inadequate delivery of the anti-angiogenic drugs to 
the tumour cells thus exacerbating its ineffectiveness.  
A reaction by many tumour types to anti-angiogenic therapy has been an increase in 
tumour cell invasiveness (Ebos et al., 2009, Paez-Ribes et al., 2009). A cessation of 
anti- angiogenic therapy or drug holiday appears to exacerbate the problem. The exact 
explanation is not known but increased matrix metalloproteinase activity has been 
described in glioblastoma tumours (Bergers and Hanahan, 2008). Once again, the 
hostile tumour environment enhanced by anti-angiogenic therapy induced vessel 
regression appears to promote metastasis. Numerous studies have reported that hypoxia 
fosters tumour metastasis in several tumour types through numerous mechanisms; in 
breast cancer, hypoxia potentiates Notch signalling leading to decreased E-cadherin 
expression whilst the up-regulation of HIF-1α affects the expression levels of E-
cadherin, vimentin and MMP-2 in prostate cancer and hepatocyte growth factor in 
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pancreatic cancer (Chen et al., 2010, Luo et al., 2006, Kitajima et al., 2008). In 
addition, metastasis can also occur via the lymphatic system; lymphatic vessel growth 
will not necessarily be blocked by anti-angiogenic therapy. 
 
1.5vi The Next Generation of Anti-angiogenic Agents- New Targets 
 
The inherent or acquired resistance to anti-angiogenic therapy highlights the need for 
targeting additional angiogenesis pathways to fully explore the potential of anti-
angiogenic therapy. There is a necessity to develop strategies that delay, minimise or 
even avoid resistance. Our increased knowledge of the tumour microenvironment and 
the involvement of cells other than tumour endothelial cells in the angiogenic process, 
have seen the emergence of new targets (Table 1.16). It is also evident that for 
prolonged efficacy, anti-angiogenic treatment plans will no longer solely focus on one 
target but be a combined therapy where different targets are treated together or 
subsequently. Furthermore, any future treatment strategy will probably still include the 
inhibition of the master regulator of angiogenesis VEGF, whether directly or indirectly. 
 
Alternative Angiogenic Pathways 
The regulation of VEGF by HIF-1α is essential in both physiological and pathological 
angiogenesis. HIF-1α I as a therapeutic target is appealing as it also regulates the 
transcription of genes involved in cell proliferation and survival, glucose metabolism, 
pH regulation and apoptosis (Patiar and Harris, 2006). In normal oxygen conditions 
HIF-1α binds to the tumour suppressor VHL protein, which facilitates its proteosomal 
degradation. However, in hypoxic conditions HIF-1α is post-translationally modified 
and remains stable, binding to hypoxia- response elements (HREs) and activating 
numerous hypoxia response genes, which includes VEGF. Cell survival factors are also 
upregulated, thereby protecting tumour cells from hypoxia- induced cell death (Longo et 
al., 2002). The ability of tumour cells to adapt to a hypoxic environment is considered 
to be partly responsible for the development of resistance to anti-angiogenic therapy 
(Weis and Cheresh, 2011).  
Until recently, no agent had been developed which directly inhibited HIF-1α. In 
previous studies, agents inhibited the HIF-1α pathway by disrupting HIF-1α/DNA or 
co-activator binding, HIF-1α translation or inhibit the stabilising prolyl hydroxylase 
enzymes (prolyl 4-hydroxylase domain (PHD) proteins). Inhibition of PHD2 by 
staurosporine or TRAIL in glioblastomas resulted in restricting the ability of tumour 
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cells to adjust to hypoxic conditions and control cell survival (Mitchell and Bryan, 
2010). However, EZN-2968 (Santaris Pharma), a HIF-1 αRNA antagonist (hybridses 
with HIF-1α mRNA under both normal and hypoxic conditions) blocks HIF-1α 
expression. In vitro and in vivo pre-clinical studies have shown its ability to limit 
tumour growth; tumour regression in mice prostate cancer xenografts, blocking 
endothelial tube formation by HUVEC cells (Greenberger et al., 2008). Phase I trial of 
EZN-2968 is in process with patients suffering with advanced solid tumours and 
lymphomas (Mitchell and Bryan, 2010) (Table 1.16). 
The hepatocyte growth factor (HGF) /c-MET tyrosine kinase signalling pathway plays a 
significant role during development and in tumourigenesis (You and McDonald, 2008). 
Normally HGF is secreted by fibroblasts and smooth muscle cells and promotes mitosis, 
cell motility and cell survival of epithelial and endothelial cells. In cancer, where it can 
be secreted by tumour cells, it can also promote cell proliferation, invasion, metastasis 
and angiogenesis (Tiecher, 2011). In the vasculature c-Met activation through paracrine 
HGF, regulates tumour angiogenesis mainly by induction of proliferation, migration and 
survival of endothelial cells resulting in vascular tubulogenesis and branching 
morphogenesis (Shojaei et al., 2010). HGF also promotes angiogenesis through up 
regulation of VEGF and also down regulating the potent anti-angiogenic factor 
thrombospondin-1 (TSP-1) (Lee and Kim, 2009). HGF/c-Met signalling increases 
VEGF levels in the tumour and VEGFR2 on endothelial cells. c-Met activation also 
effects the tumour cells directly via the signalling pathways PIK3/Akt, Src, STAT3 and 
Ras/mek; promoting proliferation, survival and increasing invasive phenotype. 
Expression of both c-Met and HGF can be induced by HIF-1α (Shojaei et al., 2010). 
Activation of HGF/ c-Met pathway is a poor prognostic factor in many cancers. In 
tumours the c-Met receptor can be constitutively phosphorylated, its gene mutated or 
amplified (Grepin and Pages, 2010). The inhibition of HGF/c-Met pathway produces 
enhanced VEGF/VEGFR axis-mediated inhibition of angiogenesis and can also 
overcome the increased response to tumour hypoxia induced by anti-angiogenic 
therapy. In pre-clinical mouse models, HGF expression levels were found to be higher 
in Sunitinib resistant tumours; however combined treatment with a selective c-Met 
inhibitor had an additive effect in inhibiting tumour growth (Shojaei et al., 2010). 
Monoclonal antibodies to HGF and c-Met, small molecule kinase inhibitors and decoy 
receptors have been developed and currently being assessed in clinical trials for 
treatment of a variety of cancer types; either as a monotherapy or in combination with 
chemotherapeutic agents (Teicher, 2011) (Table 1.16). 
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The Notch pathway is an evolutionary conserved signalling system which appears to 
provide critical regulatory information to endothelial (and smooth muscle cells) 
downstream of the initiating signal induced by VEGF. It regulates cell fate 
specification, tissue patterning and morphogenesis by modulating cell differentiation, 
proliferation, apoptosis and survival (Kuhnert et al., 2011). Recently, Notch and its 
endothelium specific ligand Dll4 (delta-like 4) have emerged as a critical regulator of 
developmental and tumour angiogenesis. Acting downstream of VEGF stimulation, it 
limits the effects of VEGF on the vasculature by means of a negative feedback loop. 
Dll4-Notch signalling decreases angiogenesis by suppressing endothelial tip cell 
formation. Functioning by a different mechanism to standard anti-angiogenic therapies; 
the blockade of Dll4-Notch signalling in tumours results in excessive, non-productive 
angiogenesis and subsequent inhibitory effect on tumour growth (Dufraine et al., 2008). 
In preclinical models, Dll4 blockade using neutralising anti-Dll4 antibodies resulted in 
growth inhibition of both VEGF –sensitive and resistant tumours.  Efficient as a 
monotherapy, the anti-tumour effects are significantly enhanced when combined with 
anti-VEGF therapy (Bevaciuzumab). Phase I trials have begun testing the effect of two 
different monoclonal antibodies, OMP-21M18 and REGN42. Gamma-secretase 
inhibitors also block Notch signalling; gamma-secretase releases the Notch intracellular 
domain permitting translocation to the nucleus where it regulates Notch target gene 
transcription. In addition a Notch decoy has shown to restrain the growth of tumour 
vasculature in the mouse mammary Mm5MT model (Dufraine et al., 2008). However, 
preclinical studies have raised safety issues concerning the adverse effect on normal 
organ homeostasis, especially liver complications and the need to selectively target 
Notch1 only as blocking Notch 2 causes severe intestinal toxicity (Kuhnert et al., 2011, 
Teicher, 2011) (Table 1.16). 
 
Targeting Mural and Stromal Cells 
Normal vasculature undergoes a process of stabilisation via the local release of PDGF, 
VEGF and Ang-1 (Carmeliet, 2005). Released by endothelial cells, PDGF attracts 
pericytes to embed in the newly formed vessel. Pericytes are mural cells which 
differentiate from pools of c-Kit+Sca-1+ VEGF-1+ perivascular progenitor cells which 
are mobilised from the bone marrow in response to PDGF-BB (Song et al., 2005). They 
have an important role in maintaining capillary structural integrity, mediating 
endothelial cell survival and blood flow regulation (Fakhrejahani and Toi, 2012). PDGF 
is structurally related to VEGF, consisting of 5 dimeric isoforms occurring as covalently 
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linked homo-or hetero-dimers which bind to two structurally related tyrosine kinases, 
denoted PDGFRα and PDGFRβ (Fredriksson et al., 2004). In the adult PDGF 
contributes to wound healing and regulates interstitial pressure (Ostman and Heldin, 
2007). 
Tumour vasculature is characterised by a lack of pericyte coverage which resulting in 
poor vascular functionality, affecting perfusion and vessel permeability (Fakhrejahani 
and Toi, 2012, Claesson-Welsh, 2012). When PDGF is overexpressed in tumour 
vessels, pericyte coverage improves, resulting in increased vessel stability and 
subsequently increased tumour growth (Ostman, 2004). PDGF overexpression has also 
been linked to atheroscleorosis and fibrotic conditions. Gene rearrangements, mutations 
and amplification of PDGFR or PDGF family members have been associated with 
gastrointestinal stromal tumours, a rare form of cancer (Ostman and Heldin, 2007). 
However, when perictyes are targeted using kinase inhibitors and PDGFRβ signalling is 
inhibited the tumour vessels recruit fewer pericytes and dilate; endothelial cell apoptosis 
is also increased. The simultaneous targeting of endothelial cells and perictyes, with 
RTKIs inhibiting VEGFRs and PDGFRβ has been shown to increase the anti- 
angiogenic effect, even in late stage solid tumours (Bergers et al., 2003). PDGFRβ 
inhibitors also appear to destabilise the larger vessels covered by smooth muscle cells, 
which supply bulk flow to tumours,  rendering them more susceptible to endothelial cell 
specific inhibitors (Carmeliet, 2005).  
The angiopoietin pathway is also implicated in vessel maturation. Opposing roles have 
been attributed to Ang-1 and Ang-2; both bind to tyrosine kinase TIE2 receptor. Ang-1 
maintains vessel integrity by recruiting and stabilising pericytes. Ang-2, normally 
expressed during wound healing and vascular remodelling, triggers loss of pericytes 
allowing endothelial cells to be exposed to pro-angiogenic factors thereby antagonising 
the stabilisation action of Ang-1. Endothelial destabilisation is initiated by Ang-2 
binding to TIE-2 receptor, which in the presence of VEGF induces an angiogenic 
response. The pathway is considered to have an important role in brain, breast, 
hepatocellular and lung carcinomas (Longo et al., 2002). A clinical trial with the 
peptibody, AMG-386 (Amgen), which prevents both Ang-1 and Ang-2 binding to TIE-2 
receptor, has shown a similar response to VEGF inhibition (Herbst et al., 2009, Mita et 
al., 2010). Numerous Phase II trials combining treatment with chemotherapeutics are 
now be progress (Teicher, 2011) (Table 1.16). 
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The tumour stroma is also an active contributor to tumour progression. Carcinoma- 
activated fibroblasts (CAFs) have been attributed to promoting angiogenesis (Guo et al., 
2008). CAFs, like pericytes, are recruited to the tumour by PGDF signalling where they 
proliferate and increase the angiogenic stimulus by releasing VEGF and PIGF (Ostman, 
2004). PGDF-BB antagonists have been shown to inhibit angiogenesis. In addition, 
interstitial fluid pressure was lowered thus improving drug delivery via the tumour 
vasculature. The exact mechanism is unknown but PDGF is thought to stimulate CAFs 
to contract the interstitial matrix via microfibrillar networks, thereby constricting the 
tumour vessels (Carmeliet, 2005).  
 
Targeting Haematopoietic Cells  
A feature of many tumours is an inflammatory infiltrate. The release of numerous 
cytokines and chemokines by the tumour attracts dendritic cells, haemotopoietic 
progenitors, macrophages, mast cells and T Cells (Coussens and Werb, 2002). 
Stimulating angiogenesis is one of the many malignancy promoting roles attributed to 
these cells; including mitogenic and survival factor release, DNA damage, ECM 
remodelling, host defence evasion (Takakura et al., 2000). They are also considered as 
contributors to the development of tumour anti-angiogenic resistance. 
Mast cells, platelets, tie-2 expressing monocytes (TEM) and tumour associated 
macrophages (TAMS) are all known to be another source of pro-angiogenic factors. 
Indeed TAMS specifically accumulate in hypoxic areas of the tumour and producing 
VEGF, VEGF-C and VEGF-D. Whilst bone marrow derived haematopoietic cells 
(recruited to tumours in response to VEGF and PIGF and are retained by SDF-1α) can 
either stimulate tumour vessels growth by releasing pro-angiogenic factors (VEGF, 
PIGF and Ang-2) or act as haemangioblasts, producing both haematopoietic and 
endothelial progenitors that can form new blood vessels (Mitchell and Bryan 2010). 
Maybe by co-targeting VEGF, PIGF and SDF-1 the migration of these cells will be 
blocked and thereby reduce angiogenesis, growth and possible metastasis (Carmeliet, 
2005). 
Bone marrow derived cells are also recruited to tumours through the interaction of HIF-
1-dependent CXCL12 and CXCR4. Many divergent pathways are stimulated by the 
binding of the CXCL12 ligand to the CXCR4 receptor resulting in angiogenesis as well 
as tumour progression, metastasis and survival (Teicher and Fricker 2010). CXCR4 
neutralising antibodies and the CXCR4 antagonist Plerixafor have been reported to 
prevent mobilisation of bone marrow derived cells and development of tumour growth, 
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subsequently stopping tumour regrowth (Kioi et al., 2010). Clinical trials are underway 
for non-Hodgkins lymphoma and acute myeloid leukemia as the CXCL12/CXCR4 
pathway is responsible for retaining these cancer cells in the bone marrow (Table 1.16). 
Termed the macrophage index, a positive correlation between the levels of TAMs and 
tumour angiogenesis have been described for many human cancers (breast, prostate, 
cervical, endometrial, liver, bladder, kidney, brain, oral and melanoma) (Singh et al., 
2009). Stimulated by the hypoxic tumour environment TAMS upregulate their 
production of CXCL8 (interleukin-8), an endothelial cell mitogen and angiogenesis 
promoter. CXCL8 binds to CXCR2 chemokine receptor. Neutrophils can also mediate 
CXCL8-induced angiogenesis in cancer. Overexpression of CXCL8 correlates with 
tumour stage as well as disease progression and recurrence. Malignant colonic epithelial 
cells overexpress CXCL8, therefore CXCR2 maybe a valid target for anti-angiogenic 
therapy in colorectal cancer (Teicher, 2011). In process are numerous preclinical studies 
using CXCR2 targeted antagonist antibodies and dual CXCR1/CXCR2 small molecule 
inhibitors, it remains to be seen whether they will progress to clinical trials (Singh et al., 
2009) (Table 1.16).  
 
Targeting Neoplastic Cells 
The conventional anti- cancer treatments of chemotherapy and radiation can also have a 
direct and indirect effect on tumour vasculature. Normally the high compressive 
mechanical stresses found within tumours compress the vasculature. However, by 
killing the tumour cells with cytotoxic therapy this pressure is removed. This improves 
blood flow thereby increasing drug delivery, which can ultimately produce tumour 
regression. In addition the death of tumour cells, which are largely responsible for 
constant supply of pro-angiogenic and pro-tumorigenic factors, helps to restore the 
angiogenic balance (Carmeliet, 2005).  
Cytotoxic agents when administered at low and frequent doses have been shown to 
supress angiogenesis; due to the high proliferative rate of tumour endothelial cells. 
Termed Metronomic Therapy, the continuous low-dose of chemotherapy appears to 
enhance the anti-angiogenic and pro-apoptotic effects of some agents in both tumour 
cells and endothelial cells, for example cyclophosphamide (Hanahan et al., 2000, 
Browder et al., 2000, Klement et al., 2000). The tumour endothelial cells are killed by 
much lower doses of chemotherapy than the tumour cells, therefore reducing the 
adverse effects to healthy tissue found with conventional dosage (Hanahan et al 2000). 
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The combining of metronomic therapy with selective anti- angiogenic inhibitors has 
also shown improved efficacy (Scharorsky et al., 2009). Klement’s study using a mouse 
model, combined metronmic doses of the chemotherapeutic vinblastine and the anti- 
angiogenic drug DC101 (anti-VEGF). Treatment only with either drug briefly slowed 
tumour growth followed by resurgence. Whereas combining the two drugs resulted in 
complete tumour regression, with no recurrence reported after 6 months. The anti-
angiogenic agent TNP-470 in combination with cytotoxic cyclophosphamide eliminated 
most drug-resistant Lewis lung carcinomas. (Browder et al., 2000). Numerous pre- 
clinical studies have been reported and clinical trials are underway. One of the first 
Phase I trials involved treating children suffering from recurrent and progressive 
cancers; the combined oral anti-angiogenic chemotherapy showed a prolonged and 
persistent disease-free status (Kieran et al., 2005). Yet, obstacles have arisen due to the 
lack of specific markers to allow the correct selection of patients for treatment and their 
subsequent monitoring to determine whether the treatment is having an anti-angiogenic 
effect (Longo et al., 2002). 
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Table 1.16: A list of the next generation of anti-angiogenic agents and their research status. 
 
Target Angiogenic Mechanism Therapeutic Agent Research Status Company 
 
Placental Growth 
Factor (PIGF) 
Ligand for VEGFR1. 
Vascular remodelling factor 
leading to normalisation of 
tumour vasculature (Hedlund 
et al., 2009, Cao et al., 2009) 
Direct effect on some 
malignant cells, increasing 
proliferation and migration 
(Chen et al., 2009). 
TB-403, humanised 
monoclonal antibody to PIGF 
(Nielsen and Sengelov, 2012, 
Martinsson, 2011) 
Phase I Roche/Thromobogenics 
and BioInvent 
International. 
Angiopoietins  
1 and 2 
(ang1 and ang2) 
Ligand for Tie-2 receptor 
Opposing roles of ang1 and 
ang2, thought to control 
vascular remodelling and 
maturation. (Teicher, 2011). 
AMG-386 peptibody, prevents 
interaction of ang1 and ang 2 
with Tie-2 receptor. (Herbst et 
al., 2009, Mita et al., 2010, 
Karlan, 2012) 
Phase II, in combination 
with chemotherapy agent 
Paclitaxel. Ovarian 
cancer. 
Amgen 
CXCL12/ 
CXCR4 
Binding of CXCL12 to 
receptor CXCR4 promotes 
mobilisation of 
haematopoietic stem cells. 
(Teicher, 2010) 
Plerixafor, CXCR4 antagonist 
(DiPersio et al., 2009) 
Phase III. In combination 
with GCSF. Non-
Hodgkins Lymphoma. 
Genzyme 
 
Plerixafor, CXCR4 antagonist 
(Nervi et al., 2009) 
Preclinical studies. Acute 
myeloid leukemia. 
Plerixafor, CXCR4 antagonist. 
(Uy et al., 2011) 
Phase I/II. Acute 
Myeloid Leukamia. 
AMD3100, small molecule 
inhibitor of CXCL12/ CXCR4 
interaction (Kioi et al., 2010). 
Preclinical studies. 
Glioblastoma. 
 
CXCR2 Interleukin-8 receptor, which SCH-479833 and SCH- Preclinical studies. Schering-Plough 
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is a endothelial cell mitogen 
stimulating angiogenesis. 
(Singh et al., 2009). 
527123, small molecule 
CXCR4 antagonists.  
(Singh et al., 2009). 
Melanoma 
Notch Pathway Regulates cell fate 
specification, tissue 
patterning and morphogenesis 
by modulating cell 
differentiation, proliferation, 
apoptosis and survival 
(Kuhnert et al., 2011). 
RG-4733, gamma secreatse 
inhibitor which inhibits Notch 
signalling.  
(Teicher, 2011). 
Phase II Roche/ Abbott 
REGN-421, human 
monoclonal antibody against 
Notch ligand Delta-like ligand-
4 (Dll4)  
(Thompson et al., 2011). 
Phase I. Solid 
malignancies. 
Sanofi-Aventis/ 
Regeneron 
OMP-21M18, human 
monoclonal antibody against 
Notch ligand Delta-like ligand-
4 (Dll4)  
(Yan et al., 2011). 
Phase I.  
Advanced solid 
malignancies. 
OncoMed 
Pharmaceuticals 
Transforming 
Growth Factor  
Pathway 
Activin receptor-like kinase-1 
(ALK1), a Type I cell surface 
recptor, regulates vessel 
growth, stability and 
maintenance of a functional 
vasculature (Mitchell et al., 
2010). 
ACE-041, soluble ALK1 
receptor which binds to 
members of TGFβ super family 
(BMP-9, BMP-10) and 
prevents signalling via ALK1. 
(Mitchell et al., 2010). 
Phase I. 
Advanced solid tumours. 
Acceleron Pharma 
PF-03446962, human 
monoclonal antibody against 
ALK1. (Mitchell et al., 2010). 
Phase I. 
Advanced solid tumours. 
Pfizer 
Hypoxia inducible 
factor -1 alpha 
(HIF-1α) 
A key transcription regulator 
of numerous genes important 
for cellular adaptation of 
hypoxic conditions. Has a 
EZN-2968, synthetic antisense 
oligodeoxynucleotide targeting 
HIF-1α, hybridises with HIF-
1α mRNA and blocks protein 
Phase I. 
Advanced solid tumours 
and lymphomas. 
Enzon Pharma / 
Santaris Pharma 
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critical role in angiogenesis, 
survival, metastasis, drug 
resistance and glucose 
metabolism (Patiar and 
Harris, 2006) 
expression (Greenberger et al., 
2008). 
Sphingosine-1-
phosphate 
(S-1-P) 
Bioactive lipid molecule 
which stimulates endothelial 
cell migration, proliferation 
and survival (Xie et al., 
2009). 
Sonepcizumab, human 
monoclonal antibody against 
S-1-P 
(Gordon et al., 2010, 
Sabbadini, 2011). 
Phase I 
Advanced solid  
malignancies 
Merck/ Serono/ Lpath 
Hepatocyte 
Growth Factor 
(HGF)/ c-Met 
tyrosine kinase 
signalling pathway 
Induces VEGF expression as 
well as downregulating 
Thrombospondin 1 (TSP-1), 
thereby stimulating 
endothelial cell proliferation, 
migration (Lee and Kim, 
2009). 
MetMAb, monovalent 
anatagonist antibody to 
receptor Met (Belalcazar et al., 
2012). 
Phase II. In combination 
with Tarceva. Lung 
cancer. 
Genentech/Roche 
SCH900105, anti-HGF 
monoclonal antibody (Patnaik 
et al., 2010). 
Phase I. Single agent and 
in combination with 
Erlotinib. Advanced solid 
tumours. 
Schering-Plough/ Aveo 
(Merck) 
TAK-701, anti-HGF 
monoclonal antibody (Jones et 
al., 2010). 
Phase I. Advanced 
malignancies 
Takeda/ Galaxy 
NK4, a competitive HGF 
antagonist and cMet receptor 
(Kubota, 2009). 
Preclinical studies: lung 
cancer. 
KringlePharma 
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1.5vii Normalisation of Tumour Vasculature 
 
Tumours are characterised by a self-perpetuating cycle of non-productive angiogenesis 
resulting in the formation of  dysfunctional and abnormal blood vessels. The irregular 
vasculature enhances tumour tissue swelling, obstructs anti-tumour immune defence (by 
commandeering inflammatory cells) and makes chemoradiotherapy ineffective whilst 
simultaneously promoting tumour invasiveness and metastasis. The expectation of anti-
angiogenic therapy was that by inhibiting tumour angiogenesis the existing tumour 
vasculature would regress and new blood vessel growth would be prevented, resulting 
in the tumour starving due to the inadequate supply of oxygen and nutrients.  
Unfortunately, success has been limited to the treatment of glioblastomas and renal cell 
carcinomas with the majority of solid tumours only showing a transient benefit, often 
followed by (aggressive) disease progression. However, for many solid tumours (breast, 
lung and colorectal) anti-angiogenic treatment (targeting VEGF) has a far greater 
clinical benefit when administered in combination with conventional chemotherapy. 
Logic would suggest that the regression (pruning) of tumour vessels caused by anti-
angiogenic therapy would actually impede vascular delivery of chemotoxic drugs. But, 
by restricting the unregulated flow of pro-angiogenic factors in the tumour, the 
vasculature is actually normalised improving perfusion and therefore drug delivery. The 
temporary benefit of anti-angiogenic treatment appears to be due in part to the 
normalisation of tumour vasculature thereby fostering a less hypoxic, malignancy 
promoting tumour environment. A consequence of prolonged anti-angiogenic treatment 
would therefore be an exacerbation of the aberrant tumour environment thereby fuelling 
tumour invasiveness and metastasis (Ebos et al., 2009, Paez-Ribes et al., 2009). 
This discovery has led to the concept of a novel anti-cancer treatment, whereby anti-
angiogenic agents are used to restore the angiogenic balance found in normal tissues, by 
inducing vessel normalisation. Tumour vessel normalisation strategies offer an 
opportunity to convert a malignant invasive, metastatic cancer into a more benign, 
encapsulated, metabolically less aggressive, poorly invasive tumour which will respond 
better to conventional anti-cancer chemoradiation therapy (DeBock et al., 2011). Vessel 
normalisation may also have potential uses in the treatment of inflammatory and 
ischaemic diseases. 
The most common target of anti-angiogenic therapy is VEGF. Neutralisation of VEGF 
by blocking either VEGF directly or its signalling pathways induces vessel 
normalisation, for example as reported in rectal cancer patients (Jain, 2005, Willett et 
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al., 2004). Immature vessels are pruned, while remaining vessels are stabilised 
(matured) by increasing their pericyte coverage. The process is mediated via induction 
of ANG-1 and PDGFRβ signalling (Winkler et al., 2004, Greenberg et al., 2008). 
Consequently, tumour vessel permeability and interstitial pressure decreases whilst 
tumour perfusion and oxygenation improves; restoring the hydrostatic pressure gradient 
across the vessel wall. Administered drugs are reported to penetrate deeper into the 
tumour and in the majority of studies chemo-radiotherapy efficacy is enhanced (Franco 
et al., 2006, Winkler et al., 2004). 
In order, to gain success in the use of anti-angiogenic agents to normalise tumour 
vasculature, lessons must be learnt from the outcomes of anti-angiogenic therapy. The 
flexibility of tumour cells to adapt and find alternative pathways must be recognised. 
But, as important is the discovery that by blocking one specific pro-angiogenic factor 
the upregulation of others occurs, thereby perpetuating the pro-malignancy agenda of 
the tumour.   
It has been reported (in models, mice and patients) that a consequence of blocking 
VEGF is an upregulation of another member of VEGF family, placental growth factor. 
Therefore, a successful normalisation of tumour vasculature may require a treatment 
strategy which neutralises both factors.  Anti- PIGF treatment has been shown to induce 
vessel normalisation in hepatocellular models and tumours (Van der Veire et al., 2010, 
Alpini et al., 2010). 
Members of the angiopoietin family are also known to regulate vessel normalisation. 
The normalisation activity of anti-VEGF relies on upregulating Ang-1 expression. Ang-
1 promotes pericyte coverage and establishment of tight endothelial intercellular 
junctions by binding its Tie2 receptor. However, Ang-2 whose expression is controlled 
by HIF-1α, induces opposing effects; inhibiting Ang-1, reducing pericyte recruitment 
and vessel maturation. Plasma levels of Ang-2 correlate with poor patient prognosis, 
whilst loss of Ang-2 has been shown to reduce early stage tumour growth (Helfrich et 
al., 2009). A consequence of anti-VEGF therapy is an upregulation of Ang-2. 
Combined targeting of both factors with a double anti-angiogenic protein, DAAP, has 
been shown to improve anti-cancer efficacy (Koh et al., 2010). 
In addition, Notch, an endothelial cell receptor for Dll4 is emerging as a potential target 
to facilitate vessel quiescence. Notch/Dll4 signalling controls vessel branching by 
suppressing the formation of endothelial tip cells. Overexpression of Dll4 by tumour 
cells reduces vessel density, while enhancing lumen size and perfusion, overall 
improving oxygenation (Li et al., 2007). Dll4 expression in patient tumour biopsies of 
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bladder cancer correlates with vessel maturation (Patel et al., 2006). When endothelial 
cells are stimulated with Dll4, a quiescent phenotype is induced and a down- regulation 
of VEGFR2 results in a reduced response to VEGF (Phng and Gerhardt, 2009). 
 
1.5viii Future Perspectives 
 
Judah Folkman, envisaged that angiogenic inhibitors would be the magic bullets that 
would eradicate cancer. Overall anti-angiogenic therapy has improved survival time but 
can certainly not be described as a cure. 
During the development of new anti-angiogenic drugs it has become obvious that the 
models used in pre-clinical research need to be more relevant to human tumourigenesis. 
Mouse models are currently used and although they have been crucial in the 
development of many cancer-targeted drugs, they do not appear to be suitable for anti-
angiogenic therapies. In relation to angiogenesis many disparities with the human 
disease exist. Firstly, habitually cancer in humans arises slowly, sometimes over a 
period of years, however in mice the disease is acute. Secondly, angiogenesis is induced 
in the mice models thereby making it more susceptible to anti-angiogenic therapy. In 
addition, human tumours grow in a highly vascularised tissue environment where 
tumour growth is not solely dependent on angiogenesis but also vessel co-option, thus 
increasing resistance to anti-angiogenic drugs (Claesson-Welsh, 2012). In addition, 
findings from mice are based on the primary tumour irrespective of any metastatic 
spread. Studies are curtailed due to ethical concerns for the animals. In humans 
however, it is secondary tumours which present with the worst clinical outcome. 
Future treatment with anti-angiogenic drugs requires a flexible approach; mirroring the 
dynamic plasticity of the tumours response to treatment. We now know that inhibition 
of a single target usually results in the upregulation of additional angiogenic factors for 
example PIGF is up regulated after anti-VEGF therapy and VEGF after anti –VEGFR2 
or anti-EGFR. New treatment strategies need to combine treatment of agents which 
have complementary targets. By targeting various angiogenic molecules and/ or 
endothelial cells and/or other pro-angiogenic cell types (fibroblasts, macrophages, 
neutrophils) there is a reduced chance the tumour will develop resistance and evade 
treatment. Unfortunately, a side effect of combined therapy will probably be increased 
toxicity. 
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Combination therapy of anti-angiogenic and conventional chemotherapy has been more 
successful than exclusively focusing on angiogenesis inhibition. However, prolonged 
anti-angiogenic therapy reduces uptake of chemotherapeutics by the tumour cells. As 
discussed previously, angiogenesis inhibition appears to initially normalise the tumour 
vasculature improving circulation and therefore drug delivery.  
Evidently, there appears to be a “window of treatment” for optimum tumour vasculature 
normalisation. Another, advantage of using anti-angiogenics for vasculature 
normalisation is that lower doses will be required, therefore milder side effects. The aim 
of the treatment is to return the balance of pro and anti- angiogenic factors; the use of 
anti-angiogenics to maintain a constant level of tumour- stimulated angiogenesis rather 
than the characterised hyperstimulation of tumour angiogenesis that subsequently leads 
to increased tumourigenesis.  
In order, for success in this approach of anti-angiogenic therapy it will require the 
development of non-invasive markers of vessel maturation concurrently with improved 
imaging techniques. The ability to “stage” an individual’s tumours vasculature and 
microenvironment will lead to a more personalised approach to treatment. Such 
personalised medicine requires improved patient screening; at present screening is 
limited not only by a shortage of validated biomarkers but also expense. Advances in 
the characterisation of tumour vasculature will possibly lead to new treatment targets 
and markers of disease stage. In addition, clinical trials of these treatments need 
biomarkers to allow for the selection of responders within the patient cohorts (Claesson-
Welsh, 2012). 
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1.6 PROJECT AIMS 
 
Chapter 3: ASSESSMENT OF THE BIOACTIVITY OF CONDITIONED 
MEDIUM 
Aims Principal Assays 
1. Primary screen of total CM collected from 
various cell lines for the presence of 
motogenic activity. 
 3D collagen gel fibroblast 
migration assay 
2. Primary screen of total CM collected from 
various cell lines for the presence of MSF-
inhibitory bioactivity.  
 3D collagen gel fibroblast 
migration assay 
 
 
Chapter 4: THE IDENTIFICATION OF MSF-I PRODUCED BY 
KERATINOCYTES. 
Aims Principal Assays 
1. To isolate the factor responsible for MSF-
inhibitory activity detected in HaCaT CM. 
 Size exclusion chromatography 
(Superdex) of HaCaT total CM. * 
 Ion exchange chromatography 
(ANX) of SEC fractions MW 16-
27kDa.* 
 SDS Electrophoresis of ANX 
unbound fraction. * 
2. To identify the factor responsible for MSF-
inhibitory activity detected in HaCaT CM. 
 Sequence analysis (tryptic digest, 
mass spectrometry) of SDS 
electrophoresis elution of MW 20-
25kDa. 
 Immunolocalisation of NGAL 
(Anti-NGAL antibody, AF1757). 
 Immunoblot for NGAL (Anti-
NGAL antibody, MAB1757). 
 Colorimetric Indirect ELISA for 
NGAL (Anti-NGAL antibody, 
AF1757) 
3. To verify the ability of NGAL to inhibit the 
motogenic bioactivity of MSF.  
NGAL from three sources tested for 
MSF-I activity: 
 NGAL isolated from 
NGAL/MMP-9 Complex 
(Calbiochem), 20-25kDa Gel 
elution 3. * 
 Eukaryotic NGAL (R&D 
Systems). * 
 Prokaryotic NGAL (In-house 
Prep). * 
4. To characterise the nature the MSF-
inhibitory activity of NGAL.  
 NGAL from three sources tested 
for MSF-I activity.* 
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 Effect of iron chelator, DFOM, on 
NGAL ability to inhibit rhMSF. * 
 NGAL pre-incubation 3D Type I 
collagen gel fibroblast migration 
experiments. 
5. To verify MSF as the factor responsible for 
the motogenic bioactivity detected in 
fractionated HaCaT CM.  
 Immunoblot for MSF (Anti-MSF 
antibody, RpVSI). 
 Immunolocalisation of MSF (Anti-
MSF antibody, 
Rp2/98pFA2pFn1). 
 IGD Function Neutralisation of 
Motogenic Activity (Pep Q 1.1 
antibody). * 
 Immunopreciptation for MSF 
(Protein G coupled to RpVSI 
antibody).* 
 NGAL inhibition of motogenic 
activity. * 
*bioactivity confirmed by testing in the 3D collagen gel fibroblast migration assay.  
 
Chapter 5: THE EXPRESSION OF MSF AND NGAL IN RELATION TO 
TUMOUR PROGRESSION. 
Aims Principal Assays 
1. To establish whether MSF was expressed by 
the other cell lines of the HaCaT series 
(BEN, MAL and MET), which displayed an 
increasing tumorigenic potential.  
 Immunoblot for MSF (Anti-MSF 
antibody, RpVSI). 
 Immunolocalisation of MSF (Anti-
MSF antibody, 
Rp2/98pFA2pFn1). 
2. To establish whether NGALwas expressed 
by the other cell lines of the HaCaT series 
(BEN, MAL and MET), which displayed an 
increasing tumorigenic potential. 
 Immunoblot for NGAL (Anti-
NGAL antibody, MAB1757). 
 Immunolocalisation of NGAL 
(Anti-NGAL antibody, AF1757). 
 Colorimetric Indirect ELISA for 
NGAL (Anti-NGAL antibody, 
AF1757). 
3. To determine whether NGAL and MSF 
expression levels could be related to 
tumorigenic potential.  
 Assays as above. 
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Chapter 6: THE EXPRESSION OF PRO- AND ANTI- MOTOGENIC 
BIOACTIVITY BY THE HACAT-RAS CLONES. 
Aims Principal Assay 
1. To ascertain bioactivity of total CM of the 
HaCaT series cell lines. 
 3D collagen gel fibroblast 
migration assay 
2. To ascertain whether the fractionated CM of 
the HaCaT series cell lines exhibited 
motogenic activity. 
 Size exclusion chromatography 
(Superdex) of HaCaT series total 
CM.* 
 SDS Electrophoresis of HaCaT 
series total CM.* 
3. To ascertain whether MSF was responsible 
for the motogenic activity of HaCaT series 
CM. 
 Immunopreciptation for MSF 
(Protein G coupled to RpVSI 
antibody).* 
 IGD Function Neutralisation of 
Motogenic Activity (Pep Q 1.1 
antibody). * 
 NGAL inhibition of motogenic 
activity.* 
4. To ascertain whether the fractionated CM of 
the HaCaT series cell lines exhibited MSF-
inhibitory activity. 
 Size exclusion chromatography 
(Superdex) of HaCaT series total 
CM.* 
 SDS Electrophoresis of HaCaT 
series total CM.* 
5. To ascertain whether NGAL was responsible 
for the MSF-I inhibitory activity of HaCaT 
series CM. 
 Colorimetric Indirect ELISA for 
NGAL (Anti-NGAL antibody, 
AF1757). 
 Immunoblot for NGAL (Anti 
NGAL antibody, MAB1757). 
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Chapter 7: THE IDENTIFICATION OF MSF-I PRODUCED BY 
ENDOTHELIAL CELLS 
Aims Principal Assay 
1. To determine whether endothelial cells 
express NGAL. 
 Immunoblot for NGAL (Anti-
NGAL antibody, MAB1757). 
 Immunolocalisation of NGAL 
(Anti-NGAL antibody, AF1757). 
2. To determine whether endothelial cells 
express MSF.  
 Immunolocalisation of MSF (Anti-
MSF antibody, 
Rp2/98pFA2pFn1). 
3. To characterise the bioactivity of endothelial 
cells expressing a sprouting phenotype. 
 Size exclusion chromatography 
(Superdex).* 
 SDS Electrophoresis.* 
4. To characterise the bioactivity of endothelial 
cells expressing a cobblestone phenotype.  
 Size exclusion chromatography 
(Superdex).* 
 SDS Electrophoresis.* 
5. To determine whether MSF was responsible 
for the motogenic activity detected in 
fractionated endothelial CM.  
 IGD Function Neutralisation of 
Motogenic Activity (Pep Q 1.1 
antibody). * 
 NGAL inhibition of motogenic 
activity.* 
6. To determine what effect MSF had on 
endothelial morphology. 
 2D Post-confluent endothelial 
sprouting assay. 
7. To determine the effect IGD Function 
Neutralisation, PEPQ 1.1 antibody had on 
endothelial morphology. 
 3D Spontaneous endothelial 
sprouting assay. 
8. To determine the effect MSF inhibitor, 
NGAL had on endothelial morphology. 
 2D Post-confluent endothelial 
sprouting assay. 
 3D Spontaneous endothelial 
sprouting assay. 
 Endothelial proliferation and 
viability assay. 
*bioactivity confirmed by testing in the 3D collagen gel fibroblast migration assay.  
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            Chapter 2:  
 
   METHODS AND MATERIALS 
 
2.1 CELL CULTURE 
 
2.1.i Cell lines and Culture Conditions. 
 
Unless stated otherwise, all cell lines were grown at 37
o
C in a humidified atmosphere 
containing 5% CO2, 95% air. Stock cultures were maintained in the following, in- house 
prepared, growth medium -  Eagle’s minimal essential medium (MEM), supplemented 
with 15% (v/v) heat-inactivated donor calf serum (DCS), 1mM sodium pyruvate, 2mM 
glutamine, non-essential amino acids (81.4mg/ml), 100units /ml penicillin and 
streptomycin. This medium will be referred to as 15% DCS MEM, or in the absence of 
serum SF-MEM. Medium on stock cultures was routinely changed every 2-3 days. 
All tissue culture plastic dishes (90, 60 and 35mm) and multi-well plates were 
purchased from the Nunc range. 
See Table 2.1 for specific cell culture requirements for the cell lines used. 
 
2.1.ii Cell Culture Maintenance Protocols. 
 
Subculture of Adherent Cell Lines. 
Upon reaching appropriate confluence the cultures were washed twice with Hanks’ 
balanced Salt solution to remove serum proteins. Cells were then brought into 
suspension by using the protease 0.05% (v/v) trypsin in EGTA (ethylene glycol 
tetraacetic acid) for 5 minutes at 37ºC. Once the cells had rounded up and begun to 
detach, an equal volume of growth medium containing 15% (v/v) DCS was added, to 
neutralise the trypsin. The dish was washed over numerous times to ensure all cells had 
been retrieved. After collecting the cells by centrifugation, for 5 minutes at 900rpm, 
they were re-suspended in growth medium and plated onto an appropriate number of 
tissue culture dishes. 
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Cryopreservation of Cell Lines. 
In order to preserve the cell lines and maintain a good viable stock, cultures were frozen 
at various passages. Following, the trpysinisation and centrifugation step of the 
subculturing protocol, a cell pellet was obtained, which was re-suspended in 22% (v/v) 
DCS and 5% (v/v) DMSO in MEM and stored in cryovials at -80
o
C.  
 
Resuscitation of Frozen Cell Lines. 
Upon removal from -80
o
C freezer, cryovials were placed in a 37
o
C waterbath (half-
submerged). When only a small amount of ice remained, the cells were added drop-wise 
into pre-warmed 15% DCS (v/v) MEM. After a 2 hour incubation at 37°C, 5% CO2 cell 
attachment was assessed microscopically. When the majority of cells had attached, 
growth medium was changed. Cultures were thawed quickly and diluted in medium to 
minimise the toxic effects of the cryoprotectant, DMSO, which can induce 
differentiation in some cell lines. 
 
2.1.iii Conditioned Medium Collection and Storage Conditions 
 
To obtain conditioned medium (CM), confluent cultures in 90mm dishes were rinsed 
with 5ml of Hanks’ balanced salt solution, followed by 2x rinses with SF-MEM and 
incubated for 1 hour at 37
o
C. This medium was discarded and dishes rinsed again with 
SF-MEM. Cells were then incubated in fresh SF-MEM, 5-7ml per 90mm dish, for 24-
48 hours. Upon collection, the CM was spun for 5 minutes at 900g, to remove any cell 
debris, and the supernatant stored at -20ºC. CM was collected in batches of a minimum 
of 50-100ml. These were concentrated by Amicon filtration (2-10 fold), using a 3,000 
kDa cut-off filter. Later, batches of conditioned medium were pre-dialysed before 
Amicon concentration to remove any salts that may also be concentrated. Dialysis was 
performed overnight against distilled water, which was changed twice. Concentrated 
samples were aliquoted and frozen at -20ºC.
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Table 2.1. The optimum culture conditions for cell lines. 
 
Name  Cell Type Source Culture Media Subculture Ratio Culture Surface Experimental Passage 
FFD4 Human fetal fibroblast. Explant culture, Ninewells 
Hospital, University of Dundee 
(Schor et al., 1985, 1988) 
15% DCS MEM 1 to 4 Plastic  12-18 
F110 a Human fetal fibroblast. Explant culture, Dr. I. Ellis, 
University of Manchester  
(Schor et al., 1985, 1988) 
15% DCS MEM 1 to 4 Plastic  12-17 
FSF44 Human foreskin fibroblast. 
Obtained from one year 
old healthy donor. 
Explant culture, Dr I. Ellis, 
University of Manchester 
(Schor et al., 1985, 1988) 
15% DCS MEM 1 to 4/5 Plastic  15-22 
DFSF1 Human adult foreskin 
fibroblast. 
Explant culture, University of 
Dundee (Schor et al., 1985, 
1988).  
15% DCS MEM 1 to 4 Plastic  12-17 
ENDO 742 Transformed human 
microvascular endothelial 
cells, derived from normal 
breast tissue.  
Gifted by Dr Micheal O’Hare, 
2001 (O’Hare et al., 2001) 
15% DCS MEM,  
50µg/ml Ascorbic 
acid  
1 to 4 0.1% (w/v) 
gelatin coated 
plastic  
--- 
HUVEC  
1666 
Human umbilical vein 
endothelial cells 
Cell Applications Inc. 
Cat No : 200-05n 
Lot No: 1666 
15% DCS MEM,  
50µg/ml Ascorbic 
acid 
1 to 3 0.1% (w/v) 
gelatin coated 
plastic 
5-10 
HOEC  Human omentum 
microvascular endothelial 
cells 
 15% DCS MEM,  
50µg/ml Ascorbic 
acid 
1 to 3 0.1% (w/v) 
gelatin coated 
plastic 
18-22 
HAEC 
 
Human aortic endothelial 
cells 
Life Technologies Ltd. 
Cat No: C-006-SC 
15% DCS MEM,  
50µg/ml Ascorbic 
acid 
1 to 3 0.1% (w/v) 
gelatin coated 
plastic 
12-16 
HUVEC Human umbilical vein 
endothelial cells 
Dr Shane Foo, CRT. Originally 
purchased from Promo Cell: 
HUVEC-c, cryopreserved,  
cat no:C-12200 
15% DCS MEM,  
50µg/ml Ascorbic 
acid 
1 to 3 0.1% (w/v) 
gelatin coated 
plastic 
18-24 
BAEC 
Clones 2 & 3 
Bovine aortic endothelial 
cells. 
In house preparation.  
Schor et al., 1983 
15% DCS MEM,  
50µg/ml Ascorbic 
acid 
1 to 3 0.1% (w/v) 
gelatin coated 
plastic 
15-22 
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BAEC 2-2 U7 Bovine aortic endothelial 
cells. 
In house preparation (Schor et 
al.,1983). 
Bovine aorta No 2 cultures 
started June2003. 
 
15% DCS MEM,  
50µg/ml Ascorbic 
acid 
1 to 3 0.1% (w/v) 
gelatin coated 
plastic 
15-25 
HACAT Spontaneously 
immortalised human trunk 
skin keratinocytes. 
Gifted by Dr. Norbett Fusenig 
(Boukmap et al., 1988). 
15% DCS MEM 1 to 5 Plastic  45-55 
BEN HACAT derived, forms 
benign tumours in vivo.  
Gifted by Dr. Norbett Fusenig 
(Boukamp et al., 1990, 1997. 
Mueller et al., 2001). 
15% DCS MEM 1 to 5 Plastic  9-20 
MAL HACAT derived, forms 
malignant tumours in vivo.  
Gifted by Dr. Norbett Fusenig 
(Boukamp et al., 1990, 1997. 
Mueller et al., 2001). 
15% DCS MEM 1 to 5 Plastic  13-20 
MET HACAT derived, forms 
metastatic tumours in vivo.  
Gifted by Dr. Norbett Fusenig 
(Boukamp et al., 1990, 1997. 
Mueller et al., 2001). 
15% DCS MEM 1 to 5 Plastic  10-21 
HEK, 102-
05a 
Normal human adult skin 
keratinocytes. 
ECACC No: 06091505, Sigma 
–Aldrich (Fuchs 1990) 
Keratinocyte growth 
medium kit (ECACC 
No: 06091505) 
1 to 3 Plastic  3-5 
Mv.1.Lu Foetal Aleutian Mink lung 
epithelial. 
ECaCC No: 88050503, LGC 
Promochem (Motegi 2008) 
15% DCS MEM 1 to 4/5 Plastic 15-25 
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2.2 3D TYPE I COLLAGEN GEL MIGRATION BIOASSAY 
 
2.2.i Extraction of Type I Collagen 
 
Type I collagen was prepared from the tendons of rat tails. Tails from freshly killed rats 
were obtained from the animal house, Ninewells Hospital and stored, protected at -20
o
C 
until required. 
Per each batch of collagen, ten tails were thawed and “sterilised” by placing in 70% 
(v/v) ethanol for approximately 30 minutes. In a laminar flow cabinet, the tendons were 
removed by using forceps to snap the tail in half and the tendon was then pulled out 
from the inside. The tendons were dissolved in 500ml 3% (v/v) acetic acid and mixed 
overnight at 4
o
C, to extract the collagen. The extract was then centrifuged at 3000rpm, 
at 4
o
C for 150 minutes. The extracted collagen was then redissolved in sterile 20% 
(w/v) NaCl, and spun overnight at 4
o
C, followed by a repeat centrifugation. 
The following day, the extracted collagen was then decanted off and placed into pre-
sterilised cellulose membrane dialysis tubing (Sigma-Aldrich) and dialysed against 
distilled water for 24 hours (the water was changed 5 times). The dialysate was then re-
centrifuged as before and diluted to 2mg/ml. (Schor, 1980). 
 
2.2.ii 3D Collagen Gel Migration Bioassay 
 
The type I collagen, 2mg/ml, extracted from rat tail tendons was used to make 2ml 
collagen gels. In order for the collagen gel to set properly, gels were made in 10ml 
batches of 5 x 2ml per 35mm plastic tissue culture dishes (8.5ml Type I collagen, 0.5ml 
Sodium Bicarbonate, 1ml 10x Eagle Minimum Essential Medium), as  described by 
Schor 1980. 
Once the 2ml collagen gels, in the 35mm dishes, had set they were overlaid with 1ml of 
either serum-free MEM (SF-MEM) containing no further additives (baseline control) or 
the material to be tested (e.g. rhMSF, conditioned medium) at 4x the final concentration 
required. All controls and unknowns were tested on duplicate gels. Confluent stock 
cultures of fibroblasts (FSF44) were trypsinised, pelleted by centrifugation, resuspended 
in growth medium containing 4% (v/v) donor calf serum at 2-3 x10
5
 cells/ml and 1ml 
aliquots were added to the overlaid gels. Considering the 2ml volume of gel, 1ml 
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medium overlay (with or without test materials) and 1ml cell inoculum, this procedure 
gives a final concentration of 1% (v/v) serum (1% DCS-MEM) in both control and test 
cultures.  
The assay cultures were incubated for 4 days at 37
o
C, 5% CO2. The percentage of 
fibroblasts found within the 3D gel matrix was determined by counting the number of 
cells on the collagen surface and within the collagen matrix in 10 randomly selected 
fields, using a Leitz Labovert microscope. (Schor 1994, 1999). 
 
2.2.iii  Assessment of the 3D Collagen Gel Migration Bioassay 
 
After 4 day incubation, the media was carefully removed from the cell culture on 
collagen gels so as not to disturb the gel. 1ml of neutral buffered formalin was added to 
fix the cells. The gels were then stored at 4
o
C, until they were counted. 
Each gel was examined using phase contrast optics with a Lietz Labovert microscope 
fitted with s SY2 photographic graticule defining an area of 0.9 x 0.65cm, using the 20x 
objective. The numbers of cells on and below the gel surface, within the area defined by 
the area of the graticule were counted at 10 randomly selected areas. A cell was defined 
as having migrated into the gel when the cells on the surface could no longer be seen. 
These data were then used to calculate the mean and standard deviation of the total cell 
number per field and the percentage of cells within the collagen gel. 
 
 
2.3     CELL PROLIFERATION AND VIABILITY BIOASSAYS 
 
2.3.i  Growth Curve: An Assessment of Cell Proliferation and Viability 
 
Numerous variations of a standard growth curve were carried out in order to: 
1. Evaluate the morphology and growth characteristics of a cell line i.e. lag time, 
population doubling time and saturation density. 
2. To assess the effect of test substances, at various concentrations, (e.g. recombinant 
proteins, conditioned media, serum) on a cell lines’ morphology, viability and 
proliferation when compared to a control.  
3. To assess the effect of plating density on cell morphology, viability and 
proliferation. 
Variations to the standard protocol were also determined by the cell line used because: 
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1. Cell lines vary in the time taken to attach to the surface of a dish, for example Mink 
Lung Cells (Mv.1.Lu) attach within 2 hours, while the tumour cell lines can take over 6 
hours. This will therefore determine when the first baseline/ attachment count is taken.  
2. Cell lines have different growth rates. This will therefore determine the time course 
and seeding/ plating density of the experiment. 
3. Some cell lines’ viability and morphology can also be affected by the seeding 
density, for example the BAEC endothelial cell line. 
  
The standard method, adapted from J.P. Mather and P.E. Roberts, 1998.  
Following the subculturing protocol, a cell suspension was obtained from stock cultures. 
A cell count of this suspension was obtained by using a Coulter Counter Z1 Series 
(Beckman Coulter). This count was then used to determine the appropriate dilution of 
the cell suspension in order to have the correct amount of medium and cells to achieve 
the desired seeding density. The diluted cell suspension was then plated out onto the 
appropriate number of dishes and incubated at 37ºC, 5% CO2 until the cells had 
attached. After which, the first baseline count was taken (x2 dishes). The media on the 
remaining dishes was then replaced with either control media or that containing the test 
substance(s). Morphology, cell viability and numbers (duplicates counted) were then 
assessed every 24/48 hour incubation, for the duration of the experiment. Cell 
morphology was assessed microscopically. Cell viability was determined by Trypan 
blue exclusion. Cell numbers were counted using the Coulter Counter. Media on the 
dishes was replaced every 2-3 days for the duration of the experiment. 
 
2.3.ii Trypan Blue Exclusion- Assessment of Cell Viability 
 
Trypan blue is a vital stain that is used to estimate the proportion of viable cells in a 
population. The reactivity is based on the fact that the chromophore is negatively 
charged and does not react with a cell unless the membrane is damaged. Live (viable) 
cells do not take up the dye and dead (non-viable) cells do. 
A cell suspension was prepared using the previously described subculturing protocol. 
0.5ml of Hanks’ balanced Salt solution was added to cell suspension, followed by 0.5ml 
0.4% (v/v) trypan blue solution (Sigma-Aldrich). The cell suspension was gently 
agitated with a fine tip pasttete and then left for 5 minutes (no longer than 15 minutes is 
recommended). After which, 200µl of the suspension was removed and placed on a 
clean slide or dish. Ten randomly selected fields were selected and examined using 
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phase contrast optics with a Lietz Labovert microscope fitted with sSY2 photographic 
graticule defining an area of 0.9 x 0.65cm, using the 20x objective. Per field, the total 
number of cells were counted in addition to the number of viable and non-viable cells. 
The percentage of viable cells was calculated as follows, cell viability, % = (total viable 
cells/ total number of cells) x 100 (Louis and Siegel, 2011). 
 
2.3.iii MTT Assay- Assessment of Cell Viability 
 
MTT assays were carried out to determine the effect that various factors have on 
cellular growth. The standard assay protocol used was adapted from Mossaman 1983 
and Wilson 2000. 
Cells used for the assay were passaged either 1 to 2 or 1 to 3, dependent on cell line, the 
day before the MTT assay was set up. On the subsequent day, cells were plated at the 
appropriate density on a 96 well plate in FCS-MEM (FCS concentration varied with 
experiment but was usually 10% (v/v) FCS) and were incubated at 37ºC, 5% CO2 until 
cells attached (for Mv.1.Lu 2 hour attachment time). One plate was set up for each time 
point.  
Plate t = 0 was assessed for the first baseline count. Media was removed; cells were 
washed twice with SF-MEM and then incubated for 3 hours with a final concentration 
of 1mg/ml filtered sterilised MTT in a total volume 100 l (at 37ºC, 5% CO2). During 
the incubation period the yellow MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide) is reduced to purple formazan in the mitochondria of any 
living cells attached to the plate. The MTT was then removed and 100 l of DMSO 
(dimethyl sulfoxide) was added to dissolve the formazan, creating a coloured solution 
(20 minutes on a shaker). The resulting coloured solution was assessed by reading the 
plate spectrophotometrically on the Flurostar Optima plate reader (BMG LABTECH) at 
550nm, reference filter 620nm. 
The remaining plates were changed to test conditions and incubated until required and 
then developed as stated for t =0. 
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2.4  ENDOTHELIAL SPROUTING ASSAYS 
 
2.4.i 2D Post-Confluent Sprouting Assay 
 
Numerous variations of this assay were performed however the foundation of the assay 
was to plate endothelial cells on a 2D surface followed by growth in a high serum 
concentration, 15-20% DCS MEM, until confluence was attained. 
Confluent stock cultures of endothelial cells were trypsinised, pelleted by centrifugation 
and resuspended in 15% DCS MEM. The cells were then plated onto a variety of 2D 
surfaces on 35mm dishes; these included a coating of 0.1% (w/v) gelatin, native 
collagen, the upper surface of a type I collagen gel and the surface of the plastic dish. 
The cells were then cultured until confluence at 37
o
C, 5% CO2; the medium changed 
every 2-3 days, as required. 
Once the endothelial cultures reached confluence and formed a uniform cobblestone 
monolayer the overlying medium was changed to test conditions. The cells were 
overlaid with 2ml of medium containing a low serum concentration (0-5% DCS) with or 
without the material to be tested. All controls and unknowns were tested in triplicate 
cultures. Over the course of the experiment the overlays were changed every 2-3 days. 
Post-confluence observational data was obtained microscopically over the time-course 
of the experiment. A variety of observations were made, focusing specifically on the 
emergence of endothelial cells exhibiting the sprouting phenotype. Typically these 
observations would include type of endothelial morphology exhibited, number of fields 
of view containing sprouting cells, 40 point counts (number of points were sprouting 
cells present), number of sprouts present as either single cells or integrated with other 
sprouts to form sprout associations. Irrespective of the method used, data was collected 
from ten fields of view per dish. 
The time course of the experiment would be determined by comparing observations of 
the test material to the control cultures and ultimately by the condition (health) of the 
endothelial cultures.  
 
2.4.ii 3D Spontaneous Sprouting Assays 
 
This assay was based on the ability of endothelial cells to spontaneously exhibit a 
homologous sprouting phenotype when plated within a type I collagen gel.    
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Confluent stock cultures of endothelial cells were trypsinised, followed by collection in 
2-5mls 15% DCS MEM. A cell count of this suspension was obtained by using a 
Coulter Counter Z1 Series (Beckman Coulter). The plating density of the endothelial 
cells was 6.5 x 10
5
 per ml of type I collagen gel. To ensure the gels to set properly they 
were made in batches of 10ml gels which therefore required a total of 6.5 x 10
6
 cells. 
The correct volume of the cell suspension was removed and pelleted by centrifugation. 
Meanwhile the components of the type I collagen gel were combined together; 8.5ml 
Type I collagen, 0.5ml Sodium Bicarbonate, 1ml 10x Eagle Minimum Essential 
Medium, as  described by Schor 1980. The cell pellet was resuspended in this mixture 
and aliquoted at the appropriate volumes; 2ml per 35mm plastic tissue culture dish, 
0.5ml per well of a 24 well tissue culture plate. The gels were left to set for at least 30 
minutes, followed by over-laying with 20% DCS MEM; 2ml per 35mm dish, 0.5ml per 
well of 24 well plate. 
After a 2-3day incubation period at 37
o
C, 5% CO2 observations of the status of the cells 
were made microscopically. Only healthy cultures displaying a typical sprout 
morphology, with single sprouts and small associations (groups of 2- 5 sprouts), were 
selected for testing. Without disturbing the collagen gel the overlying medium was 
removed and changed to the test conditions. Typically, the test factors were diluted with 
a low serum concentration of MEM, to give a final serum concentration of 1-5% DCS. 
Each control and test overlay were performed in triplicate.  
Observations were made over the time-course of the experiment, typically after each 24-
48 hour incubation period. The analysis of the effect the test material had on the 
endothelial sprouts consisted of performing a 40point count in ten fields per gel, with 
the total number of sprouts counted calculated for each variable.  The time course of the 
experiment was determined by the effect(s) seen, as compared to the control cultures, 
and the health and quality of the endothelial cells. 
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2.5  ANTIBODIES 
 
2.5.i. Antibodies Raised Against Peptides in the MSF Primary Sequence, 
Produced In House 
 
Table 2.2: In house prepared MSF specific antibodies; information regarding type, 
function and purification technique. 
Antibody  Antigen Type Purification 
technique 
Function Methods 
employed 
 
RP2 
RpVSI 
MSF-unique 
carboxyl-terminal 
decapeptide 
VSIPPRNLGY 
 
Rabbit 
polyclonal 
POROS A, 
affinity 
chromatography 
Identification 
of total MSF 
IHC, 
ELISA,  
IP 
Pep Q 1.1 
Pep Q 3.2  
Pep Q 5.1 
Pep Q 5.2 
21-mer peptide 
containing the 
IGDQ sequence 
in module 1-7 
TNEGVMYRIG
DQWDKQHDM
GH 
Mouse 
monoclonal 
Protein G 
chromatography 
IGD function 
neutralising 
antibody, 
 
Bioassays, 
ELISA, 
capture 
antibody 
 
 
 
2.5.ii. Purification of Mouse Monoclonal IgG Antibodies from Hybridoma 
Conditioned Medium, using Protein G Chromatography. 
 
Typically, a volume of 300-500ml of hybridoma conditioned media was collected under 
serum free conditions (Hybridoma SF media, Gibco Invitrogen), which was spun at 
900rpm for 5 minutes to remove any cellular matter. Followed by, dialysis with 20mM 
Sodium Phosphate pH 7.0 at 4
o
C (buffer changed after first hour and then dialysis 
continued overnight) Centrifugation was repeated to remove any particulates before 
chromatography, 10,000-20,000g for 10 minutes. 
The sample was applied slowly, 1-2ml/minute, to a pre-equilibrated HiTrap Protein G 
Sepharose (GE Biosystems) 0.2µm filtered 20mM Sodium Phosphate pH7.0. The 
column was then washed to remove any unbound material. Elution buffer, 0.1M 
Glycine pH 2.7, that had been filtered (0.2µm) was then applied to the column; the low 
pH resulting in the antibody being eluted. However, this low pH is not suitable for 
antibody storage so the pH was raised by the addition of 1M Tris-HCl pH8.0 (50µl/ml) 
to each of the antibody containing fractions. Purified antibody was immediately 
transferred to non- stick eppendorfs, for storage at -20
o
C. Before storage, the column 
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was washed with 5 column volumes of 0.2µm filtered 20% (v/v) ethanol to prevent 
microbial growth. 
Using a spectrophotometer, the antibody concentration was estimated by absorbance at 
280nm using the following calculation: Antibody concentration= (OD 280nm x10 x 
dilution factor) / 14. The blank (reference) was 1ml of elution buffer and 50µl 1M Tris-
HCl pH8.0.  
When the antibodies were required for bioassays post-purification dialysis was 
performed; the antibody was dialysed 4hours (dialysis buffer changed after first 2 
hours) at room temperature with MEM without phenol red. 
 
 
2.6 RECOMBINANT PROTEINS  
 
2.6.i Recombinant Proteins produced In House. 
 
Table 2.3. Details of in- house prepared recombinant proteins. 
Recombinant  
protein 
Source of cDNA Expression host 
and vector 
Purification method Storage 
MSF aa+ 
isoform 
 BL21 pLysS 
(host) bacteria 
(Promega) using 
the pRSET vector 
(Invitrogen Ltd., 
Paisley, UK) 
Affinity purification 
utilising the His6 
tags on nickel 
charged 1ml Hi-
Trap HP chelating 
columns 
Dialysed 
against PBS.  
-20ºC. 
NGAL, 
lipocalin 
the full length 
gene for NGAL 
was amplified 
from cDNA 
image clone ID 
5421124 
(Geneservice Ltd., 
Cambridge, UK), 
BL21 pLysS 
bacteria using the 
pRSET vector 
(Invitrogen Ltd., 
Paisley, UK) 
Affinity purification 
utilising the His6 
tags on nickel 
charged 1ml Hi-
Trap HP chelating 
columns 
Dialysed 
against 
Binding 
buffer. -20
o
C  
 
 
2.6.ii Recombinant Protein Production 
 
Preparation and Selection of Bacterial Colonies 
Escherichia coli strain BL21 (DE3) was used for the expression of the recombinant 
proteins. Stocks of the bacterial hosts harbouring the recombinant proteins were stored 
at -80
o
C. DE3 plysS transformed with the relevant plasmid were grown overnight in 
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liquid culture at 37
o
C under carbenicillin selection (50 g/ml) in 10ml of LB broth, 
shaking at 275rpm in an orbital incubator.  
These cultures were then streaked onto carbenicillin, LB-agar plates, which were then 
incubated overnight at 37
o
C. The following day the plates were inspected and an 
isolated single colony was selected using a pipette tip and placed in a 10ml aliquot of 
LB media containing 1% (w/v) glucose and 50 g/ml carbenicillin. Followed by, 
incubation overnight at 37
o
C with constant shaking at 275rpm. 
 
Protein Production By E.Coli. 
Successful 10ml cultures were added to 500ml of LB broth, 1% (w/v) glucose and 
grown at 37
o
C under carbenicillin selection (50 g/ml) in conical flasks. When the 
culture reached an OD 600nm of between 0.4-0.6, the optimum for protein production, 
isopropyl- -D-thiogalactopyranoside (IPTG) was added to give a final concentration of 
1mM. IPTG induces gene expression. The culture was left mixing for 2 hours at 37
o
C, 
afterwhich the media was split into 50ml aliquots and spun for 10 minutes, at 3000rpm. 
The supernatant was then carefully removed and discarded. The pellets were stored at -
20
o
C until required. 
 
Extraction of Bacterial Recombinant Insoluble Protein 
For each bacterial pellet, collected from 50ml culture, 2.5ml of Bug Buster (Invitrogen) 
and 1 l/ml benzonase was added and thoroughly resuspended by vortexing, followed by 
vigourous shaking for 20 minutes at room temperature.  The Bug Buster gently disrupts 
the cell wall of the E.coli and liberates the soluble proteins without denaturing them, 
whilst the benzonase, an endonuclease, is added to reduce the viscosity of the extract 
caused by the liberation of chromosomal DNA. 
The lysate was then split between four centrifuge tubes and spun at 20,000rpm for 15 
minutes. The supernatant, which will contain the soluble proteins, was decanted and 
stored at -20
o
C. Each of the four pellets, containing the insoluble proteins was 
resuspended in 5ml of Bug Buster containing 10mg/ml lysozyme; to enhance extraction 
efficiency. 20 minutes of vigourous shaking at room temperature, followed. 30ml of 
1:10 diluted Bug Buster was added to each tube and then spun at 20,000rpm for 20 
minutes. The supernatant was discarded and the pellet resuspended again in the diluted 
Bug Buster followed by centrifugation.  
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Discarding the supernatant, 2.5ml of 500mM CAPS pH11.0, 0.5% (w/v) n-
laurylsarcosine and 10mM DTT was added to each pellet and left to dissolve for a 
maximum of one hour, at room temperature. The solubilised protein solution was then 
spun, 20,00rpm for 10 minutes, and then dialysed at 4
o
C as follows; initially for 4 hours 
and then overnight in 20mM Tris-HCl ph 8.5, 0.1mM DTT, followed by 4 hours in 
20mM Tris-HCl pH 8.5. 
 
Purification of Solubilised Recombinant Protein 
The solubilised recombinant proteins were purified by virtue of their His6 tags on nickel 
charged 1ml Hi-Trap HP chelating columns (GE Healthcare, Amersham, 
Buckinghamshire, UK).  
The HiTrap Chelating Hp column was charged with nickel ions by washing the column 
with 0.1M nickel chloride. The solubilised protein sample is spun, 20,000rpm for 10 
minutes, to remove any particulate before being loaded onto the column followed by  
the binding buffer; 50mM sodium phosphate, 300mM NaCl, 10mM imidazole. The 
histidine –tagged proteins which bind to the column were eluted by the increased 
concentration of imidazole in the elution buffer; 50mM sodium phosphate, 300mM 
NaCl, 500mM imidazole. The collected fractions were stored at 4
o
C. 
 
Recombinant Protein Identification and Protein Estimation. 
Identification of the positive fractions, containing the recombinant protein, was by 
SDS- PAGE Electrophoresis. Each fraction was loaded onto a 12% resolving, 4.5% 
stacking acrylamide gel, under reducing conditions alongside known molecular weight 
markers (Biorad Broad Range). Protein bands were visualised by Coomassie blue 
staining. Fractions containing the recombinant protein were pooled together and then 
dialysed at room temperature for 4 hours against either PBS for recombinant MSF 
isoforms or the Hi- Trap Binding buffer for recombinant lipocalin. Protein 
concentration was estimated, after dialysis, by comparing the sample against  
known standards, BSA or GBD, on a 12% resolving, 4.5% stacking arcylamide gel, 
under reducing conditions. All recombinant proteins were stored at -20
o
C in non-stick 
eppendorfs. 
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2.7 PROCEDURES TO FRACATIONATE CONDITIONED MEDIUM 
 
2.7.i Ammonium Sulphate Precipitation 
 
Proteins were precipitated from conditioned medium (CM) by the stepwise addition of 
solid ammonium sulphate. To obtain the first fraction (0-10% saturation), solid 
ammonium sulphate (0.056mg/ml) was slowly added to neat CM; the sample was then 
vigorously agitated on Vortex mixer and left to form a precipitate at 4
o
C for a minimum 
of 2 hours. After centrifugation at 1000g for 5 minutes, the supernatant was aspirated 
and kept for the next step. The pellet was resuspended in 20mM Tris.HCl pH 7.4 
containing 0.1M NaCl. The following fractions were then obtained by adding the 
indicated amount of solid ammonium sulphate to the supernatant and repeating the 
above procedure in a stepwise fashion: 10-20% saturation (0.057g/ml); 20-30% 
saturation (0.059g/ml); 30-50% saturation (0.127g/ml); 50-80% saturation (0.214g/ml); 
final supernatant >80% saturation (Jakoby, 1971). 
All of the fractions were subsequently assessed for biological activity in the collagen gel 
fibroblast migration assay. Each fraction was dialysed at 4
o
C for 24 hours against PBS. 
The dialysed fractions were sterile filtered by 0.2µm Millipore filtration before use in 
the migration assay. 
 
2.7.ii Size Exclusion Chromatography (SEC) 
 
This is a separation process based on gel filtration, whereby a sample is passed through 
a column that is packed with a porous resin. The exclusion range of the resin, i.e. the 
range of pore sizes, determines the size of molecules that can be separated. Larger 
molecules, because they cannot enter the pores, flow more rapidly around the resin 
beads and emerge earlier from the column. Smaller molecules, because they can 
penetrate the pores, travel a longer path through a larger buffer volume and emerge 
later. Typically the excluded volume (i.e. the column volume experienced by larger 
molecules) is about 35% of the resin volume, while the total volume experienced by the 
small molecules is nearly equal to the total resin volume.  
Conditioned medium (CM), routinely 10x concentrated, was fractionated by SEC 
initially using Superose 12 HR 10/30 (GE Healthcare) fractionation range 1-300kDa. 
This method was subsequently scaled-up using a Superdex 75 HiLoad 26/60 (GE 
Healthcare), fractionation range 3-70kDa, to provide sufficient material for down-
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stream analyses. The Superdex column was pre-equilibrated with three column volumes 
of running buffer, 20mM HEPES, 150mM Sodium chloride, pH 7.4. Prior to sample 
loading, the column was calibrated with known molecular mass markers; including 
BSA (66kDa), ovalbumin (45kDa) and chymotrypsinogen (25kDa) (GE Healthcare). 
Prior to separation, the concentrated CM was spun at 13,000rpm for 5 minutes to 
remove any debris. 4ml aliquots of the concentrated CM was applied to the column and 
allowed to enter the resin bed.  Additional buffer was applied to the column and the 
emerging fractions were collected. Multiple runs were completed to provide sufficient 
material for downstream analyses, 100 x 3ml fractions were collected from each run (2 
ml/min). Aliquots of the resultant fractions were tested for bioactivity in the 3D 
collagen gel assay. Fractions containing biological activity, of either MSF or MSF-I, 
were pooled from each run and stored at -80°C. 
 
2.7.iii  Ion Exchange Chromatography 
 
During ion exchange chromatography a sample is passed through a charged column. 
Charged groups on the surface of a protein interact with oppositely charged groups 
immobilised on the ion exchange support. When the net overall charge of the protein is 
zero, the protein is at its isoelectric point (pl). When a protein is in a buffer with a pH 
higher than its pl, the protein will have a negative net charge and will bind to a 
positively charged support or anion exchange medium. When the buffer has a pH below 
the protein pl it will have a positive net charge and bind to a negatively charged support 
or cation exchange medium. Changing the pH of the binding buffer will allow for 
elution of the bound protein. (Current protocols in Protein Science 1990. Supp.8.4, John 
Wiley& Sons, Inc.). 
After SEC, fractions containing MSFI activity were pooled, dialysed against 20mM 
Tris-HCl pH 7.5 and then pumped at 1ml/minute onto an ANX column (Hi Trap FF 
1ml, GE Healthcare) pre-equilibrated with the dialysis buffer. Material unbound to the 
ANX column was collected and bound material eluted as a single peak by washing the 
column with 20mM Tris-HCl pH 7.5 1M NaCl. Aliquots (200-1000µl) of the bound and 
unbound fractions were tested for bioactivity in the 3D collagen gel assay, in the 
presence of 100pg/ml rhMSF. Unbound material (containing MSFI bioactivity) was 
then stored at -20°C and subsequently concentrated by freeze drying, after dialysis 
against distilled water. Freeze dried samples were stored frozen at -80ºC. 
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2.7.iv SDS- PAGE Electrophoresis 
 
Polyacrylamide gel electrophoresis is used to separate “fractions/samples” according to 
their physical properties as they are forced through a gel by an electrical current. PAGE 
was used both as an analytical tool to provide information on the molecular mass, purity 
or presence of a protein and as a preparative tool to obtain a pure protein sample. SDS-
PAGE separates proteins primarily according to size because the SDS- coated proteins 
have a uniform charge: mass ratio. Protein molecular weight was estimated by running 
standard proteins of known molecular weights in a separate lane of the same gel (Biorad 
broad range markers). Since we knew the protein we were looking for had a small 
molecular mass a high percentage acrylamide gel was used; routinely a 12% resolving 
gel and 4.5% stacking gel, under reducing conditions. 
Samples were redissolved in Laemmli loading buffer (BioRad Laboratories Ltd., Hemel 
Hempstead, Hertfordshire UK) containing 5% (v/v) 2-mercaptoethanol and heated for 5 
minutes at 80
o
C prior to loading onto the gel. Electrophoresis was performed in a 
Tris/glycine/SDS buffered cooled tank at 30mA, 150V (Biorad Mini-Protean 
Electrophoresis Apparatus, LKB Macro Drive 1 power supply). Protein bands were 
visualised using Gel code Blue Staining reagent (Perbio). (Method adapted from 
Laemmali, 1970). 
 
Table 2.4: Recipe for SDS- Polyacrylamide gel preparation. 
Reagent RESOLVING GEL 
12% Acrylamide 
STACKING GEL 
4.5% Acrylamide 
1M Tris pH 8.7 (Sigma-Aldrich) 3.76ml ----- 
 
1M Tris pH6.9 (Sigma- Aldrich) ----- 625µl 
30% (v/v) Acrylamide/ Bis (BioRad)  
4.0ml 
 
750µl 
Distilled Water 2.14ml 3.525ml 
10% (w/v) sodium dodecyl sulphate 
(Sigma-Aldrich) 
 
100µl 
 
100µl 
10% (w/v) ammonium persulphate 
(Biorad) 
 
50µl 
 
50µl 
TEMED (Sigma-Aldrich) 5µl 10µl 
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2.7.v Gel Elution of Protein Bands 
 
In order to remove any potential contaminants, SDS-PAGE gels that were to be used for 
gel elution of protein bands were pre-run for 1 hour at 150V. After which, the running 
buffer was replaced and then the samples were then loaded. After SDS PAGE, gel lanes 
were cut into 0.5cm slices and each slice placed into individual 1.5ml tubes containing 
1ml of elution buffer (100mM ammonium bicarbonate, 1mM SDS). Elution was 
performed overnight, at room temperature, by mixing end on end. After elution, 
samples were stored at -20
o
C and 4µl aliquots were subsequently tested for MSF and 
MSFI bioactivity in the 3D collagen gel assay (Kurien and Scofield, 2012). 
 
 
2.8 IMMUNOBLOT (WESTERN BLOT) - INDIRECT METHOD 
 
After electrophoresis the separated proteins were transferred onto a secondary matrix of 
nitrocellulose membrane by electroelution; 15V for 42 minutes, using a BioRad semi-
dry blotting apparatus and the conducting buffer 48mM Tris, 39mM glycine, 1.3mM 
SDS, 20% (v/v) methanol (Towbin, 1979). Buffers used during development of the 
blots were based on TBS (20mM Tris-HCl, 137mM sodium chloride pH 7.6). To 
prevent any non-specific binding, the membrane was blocked using 1% (w/v) low fat 
skimmed milk powder, 0.05% (v/v) Tween 20, in TBS for 10-30 minutes at room 
temperature. The primary antibody, diluted in blocking buffer, was incubated overnight 
at room temperature.  
The following day, the blot was washed, 3 x 20 minutes, in TBST (TBS, 0.05% (v/v) 
Tween 20). A horseradish peroxidise labelled secondary antibody that is directed 
against the primary antibody, diluted in blocking buffer, was incubated with the blot at 
room temperature for 1 hour. Finally, blots were washed 3 x 20 minutes in TBST and 
1x 5 minutes in TBS. Using the Genome Gel analysis system, bands were then detected 
by chemiluminescence using the substrate SuperSignal West Dura (Perbio). (Method 
adapted from Towbin et al., 1979). 
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Table 2.5: The operational concentrations of antibodies for performing 
immunoblotting. 
Antigen Primary Antibody Secondary Antibody 
   
NGAL Anti-NGAL MAB1757 
(R&D Systems) 
2µg/ml 
Rabbit anti-rat HRP 
(DAKO) 
1:10,000 dilution 
   
Total MSF Rp VSI 
( In house prep) 
1:10,000 dilution 
Goat anti- rabbit HRP 
(Pierce) 
1:10,000 dilution 
 
 
 
 
2.9  IMMUNOPRECIPTATION OF MSF 
 
MSF was immunoprecipitated from CM using the MSF-specific rabbit polyclonal 
antibody (RpVSI) and the Seize Classic Immunoprecipitation Kit (Perbio). Following 
SEC, fractions containing migration stimulating activity (F-msa) were pooled and 
concentrated 100 fold by freeze drying. After resuspension and dialysis against PBS, 
100µg of POROS A purified RpVSI antibody was added to a 1ml aliquot of F-msa. 
Samples were mixed gently overnight at 4ºC and on the following day 400µl of washed 
and equilibrated immobilised Protein G was added. The samples were then mixed for 3 
hours at 4ºC. The immobilised complex was washed and eluted from the beads 
according to the kit instructions. The elution was repeated 5x, eluted fractions were 
tested for MSF bioactivity in the fibroblast migration assay.   
 
  
2.10 MASS SPECTROSCOPY 
 
Protein mass fingerprint data was obtained by MALDI-Tof-Tof (MS/MS) analysis 
performed at the University of Dundee ‘Fingerprints’ Proteomics Facility, using an 
Applied Biosystems 4700 Proteomic Analyser.  
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2.11    QUANTIFICATION OF PROTEINS 
 
2.11.i   Colorimetric Indirect ELISA  
 
Polystyrene 96-well microplates (Costar, Insight Biotechnology Limited, Wembley, 
UK) were coated overnight, at room temperature in a humidified chamber, with the 
appropriate standards (serial dilutions in carbonate buffer pH 9.6, 100µl per well) and 
samples to be tested. After washing with 200µl PBS per well, non-specific binding sites 
were blocked by incubation with 200µl/well 1% (w/v) BSA PBST (PBS with 0.05% 
(v/v) Tween 20) for one hour at room temperature with gentle agitation. The plate was 
then washed, 200µl per well, with PBS, twice with PBST and again with PBS. Primary 
antibody, diluted in 1% (w/v) BSA-PBS-T was then added to each well and the plate 
incubated for 1 hour at room temperature. The four step washing procedure was then 
repeated. The secondary antibody, a HRP conjugate, diluted in1% (w/v) BSA- PBS-T 
was then added and the plate incubated for 1 hour at room temperature, followed by the 
washing procedure. Tetramethylbenzidine (TMB, DAKO), the substrate for HRP, was 
then added (50µl per well) and the plates were incubated for 10 minutes with gentle 
orbital shaking. The reaction was stopped with 50µl 2M H
2
SO
4
, and OD 450nm 
(reference 570nm) measured by plate reader (Flurostar Optima, BMG LABTECH and 
MRX DYNEX, DYNEX Technologies Limited, Worthing, West Sussex UK). (Weller 
1954).            
 
Table 2.6: The operational conditions for performing the Indirect ELISA. 
 
ANTIGEN STANDARDS PRIMARY 
ANTIBODY 
SECONDARY 
ANTIBODY 
    
NGAL 200-1.56ng/ml 
NGAL 
(In house prep) 
Goat anti-NGAL 
1µg/ml 
(AF1757, R&D Systems) 
Rabbit anti-goat HRP 
(DAKO) 
1:1000 dilution 
 
2.11.ii    Colorimetric Sandwich ELISA 
 
 Polystyrene 96-well microplates (Costar, Insight Biotechnology Limited, Wembley, 
UK) were coated overnight at room temperature in a humidified chamber with the 
capture antibody, 100μl per well diluted in coating buffer (carbonate buffer, pH 9.6, 
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Pierce) On the following day, the plate was washed with PBS and blocked for 1 hour in 
1% (w/v) BSA-PBS-T (blocking buffer, 200µl per well) with gentle agitation. 
The plate was then washed with PBS, twice with PBST (PBS with 0.05% (v/v) Tween 
20, Pierce) and again with PBS. Using the appropriate standards, a standard curve was 
prepared in serial twofold dilutions in blocking buffer. Test samples and standards were 
added 100µl per well and incubated for 90 minutes at ambient temperature. The plate 
was then washed, as described previously. The sandwich antibody, was then diluted in 
1% (w/v) BSA-PBS-T, 100µl added per well and the plate incubated for 90 minutes at 
ambient temperature. The plate was then washed, as described previously. The detection 
antibody, a HRP conjugate, was then added 100µl to each well and incubated for 90 
minutes at room temperature, followed by the washing procedure.  The substrate for 
HRP (tetramethylbenzidine, DAKO) was then added and the plates were incubated for 
10 minutes with gentle orbital shaking. The reaction was stopped with 2M H2SO4, and 
OD 450nm measured by plate reader (Flurostar Optima, BMG LABTECH or MRX 
DYNEX, DYNEX Technologies Limited, Worthing, West Sussex UK). (Palomaki, 1992) 
 
Table 2.7: The operational conditions for performing the Sandwich ELISA. 
 
 
ANTIGEN 
STANDARDS CAPTURE  
ANTIBODY 
SANDWICH 
ANTIBODY 
DETECTION 
ANTIBODY 
     
 
MSF 
(total) 
 
200-1.56ng/ml 
Recombinant 
MSF 
 
MAb Pep Q 
5.1 
10μg/ml 
RpVSI 
(protein A purified 
rabbit polyclonal 
serum 
1:1000 dilution 
(~2µg/ml) 
Goat anti-rabbit 
HRP conjugate 
(Pierce) 
1:1000 dilution 
     
 
 
2.12 IMMUNOLOCALISATION METHODS 
 
2.12.i Cell Pellet Preparation 
 
Cell lines used for immunohistochemical staining were prepared by two methods; either 
plated onto a plastic surface, namely chamber slides or 24 well plates (Nunc) or plated 
within and/or on a 3D collagen type I matrix.  
Cells were plated onto the plastic surfaces at densities of 5-9 x 10
3
cells/cm
2
 and 
incubated for 1-3 days under standard conditions, until reaching approximately 70-80% 
confluency. After which, media was removed and cells fixed with 2% (v/v) formalin in 
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PBS for 30 minutes at room temperature, followed by permeabilisation with 100% (v/v) 
methanol (VWR) for 10minutes at-20
o
C. 
For collagen gel cell pellets; 1x 90mm confluent dish of cells were trypsinised, as 
described previously, to obtain a cell suspension which was spun, for 5 minutes at 
900rpm. The cell pellet was gently resuspended in 100µl of 15% (v/v) DCS MEM 
which was then added to 2ml of collagen gel solution (1.7ml Type I Collagen 
(preparation previously described), 100µl 7.5%(v/v) solution sodium bicarbonate, 200µl 
10X MEM). After, the collagen gel had set, around 5-10 minutes, growth media was 
added and the collagen pellet was incubated at 37
o
C, 5% CO2 for 3-4 days. 
To obtain cells on the surface of the pellet, a cell suspension in 15% (v/v) DCS MEM 
was added to a set 2ml collagen gel. A 1-2 hour incubation followed to allow cells to 
attach to the gel surface. Afterwhich the growth media was replenished followed by 
appropriate incubation time. 
All cell pellets were fixed overnight at 4
o
C in 10mls neutral buffered formalin (VWR), 
followed by paraffin wax embedding (Dr. David Kellock, Department of Surgery and 
Molecular Oncology, Ninewells Hospital, Dundee). Depending on the degree of gel 
contraction, each pellet was split 1-2 or 3 and then individually embedded. Each 
paraffin block was cut into 3µm sections and baked for 30 minutes at 60
o
C to dissolve 
the wax. Before commencing staining sections were deparaffinised with xylene (VWR). 
 
2.12.ii  Immunostaining Protocol 
 
Sections were firstly, rehydrated through decreasing concentrations of ethanol. 
Endogenous peroxidase activity was blocked by immersion in 3% (v/v) hydrogen 
peroxide in PBS for 20 minutes and non-specific binding was blocked by incubating in 
20% (v/v) normal serum in PBS (same species as secondary antibody) for 30 minutes. 
Sections were ringed using an immuno pen (Dako pen, Dako, Denmark) to minimise the 
volume of reagents required. To reduce non-specific background staining sections were 
pre-treated with Avidin/ Biotin blocking step (Avidin/Biotin Blocking Kit, Vector Labs, 
Peterborough, UK). 
Following optimisation the appropriate dilution of primary antibody was made using 
20% (v/v) normal serum in PBS and incubated overnight in a humidified chamber at 
4
o
C, followed by 1 hour at room temperature. Controls were incubated with normal 
serum IgG from the same species as the primary antibody was raised in. Secondary 
antibody incubation was for 1 hour at room temperature in a humidified chamber, with 
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an appropriate dilution made in 20% (v/v) normal serum PBS. Staining was visualised 
using the avidin-biotinylated enzyme complex (Vectastain ABC Kit, Standard Elite, 
Vector Labs, Peterborough, UK) and incubation with DAB (3’, 3’-diaminobenzidine), a 
substrate for the enzyme (Sigma, Dorset, UK). Slides were counterstained with 
haemtoxylin and blueing agent. Followed by dehydration through a series of increasing 
concentrations of ethanol and cleared in two changes of xylene (this step omitted for 
plastic slides and plates) before being coverslipped with mounting medium, aqueous 
mount (Sigma, Dorset, UK) for plastics and for glass, DPX (BDH, VWR, 
Leicestershire, UK). 
 
2.12.iii Optimum Conditions for Immunostaining Reagents 
 
Table 2.8: The operational conditions for performing Immunostaining. 
 
Antigen Primary 
Antibody  
Serum Block Secondary 
Antibody 
Negative Control 
     
 
Total 
MSF 
 
Rp2/98pFA2 
pFn1, Rabbit 
Polyclonal 
 
Cells on Plastic  
2.5 - 5µg/ml 
 
Cells on/in 
collagen: 
33µg/ml 
 
 
 
20% (v/v) 
Normal Goat 
Serum (NGS)  
in PBS  
(Vector,  
S-1000) 
 
 
Biotinylated Goat 
Anti-Rabbit IgG 
(H+L) 
(Vector, BA9200)  
 
6µl/ml in 20% 
(v/v) NGS in PBS 
 
 
Normal Rabbit IgG 
preabsorbed to 
Fibronectin 
(Dako Cytomation, 
X0936) 
     
 
NGAL 
 
Anti-Human 
Lipocalin-
2/NGAL 
Polyclonal Goat 
IgG (R&D 
AF1757) 
 
Cells on Plastic: 
0.1 – 0.5µg/ml 
 
Cells on/in 
collagen: 2µg/ml 
 
20% (v/v) 
Normal Swine 
Serum (NSS)  
with PBS 
(Vector,  
S-4000) 
 
 
Polyclonal Swine 
Anti-Goat, 
Mouse, Rabbit 
IgG/ Biotinylated 
(DakoCytomation 
E0453) 
 
1:150 dilution in 
20% (v/v) NSS in 
PBS 
 
 
Normal Goat IgG  
(R&D, AB-108-C) 
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    Chapter 3: Results 
 
    THE ASSESSMENT OF THE BIOACTIVITY OF CONDITIONED MEDIUM 
 
3.1 AIMS 
 
To collect conditioned medium from various cultured cell lines, followed by the 
analysis of bioactivity in the 3D collagen gel migration assay. The primary objective 
was to test conditioned medium for the ability to inhibit the motogenic activity of 
rhMSF. The conditioned medium collected and subsequently tested was a complex 
mixture of multifarious proteins and this screening phase will only give a rudimentary 
indication of its constituents and their bioactivity. This screening procedure was the first 
step in a process to identify inhibitor(s) to Migration Stimulating Factor. 
 
 
3.2 BACKGROUND  
 
The numerous bioactivities attributed to MSF (motogenesis, matrix remodelling, 
hyaluron biosynthesis and angiogenesis), all appear to have a causal link to its 
motogenic activity. Therefore, the sensitive in vitro bioassay for assessing the 
motogenic bioactivity of MSF, the 3D collagen gel fibroblast migration assay, was 
selected as being fundamental to the identification of potential MSF-I activity. The 
preliminary search focused on assessing the ability of conditioned medium, from 
numerous cultured cell lines, to inhibit the MSF stimulated migration of adult 
fibroblasts in a 3D Type I collagen gel. 
The 3D collagen gel fibroblast migration assay was developed as a means to explore the 
activity of cultured cells within a physiologically relevant 3D macromolecular matrix. 
Collagens are triple helical proteins that occur in the extracellular matrix (ECM); 
comprising a family of over 30 collagens and collagen-related proteins. Type I collagen, 
a fibrous, structural protein consisting of D-periodic fibrils forms the major component 
and is the primary determinant of tensile strength of the ECM. Commonly used as a thin 
layer on tissue-culture surfaces, Type I collagen enhances the attachment and 
proliferation of a variety of cells including endothelial, epithelial, fibroblasts and 
hepatocytes. In vitro, collagen fibrillogenesis is a spontaneous self-assembly process 
with the Type I collagen fibrils forming a 3D supermolecular gel. However, in vivo the 
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process is not so simple with cellular mechanisms controlling the self-assembly process 
with the inclusion of fibronectin, integrins and collagen V (Kadler et al., 2008). As 
described in Chapter 2, Material & Methods, collagen I was extracted from rat tail 
tendons by incubating in a dilute acid solution (3% v/v acetic acid) and then 
reconstituted into fibrils by neutralisation, forming a homogenous 3D gel (Schor et al., 
1990).  
A collagen substratum is regarded as an appropriate biological scaffold to study diverse 
aspects of cell behaviour in vitro, including positioning and migration, cell growth and 
differentiation and matrix contraction (Schor et al., 1982, Allen et al., 1984). The fibre 
distribution and biophysical architecture is considered the closest resemblance to 
interstitial soft tissues, dermis and the network-like stroma of the lymph node cortex, 
promoting a more in vivo-like cellular morphology and function (Friedl and Brocker, 
2000). In 3D collagen gel experiments, fibroblasts retain their tissue phenotype 
including polarised morphology and in vivo like positioning (Doane and Birk, 1991).     
The sensitivity and consistent reproducibility of the 3D collagen gel fibroblast migration 
assay, in displaying the motogenic activity of MSF has been attributed to the retained 
responsiveness of the adult fibroblasts. The inability of adult fibroblasts to produce 
MSF whilst still remaining responsive to it provides a perfect internal control. That is, 
any effect on fibroblast behaviour is completely in response to the experimental 
conditions and the subsequent introduction of bioactive test materials. In each separate 
experiment the baseline migration of the fibroblasts was always measured; that is the 
level of fibroblast migration when test overlay is serum-free MEM (SF-MEM) 
containing no further additives (final concentration of 1% (v/v) serum). Details of how 
the 3D collagen gel fibroblast migration assay was assessed can be found in Chapter 2.  
Initially, MSF was purified from foetal fibroblast conditioned medium (CM) but the 
subsequent development and purification of a recombinant form further increased 
efficiency and reproducibility of the migration assay. The motogenic activity of 
recombinant MSF (rhMSF) is indistinguishable from foetal fibroblast CM; characterised 
by a bell-shaped dose-response curve with half maximal activity at femtomolar 
concentrations which can be neutralised by anti-fibronectin Gel-BD antibodies (Schor et 
al., 2003). During the course of this project a number of batches of recombinant MSF 
were produced and used. The consistency of quality and performance of the rhMSF was 
assured through a vigorous testing process including the assessment of motogenic 
activity of each batch by a dose response collagen gel fibroblast migration assay; a 
range of rhMSF (1 to 10,000pg/ml) was tested, in duplicate. A rhMSF concentration of 
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100pg/ml was selected for testing the inhibitory activity of the conditioned medium, as 
it reliably increased fibroblast migration 2 to 3 fold, above the baseline level.  
Complications may arise when analysing the effects of the test CM on fibroblast 
migration due to the bell shaped dose- response bioactivity of MSF.  MSF’s motogenic 
activity increases steadily with increasing concentration, peaking at a maximum 
(500pg/ml) followed by a mirror-image decrease in activity towards the baseline level 
as the concentration increases further. It was therefore necessary to ensure any 
inhibitory activity detected was not merely an effect of additional MSF, present within 
the test CM, shifting the bell-shaped response of MSF into the inhibitory territory of 
bioactivity. Consequently the CM was tested with and without the addition of rhMSF in 
order to assess the presence of any residual motogenic activity in the CM. 
In order for potential MSF-I activity to be assessed, a strict protocol and criteria was 
established for the collection of CM. Conditioned medium was only collected from 
cultured cell lines under serum free conditions; when the confluent cells were displaying 
a typical, normal morphology (Chapter 2). For cell lines which had the ability to exhibit 
multiple phenotypes, namely endothelial cells, separate collections of CM where made 
in order to determine any phenotypic dependent effects on bioactivity. The effect of 
different storage conditions (duration/ temperature) and CM concentration techniques 
were also assessed in order to determine optimum collection conditions. 
 
 
3.3 THE MOTOGENIC ACTIVITY OF RECOMBINANT MSF 
 
During the course of this project a number of batches of prokaryotically expressed 
rhMSF were prepared. The protein concentration of each batch was estimated, by 
comparison to known concentrations of GBD on a 12% resolving, 4.5% stacking 
acrylamide gel under reducing conditions (Chapter 2). Subsequently, the motogenic 
activity was assessed in the 3D collagen gel fibroblast migration assay. The rhMSF was 
tested at a range of concentrations from 1pg/ml to 10ng/ml in either duplicate or 
triplicate gels. The number of fibroblasts which had migrated into the gel, over a four 
day incubation period, was counted in ten separate fields of view per gel. The number of 
fibroblasts migrated under test conditions was expressed as a percentage of the SF 
MEM control baseline migration with the criteria for motogenic activity determined by 
the ability to stimulate fibroblast migration by a minimum of 50% (Figure 3.1).  
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In order to prove that the motogenic activity was indeed due to rhMSF stimulating the 
fibroblasts, the migration assays were repeated with the addition of an MSF function 
neutralising antibody, PEPQ 1.1. This mouse monoclonal antibody raised against a 21-
mer peptide containing the IGDQ sequence in module 1-7 of MSF (and fibronectin), 
TNEGVMYRIGDQWDKQHDMGH, has been shown to neutralise MSF activity. 
Furthermore, when tested alone the PEPQ1.1 antibody has no effect on baseline 
fibroblast migration. (Schor et al., 2003). Addition of the PEPQ 1.1 antibody (50ng/ml) 
was able to reduce MSF stimulated motogenic activity back to SF MEM baseline levels. 
(Figure 3.2).  
A batch of rhMSF was considered suitable for use if it met the following requirements: 
1. A molecular weight of approximately 77kDa. 
2. The ability to stimulate the migration of adult fibroblasts in the 3D collagen gel 
fibroblast migration assay with the motogenic activity being characterised by a bell- 
shaped dose- response curve. 
3. The ability of 100pg/ml rhMSF to stimulate fibroblast motogenic activity by 2-3 
times more than the SF MEM baseline levels.  
4. The rhMSF stimulated motogenic activity was neutralised by the addition of PEPQ 
1.1 antibody. 
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Figure 3.1: The motogenic activity of recombinant MSF.  
Recombinant MSF was tested at a range of concentrations in the 3D collagen gel 
fibroblast migration assay. The number of cells migrated is expressed as a percentage of 
the SF MEM control baseline migration i.e SF MEM baseline = 100 +/- 16.07%, as 
represented by the hatched and dotted lines (mean and SD respectively). This was 
equivalent to 2.8 +/- 0.45 migrated cells. 100pg/ml rhMSF only equals 8.6 +/- 0.28 
migrated cells. This is a representative experiment of the results achieved when testing 
the batches of rhMSF.  
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Figure 3.2: The effect of MSF- neutralising antibody, PEPQ1.1, on the motogenic 
bioactivity of recombinant MSF.   
A range of concentrations of rhMSF was tested in the 3D collagen gel fibroblast 
migration assay in the presence of the PEPQ1.1 antibody (50ng/ml). The number of 
cells migrated is expressed as a percentage of the rhMSF only baseline migration, at 
each individual concentration, i.e 100pg/ml rhMSF = 100%, as represented by the 
hatched line. A representative experiment is shown. 
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3.4 THE TESTING OF FIBROBLAST CELL LINES FOR BIOACTIVITY IN 
THE 3D COLLAGEN GEL FIBROBLAST MIGRATION ASSAY 
 
As previously discussed, the Schor group discovered a difference in the motogenic 
potential between adult and foetal fibroblast cell lines, with the expression of MSF 
subsequently identified as responsible for this difference (Schor et al., 1988, Grey et al., 
1989). In order, to confirm this finding CM was collected (Chapter 2) from two foetal 
and two adult fibroblast cell lines (in house cell preparations) and then tested at a range 
of dilutions (¼ to 1/40,000) with and without the presence of 100pg/ml rhMSF. The 
foetal lines selected were FFD4 and F110a, whilst the adult lines were FSF44 and 
DFSF1 (Table 3.1). 
In order to assess the results, criteria were set to determine stimulatory and inhibitory 
activity. Firstly, the CM was tested by itself without the addition of rhMSF, in order to 
determine the presence of any endogenous motogenic activity. The benchmark for 
motogenic activity was set as the ability to increase the number of fibroblasts migrated 
into the collagen gel by a minimum of 50% as compared to the negative control, the SF 
MEM baseline. This limit was set in comparison to rhMSF which reproducibly 
increased fibroblast migration by at least two fold when used at a final concentration of 
100pg/ml.  
Next, the criterion for the inhibition of MSF (MSF- inhibitory activity) was determined 
by the ability of the CM upon addition of 100pg/ml rhMSF to reduce fibroblast 
migration by at least 50% as compared to the positive control, the MSF baseline. For 
example, this would mean that the migration level for 100pg/ml rhMSF would be 
reduced down to SF MEM baseline levels. Furthermore, the possibility that endogenous 
stimulatory activity within the CM may conceal the activity of any MSF-inhibitor(s) 
present in the CM required exclusion. Therefore, instead of determining an alteration in 
migration by comparison to the positive and negative controls, the CM when tested 
alone, at each individual dilution, is considered the baseline migration. That is, MSF-
inhibitory activity was defined, upon addition of 100pg/ml rhMSF, as the inability to 
increase CM baseline migration by a minimum of 50%. 
Equivalent results were achieved for both foetal lines and the adult lines shared a strong 
similarity too. As expected, when tested alone, the foetal CM displayed a strong 
motogenic dose-responsive bioactivity; very similar to the dose response curve of 
rhMSF (Figure 3.1, Figure 3.3b). Foetal CM displayed stimulatory activity in dilutions 
1/10 to 1/1000, with activity peaking with approximately a threefold increase, compared 
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to the SF MEM baseline, at the 1/100 dilution point. The adult fibroblast CM displayed 
no bioactivity, with migration levels comparable to the SF MEM baseline (Figure 3.3a).  
When 100pg/ml rhMSF was added to the adult CM, migration increased on average by 
2.7 fold. Irrespective of whether the migration levels were compared to the rhMSF 
baseline or the CM only baseline, all dilution points displayed no MSF inhibitory 
activity (Figure 3.3 c and e). However, the foetal CM initially appeared to be displaying 
an inhibitory effect when compared to the MSF baseline level (Figure 3.3f) although a 
different picture emerged when endogenous stimulatory activity was taken into account. 
The comparison to CM only migration levels showed that the addition of MSF appeared 
to have no effect on the dilution points 1/4 to 1/1000.Whilst the addition of rhMSF 
increased migration on average by 1.9 fold at dilution points 1/5000 to 1/40,000. As 
discussed, the ability of foetal fibroblast CM to stimulate cell migration was shown to 
be due to the expression of foetal MSF (Schor et al., 1988, Grey et al., 1989). Plus, as 
seen from the dose response curve of rhMSF the motogenic activity declines at the 
higher concentrations of 1ng/ml and above. Therefore it seems that the combination of 
foetal MSF present in the lowest dilutions, where the MSF concentrations are highest, 
and the additional rhMSF have resulted in decreased migration as the total MSF 
concentration reached levels where motogenic activity is no longer detected. Whilst at 
the highest dilutions of foetal CM, where endogenous MSF concentrations will be 
considerably lower, the addition of rhMSF results in increased migration. 
In conclusion, these results corroborate previous findings that there is a difference in the 
motogenic activity of foetal and adult fibroblast conditioned media. They also show that 
no endogenous MSF- inhibitory activity was detected in either adult or foetal fibroblast 
CM. Regarding the suitability of the 3D collagen gel fibroblast migration assay as a 
means of screening CM for MSF inhibitory activity the results confirm that the FSF44 
fibroblasts used in the assay are ideal; since they respond to the presence of rhMSF and 
express no endogenous motogenic or MSF inhibitory bioactivity which may have 
caused complications with the interpretation of results. 
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b. Foetal Fibroblast, FFD4, CM Only
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         c. Adult  Fibroblast, FSF44, Tested with 100pg/ml rhMSF
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d. Foetal Fibroblast, FFD4, Tested with 100pg/ml rhMSF
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          e. Adult  Fibroblast, FSF44, Tested with 100pg/ml rhMSF
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          f. Foetal  Fibroblast, FFD4, Tested with 100pg/ml rhMSF
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Figure 3.3: The comparison of the bioactivity present in the conditioned medium 
collected from adult and foetal fibroblast cell lines, with and without the addition 
of rhMSF. Conditioned medium (CM) from the adult and foetal fibroblasts, FSF44 and FFD4 
respectively, was tested on its own and in the presence of 100pg/ml rhMSF, at a range of dilutions from 1 
in 4 to 1/40,000 in the fibroblast migration assay. The number of cells migrated is expressed as either:  
Graphs a and b: the percentage of the SF MEM control baseline migration i.e. SF MEM baseline = 100+/- 
14.23, as represented by hatched and dotted lines (mean and standard deviation respectively). Equivalent 
to 2.6 +/- 0.37 migrated cells. Graphs c and d: the percentage of CM only baseline migration at each 
individual dilution point i.e. ¼ dilution CM only = 100%, as represented by the hatched line. Graphs e 
and f: Percentage of the 100pg/ml rhMSF control baseline migration i.e. MSF baseline = 100+/- 3.01, as 
represented by hatched and dotted lines (mean and standard deviation respectively). Equivalent to 8.3 +/- 
0.25 migrated cells. The results show a representative experiment.
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3.5 THE TESTING OF ENDOTHELIAL CELL LINES FOR BIOACTIVITY 
IN THE 3D COLLAGEN GEL FIBROBLAST MIGRATION ASSAY 
 
Endothelial cells form the inner lining of blood vessels, the endothelium. They are 
essential in maintaining vessel wall integrity and blood circulation, functioning as a 
semi-permeable anticoagulant barrier. Endothelial cells are also considered to be 
dynamic multifunctional cells performing a variety of metabolic and synthetic 
functions; which are pivotal in both angiogenesis and vasculogenesis (Coultas et al., 
2005, Sumpio et al., 2002). 
In vivo, endothelial cells are capable of adopting two distinctive and reversible 
phenotypes. The endothelial cells lining blood vessel walls form a contact- inhibited 
polygonal cobblestone-like uniform monolayer and are often described as displaying a 
“resting” phenotype. Whilst during angiogenesis the “resting” cells adopt an elongated 
fibroblastoid phenotype migrating into the surrounding connective tissue where they 
self-associate into solid cords of elongated “sprouting” cells. Eventually after further 
transformations these cords form new patent vessels (Folkmann and Haundenschild 
1979 and 1980, Makarski 1982, Schor et al., 1983). 
Endothelial cells in vitro retain the ability to undergo this reversible phenotypic 
conversion. The different phenotypes are considered to be in vitro counterparts to the 
resting and angiogenic cells observed in vivo. Endothelial cells plated on to a 2D 
substratum (e.g. gelatin-coated culture dishes) will proliferate to confluence, forming a 
contact-inhibited cobblestone monolayer, morphologically similar to the endothelium 
lining of the blood vessel wall.  The second phenotype appears in post-confluent 
cultures, when the resting cells undergo a transition into a distinctive elongated 
sprouting morphology and begin to grow underneath the intact cobblestone monolayer, 
eventually forming an interactive network. These sprouting cells often appear 
vacuolated and visualisation of individual cells becomes difficult due to the 
interconnected network of loops and rings. Both cell phenotypes are considered 
endothelial in origin since they stain positive for Factor VIII (Schor et al., 1983).  
The sprouting phenotype can also be induced by culturing endothelial cells within a 3D 
matrix (e.g Type I collagen gel matrix) (Canfield et al., 1986). The cells spontaneously 
and uniformly adopt an elongated morphology, subsequently forming sprouting 
networks. It is assumed that the loss of apical- basal polarity, which cells forming a 
cobblestone monolayer experience, induces the sprouting phenotype.  Cells grown 
within a 3D environment or those growing underneath a monolayer lack a free apical 
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surface and can therefore form interactions over their entire cell surface (Schor et al., 
1983).  
The ability to culture homogenous populations of either endothelial phenotype enables 
the investigation of possible differences in protein expression. Differential synthesis of 
various matrix macromolecules including laminin, thrombospondin, type I collagen and 
heparan sulphate proteoglycan have already been described (Canfield et al., 1986, 1990, 
1992, and 1995. Cotta- Pereia et al., 1980). These differences are reputed to contribute 
to the angiogenic process.  
MSF has been shown to induce angiogenesis in vivo and in vitro. Subcutaneous 
implants of collagenous graft matrices containing MSF, induce angiogenesis in rat and 
pig models, plus MSF applied to chicken yolk-sac membranes provoke a significant 
angiogenic response (Schor 2010, unpublished observations). Also, in vitro under serum 
free culture conditions an application of rhMSF to an endothelial cobblestone 
monolayer will induce a greater number of sprouting cells compared to a serum free 
only control (Schor 2010). It was therefore of interest to explore the possibility that the 
two endothelial phenotypes may differentially express MSF or differ in their synthesis 
of an inhibitor to MSF.  
Numerous endothelial cell lines, of both bovine and human origin, were initially 
selected to be screened (HUVEC, HOEC, HAEC, BAEC, Endo 742) (Table 3.1). 
Obviously, the cell lines had to possess the ability to clearly display both phenotypes 
but also ease of culture and life- span were taken into consideration. The first line 
chosen was an in house preparation of bovine aortic endothelial cells (BAEC) which 
form typical cobblestone and sprouting phenotypes but have a limited passage capacity, 
undergoing senescence on average after 16-19 passages (Schor et al., 1983, Motegi 
2008). The second endothelial cell line was Endo 742; a transformed human mammary 
microvascular line, gifted by Dr Micheal O’Hare (O’Hare et al., 2001). Although the 
Endo 742 does not form a typical cobblestone monolayer as seen in BAEC cultures, 
there is a distinct morphological difference between confluent and post-confluent 
cultures. The major advantage of the Endo 742 line is the ease of culture, fast doubling 
time and unlimited proliferative potential, essential when collection of large volumes of 
conditioned media is required. The other human cell lines were not selected as they 
were less robust, grew slowly and were frequently adversely affected when switching to 
a new batch of donor calf serum. 
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3.5i Bioactivity of Conditioned Medium From Endothelial Cells Grown On a 2D 
Surface. 
 
The selected endothelial cell lines, BAEC 2-2 U7 and Endo 742, were grown on a 2D 
surface of 0.1% (w/v) gelatin coated plastic cell cultures dishes.  In order to assess the 
difference between the two phenotypes expressed by the endothelial cells conditioned 
medium was collected (under serum free conditions) when the cells were either 
displaying a cobblestone monolayer when confluent (cobblestone CM) or from post-
confluent cultures where sprouting cells were present underneath the monolayer 
(sprouting CM). Therefore, the “sprouting” conditioned medium was actually from a 
heterogeneous population of both resting and sprouting phenotypes. Since the confluent 
density of Endo 742 cells was less than BAEC 2-2 U7 the range of dilutions tested were 
limited accordingly. (Endo 742: 4.8 x 10
6
 cells per 90mm equivalent to 9.6 x 10
6
 cells 
per ml of CM collected. BAEC 2-2 U7: 5.9 x 10
6
 cells per 90mm is equivalent to 11.8 x 
10
6
 cells per ml of CM.) For ease of discussion the cell line BAEC 2-2 U7 will from 
now be referred to as BAEC.  
Immediately, an obvious difference emerged between the two endothelial phenotypes. 
For both BAEC and ENDO 742, the cobblestone CM displayed no motogenic 
bioactivity over a range of dilutions; cell migration was similar to the SF baseline 
(Figure 3.4a and 3.5a). However, the sprouting CM exhibited a potent motogenic 
activity. For BAEC CM, migration was stimulated by a range of sprouting CM 
dilutions, ¼ to 1/1000; when compared to the baseline, maximal activity of an average 
of 86.4% was present in ¼ to 1/10 dilutions (Figure 3.4b). Endo 742 sprout CM 
appeared to possess greater motogenic activity with an average of 119.5% increase in 
migration for dilutions ¼ to 1/40 (Figure 3.5b).    
When 100pg/ml rhMSF was added to the BAEC cobblestone medium, the migration 
level was comparable to the CM only baseline level; that is the motogenic activity of 
MSF was inhibited (Figure 3.4c). A similar effect was observed for ENDO 742 CM; 
however the higher dilutions (1/200 to 1/4000) showed a 50% increase in migration 
compared to CM only baseline levels but the high standard deviations reflect poor 
experimental reproducibility (Figure 3.4d). By comparing the amount of migration 
achieved to the MSF baseline level, the inhibitory effect was still obvious (Figure 3.4e 
and 3.5e). The conclusion being that endothelial cobblestone CM contains MSF 
inhibitory activity. 
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Endothelial sprouting CM appears to have a more complex effect on the activity of 
MSF. Applying the set criteria for the presence of MSF-inhibitory activity, as a 
reduction of migration of at least 50% when compared to the MSF control baseline 
levels (100pg/ml rhMSF only) one would conclude that no inhibitory activity was 
present in either BAEC or ENDO742 sprouting CM (Figure 3.4f and 3.5f). However, 
this assessment does not take into account the endogenous motogenic activity present in 
the sprouting CM; comparing to the CM only baseline level, a different picture emerges. 
Those dilutions of both BAEC and ENDO 742 CM which displayed motogenic activity 
when tested alone possessed the ability to inhibit MSF. Conversely, the non- motogenic 
dilutions responded to the addition of rhMSF with migration increasing 50% above the 
CM only baseline level (Figure 3.4d and 3.5d). Unfortunately, reduced experimental 
reproducibility was reflected by high standard deviations. An explanation for this could 
be that the CM was collected from a mixed population of both sprouting and 
cobblestone cells making standardisation of CM collection conditions problematic. 
Analysis of these results seems to imply that the motogenic activity observed in the 
endothelial sprouting CM is due to the expression of MSF. The highest potency of 
endogenous motogenic activity of the sprouting CM was measured in the lowest 
dilution points which would obviously contain a higher concentration of the motogen 
compared to the higher dilutions, which consequently showed no motogenic activity. 
When rhMSF was added to these low dilution points the effect was a reduction in 
migration, whilst addition to the higher CM dilutions stimulated migration. As 
previously described, MSF is characterised by a bell shaped dose response activity 
(Figure 3.1). Presuming endothelial MSF is bioactive in these low dilutions the 
subsequent addition of rhMSF would result in the total MSF present at a level which 
actually resulted in MSF having an inhibitory effect on migration (above 500pg/ml). 
Whilst addition of rhMSF to the higher dilutions, where endothelial MSF was too dilute 
to be bioactive, would  increase the total MSF concentration to levels where migration 
is stimulated (1-500pg/ml).   
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Figure 3.4: The comparison of the bioactivity present in the conditioned medium 
collected from the bovine aortic endothelial cell line, BAEC, displaying either a 
cobblestone or sprouting phenotype, when grown on a 2D surface. The CM for each 
phenotype was tested on its own and in the presence of 100pg/ml rhMSF, at a range of dilutions from 1 in 
4 to 1/40,000 in the fibroblast migration assay. The number of cells migrated is expressed as either:  
Graphs a and b: a percentage of the SF MEM control baseline migration i.e. SF MEM baseline = 100+/- 
4.55, as represented by hatched and dotted lines (mean and standard deviation respectively). Equivalent to 
2.2 +/- 0.10 migrated cells. 
Graphs c and d: a percentage of CM only baseline migration at each individual dilution point i.e. ¼ 
dilution CM only = 100%, as represented by the hatched line. 
Graphs e and f: a percentage of the 100pg/ml rhMSF control baseline migration i.e. MSF baseline = 
100+/- 2.77, as represented by hatched and dotted lines (mean and standard deviation respectively). 
Equivalent to 4.7 +/- 0.13 migrated cells. The results show a representative experiment. 
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b. Sprouting Bovine Endothelial, BAEC, CM Only.
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c. Cobblestone Bovine Endothelial, BAEC, CM
Tested with 100pg/ml rhMSF.
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d. Sprouting Bovine Endothelial, BAEC, CM
Tested with 100pg/ml rhMSF.
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e. Cobblestone Bovine Endothelial, BAEC, CM
Tested with 100pg/ml rhMSF.
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f. Sprouting Bovine Endothelial, BAEC, CM
Tested with 100pg/ml rhMSF.
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a. Cobblestone Transformed Human Endothelial,
ENDO 742, CM Only.
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b. Sprouting Transformed Human Endothelial,
ENDO 742, CM Only.
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c. Cobblestone Transformed Human Endothelial,
ENDO 742, CM Tested with 100pg/ml rhMSF.
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d. Sprouting Transformed Human Endothelial,
ENDO 742, CM Tested with 100pg/ml rhMSF.
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e. Cobblestone Transformed Human Endothelial,
ENDO 742, CM Tested with 100pg/ml rhMSF.
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f. Sprouting Transformed Human Endothelial,
ENDO 742, CM Tested with 100pg/ml rhMSF.
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Figure 3.5: The comparison of the bioactivity present in the conditioned medium 
collected from the transformed human mammary microvascular cell line, Endo 
742, displaying either a cobblestone or sprouting phenotype, when grown on a 2D 
surface. The CM for each phenotype was tested on its own and in the presence of 100pg/ml rhMSF, at a 
range of dilutions from 1 in 4 to 1/4000 in the fibroblast migration assay. The number of cells migrated is 
expressed as either: Graphs a and b: a percentage of the SF MEM control baseline migration i.e. SF MEM 
baseline = 100+/- 6.56, as represented by hatched and dotted lines (mean and standard deviation 
respectively). Equivalent to 3.2 +/- 0.21 migrated cells. Graphs c and d: a percentage of CM only baseline 
migration at each individual dilution point i.e. ¼ dilution CM only = 100%, as represented by the hatched 
line. Graphs e and f:  a percentage of the 100pg/ml rhMSF control baseline migration i.e. MSF baseline = 
100+/- 7.14, as represented by hatched and dotted lines (mean and standard deviation respectively). 
Equivalent to 7.7 +/- 0.55 migrated cells. The results show a representative experiment. 
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3.5ii Bioactivity of Conditioned Medium from Endothelial Cells Grown  
Within a 3D Collagen Matrix. 
 
As described, when performing experiments using sprouting CM from endothelial cells 
cultured on a 2D surface, inconsistencies in bioactivity were observed between different 
batches of CM. Although, for ease of description, the CM was described as sprouting it 
was actually from a mixed population of the endothelial phenotypes (sprouts beneath a 
cobblestone monolayer). Therefore, in order to ensure a homogenous population of 
source cells, CM was collected from endothelial cells cultured within a 3D type I 
collagen gel, where the cells spontaneously adopt the sprouting phenotype. As controls, 
CM was collected from endothelial cells plated on the surface of a collagen gel, where 
the cells formed a cobblestone monolayer and from a blank collagen gel (no cells).  
To collect a large volume of CM, the type I collagen gels were plated on a 90mm cell 
culture dish and to reduce any effect of the gel itself the same volume of gel, 15ml, was 
used for both the blank, as well as the sprouting and cobblestone phenotypes. For the 
sprouting CM, the endothelial cells were dispersed with 5ml of collagen gel (6.5x10
5 
cells per ml) which was sandwiched between two 5ml collagen gels; thereby 
eliminating the possibility of the cells migrating to the surface of the gel and forming a 
monolayer. The cobblestone CM was collected from endothelial cells that had been 
plated directly on the surface of a 15ml collagen gel in 5ml of medium (5x10
4
 cells per 
ml). The endothelial cells were allowed to attach and form a cobblestone monolayer 
after which the CM was collected. 5ml of SF MEM was added to each 90mm dish, with 
the CM collected after 2-3 day incubation. 
As expected, the SF media cultured on a blank type I collagen gel had no effect on cell 
migration when tested in the migration assay. The migration level for the blank gel CM 
when tested alone, at all dilution points, was similar to the SF baseline whilst the 
addition of 100pg/ml rhMSF increased migration to the MSF baseline level (Figure 3.6 
a-c). Consequently, in conclusion, any bioactivity measured from the sprout or 
cobblestone CM was considered to be solely due to factors expressed by the endothelial 
cells. 
Once again, the bioactivity of the CM from both BAEC and ENDO742 shared a 
similarity and was phenotype dependent. Cobblestone CM from both cell lines 
displayed no motogenic activity when tested alone unlike the sprouting CM, which 
stimulated fibroblast migration in a similar manner to MSF. In addition, by ruling out 
119 
 
the effect of the endogenous motogenic activity present in the sprouting CM genuine 
MSF-I activity appeared to be present in the cobblestone CM. 
Cobblestone CM from both cell lines appeared to have no bioactivity when tested alone, 
with migration levels similar to the SF MEM control (Figure 3.7a and 3.8a). However, 
upon addition of 100pg/ml rhMSF it became clear that the cobblestone CM possessed 
the ability to inhibit MSF motogenic activity with maximum MSF-I activity achieved in 
the mid- range of dilutions tested (1/500-1000) (Figure 3.7c/e and 3.8c/e). The level of 
MSF-I activity seemed comparable to that measured previously in CM collected from 
an endothelial cobblestone monolayer cultured on a 2D surface.  
The motogenic activity of sprouting CM (BAEC and ENDO742) displayed a bell-
shaped dose response activity; maximal activity in dilutions 1/500- 1/100, whilst 
reducing at the lower and higher dilution points. As the same number of both BAEC 
and ENDO742 cells were plated within the collagen gel it would appear the motogenic 
activity of their CM appears to be comparable, peaking at 189.4 +/- 6.81% and 181.0 +/- 
20.00% respectively. Although, the motogenic activity was present at a higher level 
over the range of dilution points tested in the BAEC compared; an average of 139.5 +/- 
57.23% compared to 111.9 +/- 48.9% over all dilution points, respectively (Figure 3.7b 
and 3.8b). 
As seen with the previous experiment (sprouting CM collected from 2D surface), the 
endogenous motogenic activity of the sprouting CM has to be considered when 
interpreting the effect of adding 100pg/ml rhMSF, because if the set criteria of MSF 
inhibitory activity (the reduction of migration of at least 50% when compared to MSF 
control baseline level) was applied it would appear that no inhibition occurred (Figure 
3.7f and 3.8f). However, comparison to the CM-only baseline shows that addition of 
rhMSF to the dilutions with the maximal motogenic activity results in a decrease in 
fibroblast migration (ENDO742 dilution points 1/50 and 1/500, BAEC dilution points 
1/50-1/5000) (Figure 3.7d and 3.8d). Again, this would imply that the factor expressed 
by the sprouting endothelial cells, which stimulates fibroblast migration, is endothelial 
expressed MSF. 
In conclusion, these results suggest that the bioactivity of endothelial cells is phenotype 
dependent and not matrix dependent. That is, sprouting cells whether formed on a 2D 
matrix or within a 3D matrix express a motogenic factor that stimulates fibroblasts to 
migrate in a manner similar to rhMSF. Whilst endothelial cells displaying the “resting” 
cobblestone phenotype express an MSF-inhibitory factor. Also, this endothelial 
phenotype-dependent bioactivity appears to be common to both primary and 
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transformed cell lines (and different species). A limited analysis of the other endothelial 
cell lines endorses this conclusion (Table 3.2).
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c. Blank Gel CM Tested with 100pg/ml rhMSF.
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Figure 3.6: The bioactivity of conditioned medium collected from a blank collagen 
gel. A blank type I collagen gel was cultured in SF MEM under the same conditions as for standard CM 
collection. The media was then collected and tested in the fibroblast migration assay on its own and in the 
presence of 100pg/ml rhMSF, at a range of dilutions from 1 in 4 to 1/20,000. The number of cells 
migrated is expressed as either:  
Graph a: a percentage of the SF MEM control baseline migration i.e. SF MEM baseline = 100+/- 15.23, 
as represented by hatched and dotted lines (mean and standard deviation respectively). Equivalent to 2.1 
+/- 0.32 migrated cells. 
Graph b: a percentage of CM only baseline migration at each individual dilution point i.e. ¼ dilution CM 
only = 100%, as represented by the hatched line. 
Graphs c: a percentage of the 100pg/ml rhMSF control baseline migration i.e. MSF baseline = 100+/- 
7.84, as represented by hatched and dotted lines (mean and standard deviation respectively). Equivalent to 
6.1 +/- 0.48 migrated cells. The results show a representative experiment. 
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a. Cobblestone Bovine Endothelial, BAEC, CM Only.
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b. Sprouting Bovine Endothelial, BAEC, CM Only.
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c. Cobblestone Bovine Endothelial, BAEC, CM
Tested with 100pg/ml rhMSF.
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d. Sprouting Bovine Endothelial, BAEC, CM
Tested with 100pg/ml rhMSF.
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e. Cobblestone Bovine Endothelial, BAEC, CM
Tested with 100pg/ml rhMSF.
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f. Sprouting Bovine Endothelial,  BAEC, CM
Tested with 100pg/ml rhMSF.
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Figure 3.7: The comparison of the bioactivity present in the conditioned medium 
collected from the bovine endothelial cell line, BAEC, displaying either a 
cobblestone or sprouting phenotype, when grown on or within a 3D collagen 
matrix, respectively. The CM for each phenotype was tested on its own and in the presence of 
100pg/ml rhMSF, at a range of dilutions from 1 in 4 to 1/20,000 in the fibroblast migration assay. The 
number of cells migrated is expressed as either: Graphs a and b: a percentage of the SF MEM control 
baseline migration i.e. SF MEM baseline = 100+/- 12.77, as represented by hatched and dotted lines 
(mean and standard deviation respectively). Equivalent to 2.35 +/- 0.30 migrated cells. Graphs c and d: a 
percentage of CM only baseline migration at each individual dilution point i.e. ¼ dilution CM only = 
100%, as represented by the hatched line. Graphs e and f: a percentage of the 100pg/ml rhMSF control 
baseline migration i.e. MSF baseline = 100+/- 5.69, as represented by hatched and dotted lines (mean and 
standard deviation respectively). Equivalent to 7.2 +/- 0.41 migrated cells. The results show a 
representative experiment. 
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a. Cobblestone Transformed Human Endothelial,
ENDO 742, CM Only.
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b. Sprouting Transformed Human Endothelial,
ENDO 742, CM Only.
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c. Cobblestone Transformed Human Endothelial,
ENDO 742, CM Tested with 100pg/ml rhMSF.
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d. Sprouting Transformed Human Endothelial,
ENDO 742,  CM Tested with 100pg/ml rhMSF.
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e. Cobblestone Transformed Human Endothelial,
ENDO 742, CM Tested with 100pg/ml rhMSF.
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f. Sprouting Transformed Human Endothelial,
ENDO 742, CM Tested with 100pg/ml rhMSF.
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Figure 3.8: The comparison of the bioactivity present in the conditioned medium 
collected from the transformed human mammary microvascular cell line, Endo 
742, displaying either a cobblestone or sprouting phenotype, when grown on or 
within a 3D collagen matrix, respectively. The CM for each phenotype was tested on its own 
and in the presence of 100pg/ml rhMSF, at a range of dilutions from 1 in 4 to 1/20,000 in the fibroblast 
migration assay. The number of cells migrated is expressed as either: Graphs a and b: a percentage of the 
SF MEM control baseline migration i.e. SF MEM baseline = 100+/- 10.48, as represented by hatched and 
dotted lines (mean and standard deviation respectively). Equivalent to 2.1 +/- 0.22 migrated cells. 
Graphs c and d: a percentage of CM only baseline migration at each individual dilution point i.e. ¼ 
dilution CM only = 100%, as represented by the hatched line. Graphs e and f: a percentage of the 
100pg/ml rhMSF control baseline migration i.e. MSF baseline = 100+/- 7.84, as represented by hatched 
and dotted lines (mean and standard deviation respectively). Equivalent to 6.1 +/- 0.48 migrated cells. 
The results show a representative experiment. 
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Table 3.2: List of endothelial cell lines, whose conditioned medium (CM) was 
tested for the presence of motogenic and MSF-I activity.  
The CM, collected under serum free conditions, was collected from the endothelial cells 
plated on a 2D surface when either expressing a cobblestone or sprouting phenotype. 
The collected CM was tested at a range of dilutions in the fibroblast migration assay to 
determine the presence of motogenic and MSF-inhibitory activity.  
 
Cell Line Cell Type Cobblestone CM 
dilutions displaying  
Sprouting CM 
dilutions displaying  
  Motogenic 
activity 
MSF-I 
activity 
Motogenic 
activity 
MSF-I 
activity 
BAEC 
Clone 2 
Bovine aortic 
endothelial cells 
none neat  - 1/1000 1/20-1/40 1/20 – 1/40 
BAEC 
Clone 3 
Bovine aortic 
endothelial cells 
none neat – 1/1000 1/20 – 1/40 1/20 – 1/40 
BAEC 2-
2 U7 
Bovine aortic 
endothelial cells 
none 1/4 - 1/40, 000 1/4 - 1/1000 1/4 - 1/1000 
Endo 
742 
Transformed 
human 
microvascular 
endothelial cells 
none 1/4 - 1/80 1/4 - 1/40 1/4 - 1/40 
HAEC Human aortic 
endothelial cells 
none neat – 1/25 1/10 – 1/20 1/10 – 1/20 
HOEC Bovine 
omentum 
endothelial cells 
none neat  - 1/25 not tested not tested 
HUVEC Human 
umbilical vein 
endothelial cells 
none neat – 1/25 1/10- 1/20 1/10 -1/40 
 
 
 
3.6 THE TESTING OF EPITHELIAL CELL LINES FOR BIOACTIVITY  
 IN THE 3D COLLAGEN GEL FIBROBLAST MIGRATION ASSAY. 
 
Keratinocytes are found in the epidermal layer of the skin. They are principally 
responsible for structure of the outer layer of stratified epithelium. This layer is 
fundamental to the primary function of skin; to act as the first line of defence forming a 
barrier against various forms of environmental damage (U.V. radiation, water loss, heat, 
pathogens etc.)  Keratinocyte differentiation and keratinisation are essential to 
performing this role (Proksch et al., 2008, Brenner and Hearing 2008). 
Keratinocytes also are vital in the process of wound healing and the concurrent immune 
response. Depending on how the skin barrier is breached, they have the ability to 
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express specific proinflammatory mediators or cytokines in response to the injury; thus 
facilitating the coordinated response of various cell types including melanocytes, 
Langerhanns cells, lymphocytes and fibroblasts (Myers et al., 2007). 
Previously, the Schor group tested conditioned medium from a primary keratinocyte 
culture and the preliminary experiments showed the presence of potential MSF 
inhibitory activity. Difficulties however arose because the primary keratinocytes were 
extremely challenging to culture, making the condition medium collection at the 
volumes required impracticable.  It was hoped the use of the spontaneously transformed 
epithelial cell line, HaCaT would resolve this issue as they are undemanding cell line. 
(Table 3.1). 
Petra Boukamp’s group developed the first permanent epithelial cell line from normal 
adult human skin, after a prolonged cultivation at a reduced calcium concentration and 
elevated temperature (Boukamp et al., 1988). Despite being immortal, HaCaT cells are 
considered to be similar to normal keratinocytes. They are non-tumorigenic and form an 
organised and differentiated epidermal tissue when transplanted into nude mice, with 
the keratin expression being very similar to normal keratinocyte transplants. Due to this 
preserved differentiation capacity, even after prolonged passages; they are extensively 
used as a substitute for normal keratinocytes (Schoop et al., 1999).  
 
3.6i The Testing of an Epithelial Cell Line for Bioactivity in the  
3D Collagen Gel Fibroblast Migration Assay. 
  
Testing the HaCaT CM in the 3D collagen gel migration showed that it exhibited no 
endogenous motogenic activity but did possess the ability to inhibit the motogenic 
function of rhMSF. The level of fibroblast migration of HaCaT CM tested alone was 
equivalent, at each dilution point (1/4 to 1/40,000), to the SF MEM baseline control; 
that is a migration rate of 2.3 +/- 0.21 fibroblasts per gel (Figure3.9a). Normally, the 
addition of 100pg/ml rhMSF would increase migration by 2-3 fold, however the 
presence of HaCaT CM completely eliminated this activity. HaCaT CM diluted ¼ to 
1/1000 completely inhibited the effect of MSF has on fibroblast migration (Figure 3.9b 
and c). 
The presence of an MSF inhibitor in the HaCaT CM was obvious; whether comparing 
the migration levels to the CM only baseline or to the rhMSF positive control baseline. 
Also, the higher dilutions beyond 1/1000 revealed that the inhibitor activity could be 
diminished as the concentration of HaCaT CM was reduced. The rhMSF motogenic 
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activity was restored to expected levels when tested with HaCaT CM dilutions above 
1/40,000 (Figure 3.9b and c). In addition, the lack of any endogenous motogenic 
activity in the HaCaT CM made the interpretation of the results straightforward, as 
compared to previous experiments with the other cell lines tested. 
From the observation of normal fibroblast morphology during the assay and the 
similarity to the SF MEM baseline migration we eliminated the presence of any “toxic” 
effect present in the HaCaT CM. The results were also established to be consistently 
reproducible. Various batches of HaCaT CM were tested, either freshly collected or  
stored at -20°C, in order to remove any possible effect of storage or the freeze thaw 
cycle in activating factors present within the HaCaT.  Another researcher, Dr I Ellis, 
also performed a duplicate experiment achieving the same results, therefore increasing 
confidence in attributing the effect of the HaCaT CM on the motogenic activity of MSF 
to the presence of an MSF inhibitor (MSFI). 
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a. HaCaT CM Only.
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c. HaCaT CM, Tested with 100pg/ml rhMSF
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Figure 3.9: The bioactivity of HaCaT keratinocyte conditioned medium in the 
fibroblast migration assay. The CM was tested on its own and in the presence of 100pg/ml 
rhMSF, at a range of dilutions from 1 in 4 to 1/40,000 The number of cells migrated is expressed as 
either: Graph a: a percentage of the SF MEM control baseline migration i.e. SF MEM baseline = 100+/- 
9.13, as represented by hatched and dotted lines (mean and standard deviation respectively). Equivalent to 
2.3 +/- 0.21 migrated cells. Graph b: a percentage of CM only baseline migration at each individual 
dilution point i.e. ¼ dilution CM only = 100%, as represented by the hatched line. Graph c: a percentage 
of the 100pg/ml rhMSF control baseline migration i.e. MSF baseline = 100+/- 4.59, as represented by 
hatched and dotted lines (mean and standard deviation respectively). Equivalent to 6.1 +/- 0.28 migrated 
cells. The results show a representative experiment. 
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3.7 DISCUSSION 
 
The first phase of this project was to screen for potential MSF inhibitors by testing the 
conditioned medium, collected from various cell lines, in the 3D collagen gel fibroblast 
migration assay. Through these experiments many observations can be drawn.  
Firstly, the selection of the 3D collagen gel fibroblast migration assay as a MSF-I 
screening tool was advocated.  Substantiating previous findings, that the adult 
fibroblasts (FSF44) used in the assay do not express either MSF or any MSF-I, but 
respond reproducibly to the motogenic activity of rhMSF (Schor et al., 2003). 
Therefore, the effect on fibroblast migration can be attributed only to the specific 
experimental conditions and the relationship between rhMSF and the test CM.  
Secondly, two sources of MSF-I activity were identified. MSF-I activity was detected 
within the CM collected from two different cell types, endothelial and keratinocyte. In 
addition, the expression of the endothelial MSF-I appears to be phenotype dependent; 
bioactive in “resting” cobblestone CM but not detected in sprouting CM. Whilst, 
sprouting endothelial cells appear to be producing a motogen that has a similar activity 
to rhMSF.  
No presumptions could be made that MSF-I present in the keratinocyte and cobblestone 
endothelial CM is the same factor. Therefore, the next stage was to isolate and identify 
the MSF-I from each source. Since, the culture and collection of HaCaT CM was more 
efficient this avenue was pursued first, thereby developing a protocol that could 
subsequently be applied to the endothelial CM.  In addition, conditioned medium is a 
complex mixture and the results achieved from this MSF-I screening process can only 
be seen as a crude indication of its constituents; the fractionation and purification of the 
CM is therefore the essential next stage in achieving the identification of MSF 
inhibitor(s). 
The situation with the endothelial cells was further complicated by what emerged to be 
a phenotype dependence of MSF-I expression and by the presence of an endogenous 
motogenic activity, caused by endothelial MSF-like motogen. The next stage was to 
determine, the identity of the MSF inhibitor and the motogen and to subsequently 
understand the relationship between the two.  
In addition, the HaCaT keratinocyte cell line has been further developed by the Fusenig/ 
Boukmap group into an in vitro model used to study human skin carcinogenesis. 
HaCaT-ras clones, each displaying a shift in tumourigenic potential, have been 
established as the cell lines BEN, MAL and MET representing respectively the benign, 
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malignant and metastatic stages of carcinogenesis (Fusenig and Boukamp 1998).  It 
would therefore be interesting to determine whether the presence and bioactivity of 
keratinocyte MSF-I can be related to tumorigenic potential.
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Table 3.1: List of cultured cell lines of which conditioned medium was collected under serum free conditions and used for testing for the 
presence of MSF- inhibitory activity in the 3D collagen gel fibroblast migration assay.  
Details include cell type, source and reference. 
Name  Cell Type Source Reference 
FFD4 Human fetal 
fibroblast. 
Explant culture, 
Ninewells 
Hospital, 
University of 
Dundee 
Unpublished 
F110 a Human fetal 
fibroblast. 
Explant culture,  
Dr. I. Ellis, 
University of 
Manchester.  
R.G.Ham. Dermal fibroblasts. In Methods in Cell Physiology, Vol 21 (ed. C. Harris, 
B.F. Trump & G.Stoner) New York, Academic Press, 255-276. 
FSF44 Human foreskin 
fibroblast. 
Obtained from 
one year old 
healthy donor. 
Explant culture,  
Dr I. Ellis, 
University of 
Manchester 
R.G.Ham. Dermal fibroblasts. In Methods in Cell Physiology, Vol 21 (ed. C. Harris, 
B.F. Trump & G.Stoner) New York, Academic Press, 255-276. 
S.L.Schor. Cell proliferation and migration on collagen substrata in vitro. Journal of 
Cell Science. 1980, 4,159-175. 
S.L. Schor et al. Foetal and cancer patient fibroblasts produce an autocrine migration-
stimulating factor not made by normal adult cells. Journal of Cell Science, 1988, 90, 
391-399. 
S.L.Schor et al. Substratum- dependent stimulation of fibroblast migration by the 
gelatine binding domain of fibronectin. Journal of Cell Science, 1996, 109, 2581-2590. 
S.L.Schor et al. MSF: A genetically truncated oncofoetal fibronectin isoform expressed 
by carcinoma and tumour-associated stromal cells. Cancer Research, 2003, 63 (24), 
8827-8836. 
S.L.Schor et al. A novel sandwich assay for quantifying chemo-regulated cell 
migration within a 3Dmatrices: wound healing cytokines exhibit distinct motogenic 
activities compared to transmembrane assay. Cell Motility Cytoskeleton, 2006, 63, 
287-300. 
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C.J.Millard et al. The role of the fibronectin IGD motif in stimulating fibroblast 
migration. Journal of Biological Chemistry, 2007, 282 (49), 35530-35535. 
S.J.Jones et al. Co-expression by keratinocytes of migration stimulating factor (MSF) 
and a functional inhibitor of its activity (MSF-I). Experimental Cell Research, 2007, 
313, 4145-4157. 
K.Motegi. Differential involvement of TGFβ-1 in mediating the motogenic effects of 
TSP-1 on endothelial cells, fibroblasts and oral tumours. Experimental Cell Research 
2008, 314, 2323-2333. 
DFSF1 Human adult 
foreskin 
fibroblast. 
Explant culture, 
University of 
Dundee 
 
R.G.Ham. Dermal fibroblasts. In Methods in Cell Physiology, Vol 21 (ed. C. Harris, 
B.F. Trump & G.Stoner) New York, Academic Press, 255-276. 
ENDO 
742 
Transformed 
human 
microvascular 
endothelial cells 
Dr Micheal 
O’Hare  
M. J. O’Hare, J. Bond, C.Clarke, Y. Takeuchi, A. J. Atherton, C. Berry, j. Moody, 
A.R.J. Silver, D.C. Davies, A.E. Alsop, A.M. Neville, P.S. Jat, Conditional 
Immortalisation of Freshly Isolated Human Mammary Fibroblasts and Endothelial 
Cells. Proceedings of National Academy of Science, USA , 2001, 98, 646-65. 
K.Motegi. Differential involvement of TGFβ-1 in mediating the motogenic effects of 
TSP-1 on endothelial cells, fibroblasts and oral tumours. Experimental Cell Research, 
2008, 314, 2323-2333. 
HUVEC  
1666 
Human 
umbilical vein 
endothelial cells 
Cell Applications 
Inc. 
Cat No : 200-05n 
Lot No: 1666 
J.Wojta, M Gallicchio, et al. Interleukin-4 Stimulates expression of urokinase- type- 
plasminogen activator in cultured human foreskin microvascular endothelial cells. 
Blood 1993, 81 (12), 3285-3292. 
B. Furie, B.C.Furie. The Molecular Basis of Blood coagulation. Cell, 1988, 53 (4), 
505-518. 
HOEC  Human 
omentum 
microvascular 
endothelial cells 
 N.Chung-Welch et al. Two-stage isolation procedure for obtaining homogenous 
population of microvascular endothelial and mesothelial cells from human omentum. 
Microvascular Research, 1997, 54, 121-134. 
HAEC 
 
Human aortic 
endothelial cells 
Life Technologies 
Ltd. 
Unpublished 
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Cat No: C-006-
SC 
HUVEC Human 
umbilical vein 
endothelial cells 
Dr Shane Foo, 
CRT. Originally 
purchased from 
Promo Cell: 
HUVEC-c, 
cryopreserved,  
cat no:C-12200 
K.Motegi. Differential involvement of TGFβ-1 in mediating the motogenic effects of 
TSP-1 on endothelial cells, fibroblasts and oral tumours. Experimental Cell Research, 
2008, 314, 2323-2333. 
BAEC 
Clones 2 
& 3 
Bovine aortic 
endothelial cells 
In house 
preparation.  
A.M. Schor, S.L.Schor, T.D.Allen 
Effects of Culture Conditions on the Proliferation, Morphology and Migration of 
Bovine Aortic Endothelial Cells. 
Journal of Cell Science, 1983, 62, 267-285. 
A.B.Sutton et al. The response of endothelial cells to TGF-β1 is dependent upon cell 
shape, proliferative state and the nature of the substratum. Journal of Cell Science, 
1991, 99, 777-787. 
BAEC 
2-2 U7 
Bovine aortic 
endothelial cells 
In house 
preparation.  
Bovine aorta 
No:2. cultures 
started June2003 
 
A.M. Schor, S.L.Schor, T.D.Allen 
Effects of Culture Conditions on the Proliferation, Morphology and Migration of 
Bovine Aortic Endothelial Cells. 
Journal of Cell Science, 1983, 62, 267-285. 
A.B.Sutton et al. The response of endothelial cells to TGF-β1 is dependent upon cell 
shape, proliferative state and the nature of the substratum. Journal of Cell Science, 
1991, 99, 777-787. 
K.Motegi. Differential involvement of TGFβ-1 in mediating the motogenic effects of 
TSP-1 on endothelial cells, fibroblasts and oral tumours. Experimental Cell Research, 
2008, 314, 2323-2333. 
HACAT Spontaneously 
immortalised 
human trunk 
skin 
Dr. Norbett 
Fusenig 
 
P. Boukamp, R.T. Petrussevska, D. Breitkreutz, J. Hornung, A. Markham, N.E. 
Fusenig, Normal Keratinization in a Spontaneously Immortalized Aneuploid Human 
Keratinocyte Cell Line. Journal of  Cell Biology, 1988, 106, 761-771. 
M.M. Mueller, W. Peter, M. Mappes, et.al., Tumour Progression of Skin Carcinoma 
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keratinocytes cells in Vivo promoted by Clonal selection, Mutagenesis, and Autocrine Growth 
Regulation by Granulocyte Colony-stimulating factor and Granulocyte- macrophage 
Colony Stimulating factor. American Journal of Pathology, 2001, 159, 1567-1579. 
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Chapter 4: Results 
 
THE IDENTIFICATION OF MSF-I PRODUCED BY KERATINOCYTES. 
 
4.1 AIMS 
 
The initial screening of the conditioned medium of the spontaneously immortalised 
human keratinocyte cell line, HaCaT, showed it possessed the ability to consistently 
inhibit the bioactivity of rhMSF in the 3D collagen gel fibroblast migration. The next 
phase was therefore to isolate and identify the factor(s) responsible for this MSF 
inhibitory activity from the complex mixture of proteins present within the HaCaT 
conditioned media.  Furthermore, although no motogenic bioactivity was detected when 
the total HaCaT conditioned medium was tested the process of fractionation may 
potentially disrupt protein interactions resulting in the appearance of previously masked 
bioactivities. Therefore, the fractionated HaCaT conditioned medium, was analysed in 
the 3D collagen gel fibroblast migration assay for the presence of both motogenic and 
MSF inhibitory activity.  
 
Please note that the SEC and Ion Exchange fractionation of the HaCaT CM was 
performed by Dr S.J. Jones, whilst subsequent handling and analysis of the bioactivity 
of fractions was carried out by M.M. Florence. In order to validate results Dr. I.R. Ellis 
and M.M. Florence concurrently performed the 3D collagen gel fibroblast migration 
assays.  
 
4.2 BACKGROUND  
 
The HaCaT human keratinocyte cell line is a spontaneously immortalised cell line 
derived from histologically normal adult body skin. Named after its development from 
prolonged cultivation at a reduced calcium concentration and elevated temperature 
(Boukamp et al., 1988). It is unique, as the first clonal origin, permanent epithelial cell 
line from adult human skin which exhibits practically normal differentiation. However, 
despite displaying transformed phenotype in vitro, HaCaT keratinocytes are non-
tumorigenic and non invasive in vivo (Boukamp et al., 1997, Fusenig and Boukamp 
1998).  
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It has been discovered that, unlike rodent tissue, human cells are rather resistant to 
transformation; a difference that has been ascribed to the higher stability of the human 
genome (Sager et al., 1983, Dipalo 1983). Previous attempts to immortalise human cells 
using DNA viruses (simian virus 40, adenovirus types 5 and 12, human papilloma virus 
types 16, 18 and 31) resulted in cells exhibiting altered growth properties and a 
significant reduction of normal keratinisation with a partial re-expression of foetal 
characteristics (Boukamp et al., 1997). 
Although the exact mechanism of spontaneous immortalisation remains elusive, 
evidence does suggest that numerous genetic alterations are required including the 
inactivation of senescence genes or activation of immortalising genes. These genetic 
changes are visible as chromosomal alterations. The immortalisation of HaCaT cells is 
thought to be a consequence of UV type mutations in both alleles of the p53 tumour 
suppressor gene similar to those found in a high percentage of skin carcinomas and 
premalignant lesions (Lehmann et al., 1993, Brash et al., 1991). They also show a loss 
of chromosomes 3p, 4p and 9p; the location of senescence genes. Yet in spite of these 
genetic alterations HaCaT cells still retain a stable chromosome content and remain 
non-tumorigenic throughout 320 passages (Boukamp et al., 1997). 
Cell immortalisation is considered to be a foremost step in the transformation process of 
human cells and is typically associated by a loss or reduction in a cell’s differentiation 
potential. However, HaCaT keratinocytes retain their differentiation capacity, 
possessing the ability to form a practically normal epidermal architecture when 
transplanted onto subcutaneous tissue of athymic mice and when grown in an 
organotypic co-culture system (Boukamp et al., 1988, Ryle et al., 1989, Schoo et al., 
1996). The organised epithelium formed, typically expresses most differenation- 
specific keratins (1 and 10) and markers (invocularin and flaggarin) and ultrastructurally 
closely resembles the epidermis including the formation of a basement membrane 
(Boukamp et al., 1988, Breitkreutz et al., 1998, Schoop et al., 1999). 
Due to the similarity to normal human keratinocytes in their growth and differentiation 
potential the HaCaT cell line is a regularly used model system to study keratinocyte 
biology and transformation. Including examining epithelial –mesenchymal interactions 
and the effect matrix components and paracrine acting differentiation factors have on 
tissue organisation and keratinisation in vitro (Schoop et al., 1996). HaCaT 
keratinocytes are also one of the most frequently used cell lines in three dimensional 
culture and artificial skin models; aiding in the study of epidermal gene expression, 
epidermal-dermal interactions and wound healing. These models are also increasingly 
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been adopted as an in vitro pharmacotoxiclogical test (Gay et al., 1992). Furthermore, 
HaCaT cells can be stably transfected with candidate genes, enabling the investigation 
into oncogenes and other factors in the process of malignant conversion of human 
epithelial cells (Schoop et al., 1999). 
Ever since Boukamp et al., (1988) established the HaCaT cell line, they have become a 
valuable tool in the study of human epithelial cells. In comparison to other epithelial 
lines, there are numerous advantages in using the HaCaT cells including their 
independence of donor variation and availability in unlimited quantities. Also, since 
they are not virally transformed, they do not contain any viral sequences which could 
cause genetic instability, thus maintaining their non-tumourigenic phenotype for 
extended culture passages (Boukamp et al., 1997). Finally, because of their genetic and 
phenotypic characteristics HaCaT keratinocytes are considered analogous to cells 
present at the very early stage of skin carcinogenesis and have become the foundation of 
a multistage skin carcinogenesis model system (Fusenig et al., 1998, Mueller et al., 
2001).  
 
 
4.3 THE SUPERDEX FRACTIONATION OF HACAT  
CONDITIONED MEDIUM 
 
The MSF inhibiting activity of conditioned medium (CM) collected from cultured 
HaCaT keratinocytes can be detected up to CM dilutions of 1:1000. This activity was 
attributed to the presence of a putative inhibitor of MSF, referred to as MSF-I. In order 
to isolate and ultimately identify this MSF-I, the HaCaT CM was fractionated by 
molecular weight using size exclusion chromatography (SEC). 
Initial SEC experiments were performed using the Superose 12HR 10/30 column (GE 
Healthcare) and subsequently with the Superdex 75 HiLoad 26/60 (GE Healthcare) 
column, which has a fractionation range of 3-70kDa. Multiple runs using ten times 
concentrated CM was performed in order to provide sufficient material for downstream 
analyses. Per run, 4mls of ten times concentrated CM was loaded onto the column, as 
described previously in Materials & Methods, Chapter 2. For each individual run 100 x 
3ml fractions were collected (2ml/min) and numbered 1 to 100; the corresponding 
fractions from the duplicate runs were then pooled together. Subsequently the fractions 
were pooled into groups of three; Groups 1 to 33. For each cell line Groups 9-18 
(fractions 30-59), which span the two main absorbance peaks with a molecular weight 
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range of approximately >70kDa to 20kDa, were tested for bioactivity in the 3D collagen 
gel fibroblast migration assay (Figure 4.1). 
 
 
4.4       THE BIOACTIVITY OF SIZE- EXCLUSION FRACTIONATED 
HACAT CONDITIONED MEDIUM. 
 
As previously described for HaCaT total CM, the SEC fractionated HaCaT CM was 
tested alone and in the presence of 100pg/ml rhMSF in the 3D collagen gel fibroblast 
migration assay. Fraction groups 9-18 were tested at a final dilution of 1/20 (all 
dilutions made with SF MEM). A criterion was set in order to determine each fraction’s 
bioactivity. For a fraction to be considered motogenic, when tested alone, it must have 
stimulated fibroblast migration by a minimum of 50% as compared to the SF MEM 
control baseline levels. While the existence of MSF-inhibitory bioactivity was 
established as a fraction’s ability to reduce fibroblast migration by at least 50% upon 
addition of 100pg/ml rhMSF, as compared to MSF baseline. Another method of 
analysis took into account the existence of any motogenic activity present in the 
fractions which may mask the effect of any MSF-inhibitors present. The baseline was 
set as the level of migration achieved for each fraction group when tested alone and 
MSF- inhibition determined as the failure to increase migration by 50% above this level 
upon addition of 100pg/ml rhMSF. 
Total HaCaT CM displayed only MSF-I bioactivity, however upon fractionation 
motogenic activity was also detected within the HaCaT CM. When tested alone it was 
clearly apparent that motogenic activity was present in the high molecular weight 
fraction groups 11 and 12, equivalent to 63-84kDa. Reproduced in four separate 
experiments, fraction groups 11 and 12 on average stimulated migration by 2-3 fold, as 
compared to the SF MEM control baseline migration. The remaining fraction groups 
displayed migration levels comparable to the SF MEM control (Figure 4.2). 
While testing the fraction groups in the presence of rhMSF, distinct MSF- inhibitory 
activity was observed in the lower molecular weight fractions (Figure 4.3) Equivalent to 
16-27kDa, fraction groups 15-17 inhibited the activity of 100pg/ml rhMSF by 57.0 +/- 
9.08% (in an average of six experiments). A borderline MSF-I activity was also 
detected in Fraction groups 11 and 12 (3/6 experiments) (Figure 4.4). As motogenic 
activity had also been detected in this area, plus the molecular weight corresponded to 
that of MSF it was hypothesised that HaCaT expressed MSF must be responsible for 
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this bioactivity. Therefore, this inhibitory activity was actually due to the nature of 
MSF’s bell shaped dose response bioactivity; the addition of “excess” rhMSF causing a 
shift in the bell-shaped response resulting in an inhibition of migration as compared to 
the rhMSF control baseline.  
These results from fractionated CM indicate that the HaCaT keratinocytes are 
expressing two opposing factors; one which stimulates migration in a manner similar to 
MSF and another which possesses the ability to inhibit the motogenic activity of MSF. 
Since, the only bioactivity detected in the total HaCaT CM was MSF inhibition one 
could propose that the endogenous motogenic activity discovered is normally rendered 
inactive by the co-secretion of an inhibitor. The next stage therefore, was to identify the 
factors responsible for this bioactivity. 
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Figure 4.1: The fractionation of HaCaT keratinocyte conditioned medium by Size-
Exclusion Chromatography. 4ml of 10x concentrated conditioned medium (CM) from 
HaCaT keratinocytes was applied to a Superdex 75 HiLoad 26/60 column (performed by Dr. S 
Jones). The eluant was monitored for absorbance at 254nm and 280nm. 100 x 3ml fractions 
were collected (2ml/min). The collected fractions were pooled together into groups of three. 
Fraction groups 9 to 18, equivalent to the main absorbance peak, were assayed for biological 
activity in the 3D collagen fibroblast migration assay. 
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Figure 4.2: The motogenic activity of Superdex 75 fractionated conditioned 
medium from HaCaT keratinocytes. The fractionated conditioned medium (CM), fraction 
groups 9-18, from the HaCaT cell line was tested alone (final dilution 1/20), in the 3D collagen 
gel fibroblast migration assay. The number of cells migrated is expressed as a percentage of the 
SF MEM control baseline i.e. SF MEM Baseline = 100 +/- 8.6% as represented by the hatched 
and dotted lines (mean and SD respectively). This is equivalent to 2.2 +/- 0.66 migrated cells. 
The results represent an average of four experiments (one of the four experiments was 
performed by Dr.I.Ellis). 
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HaCaT Fractioned CM, Tested with 100pg/ml rhMSF
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Figure 4.3: The MSF-Inhibitory activity of Superdex 75 fractionated conditioned 
medium from HaCaT keratinocytes. The fractionated conditioned medium (CM), fraction 
groups 9-18, from HaCaT cell line was tested in the 3D collagen gel fibroblast migration assay 
(final dilution 1/20), in the presence of 100pg/ml rhMSF. The number of cells migrated is 
expressed as a percentage of the 100pg/ml rhMSF control baseline migration i.e. MSF Baseline 
= 100 +/- 13.86%, as represented by the hatched and dotted lines (mean and SD respectively). 
This is equivalent to 5.7 +/- 0.79 migrated cells. The results represent an average of 6 
experiments (one of the six experiments was performed by Dr.I.Ellis).
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Figure 4.3: The motogenic activity of exogenous rhMSF in the presence of 
Superdex 75 fractionated conditioned medium from HaCaT keratinocytes. The 
fractionated conditioned medium (CM), fraction groups 9-18, from HaCaT cell line was tested 
in the 3D collagen gel fibroblast migration assay (final dilution 1/20), with and without the 
presence of 100pg/ml rhMSF. The number of cells migrated is expressed as a percentage of 
each individual fraction group only baseline migration i.e. Fraction group 9 = 100%, as 
represented by the hatched line. The results represent an average of 4 experiments (one of the 
four experiments was performed by Dr.I.Ellis). 
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4.5 THE IDENTIFICATION OF MSF EXPRESSION BY HACAT 
KERATINOCYTES 
 
Total CM collected from cultured HaCaT keratinocytes showed no motogenic activity, 
however upon SEC fractionation stimulatory activity was discovered in the high 
molecular weight fractions (63-84kDa), equivalent to fraction groups 11 and 12. Due to 
the nature of the bioactivity and the molecular weight it was proposed that the HaCaT 
cells must be expressing MSF. In order to prove the hypothesis various biochemical, 
immunohistochemical and biological activity investigations were performed. 
 
4.5.i Western Blot Identification of MSF  
 
Using a specific anti-MSF antibody, RpVSI, attempts were made to identify MSF by 
immunoblotting of the total CM collected from HaCaT keratinocytes. CM was 
separated by 12% SDS PAGE under reducing conditions followed by immunoblotting 
with the RpVSI antibody. On each gel, 250pg rhMSF (25ng/ml) was loaded as a 
positive control; this resulted in a clear, strong main band of approximately 70-80kDa 
on the immunoblot. Unfortunately, no similar bands were ever observed for the HaCaT 
CM even when using CM concentrated by factor of up to 50 (Amicon method). Since, 
the same volume of the HaCaT samples as the rhMSF standard was loaded onto the gel 
one can conclude that if MSF is present in the HaCaT CM it is at a concentration below 
the limit of detection of this assay, which is less than 25ng/ml. 
 
4.5.ii Colorimetric Sandwich ELISA for Total MSF 
 
The development of a Colorimetric Sandwich ELISA assay for MSF had the potential to 
both identify and quantify MSF present within the HaCaT CM. The anti-IGD antibody, 
MAb PepQ 5.1, was employed for capture and the specific anti-MSF antibody, RPVSI, 
for identification (Materials & Methods chapter 2). A standard curve of rhMSF was 
included in every experiment; a maximum concentration of 200ng/ml serially diluted to 
1.5625ng/ml. 100µl of each standard or sample was tested per well, with duplicate wells 
tested for each variable and an average reading calculated. SF MEM and coating buffer 
were used as negative controls. (Figure 4.4). 
Unfortunately, whether using neat or 10x concentrated CM, OD readings consistently 
failed to be higher than the negative controls. Again, this would imply that either MSF 
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is not expressed by the HaCaT cells or it is present at concentrations below the assay’s 
sensitivity, 12.5ng/ml. In addition the quality of the standard curve obtained in replicate 
experiments would suggest the assay is limited due to the suitability and quality of the 
antibodies used.  
 
 
Figure 4.4: The standard curve of colorimetric Sandwich Elisa for Total MSF. An 
anti-IGD monoclonal antibody, MAb PepQ5.1 was employed for capture and a specific anti-
MSF antibody, RpVSI, was used for the identification of a range of rhMSF standards (200- 
1.56ng/ml). OD readings were measured at 450nm. The results shown are an average of four 
individual experiments. 
 
 
4.5.iii Immunolocalisation of MSF in HaCaT Keratinocytes. 
 
By adopting an immunohistochemical method of detection, it was hoped any 
complications of MSF degradation in the HaCaT CM would be eliminated. Concerns 
were raised that the inability to detect MSF by the Western Blot and Sandwich ELISA 
techniques was a result of MSF having a short half-life in the CM; either due to the 
action of proteases present within the CM or as a consequence of storage (effect of 
freeze/ thaw cycles). It was also thought that the fixation step required in this technique 
could possibly assist in preserving any MSF present. 
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As described in Materials and Methods, Chapter 2, a rabbit polyclonal anti-VSI 
antibody (Rp2), raised against the MSF unique carboxyl terminal decapeptide, was used 
for the immunolocalisation of MSF in the HaCaT keratinocytes. A series of 
optimisation experiments were initially performed to select the optimum antibody 
concentration which ensured the best possible staining but also a consistent negative 
control at the same concentration (normal rabbit IgG) and no cross- reaction with the 
biotinylated secondary antibody (Goat Anti-Rabbit IgG). The known MSF negative cell 
line, FSF44, was also included in each experiment as additional control. In addition the 
primary keratinocyte cell line HEK 102-05a (ECACC No. 06091505) was also included 
in order to determine whether primary and transformed keratinocytes share a similar 
MSF expression. 
Each cell line was plated onto plastic cell culture dishes and allowed to attach for 24-48 
hours before fixation. Consistently the FS44 cells showed no MSF localisation, once 
again justifying their suitability in the 3D collagen gel migration. The HaCaT cells 
however repeatedly displayed a heterogeneously positive localisation of MSF. Whilst 
the HEK primary keratinocytes were also positive for MSF but displayed a more 
homogenous staining pattern; the staining also appeared to be stronger in intensity 
compared to the HaCaT cells. Staining with a normal rabbit IgG, at the same 
concentration as the anti-MSF antibody, was negative for all the cell lines assessed. This 
result therefore confirms that HaCaT cells express MSF and that MSF could possibly be 
responsible for the migration stimulating bioactivity detected in the fractionated HaCaT 
CM (Figure 4.5). 
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Figure 4.5: Immunolocalisation of MSF in human fibroblasts and keratinocytes. 
Cells were plated onto plastic cell culture dishes and assessed for the presence of MSF by 
immunocytochemistry using the specific anti-MSF rabbit polyclonal Rp2 antibody (5µg/ml). 
MSF positive expression resulted in brown coloured staining. Control cultures were incubated 
with normal rabbit IgG at the same concentration as the MSF specific antibody (5µg/ml) (B).  
Images and observations were made at x20 magnification. Results showed that FSF44 
fibroblasts (D) were negative for MSF, whilst both primary (C) and transformed keratinocytes 
(A) express MSF. However, there appears to be a difference in the intensity and distribution; 
primary keratinocytes displayed homogenous staining whereas HaCaT cultures showed a 
heterogeneous expression. Negative results were achieved with all cultures stained with the 
normal rabbit IgG. 
A. HaCaT, Anti-MSF Rabbit polyclonal Rp2. 
B. HaCaT, Normal Rabbit IgG 
C. HEK, 102-5a primary keratinocytes, Anti-MSF Rabbit polyclonal Rp2. 
D. FSF44. Anti-MSF Rabbit polyclonal Rp2. 
 
 
4.5.iv The Characterisation of HaCaT Endogenous Motogenic Bioactivity. 
 
The IGD function-neutralising monoclonal antibody, PEPQ 1.1, is a known inhibitor of 
MSF stimulated migration in the fibroblast collagen gel assay. It reliably inhibits the 
stimulatory activity of rhMSF back to SF MEM baseline levels, with maximal inhibition 
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of up to 1ng/ml rhMSF. By testing the motogenically active SEC fractions of HaCaT 
CM with the addition of PEPQ 1.1 antibody it is possible to determine whether the 
stimulatory activity detected is actually due to the presence of HaCaT expressed MSF.  
The motogenic SEC fraction groups 11 and 12 (63-84kDa) were pooled together (now 
referred to as F-msa; fractions displaying migration stimulating activity) and tested 
(final 1/20 dilution) in the presence of the PEPQ 1.1 antibody (50ng/ml). The criteria set 
for the inhibition of motogenic activity was a reduction in migration by at least 50% 
compared to the baseline level.  
With SF MEM and 100pg/ml rhMSF acting as controls it was shown that the PEPQ 1.1 
antibody had no effect on the SF MEM only baseline migration but was capable of 
completely inhibiting the rhMSF stimulated migration back to SF MEM only levels 
(approximately a 70% reduction in migration). A similar level of inhibition was seen in 
two separate experiments with the HaCaT F-msa sample. When tested alone F-msa 
stimulated migration by 3.7 fold more than SF MEM only baseline level, however upon 
addition of the PEPQ 1.1 antibody motogenic activity was inhibited on average by 60-
70%. (Figure 4.6). These results suggest that the motogenic activity present in the 
HaCaT CM is due to the presence of an IGD motif, as found in MSF or other 
fibronectin- related molecules ( i.e. fibronectin breakdown products). 
 
4.5.v The Identification of MSF Expression in HaCaT Size Exclusion  
Fractionated Conditioned Medium. 
 
As shown, the motogenic activity discovered in the SEC fractionated CM of HaCaT 
keratinocytes possesses characteristics similar to MSF. However, in order to provide 
definitive proof that HaCaT keratinocytes do express MSF immunopreciptation (IP) 
with Protein G using the specific identification antibody, RpVSI, was performed. The 
rabbit polyclonal VSI antibody only recognises the MSF-unique carboxyl terminal 
decapeptide and consequently, under the appropriate conditions, any protein which 
binds to it must be MSF.  
As described in Chapter 2, Materials & Methods, this technique involves the binding of 
any MSF present in the HaCaT SEC fraction groups 11 and 12 (F-msa)  to the specific 
anti-MSF VSI antibody, and then capturing the complexes with immobilised protein G, 
thereby removing them  from solution. After which the complexes are eluted and tested 
for bioactivity in the 3D collagen gel fibroblast migration assay. If the bound elution 
possesses the same motogenic activity as the original F-msa sample then the conclusion 
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would be that MSF is present in the HaCaT CM. In preparation, F-msa (MW 63-84kDa) 
from two separate SEC runs were pooled, dialysed against distilled water and then 
concentrated 100x by freeze drying. Immunopreciptation was performed using 1ml of 
the resuspended F-msa sample. The resultant fractions were then tested for bioactivity 
in the collagen gel assay and where possible each was tested in duplicate at a range of 
dilutions; the 100x concentrated F-msa sample, unbound material and bound elutions 1 
and 2. The same criteria as previously used to determine motogenic activity was 
adopted, namely an increase in migration of at least 50% as compared to SF MEM 
control baseline. 
As expected, the 100x concentrated F-msa sample displayed the ability to stimulate 
fibroblast migration to a similar extent as 100pg/ml rhMSF control; a 3.-3.5 fold 
increase above SF MEM baseline levels. Following IP it would appear that all 
motogenic activity had been removed, as no stimulatory activity was detected in the 
unbound sample. However, the samples tested after the first elution (bound elution 1) 
demonstrated once again a level of motogenic activity similar to the rhMSF control; 
approximately a 2.8 fold increase above SF MEM baseline levels. Further elutions 
displayed no bioactivity. Figure 4.7.  
As stated previously, the RpVSI antibody recognises the MSF-unique carboxyl terminal 
decapeptide. Therefore the discovery that the motogenic activity present in the high 
molecular weight SEC fractions of HaCaT CM could be removed upon binding to 
RpVSI would imply that the motogen responsible must possess the same unique VSI 
sequence. This result, coupled with the IHC and PEPQ1.1 antibody experiments, would 
validate the proposal that HaCaT keratinocytes express a bioactive form of MSF. 
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Figure 4.6: The effect of the MSF-Inhibitor, function neutralising antibody PEPQ 
1.1, on the endogenous motogenic bioactivity of HaCaT Fractionated CM. The 
motogenic active Superdex 75 fraction groups 11 and 12 were pooled (referred to as F-msa) and 
tested (final dilution 1/20), with PEPQ1.1 (50ng/ml) antibody in the 3D collagen gel fibroblast 
migration assay. The number of cells migrated is expressed as a percentage of the variable only 
baseline migration i.e. HaCaT F-msa only = 100%. The effect of PEPQ 1.1 antibody on SF 
MEM and 100pg/ml rhMSF is shown for comparison. (SF MEM only migration is equivalent to 
1.9 +/ -0.3 cells migrated, whereas 100pg/ml rhMSF is 6.8 +/- 0.3). The results represent an 
average of two experiments (one of the two experiments were performed by Dr.I.Ellis).  
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Figure 4.7: The motogenic activity of HaCaT SEC fractionated CM before and 
after immunopreciptation with MSF-specific identification antibody RpVSI. The 
motogenic SEC fraction groups 11 and 12, equivalent to MW 63-84 kDa, were pooled (referred 
to as F-msa), dialysed and then concentrated 100x by freeze drying (100x F-msa). After which, 
immunopreciptation with RpVSI MSF identification antibody was performed; unbound and two 
bound elutions were collected and tested. (The immunopreciptation was performed by Dr S. 
Jones).  All variables were tested alone in the 3D collagen gel fibroblast migration assay at a 
final dilution of 1/100. The number of cells migrated is expressed as a percentage of the SF 
MEM control baseline i.e. SF MEM Baseline = 100 +/- 9.52 represented by hatched and dotted 
lines (mean and SD respectively). This was equivalent to 2.1 +/-0.2 migrated cells. 100pg/ml 
rhMSF is shown for comparison (6.6 +/-0.2 migrated cells). 
 
 
4.6 THE ISOLATION AND IDENTIFICATION OF MSF-I 
 
It has been consistently shown that conditioned medium collected from cultured HaCaT 
keratinocytes contains a molecule with the ability to inhibit the motogenic activity of 
rhMSF. After SEC fractionation this MSF- inhibitory activity was located in the lower 
molecular weight fraction groups 15-17, equivalent to 16-27kDa. The next stage was to 
isolate and then, ultimately identify this MSF inhibitor (MSF-I). 
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4.6.i The Ion Exchange Fractionation of HaCaT Conditioned Medium. 
 
SEC fractionation of HaCaT CM established that MSF-I must have a molecular weight 
below 30kDa but in order to identify the molecule responsible for the bioactivity further 
purification steps were required. By undertaking ion exchange chromatography the 
proteins present in the MSF-I active SEC fraction groups 15-17 would be separated 
further by the nature and degree of their ionic charge. 
Initially optimisation experiments were performed, assessing the suitability of various 
anionic and cationic columns. The process of selection was determined by whether 
MSF-I bioactivity could be retained in the fraction containing the lowest percentage of 
total protein, thereby making subsequent purification steps easier. Before application to 
the columns, the MSF-I active SEC fraction groups 15-17 were pooled and dialysed 
against the appropriate buffer. Both bound and unbound fractions were then collected 
and tested in the 3D collagen gel fibroblast migration assay for the presence of MSF-I 
bioactivity; MSF-I activity determined by the ability to reduce 100pg/ml rhMSF 
motogenic activity by at least 50%, as compared to rhMSF control baseline. Where 
sample size permitted, each fraction was tested in duplicate and at a selection of 
dilutions. 
Optimum results were achieved using the anion-exchange ANX column, where proteins 
with an overall negative charge bind to the column. As described in Chapter 2, 
Materials & Methods, the pooled SEC fractions were dialysed against 20mM Tris-HCl 
and then applied to the ANX column at a rate of 1ml/minute. Material unbound to the 
ANX column was collected and the bound material eluted as a single peak by washing 
the column with 20mM Tris-HCl pH 7.5 1M NaCl. Figure 4.8. Testing at a final 
dilution of 1/20 revealed that the MSF-I bioactivity was present in the unbound fraction, 
which represented 32% of the total protein applied to the column. On average the 
unbound material had the ability to inhibit rhMSF by 43.4% (+/- 7.01%). Figure 4.9. 
MSF-I, therefore, appears to have an overall positive charge at pH 7.5. 
 
4.6.ii The SDS Electrophoresis Separation of HaCaT  
Anion Exchange Unbound Fractions. 
 
Thus far, two chromatographic methods have been used, SEC and anion-exchange, to 
purify the MSF inhibitor present in the HaCaT CM. They have been successful in 
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separating MSF-I into a smaller and smaller subset of proteins. The final stage in MSF-I 
purification was to separate the components of the ANX unbound fraction by SDS 
electrophoresis under reducing conditions.  
In preparation, the unbound material from several ANX runs were pooled together and 
concentrated by freeze drying, after dialysis against distilled water. The sample was 
redissolved in Laemmli loading buffer containing 5% (v/v) 2-mercaptoethanol and 
heated for 5 minutes at 95˚C, prior to loading onto a pre-run 12% separating 5% 
stacking SDS polyacrylamide gel. (Chapter 2, Materials & Methods). Two lanes were 
run, one was stained with Coomassie for visualisation, and the other was cut into nine 
0.5cm slices for protein elution. The protein present in each of the gel segments, S1-9 
(from low to high molecular weights), was eluted during an overnight incubation in 1ml 
of elution buffer. Subsequently, the presence of MSF-I bioactivity in the gel elutes was 
determined in the 3D collagen gel fibroblast migration assay; that is the ability to reduce 
100pg/ml rhMSF motogenic activity by at least 50%, as compared to rhMSF control 
baseline. Each elution tested at a final dilution of 1/1000. 
The Coomassie stained lane displayed four distinct protein bands at 20-25kDa, 25kDa, 
37kDa and 60kDa.  Meanwhile, definitive MSF-I bioactivity was located in the gel 
elutions 3, 4 and 5; the elutions displaying the ability to inhibit 100pg/ml rhMSF by an 
average of 66%. Both elutions 4 and 5 corresponded to a protein band at 20-25kDa and 
25kDa respectively (Figure 4.10 and 4.11A). 
 
4.6.iii The Identification of MSF-I by Peptide Mass Fingerprinting.  
 
The two protein bands, 4 and 5, possessing MSF-I bioactivity were sent to the 
University of Dundee’s “Fingerprints” Proteomics Facility for protein identification. 
Each band underwent tryptic digest before analysis by mass spectrometry, MALDI-Tof-
Tof (MS/MS) technique, using an Applied Biosystems 4700 Proteomic Analyser. 
Subsequently the “peak list” of protein masses was then compared to database data of 
known protein sequences, in order to find the best match. 
The identity of the proteins in bands 4 and 5 were neutrophil gelatinase associated 
lipocalin (NGAL or lipocalin-2) and triosephophosphate isomerise (TPI), respectively. 
A literature search on both proteins revealed that NGAL is a member of a large family 
of small secreted glycoproteins, which are characterised by a highly conserved tertiary 
structure, 8-stranded anti-parallel -barrel, and their ability to bind and transport small 
lipophillic molecules (Flower 1996, 2000). NGAL was first isolated from neutrophils as 
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a heterodimer covalently linked to matrix metalloproteinase-9 (MMP-9) (Kjeldsen et 
al., 1993). NGAL is a multifunctional protein having numerous roles attributed 
including bacteriostatic agent, acute-phase protein, inducer of mesenchymal-epithelial 
transition during development and the opposing roles of both tumour promoter and 
suppressor (Gwira 2005, Bratt 2000). TPI is a glycolytic enzyme present in all cells and 
is essential for efficient energy production. A deficiency of TPI in humans is a rare 
autosomal recessive multisystem disorder characterised by progressive neurological 
dysfunction and childhood death (Orosz et al., 2006, Olah et al., 2002). 
The information gathered from the literature search indicated that NGAL would appear 
to be the most likely candidate responsible for the MSF-I activity present in HaCaT 
CM. The main reasons being firstly, that NGAL was located in band 4 which possessed 
the maximal MSF inhibitory activity. Also, since primarily experiments revealed that 
not all cell types possess the ability to inhibit MSF bioactivity, the knowledge that TPI 
is found in all cells in numerous organisms does not tally with our findings. It has also 
been reported that keratinocytes do express NGAL (Mallbris et al., 2002, Seo et al., 
2004). Finally, of the numerous functions attributed to NGAL its association with 
MMP-9, where it acts in a protective manner preserving MMP-9 from degradation, 
suggested that it has the potential to bind to MSF (Yan et al., 2001). MSF shares some 
structural similarity to MMP-9, with both molecules containing fibronectin type II 
domains and zinc binding motifs, with the conserved sequence HEXXH in MSF and 
AHEXGHXXGXXH in MMP-9 (Houard et al., 2005, Van dee Steen 2001).  
Consequently, the next stage was to prove definitively that NGAL is indeed responsible 
for the MSF inhibitory activity present in HaCaT CM. 
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Figure 4.8: The purification of MSF-I active SEC fractions by Anion- Exchange 
Chromatography. After HaCaT conditioned medium was fractionated by size exclusion 
chromatography (SEC), the MSF-I bioactive fractions (MW16-27kDa) were applied to an ANX 
anion-exchange column (Hi trap FF), at a flow rate of 1ml/min, for further separation. Analysis 
of protein peaks (measured at 254nm) revealed that 68% of the total protein bound to the 
column, with 32% in the unbound fraction. Fractionation performed by Dr S. Jones. 
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Figure 4.9: The bioactivity of Anion-Exchange, ANX, purified MSF-I bioactive 
HaCaT SEC fractions. After HaCaT conditioned medium was fractionated by size exclusion 
chromatography (SEC), the MSF-I bioactive fractions (MW16-27kDa) were applied to an ANX 
anion-exchange column (Hi trap FF), at a flow rate of 1ml/min, for further separation. The 
unbound and bound material was then tested in the 3D collagen gel fibroblast migration assay 
(final dilution 1/20), in presence of 100pg/ml rhMSF. The number of cells migrated is expressed 
as a percentage of the 100pg/ml rhMSF control baseline migration i.e. MSF Baseline = 100 +/- 
1.24% (mean and SD). This is equivalent to 5.65 +/-0.07 migrated cells. 
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Figure 4.10: The MSF-Inhibitory activity of gel elutions from the SDS 
Electrophoresis fractionation of ANX purified MSF-I bioactive HaCaT SEC 
fractions. After the SDS electrophoresis of the HaCaT ANX sample and segmentation of the 
gel, the protein eluted from each segment (S1-9) was tested (final dilution 1/1000) in the 3D 
collagen gel fibroblast migration assay in the presence of 100pg/ml rhMSF. The number of cells 
migrated is expressed as a percentage of the 100pg/ml rhMSF control baseline migration i.e. 
MSF Baseline = 100 +/- 1.25, as represented by the hatched and dotted lines (mean and SD). 
This is equivalent to 8.0 +/- 0.1 migrated cells. 
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Figure 4.11:  
A. The purification of MSF-I by SDS electrophoresis. The unbound material of the 
ANX fractionation of HaCaT SEC fractions, possessing MSF-I bioactivity was pooled, 
concentrated and then further separated by 12%SDS PAGE under reducing conditions. Two 
identical sample lanes were run, one for protein elution (see Figure 4.9) and the other, as shown, 
stained with Coomassie blue to visualise protein bands. The major protein band at 20-25kDa 
corresponded to maximal MSF-I bioactivity as detected in the fibroblast migration assay. The 
image shown was performed by Dr S. Jones. 
B. The identification of NGAL in HaCaT un-fractionated CM by Immunoblotting. 
Immunoblot of the 12% SDS PAGE separation of HaCaT Series 5x concentrated CM, under 
reducing conditions, with specific anti-NGAL antibody, Mab1757. A distinct band was seen at 
approximately 25kDa, confirming the presence of NGAL. A lane of standards is shown as a 
molecular weight reference. The image shown was performed by Dr S. Jones. 
 
 
4.7 THE VERIFICATION OF NGAL AS THE HACAT MSF-I 
 
In order to purify MSF-I bioactivity and identify NGAL as the molecule responsible, 
the HaCaT CM underwent a series of fractionation and concentration steps.  
It was therefore necessary to prove definitively that the HaCaT keratinocytes do express 
NGAL and that it is present within HaCaT CM, thereby silencing any suggestion that 
the discovery is either an artefact of the process or a contaminant. It is also necessary to 
confirm that NGAL alone is responsible for the MSF-I bioactivity of HaCaT CM and is 
not reliant on another, as yet, unidentified factor(s) in the HaCaT CM. 
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4.7.i Western Blot Identification of NGAL in Un-Fractionated HaCaT CM 
 
The simplest method to prove that NGAL was present in the HaCaT CM was to perform 
an immunoblot using a specific anti-NGAL antibody, Mab1757. Total HaCaT CM was 
tested neat and concentrated 5x, using the Amicon method and then separated by 12% 
SDS PAGE under reducing conditions, followed by immunoblotting with the anti-
NGAL antibody (Chapter2, Materials & Methods).Visualisation by chemiluminescence 
identified a clear band at approximately 20-25kDa, in both neat and concentrated 
samples. Thereby, confirming that NGAL is present in the HaCaT CM (Figure 4.11B). 
 
4.7.ii Colorimetric Indirect ELISA for NGAL in Un- Fractionated HaCaT CM. 
 
The concentration of NGAL in HaCaT CM was determined by indirect ELISA using a 
specific anti-NGAL antibody (polyclonal antibody AF1757), as described in Materials 
& Methods Chapter 2. Included in each experiment was a standard curve for NGAL, 
performed using recombinant human NGAL (in house preparation) at a range of 
concentrations from 1.5625 to 300ng/ml (Figure 4.12). Each standard or sample of 
HaCaT CM was tested in duplicate, 100 l per well, and an average reading calculated. 
SF MEM and coating buffer were used as negative controls. 
Initial experiments were performed using concentrated HaCaT CM but it soon became 
apparent that the concentration of NGAL present in the CM was higher than expected, 
since all OD readings were off the standard scale. However, by using neat CM and 
subsequently diluting it with coating buffer credible readings were achieved.  
As shown in Table 4.1, it would appear that on average the NGAL concentration per ml 
of HaCaT CM is 1.77 +/- 0.05µg/ml. Taking into account the standard protocol for the 
collection of CM; whereby 7ml of SF MEM is used per 90mm dish of confluent HaCaT 
cells for a 48hr incubation period, and that on average each confluent dish would 
contain 5.4 x10
6
 cells (as measured with the Z1 Series Coulter Counter), which  gives a 
total of 7.7 x10
5
 cells per ml of CM. Estimating therefore, that  each HaCaT 
keratinocyte must be responsible for producing 2.3pg of NGAL per ml of CM, during a 
48hr incubation period. This is of course an extremely approximate value as no 
accountability has been taken for the role which storage conditions and proteolysis may 
play in affecting the NGAL concentration.  
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Figure 4.12: The standard curve of NGAL Indirect Elisa. Using a specific anti-NGAL 
antibody (polyclonal antibody AF1757) the OD readings for a range of rhNGAL concentrations 
(in –house preparation), were measured at 450nm. The results shown are an average of five 
individual experiments. 
 
 
Table 4.1: The OD readings and calculated concentration of NGAL in HaCaT 
conditioned medium, as measured in the Indirect ELISA assay using a specific 
anti-NGAL antibody (polyclonal antibody, AF1757). OD readings measured at 450nm 
and all conditioned medium (CM) dilutions made using coating buffer. These results imply that 
the average concentration of NGAL per ml of HaCaT CM is 1.77 +/- 0.05 g/ml. 
 
CM Dilution 
(Coating buffer 
diluent) 
Final OD 
(450nm) 
Minus Blank. 
NGAL 
Concentration 
(ng/ml) 
NGAL Concentration- 
Adjusted for dilution 
( g/ml) 
1:8 0.472 220.05 1.76 
1:16 0.231 107.69 1.72 
1:32 0.122 56.88 1.82 
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4.7.iii  Immunolocalisation of NGAL in HaCaT Series  
 
As previously discussed, a successful method of proving HaCaT cells expressed MSF 
was by immunolocalisation using the specific anti-MSF, rabbit polyclonal anti-VSI, 
antibody. Therefore immunolocalisation of NGAL in the cultured HaCaT keratinocytes 
was performed in order to determine whether there was any variation in the staining 
patterns of MSF and NGAL. As with the MSF identification, cells were plated onto 
plastic tissue culture dishes. Using a polyclonal antibody specific for NGAL, (AF1757), 
optimisation experiments were performed first. Thereby, enabling the selection of the 
most appropriate concentration of anti-NGAL antibody; that is optimum staining whilst 
ensuring the negative control (normal serum goat IgG) used at the same concentration 
was consistently negative. The secondary antibody, biotinylated polyclonal swine anti-
goat IgG, was also optimised to ensure no cross-reactivity. In each experiment, the 
FSF44 fibroblast cell line acted as an internal negative control. In addition the primary 
keratinocyte cell line HEK102-05a (ECACC No. 06091505) was also included. 
Confirming the results of the immunoblotting and ELISA experiments, staining of 
HaCaT cells with a specific anti-NGAL antibody resulted in a positive result. NGAL 
and MSF appear to have a similar staining pattern; HaCaT cultures showing a 
heterogeneous expression whilst the primary keratinocytes displayed a homogenous 
expression with a slight increase in intensity too. As anticipated, the FSF44 fibroblasts 
did not express NGAL. A consistent negative result was also attained when using the 
normal goat IgG (Figure 4.13). 
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Figure 4.13: Immunolocalisation of NGAL in human fibroblasts and keratinocytes. 
Cells were plated onto plastic cell culture dishes and assessed for the presence of MSF by 
immunocytochemistry using the specific anti-NGAL goat polyclonal AF1757 (0.5µg/ml). 
NGAL positive expression resulted in brown coloured staining. Control cultures were incubated 
with normal goat IgG at the same concentration as the NGAL specific antibody (0.5µg/ml) (B).  
Images and observations were made at x20 magnification. Results showed that FSF44 
fibroblasts (D) were negative for NGAL, whilst both primary (C) and transformed keratinocytes 
(B) express NGAL. However, there appears to be a difference in the intensity and distribution; 
primary keratinocytes displayed homogenous staining, whereas HaCaT cultures showed a 
heterogeneous expression. Negative results were achieved with all cultures stained with the 
normal goat IgG. 
A. HaCaT, anti-NGAL goat polyclonal AF1757. 
B. HaCaT, Normal Goat IgG 
C. HEK, 102-5a primary keratinocytes, anti-NGAL goat polyclonal AF1757. 
D. FSF44, anti-NGAL goat polyclonal AF1757. 
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4.7.iv  The MSF Inhibitory Activity of NGAL 
 
NGAL isolated and purified from HaCaT CM has been shown to have the ability to 
inhibit the motogenic bioactivity of rhMSF in the 3D collagen fibroblast migration 
assay. Using the same assay, NGAL from three different sources was tested in order to 
validate the findings; NGAL isolated from a MMP-9/ NGAL complex isolated from 
activated neutrophils (complex purchased from Calbiochem), eukaryotic rhNGAL 
(purchased from R&D Systems) and prokaryotic rhNGAL (in-house preparation). 
As with the first isolation of NGAL by Kjeldsen et al., 1993, from neutrophils as a 
heterodimer covalently linked to MMP-9, NGAL was isolated from a MMP-9 complex 
(Calibiochem) (performed by Dr S.J. Jones). The complex was fractionated into its 
separate components by electrophoresis under reducing conditions, using loading buffer 
containing 2-mercaptoethanol followed by separation on 12% SDS PAGE . Each lane 
was loaded with 1.5µg of the reduced complex. Using a lane for visualisation; staining 
with Coomassie blue revealed three distinct protein bands at the following molecular 
weights 15-20kDa, 20-25kDa and 75-100kDa. An immunoblot, using specific anti-
NGAL antibody, Mab1757, was performed and the bands at 20-25kDa and 75-100kDa 
were identified. One could presume that the larger molecular weight band of 75-100kDa 
corresponded to non-reduced MMP-9/ NGAL complex (and free MMP-9), while the 
20-25kDa band represented free NGAL. The 15-20kDa may correspond to the C-
terminus fragment of MMP-9. A subsequent lane was used for protein elution; where 
upon each protein band was isolated and the proteins eluted overnight in elution buffer 
(Material & Methods, Chapter 2).  
In order to determine which band contained the isolated NGAL each of the three 
elutions were tested in the 3D collagen gel fibroblast migration assay at a range of 
dilutions (1/1000 to 1/30,000). The majority of MSF inhibitory activity was discovered 
in the elutions of the lower molecular weight protein bands 15-20kDa and 20-25kDa; 
elutions 2 and 3 respectively (similar results in 3/3 experiments). Observations from the 
SDS PAGE gel formed the conclusion that elution 3, 20-25kDa, probably contained the 
majority of the free NGAL. 
It was estimated that elution 3 diluted 1/20,000 with SF MEM, would contain an 
estimated NGAL concentration of 5-10ng/ml. This dilution was then subsequently 
tested in the 3D collagen gel fibroblast migration assay, against a range of rhMSF 
concentrations (1pg- 10ng/ml). When tested by itself, the NGAL elution had no effect 
on fibroblast migration, with levels similar to the SF MEM control. rhMSF tested by 
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itself displayed a typical bell-shaped dose response; migration stimulated by rhMSF 
concentrations 1pg/ml to 10ng/ml, with maximal motogenic activity at 500pg/ml, an  
average 3 fold increase above the SF MEM levels. The addition of the NGAL elution 
inhibited MSF activity, with MSF stimulated migration (10-500pg/ml) inhibited on 
average by 54% +/- 4.00. However, at the higher rhMSF concentration of 10ng/ml, the 
addition of  the NGAL elution actually caused an increase in cell migration This is 
thought to be due to partial inhibition of MSF by NGAL, thereby shifting the dose 
response to levels where migration is actually stimulated (Figure 4.14 a and b). 
This NGAL elution was also tested with the HaCaT sample referred to as Fmsa 
(fractions displaying migration stimulatory activity). As previously described Superdex 
fractionated HaCaT CM exhibited MSF- like bioactivity in fraction groups 11 and 12, 
equivalent to 63-84kDa.  These MSF active fraction groups from numerous Superdex 
runs were pooled and subsequently concentrated by freeze drying; referred to now as F-
msa. The 100x F-msa was tested at a range of dilutions (1/100 to 1/10,000) with the 
NGAL elution (1/20,000 dilution). As expected, from previous experiments the HaCaT 
F-msa exhibited the ability to stimulate fibroblast migration in a dose response manner 
similar to rhMSF; peak activity at 1/250 dilution. The addition of the NGAL elution 
inhibited this migratory activity; 1/250 dilution migration reduced by 60% (Figure 
4.14c). This result and previous evidence supports our finding that the HaCaT cell line 
expresses both MSF and a MSF inhibitor (MSF-I), identified as NGAL (Figure 4.14 c). 
The other two types of NGAL which were tested was from both a eukaryotic (R&D, 
1757-LC) and prokaryotic (in-house preparation) source. Each was tested in the 3D 
collagen gel fibroblast migration assay at a range of concentrations (100pg/ml to 
1µg/ml) with a constant rhMSF concentration of 100pg/ml rhMSF. At the range of 
concentrations tested, both eukaryotic and prokaryotic NGAL had no effect on baseline 
migration. For example, in a comparison of three experiments using the prokaryotic 
NGAL, the average migration measured for all NGAL concentrations, when tested 
alone, was 2.16 +/-0.233 cells compared to 2.57 +/-0.551 for the SF MEM. A similar 
result was achieved for the eukaryotic NGAL; average NGAL only migration being 
3.175 +/-0.222 as compared to 3.79 +/-0.293 for SF MEM baseline.  
Consistently, migration is stimulated by approximately 50% upon addition of 100pg/ml 
rhMSF to SF MEM. Eukaryotic NGAL could inhibit this activity by an average of 44.4 
+/-5.01% over a range of concentrations from 1ng/ml to 1µg/ml, with peak inhibitory 
activity of 51.53 +/- 3.50% at 1ng/ml (an average of three experiments). Prokaryotic 
NGAL had the same rhMSF inhibitory range of 1ng/ml to 1µg/ml with an average 
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inhibition of 59.6% +/- 9.13, peaking at 100ng/ml with migration reduced by 72.73 +/-
8.18% (an average of three experiments) (Figure 4.15). 
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Figure 4.14. The MSF-Inhibitory activity of NGAL purified from MMP-9/NGAL 
complex. NGAL was purified from the MMP-9/NGAL complex (Calbiochem) by SDS PAGE 
separation followed by gel elution. The majority of free NGAL was found to be present in Gel Elution 3 
(20-25kDa) at an estimated concentration of 5-10ng/ml when diluted 1/20,000 with SF MEM. This 
dilution was tested against a range of concentrations of rhMSF (1pg/ml to 10ng/ml) and also a range of 
dilutions of the HaCaT F-msa (Superdex fractions of HaCaT CM displaying migration stimulating 
activity) in 3D collagen gel fibroblast migration assay. A representative experiment is shown. Graph a. 
Effect of purified NGAL on a dose response of rhMSF, expressed as the percentage of cells migrated. SF 
MEM baseline migration = 1.425 +/- 0.310, as represented by the hatched and dotted lines (mean and SD 
respectively). Graph b. Effect of purified NGAL on a dose response of rhMSF. The number of cells 
migrated expressed as a percentage of MSF baseline for each rhMSF concentration point i.e. 1pg/ml to 
10ng/ml rhMSF baseline = 100%, as represented by hatched line. Graph c. Effect of purified NGAL on a 
dose response of HaCaT Fmsa, expressed as the percentage of cells migrated. SF MEM Baseline = 1.28 
+/- 0.250, as represented by the hatched and dotted lines (mean and SD respectively). 
162 
 
0
0.
1 1 10 10
0
10
00
0
50
100
150
MSF
Baseline
SF MEM
   only
a. Eukaryotic NGAL Tested with 100pg/ml rhMSF.
Eukaryotic NGAL (ng/ml)
C
e
ll
s
 M
ig
r
a
t
e
d
(
%
 o
f 
 M
S
F
 B
a
s
e
li
n
e
 M
ig
r
a
t
io
n
)
b. Prokaryotic NGAL Tested with 100pg/ml rhMSF.
0
0.
5 1 10 10
0
25
0
50
0
10
00
0
50
100
150
MSF
Baseline
SF MEM
    only
Prokaryotic NGAL (ng/ml)
C
e
ll
s
 M
ig
r
a
t
e
d
(
%
 o
f 
 M
S
F
 B
a
s
e
li
n
e
 M
ig
r
a
t
io
n
)
Figure 4.15 The MSF-Inhibitory activity of NGAL purified from a eukaryotic and 
prokaryotic source. A range of concentrations of both eukaryotic and prokaryotic expressed 
NGAL were tested in combination with a single concentration of 100pg/ml rhMSF in the 3D 
collagen gel fibroblast migration assay.  
Graph a. The MSF-I activity of Eukaryotic NGAL. The number of cells migrated is expressed 
as a percentage of 100pg/ml rhMSF control baseline migration. i.e. MSF Baseline = 100 +/- 
7.526, as represented by the hatched and dotted lines ( mean and SD respectively). This is 
equivalent to 7.84 +/- 0.590 migrated cells. The results represent an average of three 
experiments (one of the three experiments performed by Dr I. Ellis). 
Graph b. The MSF-I activity of Prokaryotic NGAL. The number of cells migrated is expressed 
as a percentage of 100pg/ml rhMSF control baseline migration. i.e. MSF Baseline = 100 +/- 
4.17, as represented by the hatched and dotted lines (mean and SD respectively). This is 
equivalent to 6.05 +/- 0.252 migrated cells. The results represent an average of three 
experiments (one of the three experiments performed by Dr I.  Ellis). 
 
 
4.7.v    The Effect of NGAL on Fibroblast Morphology, Viability 
            and Proliferation. 
 
No obvious toxicity problems had been observed when testing NGAL (all sources), 
alone or in combination with rhMSF, in the 3D collagen gel assay. Fibroblast 
morphology was normal and indistinguishable from the controls. However, as the assay 
requires the FSF44 fibroblasts to be plated at a high density (2 x 10
5 
per gel) 
proliferation is limited; the number of cells on the collagen gel surface remains constant 
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over the four day period incubation period. Therefore, a simple growth curve 
experiment was performed in order to determine the effect NGAL had on fibroblast 
proliferation. Cells were plated at a low density (2 x 10
4
per 35mm dish) in the presence 
of 1%DCS MEM with and without the addition of various concentrations of prokaryotic 
expressed rhNGAL. Cell counts were measured successively over a 7 day period. The 
trypan blue assay was used to calculate cell viability (Chapter 2, Materials & Methods). 
In six experiments, prokaryotic rhNGAL tested at 0.01-1µg/ml had no effect on 
fibroblast morphology, viability and proliferation. Observations of the fibroblasts in the 
control (1%DCS MEM only) and those with the addition of NGAL showed no apparent 
differences and this were confirmed by comparable levels of cell viability and 
proliferation rates.  The incubation period of the 3D collagen gel assay is 4 days and in 
a 4 day period in the growth curve assay cell numbers for all the variables tested was 
practically identical; a 3.525 +/- 0.096 fold increase in cell numbers whilst cell viability 
was a healthy 88.3 +/- 2.14% (Figure 4.16) 
 
4.7.vi    The MSF- Inhibitory Activity of NGAL can be Temporally  
             Separated from MSF. 
 
In all previous experiments the effect of NGAL on the MSF stimulated migration of 
fibroblasts in the collagen gel was performed with the co-incubation of rhNGAL and 
rhMSF. In order to understand the nature of NGAL’s ability to inhibit MSF, it was 
investigated whether NGAL required direct contact with MSF for inhibition to occur. A 
variation of the 3D collagen gel fibroblast migration assay was performed; fibroblasts 
were plated onto the gels as normal but then pre-incubated with rhNGAL, after which 
media was removed and the gels washed with SF MEM, followed by a four day 
incubation with rhMSF. Three pre-incubation times were tested (1, 6 and 24 hours) with 
two concentrations of rhNGAL (prokaryotic source) in SF MEM; 10ng/ml and 50ng/ml 
having previously shown the ability to inhibit 100pg/ml rhMSF stimulated migration to 
baseline levels. The 100pg/ml rhMSF incubation was at a final serum concentration of 
1%DCS MEM. Controls were performed to eliminate any possible artefacts occurring 
due the effect of washing the gels after NGAL pre-incubation.  
It would appear from the results that pre-incubating the fibroblasts with NGAL for a 
minimum of 24 hours induces the same MSF inhibitory activity as seen with co-
incubation of NGAL and MSF. The number of cells migrated into the gels in the 
controls were comparable to those under the standard protocol; 100pg/ml MSF 
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stimulating migration on average by 2 fold above SF MEM baseline levels. For 
rhNGAL to exert MSF inhibition to the same extent as measured during NGAL/MSF 
co-incubation the pre- incubation must be at least 24 hours; no effect was seen after a  
one hour incubation and partial MSF inhibition detected after six hours (Figure 4.17). 
 
4.7.vii       The MSF-Inhibitory activity of NGAL is Iron Independent. 
 
The acquisition of iron is critical in development, cell growth and survival as iron 
contributes to enzyme activity in DNA synthesis, metabolism and oxygen response 
(Dunn et al., 2007). Although, most cells acquire iron by capturing iron-loaded 
transferrin, another pathway is mediated by NGAL. NGAL is considered to play an 
important role in iron metabolism both during organogenesis and host defence (Iannetti 
et al., 2008). The cellular uptake and delivery of NGAL-bound iron to epithelial cells is 
essential for epithelial cell differentiation in the developing kidney (Yang et al., 2002). 
It has also been proposed that the expression of NGAL by numerous epithelial tumours 
bestows these cells with an iron retrieving mechanism that adds to the growth potential 
of the tumour (Hvidberg et al., 2005).  The pro-survival activity of NGAL in human 
thyroid cancer cells is mediated by its ability to bind iron and to transport it inside the 
cells, preventing apoptosis (Devireddy et al., 2005, Iannetti et al., 2008). 
Therefore an investigation as to whether the MSF inhibitory activity of NGAL was 
dependent on its ability to sequester iron was performed. The iron chelator, 
deferoxamine mesylate (DFOM, Sigma-Aldrich) was selected as it had previously been 
shown to reverse the effects of NGAL on the phenotype of Ras- transformed breast 
cancer cells. DFOM removes both free iron and bound iron from hemosiderin; it has 
been shown to deplete iron from an intracellular pool as concentrations of 2-5µM in 
tissue culture (Hanai et al., 2005). 
A 3D collagen gel fibroblast migration assay was performed whereby the cells were 
incubated with DFOM alone or in combination with 100pg/ml rhMSF and 10ng/ml 
rhNGAL. The two concentrations of DFOM tested, 2 and 5µM, appeared to have no 
effect on the SF MEM baseline level of cell migration. Fibroblast morphology appeared 
unaffected by the presence of DFOM and cell numbers of fibroblasts present on the cell 
surface were comparable to the controls. A cell viability and proliferation assay 
confirmed that neither concentration of DFOM had any detrimental effect upon the cells 
(Table 4.2) 
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The motogenic bioactivity of rhMSF appears to be affected by incubation with DFOM. 
Increasing concentrations of DFOM having a greater ability to inhibit MSF stimulated 
fibroblast migration; compared to the 100pg/ml rhMSF control the addition of 2 and 
5µM DFOM reduced migration by 43.5% and 69.4% respectively. This obviously 
limited the assessment of the effect iron chelation had on the MSF- inhibitory activity of 
NGAL. However, although 2µM DFOM reduced MSF stimulated migration it was still 
1.8 fold more than the SF MEM baseline level. The addition of 10ng/ml rhNGAL 
reduced this increase back to the SF MEM levels. This effect was confirmed in two 
experiments. As MSF activity was completely diminished by 5µM DFOM, the addition 
of rhNGAL had no effect on migration levels (Figure 4.18). 
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Figure 4.16. The effect of NGAL on fibroblast viability and proliferation. 
Fibroblasts, FSF44, were plated at low density (2x10
4 
per 35mm) in the presence of 1%DCS 
MEM with and without the addition of 0.1- 1µg/ml rhNGAL. Cell viability and cell counts were 
taken over a 4-7day incubation period. An average of six experiments is shown.  
Graph a. The percentage of cell viability of each variable was measured by the trypan blue 
assay.  Graph b. The average cell count at each time point, for each variable was measured with 
the Coulter Counter Z1 Series (Beckmann Coulter). 
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Figure 4.17. The effect of a NGAL pre-incubation on MSF bioactivity in the 3D 
collagen gel fibroblast migration assay. A variation of the standard 3D collagen gel 
fibroblast migration assay was performed; fibroblasts plated onto the surface of the collagen gel 
were pre-incubated (1 or 24 hours) with rhNGAL (10 or 50ng/ml), after which the gels were 
washed and then followed by the standard four day rhMSF incubation. The number of cells 
migrated is expressed as a percentage of SF MEM control baseline migration. i.e. MSF Baseline 
= 100 +/- 4.24, as represented by the hatched and dotted lines (mean and SD respectively). This 
is equivalent to 3.3 +/- 0.140 migrated cells. A representative experiment is shown. 
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Figure 4.18. The effect of the iron chelator Deferoxamine mesylate (DFOM) on the 
MSF inhibitory activity of NGAL. A 3D collagen gel fibroblast migration assay was 
performed with and without the addition of DFOM (2 or 5µM), either alone or in the presence 
of 100pg/ml rhMSF and/ or 10ng/ml rh NGAL. The number of cells migrated is expressed as a 
percentage of SF MEM control baseline migration. i.e. SF MEM Baseline = 100 +/- 18.750, as 
represented by the hatched and dotted lines (mean and SD respectively). This is equivalent to 
1.6 +/- 0.30 migrated cells. A representative experiment is shown. 
 
 
 1% DCS MEM 2µM DFOM 5µM DFOM 
Time Line Cell 
count 
% 
Viability 
Cell 
count 
%  
Viability 
Cell 
count 
%  
Viability 
Baseline 1.25 x 10
4
 83.9 +/- 9.78 -  -  
Post 1 day 1.8 x 10
4
 93.7 +/- 4.45 1.65 x 10
4
 94.0 +/- 3.75 1.75 x 10
4
 97.0 +/-4.75 
Post 4 days 6.63 x 10
4
 87.5 +/- 6.26 7.83 x 10
4
 97.0 +/- 4.75 6.05 x 10
4
 84.5 +/- 4.85 
 
Table 4.2. The effect of the iron chelator Deferoxamine mesylate (DFOM) on 
fibroblast viability and proliferation. Fibroblasts, FSF44, were plated (2x104 per 35mm) 
in the presence of 1%DCS MEM with and without the addition of 2-5µM DFOM. Cell viability 
(trypan blue test) and cell counts (measured on the Coulter counter Z1 series) were taken over a 
four day incubation period. An average of two experiments is shown.  
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4.8  DISCUSSION 
 
Analysis of conditioned medium collected from the immortalised human keratinocyte 
cell line HaCaT showed that it possessed the ability to inhibit the motogenic activity of 
MSF in the 3D collagen gel fibroblast migration assay.  A process of fractionation of 
the HaCaT CM, by both molecular weight and ionic charge, followed by sequence 
analysis led to the identification of the protein responsible for the MSF- inhibitory 
activity as Neutrophil Gelatinase Associated Lipocalin (NGAL).  The fractionation 
process also unexpectedly revealed the presence of motogenic bioactivity, which is 
normally obscured within the HaCaT CM; which was subsequently identified as MSF.   
It therefore transpired that cultured HaCaT keratinocytes express MSF but its motogenic 
bioactivity appears to be inactivated by the co-expression of an inhibitor, NGAL. 
The identification of NGAL as accountable for the MSF-inhibitory activity detected in 
HaCaT CM followed a fractionation process involving separation by size exclusion and 
ion exchange chromatography followed by SDS electrophoresis (reducing conditions) 
(Figure 4.19). At each stage in the process the bioactivity of the resultant fractions were 
tested in 3D collagen gel fibroblast migration assay for their ability to inhibit MSF 
stimulated fibroblast migration. After, the initial molecular weight separation on the 
Superdex 75 HiLoad 26/60 column the unforeseen presence of the two opposing 
bioactivities where discovered in the HaCaT CM; molecular weight fractions  63-84kDa 
displayed the ability to stimulate fibroblast migration whilst 16-27kDa fractions 
possessed MSF-inhibitory activity.  
This motogenic activity was shown to be inhibited by the IGD function neutralising 
monoclonal antibody, PEPQ1.1, thereby implying that the protein contained an IGD 
motif, similar to MSF. Subsequently, immunoprecipatation with Protein G showed that 
the motogenic fraction bound to the RpVSI antibody which recognises the MSF unique 
carboxyl terminal decapeptide. These findings, plus the nature of the motogenic 
bioactivity and molecular weight lead to the conclusion that the HaCaT keratinocytes 
express MSF. Immunolocalisation confirmed that both cultured HaCaT and primary 
keratinocytes express MSF. A summary of the experimental data that lead to the 
disclosing that HaCaT keratinocytes express MSF, is shown in Table 4.3. 
The identification of NGAL as the protein isolated from HaCaT CM responsible for the 
MSF-inhibitory bioactivity was confirmed by the same activity being displayed by 
NGAL obtained from an additional three different sources; a eukaryotic and a 
prokaryotic sourced recombinant protein and NGAL isolated from MMP-9/NGAL 
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complex produced by activated neutrophils (Table 4.5). Similar levels of MSF-I activity 
was measured in all types of NGAL tested and toxicity issues were eliminated by 
morphology, viability and proliferation assays showing no adverse effects at NGAL 
concentrations displaying MSF-I activity. In addition, proof that HaCaT keratinocytes 
normally express NGAL was provided by Western Blot and indirect ELISA analysis of 
unfractionated HaCaT CM and confirmed by immunolocalisation of NGAL in the 
cultured cells (Table 4.4). 
The inhibition of MSF by NGAL is a novel activity. NGAL is known by a variety of 
names including neutrophil glusoaminidase-associated lipocalin, 24p3, utercalin, 
siderocalin, lipocalin 2, p25, human neutrophil lipocalin (HNL) and α1-microglobulin 
(Li and Cahn, 2011, Chakraborty et al., 2012). It is a member of the Lipocalin family; a 
diverse family of small secreted proteins that act as carriers, transporting predominantly 
small lipophilic molecules although additional functions including cell regulation, 
differentiation, cell to cell adhesion and cell survival have recently been revealed 
(Chakraborty et al., 2012) . Members of the lipocalin family share little amino acid 
similarity but share a common secondary and tertiary structural feature called the 
“lipocalin fold” ; an anti-parallel beta barrel structure comprising of 8 beta sheets that 
are hydrogen bonded to one another  forming a calyx- or cup-shaped cavity (with a lid-
like structure) that can bind specific ligands (Flower, 2000). The difference in sequence 
identity enables a wide variety of ligands to be bound by the lipocalin family. The 
lipocalin family has been further classified by the presence of structurally conserved 
regions, as either kernel or outer lipocalins. NGAL is a kernel lipocalin (Flower, 1996 
and 2000, Kjeldsen et al., 1993, Kjeldsen et al., 2000). 
NGAL is a 198 amino acid long secreted glycoprotein encoded by a gene located at the 
chromosome locus 9q34.11 (Chakraborty et al., 2012). It was first purified from a 
culture of murine kidney cells infected with the simian virus (SV-40) or the polyma 
virus (Hraba-Renevey et al., 1989) and subsequently isolated as a 25kDa protein 
disulphide bonded to the monomeric inactive form of matrix metalloproteinase-9 
(MMP-9) (Triebel et al., 1992, Kjeldsen et al., 1993, Yan et al., 2001). MMP-9 is a 
gelatinase secreted by neutrophils that degrades basement membranes and ECM 
components (Triebel et al., 1992). The binding of NGAL to MMP-9 does not affect the 
activity of the enzyme but enhances its stability by protecting it against inactivation by 
its natural inhibitor TIMP-1 (Yang et al., 2001, Van der Steen et al., 2006, Chakraborty 
et al., 2012).  
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The knowledge that NGAL binds to MMP-9 initially suggested that its capacity to 
inhibit MSF was also due to a direct relationship since MSF shares some structural 
similarity to MMP-9; both molecules contain fibronectin type II domains and zinc 
binding motifs, with the conserved sequence HEXXH in MSF and AHEXGHXXGXXH 
in MMP-9 (Houard et al., 2005, Van dee Steen 2001). However, pre-incubation 
experiments have shown that NGAL does not have to be in direct contact with MSF in 
order to exert an inhibitory effect; fibroblasts pre-incubated with NGAL for 24 hours 
become unresponsive to MSF.  This would imply that NGAL inhibits MSF either by 
blocking an MSF-activated signal transduction pathway or indirectly via an 
intermediate molecule.  
The first ligands to be identified for NGAL were bacterial catecholate-type ferric 
siderophores. NGAL has since been identified as a potent bacterostatic agent; inhibiting 
bacterial growth by sequestering the iron-binding bacterial siderophores and blocking 
bacterial access to iron (Strong et al., 1998, Goetz et al., 2002, Flo et al., 2004). NGAL 
deficient mice showed increased susceptibility to bacterial infections (Cramer et al., 
2012). In healthy humans NGAL was found to be concentrated in tissues predisposed to 
contact with microorganisms (the trachea, lung and stomach) and also highly expressed 
at the sites of inflammation (an acute-phase protein) having a key role in the innate 
immune response (Lim et al., 2007). NGAL is proposed to have a role in mammalian 
iron metabolism and thereby regulation of iron-responsive genes (Gwira et al., 2005). 
During kidney development by delivering iron inside mesenchymal progenitor cells, 
NGAL induces their differentiation into epithelial tubules (Yang et al., 2002 and 2009). 
NGAL also has the ability to induce apoptosis by affecting the intracellular iron content 
of cells (Devireddy et al., 2005).  
The MSF-inhibitory activity of NGAL does not appear reliant on its ability to transport 
iron. Identical MSF-I bioactivity was described for  NGAL from three different sources 
(purified from HaCaT CM and recombinant NGAL from eukaryotic and prokaryotic 
sources) which would imply iron independence, as each source would have varying 
amounts of bound iron (Goetz et al., 2002). Plus the addition of the iron chelator, 
DFOM, had no effect NGAL inhibition of MSF in the 3D collagen gel fibroblast 
migration assay. Finally, NGAL inhibition of MSF takes place at concentrations (1-
10ng/ml) which are 5000 fold lower than those required for iron-dependent 
transcriptional effects (Hanai et al., 2005, Yang et al., 2002). 
NGAL is a multifunctional protein but the exact pathophysiological roles of NGAL are 
not fully understood. In addition to suppression of bacterial growth and iron 
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transportation, several functions have been ascribed to NGAL; induction of apoptosis, 
modulation of inflammatory response, fatty acid transportation and protection of cells 
against thermal and oxidative stress conditions (Wang et al., 2012). It has been 
attributed in playing an important role in a seemingly diverse range of conditions 
including infectious disease, renal and cardiac disease or injury, metabolic syndrome 
and thermal dysregulation, dermatitides and the inflammatory disease of lung and bone 
(Bando et al., 2007, Saiga et al., 2008, Martineau et al., 2007, Eagan et al., 2010, Li and 
Chan, 2011, Chakraborty et al., 2012). Three major categories of cellular stress have 
been described as causing increased expression of NGAL; environmental (hypoxia, 
ischemia- reperfusion, pathogen- associated molecular pattern activated by infections or 
LPS), metabolic (hyperlipidemia, obesity, insulin resistance) and developmental 
(conceptus attachment and reproductive tissue involution, bone plate maturation, 
epithelial-mesenchymal transformation and malignancy) (Li and Chan, 2011). 
NGAL expression has been observed in many human solid and hematopoietic tumours 
including breast (Stoesz et al., 1998), colon (Nielsen et al., 1996), lung (Shi et al., 
2008), ovary (Bartsch and Tschesche, 1995), pancreas (Furuntani et al., 1998), thyroid 
(Iannetti et al., 2008) and chronic myelogenous  leukaemia (Leng et al., 2009). It has 
been suggested that NGAL influences cancer progression by affecting two critical 
processes; cell survival via apoptosis and cell migration preceding tumour invasion and 
metastasis (Yang and Moses, 2009, Chen and Chan, 2011).  A literature review 
indicates that the functional role of NGAL, whether pro or anti- tumorigenic is 
neoplasia-specific and also varies with the different stages of cancer progression and 
degree of tumour differentiation.  A pro- tumoural effect has been described in breast, 
stomach, oesophagus, kidney and thyroid cancer, whilst attributed to anti-tumoural 
activity in ovary and pancreatic cancer. Studies on colorectal cancer have reported 
conflicting results (Wenners et al., 2012). (Table 4.6 is a review of the reported roles of 
NGAL in malignant disease). Due to its small size, secreted nature and the availability 
of robust quantitative assays NGAL has become an extremely attractive target both as a 
diagnostic and prognostic biomarker in solid organ malignancies (it is already used in 
clinical monitoring of tissue response to renal and cardiac injuries as well as several 
sepsis)(Haase et al., 2009, Li and Chan, 2011). 
The epithelial to mesenchymal transition (EMT) is one of the key mechanisms 
underlying tumour invasion and metastasis (Thiery et al., 2006). EMT causes tumour 
cells to adopt a more mobile phenotype, thereby facilitating their invasion into the local 
extracellular matrix, intravasation and extravasation of blood vessels with the resultant 
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invasion and settlement in secondary organ sites (Yang and Moses, 2009). Conflicting 
reports have been published on the relationship between epithelial differentiation and 
NGAL expression levels. For example, in ovarian tissue increased NGAL levels were 
associated with well-differentiated epithelial ovarian tumours with expression reduced 
as the cancer progressed and the epithelial tumours became poorly differentiated (Cho 
and Kim, 2009). The opposite situation was described in a breast cancer study by Bauer 
and colleagues (2008). 
Malbris and colleagues (2002) have also reported that HaCaT keratinoctyes have a high 
expression level of NGAL as determined by RT-PCR analysis. They also described that 
in normal adult skin, NGAL expression was weak and limited to hair follicles. 
However, in agreement with our results, they discovered that cultured normal 
keratinoctyes from normal skin unlike their in vivo counterparts express NGAL. This 
highlights the difference in cell status between in vitro and in vivo situations which 
results in substantial changes in protein expression (Lee et al., 2008). Due to the 
embryonic spatio-temporal expression pattern and increased expression in skin 
disorders characterised by dysregulated epithelial differentiation (psoriasis, pityriasis 
rubra and squamous cell carcinoma) they suggested that NGAL plays a role in epithelial 
differentiation. Foetal skin and adult skin undergoing de-differentiation have the same 
NGAL expression pattern.  Interestingly, in the skin epithelium, MMP-9 was not co-
expressed with NGAL mRNA. 
MSF is an oncofetal protein, expressed during foetal development by keratinocytes, 
fibroblasts and endothelial cells with expression lost in the equivalent healthy adult 
cells. However, MSF is persistently re-expressed by both tumoral and stromal cells in 
various human cancers including breast, lung, colorectal, oral, prostate and oesophageal 
(Schor et al., 2003, 2005, Jones et al., 2007).  The discovery that NGAL inhibits the 
motogenic activity of MSF proposes numerous questions about their relationship during 
cancer progression. The use of the in vitro model for human skin carcinogenesis 
developed by the Fusening and Boukamp group enabled the investigation of the 
expression levels of MSF and NGAL in relation to the different stages of 
carcinogenesis. The HaCaT-ras clones (BEN, MAL and MET) represent a shift in 
tumourigenic potential from the benign to malignant to metastatic. In addition, the 
bioactivity present within the conditioned medium of the HaCaT-ras clones was 
examined and related to the expression levels of NGAL and MSF. That is, with 
increasing degree of malignancy does NGAL continue to mask the motogenic activity 
of MSF? 
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Figure 4.19. A systematic representation of the protocol employed for the isolation 
and subsequent identification of the protein responsible for the MSF inhibitory 
activity of total HaCaT conditioned medium- NGAL. The process involved separation 
by molecular weight and ionic charge (green circles).  At each stage the subsequent fractions 
where analysed for the presence of MSF inhibitory activity by testing in the 3D collagen gel 
fibroblast migration assay. 
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Table 4.3. Summary of experimental data providing evidence of that cultured HaCaT keratinocytes express MSF. 
Technique Experimental Details. Sample Tested Results 
1. Immunolocalisation 
of MSF. 
Anti-MSF antibody, Rp2/98pFA2pFn1. Cultured HaCaT 
keratinoctyes. 
Heterogeneous staining for MSF in HaCaT 
cells. Controls consistently negative. 
2. IGD Function 
Neutralisation of 
Motogenic Activity. 
Motogenic active HaCaT fractions 
tested in the 3D collagen gel fibroblast 
migration assay with addition of  
Pep Q 1.1- IGD function neutralising 
antibody. 
SEC Fractionated 
HaCaT CM- 
motogenic fractions of 
MW 63-84kDa  
(F-msa). 
HaCaT fractions alone stimulated fibroblast 
migration by 3.7 fold. Addition of PepQ1.1 
inhibited this motogenic activity by 60-70%. 
3. Immunopreciptation 
for MSF. 
Protein G coupled to RpVSI antibody 
which recognises MSF unique carboxyl 
terminal decapeptide. 
Unbound and bound elutions tested for 
motogenic activity in the 3D collagen 
gel fibroblast migration assay. 
SEC Fractionated 
HaCaT CM- 
motogenic fractions of 
MW 63-84kDa  
(F-msa). 
Motogenic activity of HaCaT F-msa 
immobilised on RpVSI coupled Protein G.  
No motogenic activity present in unbound 
sample. Motogenic activity present in 
elutions; 2.8 fold increase in fibroblast 
migration. 
4. NGAL inhibition of 
motogenic activity. 
Motogenic active HaCaT fractions 
tested in the 3D collagen gel fibroblast 
migration assay with addition of NGAL 
isolated from MMP-9/NGAL complex. 
SEC Fractionated 
HaCaT CM- 
motogenic fractions of 
MW 63-84kDa  
(F-msa). Various 
dilutions tested. 
Peak motogenic activity of HaCaT F-msa at 
1/250 dilution inhibited by 60% by addition 
of NGAL. 
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Table 4.4: Summary of experimental data providing evidence of that cultured HaCaT keratinocytes express NGAL. 
Technique Experimental Details. Sample Tested Results 
1. Immunolocalisation of 
NGAL. 
Anti-NGAL  antibody, 
AF1757  
(R&D Systems). 
Cultured HaCaT 
keratinoctyes. 
Heterogeneous staining for NGAL in HaCaT 
cells. Controls consistently negative 
2. Immunoblot For NGAL. Anti-NGAL antibody, 
MAB1757  
(R&D Systems). 
Total HaCaT conditioned 
medium (neat and 5x 
concentrated). 
Clear band identified, MW 20-25kDa in both 
neat and concentrated HaCaT CM. 
3. Colorimetric Indirect 
ELISA for NGAL. 
Anti-NGAL antibody, 
AF1757 
(R&D Systems), 
Total HaCaT conditioned 
medium. 
NGAL concentrated per ml of unstandardised 
CM measured as 1.77 +/-0.05µg/ml. 
 
 
176 
 
 
Table 4.5: The verification of NGAL as an inhibitor of MSF motogenic bioactivity.  
NGAL from three different sources was tested in the 3D collagen gel fibroblast migration assay 
for its ability to inhibit the motogenic of rhMSF. 
 
NGAL Source Concentration 
Tested 
Effects in 3D Collagen Gel Fibroblast Migration 
Assay 
                      
Tested Alone 
(as compared 
to SF MEM 
Baseline) 
Percentage Inhibition of 
100pg/ml rhMSF 
(as compared to rhMSF 
Baseline) 
  
             All 
Concentrations 
Average / SD 
All 
concentrations 
Peak Activity  
Concentration 
(Aver/ SD)  
Isolated from 
NGAL/MMP-
9 Complex 
(Calbiochem), 
20-25kDa Gel 
elution 3 
Diluted 
1/20,000, 
est. 5-10ng/ml 
None 54.4 +/- 4.00% 
est. 5-10ng/ml 
54.4 +/- 4.00% 
 
Eukaryotic 
NGAL 
(R&D 
Systems) 
 
1ng-1µg/ml None 44.4 +/-5.01% 
1ng/ml 
rhNGAL 
51.5 +/- 3.50% 
 
Prokaryotic 
NGAL 
( In-house 
Prep) 
 
1ng-1µg/ml None 59.6 +/- 9.13% 
1ng/ml 
rhNGAL 
72.7 +/- 8.18% 
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Table 4.6: The role of NGAL in malignant disease. Observations in animal models and human studies have reported NGAL expression in a number of 
cancers thereby making it an attractive target as both a biomarker and for pathophysiologic study. The conundrum is whether to assign NGAL a pro or anti-cancer 
role. The following table lists contradicting evidence of NGALs involvement in tumour development. In conclusion, the role of NGAL in promoting or suppressing 
tumour growth appears to be highly dependent on the tissue of origin and neoplasia-specific. 
 
i. Evidence supporting NGAL as a tumour promoter. 
Tissue- GENERAL 
 M. Coles et al., 1999. L. Yan et al., 2001 
NGAL enhances MMP-9 activity by protecting the enzyme from degradation. MMP-9 is implicated in cancer progression; promotes tumour 
invasion and metastasis by degrading basement membrane, also promotes tumour growth and proliferation via angiogenesis. 
Tissue- BLOOD 
 C. Villalava et al., 2008. X. Leng et al., 2008 
NGAL expression correlated with expression of BCR-ABL fusion oncogene which is found in the majority of chronic myeloid leukemia (CML) 
patients. Serum NGAL levels elevated in CML patients. Mechanistic studies indicated that NGAL may mediate BCR-ABL induced tumourgenesis; 
NGAL expression in tumour cells was induced by BCR-ABL resulting in apoptosis in normal hematopoietic cells thereby facilitating tumour cell 
expansion. 
Tissue- BRAIN 
 M-F Liu et al., 2011. 
NGAL and NGALR are overexpressed in gliomas and appear to correlate with tumour grade; associated with a poor prognosis as it represents a 
more malignant phenotype. 
Tissue- BREAST  
 S.P Stoesz et al., 1998.  
A significant association between NGAL expression and several other markers of poor breast cancer prognosis, including estrogen and 
progesterone receptor-negative status and high proliferation (confirmed in breast cancer cell lines MCF-7 and T47D). However, no significant 
relationship between NGAL expression and disease- free or overall survival observed.  
 P. Seth et al., 2002.  
Addition of recombinant NGAL to MCF10, an immortalised normal breast epithelial cell line, resulted in a significant increase in the number of 
colonies. Suggesting that NGAL may stimulate proliferation in normal breast epithelial cells. 
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 Fernandez et al., 2005.  
NGAL found to be over-expressed in breast cancer cells. Cells exhibit increased growth rates, angiogenesis and proliferation. Breast cancer patient 
urine samples shown to contain NGAL /MMP-9 complex. 
 H. Shi et al., 2008.  
In vitro, overexpression of NGAL in 4T1 mouse mammary cancer cells increased migration and invasiveness. Whilst, in vivo overexpression 
promoted lung metastasis through inhibition of PI3/Akt pathway. However, NGAL did not affect cancer cell proliferation rate. 
 M. Bauer et al., 2008.  
NGAL shown to be an independent prognostic marker for decreased survival in breast cancer. NGAL expression strongly correlated with 
characteristics associated with poor prognosis (poor histologic grade, lymph node metastasis, high proliferation).  NGAL detection may have the 
potential to be used as a risk assessment to identify patients requiring more aggressive adjunct therapy. Suggested that NGAL probably contributes 
directly to cancer progression. 
 J.Yang et al., 2009. J.Jang and M.A. Moses, 2009.  
NGAL expression elevated in Stage I-III breast cancer samples compared to normal breast tissues. Increased urine NGAL levels in metastatic 
breast cancer patients compared to healthy controls; urine levels increase with disease progression. NGAL shown to induce the epithelial to 
mesenchymal transition (EMT) in human breast cancer. Propose NGAL as a potential non-invasive biomarker for breast cancer. 
 X. Leng et al., 2009. 
Used a spontaneous mouse breast cancer model to study the function of NGAL in breast tumourgenesis. Mice lacking NGAL displayed delayed 
tumour formation and metastasis, associated with reduced serum MMP-9 activity. NGAL expression appeared to enhance aggressive behaviour 
including lung metastasis, tumour cell migration and invasion and anchorage-dependent growth. Injection of an anti-NGAL antibody into mice 
bearing established breast tumours resulted in a significant inhibition of lung metastasis.  Proposed that NGAL is a critical factor in enhancing 
breast tumour formation and progression, possibly via MMP-9 stabilisation. Inhibition of NGAL could have potential as a breast cancer treatment, 
especially aggressive forms.  
Tissue- COLON 
 L. Hu et al., 2009. 
Overexpression of NGAL in a stably transfected colon carcinoma cell line, KM12C, altered subcellular localisation of E-cadherin and catenins 
resulting in decreasing E-cadherin mediated cell-cell adhesion, enhanced matrix attachment, increased cell motility and in vitro invasion. The 
NGAL regulation of cell migration maybe mediated via an alteration in the subcellular localisation of Rac1. 
 Y. Sun et al., 2011. 
Immunohistochemical analysis of colorectal tissue showed an overexpression of NGAL correlated with colorectal adenoma- carcinoma sequence. 
Animal model experiments indicated that NGAL overexpression increased tumourgenesis and liver metastasis of colorectal cancer cells. Plus 
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survival analysis showed NGAL expression was an independent predicator for colorectal cancer patient survival. 
Tissue- ENDOMETRIUM 
  T. Miyamoto et al., 2011. 
Ectopic expression of NGAL in endometrial cancer cells increases in vitro rate of proliferation. NGAL expressing cells showed increased 
invasiveness, suggesting possible role for NGAL in growth and metastasis of human endometrial cancer. NGAL expression (strong cytoplasmic 
and nuclear) was associated with a significant reduction in overall survival among endometrial carcinoma patients suggesting possible use of 
NGAL as prognostic marker. 
Tissue- LIVER 
 A.A. Zabron et al., 2011. 
NGAL levels in bile were significantly higher in patients with malignant compared to benign biliary obstruction. However, no difference observed 
in NGAL serum or urine levels. Suggestion that NGAL has potential to be a bile biomarker. 
Tissue- LUNG 
 Z. Tong et al., 2005. 
In vitro, NGAL expression is upregulated in A549 and human breast MCF-7 cancer cells in response to apoptosis inducing agents. NGAL acts as a 
survival factor in lung cancer A549 cells by reducing sensitivity to apoptosis inducing agent OSU03012. 
 S.U.R Mir et al., 2012. 
Revealed that NGAL is required for tumour formation in lung cancer cells (A549). NGAL transcription and activation of NGAL/MMP-9 complex 
is directed by S2R
Pgrmc1
 (also elevated in lung cancer); S2R
Pgrmc1
 activates NFᵏB via EGFR. 
Tissue- OESOPHAGUS 
 Li et al., 2003 
NGAL shown to promote tumour cell invasion of the oesophageal carcinoma cell line, SHEEC. 
  H. Zhang et al., 2007.  
NGAL upregulated in a heterogeneous pattern in oesophageal squamous cell carcinoma tissue (ESCC); expression level correlating positively to 
cell differentiation. Enzymatic activity of NGAL/MMP-9 complex elevated in ESCC compared to normal mucosa. 
 W.K. Fang et al., 2007. 
Identified a novel splice variant of NGAL receptor in oesophageal carcinoma cells;  NgalR-3  exhibits co-localisation and interaction with NGAL 
protein in vivo implying it may play a role in NGAL-mediated iron transport in oesophageal carcinoma. 
 L. Cui et al., 2008. 
Expression of NGAL receptor found to be higher in oesophageal squamous cell carcinoma (ESCC) than in normal oesophageal epithelium. 
NGALR hypomethylation contributed to its expression in ESCC. NGALR overexpression may therefore play a role in pathogenesis. 
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 Z-P Du et al., 2011. 
High expression of NGAL and its receptor observed in ESCC compared to low expression in normal oesophageal tissue; NGAL/NGALR co-
expression correlated to histological differentiation grade.   Overexpression of NGAL was associated with poor prognosis. NGAL and NGALR 
appear to act independently; potential as prognostic factors. 
Tissue- OVARY 
 R. Lim et al., 2007. H. Cho et al., 2009. 
NGAL associated with the progression of epithelial ovarian malignancies; expression in ovarian tumours changed with disease grade as reflected in 
serum NGAL concentration. NGAL has a negative expression in normal ovaries and weak in benign. Highest level displayed in borderline and 
Grade 1 tumours whilst decreased in Grade 2 and 3. NGAL expression is linked to the epithelial phenotype of the ovarian tumour, being lost as the 
cancer progresses and the tumours become poorly differentiated. NGAL expression downregulated in ovarian cancer cell lines undergoing EMT.  
NGAL may be involved in the progression of epithelial ovarian malignancies and could possibly be used as a marker to monitor changes of ovarian 
cancer progression from benign to malignant. 
Tissue- STOMACH 
  H.J.Wang et al., 2010 
NGAL is upregulated in the early stage of gastric carcinogenesis; may play an important role in the early development of gastric cancer. NGAL 
could serve as an early diagnostic marker as serum NGAL levels found to be higher in gastric cancer patients than healthy controls. A significant 
correlation was observed between serum NGAL level and NGAL expression in tumour cells, suggesting that the serum NGAL levels could tumour 
derived. The high expression of NGAL in gastric cancer tissues indicates tumour metastasis and poor prognosis. 
Tissue- THYROID 
 A. Iannetti et al., 2008. 
NGAL required for survival of thyroid cancer cells in serum deprived conditions in vitro. NGAL silencing leads to reduction in anchorage 
independent clonogenic growth in vitro and decreased tumorigenecity and tumour size in nude mice. NGAL expression elevated in papillary, 
follicular and anaplastic thyroid carcinoma. 
Tissue- UTERUS 
 T. Miyamoto et al., 2011. 
The ectopic expression of NGAL in endometrial cancer cells increases in vitro rate of proliferation. NGAL expressing cells showed increased 
invasiveness, suggesting possible role for NGAL in growth and metastasis of human endometrial cancer. NGAL expression (strong cytoplasmic 
and nuclear) was associated with a significant reduction in overall survival among endometrial carcinoma patients suggesting possible use of 
NGAL as prognostic marker. 
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ii. Evidence supporting a role NGAL as a tumour suppressor. 
Tissue- GENERAL 
 P. Bahmani et al., 2010. 
Protective role for NGAL against cell injury mediated by reactive oxygen species (ROS). NGAL inhibits the reduction of iron and generation of 
hydroxyl free radicals. 
Tissue- BREAST 
 J. Hanai et al., 2005. 
NGAL shown to be a suppressor of metastasis in Ras- transformed 4T1 mouse mammary tumour cells; stimulating epithelial phenotype,  reversing 
metastatic potential and reducing tumour growth. 
 S. Venkatesha et al., 2006. 
Ras- induced expression of VEGF in 4T1 mouse mammary tumour cells is inhibited by NGAL via down-regulation of MAPK and ras-PI3K 
signalling. Tumour angiogenesis, as demonstrated by the intradermal tumour angiogenesis assay, was suppressed by NGAL (mediated by caveolin-
1). Tumours formed by 4T1-ras cells into which NGAL was stably introduced displayed an increased expression of the anti-angiogenic molecule 
thrombospondin-1. 
 E.P. Cramer et al., 2012. 
MMTV-PyMT/FVB/N Mouse model for breast cancer showed that NGAL did not affect the aggressiveness of the breast cancers; despite being 
upregulated in breast cancer cells, no significant effect on tumour growth and metastasis was observed. In addition, demonstrated that unlike the 
human orthologue, mouse NGAL cannot bind directly to MMP-9 and therefore lacks the ability to mediate MMP-9 activation or inhibit 
degradation. 
Tissue- COLON 
 H.J. Lee et al., 2006. 
Ectopic NGAL expression suppressed the ability of human colon carcinoma cells, KM12SM, to invade Matrigel in vitro and substantially inhibited 
liver metastasis in vivo. NGAL may serve as a suppressor of colon cancer metastasis. 
Tissue- KIDNEY 
 Gwira et al., 2005. 
Study of mouse inner medullary collecting duct (mIMCD)-3 cells (kidney epithelial) showed that NGAL binds directly to Hepatoctye Growth 
Factor, inhibiting HGF-stimulated c-Met receptor phosphorylation and downstream signalling. Resulting in an inhibition of HGF –stimulated cell 
migration and single-cell morphogenesis. 
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Tissue- LIVER 
 E.K Lee et al., 2011.  
NGAL may play a protective role against the progression of human hepatocellular carcinoma (HCC) by supressing cell proliferation and invasion. 
NGAL expression level increased in HCC compared to normal liver tissue. Ectopic expression of NGAL in HCC cell line, in vivo and in vitro, 
inhibited the growth of the cells, reduced HCC cell invasive potential and inhibited MMP-2 expression. Actions thought to be due to NGAL 
inhibition of C-Jun N-terminal kinase and PI3K/Akt signalling pathways. 
Tissue- PANCREAS 
 M. Furutani et al., 1998. H. Han et al., 2002. 
Microarray analysis revealed that NGAL is up regulated by nearly 27 fold in pancreatic cancer cells compared to normal ductal cells. 
 N. Moniaux et al., 2008. 
A specific and differential expression pattern of NGAL observed in pancreatic adenocarcinoma compared to normal controls. NGAL expression 
found to be low in normal pancreas and in pancreatitis but very high in early dysplastic lesions (PanINs); suggests that NGAL could be a marker of 
early dysplasia in the pancreas. In adenocarcinomas, NGAL expression correlated positively with the grade of differentiation; moderate levels for 
highly differentiated whilst negative for poorly differentiated cancer. Hypothesise that loss of NGAL expression promotes the progression of 
pancreatic ductal carcinoma from well to poorly differentiated tumour. In addition serum NGAL levels elevated in both pancreatic inflammation 
and malignancy but no defining difference between pancreatitis and cancer. 
 Z. Tong et al., 2008. 
NGAL overexpression resulted in reduction of pancreatic cancer cell adhesion, invasion and angiogenesis, in vitro. Reduction in cellular invasion 
attributed to NGAL inhibition of FAK phosphorylation whilst anti-angiogenic effect due to inhibition of VEGF expression. In addition, NGAL 
overexpression in an orthotopic Nude mouse pancreatic cancer model displayed inhibited local/distant metastasis and reduced tumour microvessel 
density. Proposed that loss of NGAL expression is a biomarker for pancreatic cancer progression and possibly means of controlling angiogenesis 
and metastasis by altering NGAL expression. 
 S.Chakraborty et al., 2012 
              Plasma NGAL levels (and pancreatic juice) shown to be highly specific (88%) in differentiating pancreatic cancer and chronic   
              pancreatitis patients from healthy controls. Potential as a novel diagnostic biomarker, although NGAL levels not able to discriminate  
              between pancreatic cancer and chronic pancreatitis. 
Tissue- UTERUS 
 C-J. Liao et al., 2012. 
NGAL expression was significantly increased in endometrial hyperplasia compared to adenomyosis and correlated positively with the COX-2 and 
E-cadherin expression. Liao et al., propose that NGAL may assists in preventing the transition of epithelial cells to mesenchymal cells; acting as 
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protective factor against cell stress. High NGAL expression in tissues may imply imminent tumourigenesis, thereby altering NGAL expression in 
endometrial hyperplasia may control carcinoma development. 
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   Chapter 5: Results 
 
  THE EXPRESSION OF MSF AND NGAL IN RELATION TO  
     TUMOUR PROGRESSION. 
 
 
5.1 AIMS 
 
The fractionation of HaCaT conditioned medium has shown that the non-tumourigenic 
transformed human keratinocyte cell line expresses both MSF and NGAL. However, 
upon analysis of the HaCaT total CM in the 3D collagen gel fibroblast migration assay, 
the motogenic bioactivity of the endogenous MSF is masked due to inactivation by the 
co-secreted NGAL (Jones et al., 2007).  
The HaCaT cell line is the founding member of the HaCaT/ HaCaT-ras in vitro human 
skin carcinogenesis model. The three subsequent HaCaT –ras clones (BEN, MAL and 
MET) display a shift tumourigenic potential (Fusenig and Boukamp, 1998).  
The dysregulated expression of both MSF and NGAL has been implicated in various 
benign and malignant diseases (Schor et al., 2003 and 2005, Hu et al., 2009, 
Chakraborty et al., 2012). The aim was therefore to establish whether MSF and NGAL 
are expressed by the tumorigenic keratinocytes cell lines (BEN, MAL and MET) in 
order to determine whether expression levels can be related to the tumorigenic potential 
of each clone.  
For ease of discussion the cell lines of the HaCaT/ HaCaT-ras in vitro human skin 
carcinogenesis will be referred to as the HaCaT series. The presence of MSF and NGAL 
in the HaCaT series conditioned medium was explored by Western Blot analysis and 
ELISA techniques, whilst immunolocalisation was employed for direct visualisation of 
expression. 
 
5.2 BACKGROUND  
 
The HaCaT cells were developed from normal adult human skin keratinocytes during 
prolonged cultivation at a reduced calcium concentration and elevated temperature. The 
cell line is considered by many researchers to be a close approximation to normal 
keratinocytes in both growth and differentiation potential and is frequently used as a 
model system to study keratinocyte biology and transformation (Boukamp et al., 1988). 
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The cells remain non-tumourigenic through extended culture passages and maintain a 
stable chromosome content. Because of their genetic stability and primarily maintained 
phenotypic normality, these immortalised keratinocytes are considered to represent a 
very early stage in skin tumorigenesis (Fusenig and Boukamp, 1998). 
Using the HaCaT cell line Fusenig and colleagues developed an in vitro model to study 
process of human skin carcinogenesis, characterising the different stages of tumour 
development and progression, similar to the Fearon and Vogelstein’s model for colon 
cancer (Fearon and Volgestein, 1990). The tumourigenic conversion of HaCaT cells 
was achieved by introducing additional genetic alterations via transfection with the 
mutated val-12 Harvey-ras oncogene (Boukamp et al., 1990). Mutant ras genes are 
present in various human tumours and activated ras has been detected in squamous and 
basal cell carcinoma (Ananthaswamy and Pierceall, 1992). The transfected cells attained 
a selective growth advantage and altered phenotype. 
Numerous HaCaT-ras clones were produced, which after subcutaneous injection into 
nude mice grew into tumours. The tumours were classified by their growth behaviour 
and histological phenotype. Clones which grew slowly eventually forming epidermoid 
cysts were designated as benign, while those forming well- differentiated squamous cell 
carcinomas as malignant. The malignant clones were associated with the loss of copies 
of chromosome 15 (Boukamp et al., 1990 and 1997). A metastatic phenotype was only 
achieved by the in vivo passaging of a benign HaCaT-ras clone; resulting in a very fast 
growing clone which, after subcutaneous injection into nude mice spontaneously 
metastasised to the lung and lymph nodes (Mueller et al., 2001). 
The HaCaT-ras clones, each displaying shifting tumourigenic potential, were 
established as the cell lines BEN (benign), MAL (malignant, non-metastatic) and MET 
(metastatic). Each clone, originating from the same parental line, represented a distinct 
stage in tumour progression, thereby creating an in vitro carcinogenesis model for 
human skin keratinocytes. The model is comparable to the known stages of human 
epithelial skin carcinomas in vivo as well as of derived carcinoma cell lines and has 
enabled the identification of genetic alterations and phenotypic characteristics 
associated with the different stages of transformation (Fusenig and Boukamp, 1998). 
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5.3 THE IDENTIFICATION OF MSF EXPRESSION IN THE  
HACAT SERIES CELL LINES. 
 
5.3.i Western Blot Identification of MSF  
 
The unfractionated CM from each cell line was separated by 12% SDS PAGE under 
reducing conditions followed by immunoblotting with a specific anti-MSF antibody, 
RpVSI. A control sample of rhMSF (250pg) was always included as a positive control 
and an appropriate main band of approximately 77kDa was consistently observed as a 
clear strong band on the immunoblot.  
Numerous attempts were made to identify MSF in the CM of the HaCaT series 
keratinocytes, but none proved successful. Various concentrations of the CM were 
tested; the maximum being a 1000x concentrated sample prepared by Amicon 
concentration followed by dialysis and subsequent freeze drying. However, the problem 
with concentrating the CM to such an extent is that some of the protein tends to come 
out of solution and cannot be efficiently resuspended again. This has been observed 
even with 10x concentrated CM. One must conclude that if MSF is present in the 
HaCaT series CM it is at such a concentration that it cannot be detected by Western blot 
analysis; that is less than 25ng/ml.  
 
5.3.ii Colorimetric Sandwich ELISA for Total MSF 
 
Identification and quantification of MSF in the HaCaT series CM was also attempted by 
the colorimetric sandwich ELISA assay for total MSF. An anti-IGD antibody, MAb 
PEPQ 5.1, was used for capture and a specific anti-MSF antibody, RpVSI, for 
identification (Chapter 2, Materials & Methods). For each ELISA experiment a standard 
curve for MSF was performed using recombinant MSF; a maximum concentration of 
200ng/ml serially diluted to 1.5625ng/ml. 100µl of each standard or sample was tested 
per well, duplicate wells were tested for each variable and an average reading 
calculated. SF MEM and Coating buffer were used as negative controls. 
Initially neat CM from each cell line was tested but this proved unsuccessful in 
identifying MSF in the CM. 10x concentrated CM was then trialled but this was also 
negative, failing to give final OD readings above those of the negative controls. Once 
again, it would appear that either MSF is not expressed by the cells or that if MSF is 
present in the HaCaT series CM, it is present at concentrations below this assay’s 
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sensitivity, 12.5ng/ml. As discussed previously in regards to the HaCaT CM (4.5.ii, 
Chapter 4) the poor standard curve that was achieved using rhMSF standards questions 
the reliability and suitability of the antibodies used.  
 
5.3.iii Immunolocalisation of MSF in HACAT Series Keratinocytes. 
 
The two previous methods adopted to detect MSF expression were based on its 
identification in the CM collected from the cultured cells. The inability to detect MSF in 
the CM by Western Blot and Sandwich ELISA techniques may be due to sensitivity. 
Another explanation could be that any MSF present in the CM has become 
unrecognisable to the specific anti-MSF antibodies. MSF may have a short half-life in 
the CM, being degraded by the actions of proteases present within the CM or due to a 
consequence of storage (freeze/thaw cycles). Therefore, a method was chosen that 
would identify MSF directly within the cell i.e. immunohistochemistry. As this 
technique includes a fixation step it may assist in preserving any MSF present. 
A rabbit polyclonal anti-VSI antibody (Rp2), raised against the MSF unique carboxyl 
terminal decapeptide, was used for the immunolocalisation of MSF in the HaCaT series 
cell lines. Optimisation experiments allowed the selection of the most appropriate 
concentration of anti-MSF antibody which gave the best possible staining whilst 
ensuring a consistent negative control (normal rabbit IgG) and no cross- reaction with 
the biotinylated secondary antibody (Goat Anti-Rabbit IgG). The cell line FSF44, 
previously identified as not expressing MSF (Chapter 4.5 iii) was included in each 
experiment, as a negative control. 
Since all CM tested was from confluent cultures grown directly on plastic dishes it was 
appropriate to perform MSF immunolocalisation under these same conditions. 
However, the significance of the matrix has become increasingly apparent to researchers 
regarding cellular activity and the affect upon protein expression (Merne and Syranen, 
2003). Consequently, the cells when cultured on other 2D matrices (native collagen and 
gelatin coated dishes) and when plated within a 3D type I collagen gel were tested. For 
each of the different matrices IHC experiments were repeated a minimum of twice, with 
cells at different passages, to confirm reproducibility. Observations were performed in 
ten fields per experiment for each variable and categorised by the overall percentage of 
positive cells, the level of staining intensity and background staining. Assesment was 
made by myself and Dr. Ana Schor. 
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The keratinocyte cell lines BEN, MAL and MET were all shown to express MSF. The 
staining for MSF was heterogeneous on all four matrices and the overall intensity was 
highest when the cells were plated within the 3D type I collagen gel. There appeared to 
be little variation in the pattern of staining between the three 2D matrices tested. The 
cell line which consistently displayed the most intensely stained cells was the MET, 
which also infrequently exhibited negative cells. When compared to the MET, the MAL 
and BEN cells had fewer of the highest intensity but more of the moderate and weaker 
stained cells. (Figure 5.1, Table 5.1). 
When the cells were plated on the 2D matrices it became apparent that cells in certain 
areas were expressing MSF at a greater extent than others. This heterogeneous 
expression was most obvious with the MET cell line, where the maximum staining 
intensity for MSF was located in compact areas dense with multiple layers of cells. 
Morphologically these dense areas look like separate colonies, but when isolated and 
subsequently grown to confluence under standard culture conditions they display 
exactly the same MET morphology as their original culture. Also, MET cells plated at a 
lower cell density and stained when subconfluent display a homogenous staining 
intensity in all cells. Therefore one could conclude that cell density and cell to cell 
contact appears to have an impact on MSF expression.  
On observing the staining of the type I collagen gel pellets it was obvious that the 
background was consistently scoring at the highest level. It appeared that the collagen 
gel was being stained, especially in the vicinity of cells. It was hypothesised that the 
high background could actually be due to the cells secreting MSF into the collagen 
matrix. A number of experiments were carried out to prove whether this was the case 
using the protein transport inhibitor Brefeldin A (BFA). BFA is a fungal lactone 
antibiotic which inhibits the Arflp GTPase, thus interfering with protein transport from 
the ER to the Golgi apparatus resulting in the accumulation of protein within the ER. 
(Fishman and Curran 1992, Klausner, 1992). 
Firstly, in order to eliminate concerns about BFA toxicity the cells (FSF44 and HaCaT 
series) were initially plated on plastic dishes and incubated at a range of BFA 
concentrations (maximum concentration 5µg/ml); thereby allowing any adverse effects 
to be observed. Subsequently, cells were plated within type I collagen gels and 
incubated with BFA at 2.5 and 5µg/ml, after which the gels were fixed and processed 
into paraffin blocks. Immunolocalisation of MSF on the BFA treated keratinocytes 
showed very little difference in the level of collagen gel staining although the staining 
intensity of the actual cells did appear overall to be stronger. No difference was 
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observed between BFA treated and untreated FSF44 cells. As an additional control, the 
cells (FSF44 and the keratinocytes) were also plated onto plastic and treated in the same 
manner with the BFA followed by fixation and immunolocalisation for MSF. As with 
the cells in the collagen gels, the stain intensity was slightly increased but overall there 
were no major differences to the untreated cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
190 
 
 
Figure 5.1: Immunolocalisation of MSF in human fibroblasts and keratinocytes. 
Cells were plated onto or within four different matrices: A. Plastic cell culture dishes, B. Native 
collagen coated dishes, C. Gelatin coated dishes, D. Type I collagen gel pellet. 
A specific anti-MSF antibody, Rp2, was used at the following concentrations: Matrices A, B 
and C- 5µg/ml. Matrix D- 33µg/ml. Positive staining resulted in a brown colour. Control 
cultures incubated with normal rabbit IgG were all negative when tested at both antibody 
concentrations (pictures not shown). Images and observations were made at x20 magnification. 
Results showed that the human FSF44 fibroblasts were negative for MSF.  BEN, MAL and 
MET keratinocytes all express MSF heterogeneously. The level of MSF expression does appear 
to be dependent on the plating matrix. 
 
 
 
A B 
C 
A B 
C 
BEN Keratinocytes MAL Keratinocytes 
D D 
A B 
C 
 B 
C 
A 
C 
FSF44 Fibroblasts MET Keratinocytes 
D  D 
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Table 5.1: Immunolocalisation of MSF in human fibroblasts and keratinocytes. 
Cells were plated onto or within four different matrices: A. Plastic cell culture dishes, B. Native 
collagen coated dishes, C. Gelatin coated dishes, D. Type I collagen gel pellet. 
A specific anti-MSF antibody, Rp2, was used at the following concentrations: Matrices A, B 
and C- 5µg/ml. Matrix D- 33µg/ml. Observations were made at x20 magnification. 
Observations from multiple experiments were categorised as follows:  
1. Overall % of cells stained positive.  
2. % of cells stained at each level of staining intensity: high (3), medium (2), weak (1) and 
negative (0). 
3. Overall score of staining intensity, calculated as (% of cells at high intensity x 3) + (% of 
cells at medium intensity x 2) + (% of cells at weak intensity x 1) + (% of cells negative x 0). 
4. Level of background staining: negative, low, medium, high. 
 
Matrix A. Plastic cell culture dishes 
Cell 
Line 
% of  Cells 
Stained Positive 
% of Cells at each 
Level of Stain Intensity 
% 
Overall 
Score 
Background 
Level 
  High 
(3) 
Medium 
(2) 
Weak 
(1) 
Negative 
(0) 
FSF44 0 0 0 0 100 0 Negative 
BEN 90-100 5 10-20 70-80 0-10 105- 135 Negative 
MAL 90-100 10 60-70 20-30 0-5 170- 200 Negative 
MET 100 20 5-10 60-70 0 130- 150 Negative 
 
Matrix B. Native Collagen coated dishes. 
Cell 
Line 
% of  Cells 
Stained Positive 
% of Cells at each 
Level of Stain Intensity 
% 
Overall 
Score 
Background 
Level 
  High 
(3) 
Medium 
(2) 
Weak 
(1) 
Negative 
(0) 
FSF44 0 0 0 0 100 0 Negative 
BEN 90-100 5 40-50 40-50 10 135- 165 Negative 
MAL 90-100 5 20-30 60-70 0-10 115- 145 Negative 
MET 100 10-20 5 65-75 0 105- 145 Negative 
 
Matrix C. Gelatin coated dishes. 
Cell 
Line 
% of  Cells 
Stained Positive 
% of Cells at each 
Level of Stain Intensity 
% 
Overall 
Score 
Background 
Level 
  High 
(3) 
Medium 
(2) 
Weak 
(1) 
Negative 
(0) 
FSF44 0 0 0 0 100 0 Negative 
BEN 90-100 10 40-50 40-50 0-10 150- 180 Negative 
MAL 90-100 5 40-50 40-50 0-10 135- 215 Negative 
MET 100 20 5-10 65-75 0 135- 155 Negative 
 
Matrix D. 3D Type I Collagen gel pellet 
Cell 
Line 
% of  Cells 
Stained Positive 
% of Cells at each 
Level of Stain Intensity 
% 
Overall 
Score 
Background 
Level 
  High 
(3) 
Medium 
(2) 
Weak 
(1) 
Negative 
(0) 
FSF44 0 0 0 0 100 0 Low-Med 
BEN 70-80 20-30 10-20 10-20 20-30 90- 150 High 
MAL 90-100 60-70 10-20 10-20 0-10 210- 270 High 
MET 100 80-90 0-10 0-10 0 240- 300 Med- High 
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5.4 THE IDENTIFICATION OF NGAL EXPRESSION  
IN THE HACAT SERIES CELL LINES. 
 
5.4.i Western Blot Identification of NGAL  
 
Unfractionated CM from each cell line was separated by 12% SDS PAGE under 
reducing conditions followed by immunoblotting with a specific anti-NGAL antibody 
Mab1757. The method was optimised using different concentrations of CM with the 
best results achieved using the 5x Amicon concentrated CM (Materials and Methods, 
Chapter 2). 
For all the HaCaT cell lines a clear, strong band was visualised by chemiluminescence 
at approximately 20-25kDa, confirming NGAL was present in the CM. (Figure 5.2). 
Two other, but very much weaker, bands were observed in the BEN and MET lanes at 
higher molecular weights. These bands were located to 37-50 kDa and 100-150kDa 
ranges and probably correspond to other known forms of NGAL; the 46kDa disulfide 
linked homodimer and the 135kDa disulfide linked heterodimer with neutrophil 
gelatinase. A further even weaker band was also seen at approximately 50kDa in the 
BEN and MET lanes. 
Immunoblotting for NGAL was adopted as an initial assessment of the CM for the 
presence of NGAL. The CM screened was not standardised and therefore no conclusion 
can be made over the relative NGAL expression levels of each cell line. Also, as the 
CM tested was concentrated approximately 5x, one must not discount the likelihood that 
some protein may come out of solution during the concentration process and therefore 
making comparisons problematic. 
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Figure 5.2. The identification of NGAL in HaCaT Series CM by immunoblotting. 
Immunoblot of 12% SDS PAGE separation of HaCaT Series 5x concentrated CM, 
under reducing conditions, with specific anti-NGAL antibody, Mab1757. A distinct 
band was seen at approximately 25kDa, confirming the presence of NGAL. 
 
 
 
5.4.ii Colorimetric Indirect ELISA for NGAL. 
 
NGAL concentration was determined by indirect ELISA using a specific anti-NGAL 
antibody (polyclonal antibody AF1757), as described in Chapter 2, Materials & 
Methods. For each ELISA experiment, a standard curve for NGAL was performed 
using recombinant human NGAL (in house preparation) at a range of concentrations 
from 1.5625 to 300ng/ml (Figure 5.3). 100µl of each standard or sample were tested per 
well, duplicate wells were tested in each experiment and an average reading calculated. 
SF MEM and coating buffer were used as negative controls. 
Initial experiments confirmed that all members of the HaCaT series secreted NGAL 
which could be measured by the indirect ELISA method.  
The CM was then standardised by cell number to enable a direct comparison of NGAL 
concentration between the different cell lines. Although, all CM was collected using the 
same protocol (7ml SF MEM per 90mm) variation existed between the cell lines 
regarding the total number of cells present per 90mm when at confluence. (Table 5.2). 
Therefore, the CM for each cell line was adjusted/ diluted to the equivalent cell numbers 
i.e. 5.0 x 10
5
 cells per ml of CM (dilutions made with SF MEM). These CM 
1 2 3 4 5 6 7 LANE 
25kDa► 
37kDa► 
50kDa► 
75kDa► 
 
Lane 1:  Ladder (BioRad) 
Lane 2: Recombinant NGAL, 300ng 
Lane 3: HACAT Cm, 5x concentrated 
Lane 4: BEN CM, 5x concentrated 
Lane 5: MAL CM, 5x concentrated 
Lane 6: MET CM, 5x concentrated 
Lane 7: Recombinant NGAL, 600ng 
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preparations were then tested in the indirect ELISA both neat and at a range of dilutions 
(dilutions made with coating buffer). 
Using the standardised CM, NGAL was detected in the CM of the all members of the 
HaCaT series except the MET cells (Table5.3). NGAL had been measured in the CM of 
the MET, however when it was standardised to equal 5.0 x 10
5 
cells per ml, the amount 
of NGAL present was too low to be detected by the indirect ELISA method.  
According to the results from the analysis of HaCaT CM by indirect ELISA for NGAL, 
NGAL expression in un-concentrated CM is from highest to lowest; MAL, BEN, 
HaCaT, MET.  
 
 
Figure 5.3. The standard curve of Colorimetric Indirect Elisa for NGAL. A specific 
anti-NGAL antibody, polyclonal AF1757 (R&D Systems) was used for the 
identification of a range of rhNGAL standards (300 to 1.5625ng/ml). OD readings were 
measured at 450nm. The results shown are an average of three individual experiments.  
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Table 5.2. The average cell counts per 90mm dish for the HaCaT series 
keratinocytes. 
Cells from each keratinocyte cell line were plated onto 90mm plastic culture dishes and 
grown to confluence. After trypsinisation, cell counts were measured for each cell line 
from 5 separate dishes, with average cell count calculated. Cell counts measured by the 
Coulter Counter Z1series cell counter. Conditioned medium was collected by incubating 
confluent 90mm dishes with 7ml of SF MEM, therefore the average number of cells per 
ml of CM was calculated. 
 Cell Line       Confluent 90mm 
    Average Number of         
         Cells present. 
 
     Confluent 90mm  
Number of cells  
       per ml of CM 
   
HaCaT           5.4 x 10
6
          7.7 x 10
5
 
BEN           5.8 x 10
6
          8.3 x 10
5
 
MAL           5.4 x 10
6
          7.7 x 10
5
 
MET           4.1 x 10
6
          5.9 x 10
5
 
   
 
 
 
Table 5.3: The concentration of NGAL in HaCaT Series conditioned medium, as 
measured by the Colorimetric Indirect Elisa for NGAL.  
Cell Line NGAL Concentration (ng/ml) 
 Unstandardised  CM Standardised CM 
(5 x10
5
 cells per ml) 
HaCaT 1059.1 370.6 
BEN 1775.1 692.7 
MAL 1569.05 808.7 
MET 863.0 undetected 
 
  
 
5.4.iii Immunolocalisation of NGAL in HaCaT Series  
 
Although NGAL had been identified in the CM of the HaCaT series by immunoblotting 
and indirect ELISA (unlike MSF) immunolocalisation of NGAL was also performed. 
IHC was used to determine if there was any variation in the staining patterns of MSF 
and NGAL. Cells were plated onto the four different matrices, as for the MSF 
identification. As discussed previously, unlike cultured keratinocytes normally NGAL 
expression in skin is very restricted and the process of culturing keratinocytes is thought 
to be responsible for changes in their protein expression. As cell-matrix interactions 
have been shown to influence epithelial structure, growth and differentiation, the 
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HaCaT series was cultured on different 2D and 3D matrices in order to determine 
whether the matrix type would affect NGAL expression (Merne and Syranen, 2003). 
An antibody specific for NGAL, anti-NGAL goat polyclonal AF1757, was used for the 
immunolocalisation of NGAL in the cells. Optimisation experiments were performed 
first, to enable the selection of the most appropriate concentration of anti-NGAL 
antibody that gave the best staining whilst ensuring that the negative control, normal 
serum goat IgG, used at the same concentration was consistently negative. The 
secondary antibody, biotinylated polyclonal swine anti-goat IgG, was also optimised to 
ensure no cross-reactivity. The FSF44 fibroblast cell line was included in each 
experiment as an internal negative control, as had previously been showed not to 
express NGAL (Chapter 4.7iii). 
As expected, the cells of the different members of the HACAT series all expressed 
NGAL while the FSF44 fibroblasts were negative. The BEN, MAL and MET cells 
stained heterogeneously for NGAL on all the matrices tested. For each cell line, the 
proportion of positive to negative cells did not vary significantly with the different 
matrix types; NGAL expression was independent of the plating matrix. However, 
variations were noted when comparing between each keratinocyte cell line. In 
confirming the ELISA results, overall, NGAL expression was highest in the BEN and 
MAL, and lowest in the MET (Figure 5.4, Table 5.4). 
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Figure 5.4: Immunolocalisation of NGAL in human fibroblasts and keratinocytes. 
Cells were plated onto or within four different matrices: A. Plastic cell culture dishes, B. Native 
collagen coated dishes, C. Gelatin coated dishes, D. Type I collagen gel pellet. 
A specific antibody, anti-NGAL goat polyclonal AF1757, was used at the following 
concentrations: Matrices A, B and C- 0.5µg/ml. Matrix D- 2µg/ml. Positive staining resulted in 
a brown colour. Control cultures incubated with normal goat IgG were all negative when tested 
at both antibody concentrations (pictures not shown). Images and observations were made at 
x20 magnification. 
Results showed that the human FSF44 fibroblasts are negative for NGAL. BEN, MAL and 
MET keratinocytes all express NGAL heterogeneously. NGAL expression appears to be 
independent of the matrix. 
 
 
 
                      
 
A B 
C 
A B 
C 
BEN Keratinocytes MAL Keratinocytes 
D D 
A B 
C 
 B 
C 
A 
C 
FSF44 Fibroblast MET Keratinocytes 
D 
D 
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Table 5.4: Immunolocalisation of NGAL in human fibroblasts and keratinocytes. 
Cells were plated onto or within four different matrices: A. Plastic cell culture dishes, B. Native 
collagen coated dishes, C. Gelatin coated dishes, D. Type I collagen gel pellet. 
A specific antibody, anti-NGAL goat polyclonal AF1757, was used at the following 
concentrations: Matrices A, B and C- 0.5µg/ml. Matrix D- 2µg/ml. Observations made at x20 
magnification. 
Observations from multiple experiments was categorised as follows:  
1. Overall % of cells stained positive.  
2. % of cells stained at each level of stain intensity: high (3), medium (2), weak (1) and negative 
(0). 
3. Overall score of stain intensity, calculated as (% of cells at high intensity x 3) + (% of cells at 
medium intensity x 2) + (% of cells at weak intensity x 1) + (% of cells negative x 0). 
4. Level of background stain: negative, low, medium, high. 
  
Matrix A. Plastic cell culture dishes. 
Cell 
Line 
% of  Cells 
Stained Positive 
% of Cells at each 
Level of Stain Intensity 
% 
Overall 
Score 
Background 
Level 
High 
(3) 
Medium 
(2) 
Weak 
(1) 
Negative 
(0) 
FSF44 0 0 0 0 100 0 Negative 
BEN 90-100 40-50 40 10 0-10 210- 240 Negative 
MAL 80-90 10-20 70 10 10-20 180- 210 Negative 
MET 60-70 5-10 10 40-50 30-40 75- 100 Negative 
 
Matrix B. Native collagen coated dishes. 
Cell 
Line 
% of  Cells 
Stained Positive 
% of Cells at each 
Level of Stain Intensity 
% 
Overall 
Score 
Background 
Level 
High 
(3) 
Medium 
(2) 
Weak 
(1) 
Negative 
(0) 
FSF44 0 0 0 0 100 0 Negative 
BEN 90-100 30-40 40 10-20 0-10 180- 220 Negative 
MAL 80-90 10-20 70 10 0-10 180- 210 Negative 
MET 60-70 5-10 40-50 5-10 30-40 100- 140 Negative 
 
Matrix C. Gelatin coated dishes. 
Cell 
Line 
% of  Cells 
Stained Positive 
% of Cells at each 
Level of Stain Intensity 
% 
Overall 
Score 
Background 
Level 
High 
(3) 
Medium 
(2) 
Weak 
(1) 
Negative 
(0) 
FSF44 0 0 0 0 100 0 Negative 
BEN 90-100 40-50 40 10 0-10 210- 240 Negative 
MAL 80-90 10-20 40 40 0-10 150- 180 Negative 
MET 60-70 5-10 40-50 5-10 30-40 100- 140 Negative 
 
Matrix D. 3D Type I collagen gel pellet. 
Cell 
Line 
% of  Cells 
Stained Positive 
% of Cells at each 
Level of Stain Intensity 
% 
Overall 
Score 
Background 
Level 
High 
(3) 
Medium 
(2) 
Weak 
(1) 
Negative 
(0) 
FSF44 0 0 0 0 100 0 Low-Med 
BEN 80-90 30-40 30-40 10-20 10-20 160-240 Med- High 
MAL 80-90 30-40 30-40 10-20 10-20 160-240 Med- High 
MET 70-80 20-30 10-20 10-20 10-20 90-170 Med- High 
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5.5 DISCUSSION 
 
Cancer development is a multistep process whereby, due to the accumulation of genetic 
alterations, a cell gradually progresses from a normal to malignant phenotype.  
The mechanism for malignancy development it is still uncertain; as to whether a 
required amount of genetic alterations must occur or if there is a defined sequence of 
genetic events. Various experimental procedures have been adopted to study the 
conversion to malignancy including the use of rodent models, carcinoma derived cell 
lines or non-malignant cells treated with potent oncogenic stimuli.  
Experimental animal model systems and cultured rodent cells traditionally formed the 
basis of many studies however major differences to humans exist. Inter- species 
discrepancies in sensitivity to carcinogenic agents and subsequent transformation are 
reflected in the frequency of immortalisation. Human cells, unlike rodent, possess a 
notable resistance to transformation by oncogenes and chemical or physical 
carcinogens. Species- related factors such as natural life span, degree of rodent 
inbreeding and the higher genetic stability of human genome have been attributed for 
the disparity (Sager, 1984, Fusenig and Boukamp, 1998). 
Cell lines derived from primary tumours, especially from epithelial tissues, are often 
difficult to culture. Established lines are often considered to represent an elite subset of 
tumour cells which have the capacity to survive and adapt to the cell culture 
environment. The intensity of the selection pressures imposed on them during extensive 
cell culture may result in a genetic or phenotypic drift. This may explain the often 
contradictory data arising from studies using cancer cell lines, where results reflect a 
distinctive characteristic of a specific cell line (Marques et al., 2006). 
Successful immortalisation of human cells is rare when using chemical and physical 
agents but can be reproducibly induced by DNA viruses such as simian virus 40, 
adenovirus types 5 and 12, human papilloma virus types 16, 18 and 33(Rhim et al., 
1990). However, subsequent changes to the cell(s) may be virus- related rather than a 
result of transformation. For example, the immortalisation of human keratinocytes with 
SV40 was accompanied by dramatic changes in differentiation potential (Steinberg and 
Defendi, 1983). Unlike the spontaneously immortalised HaCaT cell line, which exhibit 
practically a normal amount of morphologic differentiation with the ability to form a 
well structured epidermis after transplantation in vivo (Boukamp et al., 1988). The 
development of permanent and stable in vitro cultures, like the HaCaT keratinocytes, 
has offered unlimited sample amount and more flexibility.  
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Researchers also noted that many of the models studied lacked the capacity to 
investigate the intermediate stages of cancer progression. However, the introduction of 
additional genetic alterations in the in vitro cultures offered the potential to develop 
models characterising the different stages of tumour development and progression. In 
vitro model systems similar to the HaCaT series have been established for other tissue 
types including breast (MCF10A and HMT-3522) and prostate (PC346) (Soule et al., 
1990, Dawson et al., 1996, Rizki et al., 2008, Marques et al., 2006). 
The HaCaT series model of human skin carcinogenesis has revealed that both MSF and 
NGAL are expressed by keratinocytes representing the different stages of tumour 
development. All members of the HaCaT series; BEN, MAL and MET express both 
MSF and NGAL, although at varying degrees. Overall, the results show that during 
tumour progression the expression level of NGAL decreases whilst that of MSF 
increases. 
NGAL was easily identified in the conditioned medium collected from each cell line of 
the HaCaT series by using the techniques of immunoblotting and indirect ELISA and 
subsequently confirmed by immunolocalisation using a specific anti-NGAL antibody. 
By standardising the conditioned medium, taking into account the variation in cell 
numbers from which the CM was collected, analysis by indirect ELISA revealed that 
MET cells expressed the lowest amount of NGAL while BEN and MAL express the 
most. This result was confirmed by the semi-quantitative assessment of the stained 
keratinocytes cultured on plastic dishes; the greatest percentage of high intensity 
staining was consistently detected in the BEN as opposed to the MET cultures which 
possessed the highest percentage of negatively stained cells.  
Testing of the standardised HaCaT series CM for NGAL by indirect ELISA identified a 
pattern of expression from highest to lowest as being- BEN/ MAL > HaCaT > MET. 
That is compared to normal HaCaT keratinocyte levels, NGAL expression increases 
during the benign and low –grade malignancy phases of tumour progression but is then 
drastically reduced at the advanced metastatic stage. A similar situation has been 
described in studies on ovarian, pancreatic and colon carcinoma with many believing 
NGAL could potentially be an early stage biomarker for a variety of cancers (Lim et al., 
2007, Tong et al., 2008, Lee et al., 2006, Yang and Moses 2009). In these carcinomas, 
NGAL seems to have an anti-metastatic action. For example, in ovarian cancer NGAL 
expression blocked the epithelial to mesenchymal transition (EMT), which is crucial for 
invasive neoplasia (Lim et al., 2007). Cho and Kim (2009) showed NGAL 
immunoreactivity in ovarian cancers was significantly associated with tumour 
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differentiation; well-differentiated tumours having the highest expression values 
compared with moderately and poorly differentiated tumours. A grade specific pattern 
of NGAL expression has also been described for pancreatic tumours and oral squamous 
cell carcinoma (Hana et al., 2005, Moniaux et al., 2008, Lin et al., 2012). 
Mallbris et al (2002) also proposed a role linking NGAL to keratinocyte differentiation 
pathway.  
However, the opposite situation has been described in breast cancer studies where 
elevated NGAL expression is associated with a poor prognosis; suggested NGAL 
promotes breast cancer progression by regulating EMT due to its ability to stabilise 
MMP-9 (Yang et al., 2009, Leng et al., 2009). Increased NGAL levels are also 
considered a poor prognostic indicator in gastric, oesophageal squamous cell and 
anaplastic thyroid carcinoma (Kubben et al., 2007, Zhang et al., 2007, Iannetti et al., 
2008, Wang et al., 2010).  Overexpression of NGAL has been ascribed an important 
role in the malignant transformation of human immortalised oesophageal epithelial cells 
and shown to enhance the differentiation and invasion of oesophageal squamous cell 
carcinoma cells (Du et al., 2011). The effects of NGAL therefore appear to be 
neoplasia- specific; a description that is often used when reviewing NGAL research 
(Bolignano et al., 2010, Chakraborty et al., 2012). See Table 4.6 for literature review. 
The identification of MSF expression proved to be more elusive. Analysis of MSF by 
immunoblotting and the sandwich ELISA failed to give a positive result. However, 
immunolocalisation of MSF in the cultured cells proved both successful and 
reproducible. Consequently, the conclusion was that the HaCaT series keratinocytes do 
express MSF but it must be present in the CM at concentrations below the limits of 
sensitivity of the assays (25ng/ml limit of the Western Blot and 12.5ng/ml limit of the 
Sandwich ELISA). Semi-quantitative evaluation of the MSF stained keratinocytes 
suggested an opposite expression pattern to NGAL. MET cells displayed the highest 
intensity of MSF localisation and had the fewest number of negative cells. The BEN 
cultures had the most MSF-negative cells. 
MSF is an oncofetal protein; expressed during foetal development but diminished in 
healthy adult cells. Expression is transiently switched on during acute wound healing 
and persistently expressed by both tumour and stromal cells in various human cancers 
(Schor et al., 2003, 2005, Jones et al., 2007). The discovery that the highest intensity of 
MSF expression is greatest in the keratinocyte cell line representing the metastatic stage 
of carcinogenesis concurs with the observation that an elevated expression of MSF in 
breast tumours is associated with a poorer prognosis (Aljorani et al., 2011). 
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Predominantly, when cultured within the 3D type I collagen matrix the HaCaT series 
model of human skin carcinogenesis displayed an increased MSF expression with 
increasing tumour progression. 
The inability to identify MSF in the HaCaT series CM may lead to the presumption that 
if the conditioned medium was tested in the fibroblast migration assay any MSF 
bioactivity would be masked by the NGAL present. A situation similar to that described 
for the HaCaT keratinocytes. However, MSF possesses a potent motogenic bioactivity, 
with half-maximal response exhibited at femtomolar concentrations, 0.1-1pg/ml. This is 
clearly below the limits of the assays adopted to identify MSF in the CM. Another 
consideration is that the antibodies used in the identification assays only recognise the 
unique decapeptide sequence of MSF. It maybe that this is no longer recognisable when 
MSF is secreted into the CM either due to change in conformation, the vulnerability of 
the VSI sequence to the action of proteoloytic enzymes due to its C-terminus location or 
masking due association with an accessory protein. However, the motogenic activity of 
MSF located in the GBD domain and retains its bioactivity after cleavage. (Schor et al., 
1996 and 2003). 
Ambiguous results were achieved in the assessment of the effect different culture matrix 
compositions had on keratinocyte NGAL and MSF expression. Each of the HaCaT 
series was cultured on a selection of 2D matrices (plastic, gelatin and native collagen 
coated dishes) and within a 3D type I collagen gel. NGAL staining appeared to follow a 
similar if not an identical pattern irrespective of the matrix, that is BEN and MET 
having the highest and lowest overall scores respectively. MSF staining patterns were 
similar for the plastic and 3D collagen matrix, but at odds with those for gelatin and 
native collagen. It was also clear that MSF staining intensity was maximal when the 
keratinocytes were cultured within the type I collagen. These results support the concept 
that matrix composition can influence keratinocyte protein expression. Although the 
cells are plated as monolayers on all the 2D surfaces different cell-matrix interactions 
will occur, indeed the inert and uniform nature of the plastic surface immediately set it 
apart. Plating the keratinocytes within the 3D collagen matrix results in differences in 
cell-matrix and cell-cell interactions which ultimately effect both morphology and 
protein expression. Although the results are less informative than expected, they do 
highlight and agree with Merne and Syrjanen (2003) on the importance of using a 
standardised matrix to avoid the confounding effects on keratinocyte protein expression. 
In conclusion, the analysis of MSF and NGAL expression in the HaCaT series model of 
human skin carcinogenesis has shown that during tumour progression NGAL 
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expression decreases while MSF increases. Each of the HaCaT-ras clones (BEN, MAL 
and MET) represents a shift in tumourigenic potential from the benign situation, 
malignancy and finally to metastasis. The next step was to assess the bioactivity of CM 
collected from the HaCaT series cell lines in the 3D collagen gel fibroblast migration 
assay. The presence of both pro- and anti- motogenic activity was evaluated  in order  to 
determine whether the expression levels of NGAL and MSF can be related to the 
bioactivity present in the conditioned medium of the HaCaT-ras clones? The analysis of 
the HaCaT total CM in the 3D collagen gel fibroblast migration assay showed that the 
motogenic bioactivity of the endogenous MSF is masked due to inactivation by the co-
secreted NGAL (Jones et al., 2007). Consequently, the proposed question is- will the 
stoichiometric relationship between NGAL and MSF alter with the increasing degree of 
malignancy of the HaCaT-ras clones? 
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    Chapter 6: Results 
 
    THE EXPRESSION OF  PRO- AND ANTI- MOTOGENIC BIOACTIVITY  
BY THE HACAT-RAS CLONES. 
 
6.1 AIMS 
 
To assess the bioactivity of CM collected from the HaCaT –ras clones (HaCaT series 
cell lines) in the 3D collagen gel fibroblast migration assay. To ascertain the presence of 
both pro- and anti- motogenic activity, in order to identify the possible contribution 
made by MSF and NGAL during tumour progression. 
 
6.2 BACKGROUND  
 
It has already been established that both MSF and NGAL are expressed by cultured 
non-tumourigenic HaCaT and tumorigenic BEN, MAL and MET keratinocyte cell lines. 
However, expression levels are not uniform; as the tumourigenic potential increases 
there is a relative elevation in MSF and a decline in NGAL expression.  
Previous experiments, analysing the bioactivity of conditioned medium (CM) collected 
from the HaCaT line demonstrated that the motogenic activity of the HaCaT MSF is 
undetected due to inactivation by the co-secreted NGAL. With the discovery that the 
HaCaT series lines also express MSF and NGAL, one could conclude that the 
endogenous NGAL would also have the potential to suppress any endogenous MSF 
bioactivity in the CM too. However, ELISA analysis of the HaCaT series CM for 
NGAL has shown that while BEN and MAL express more NGAL than the HaCaT cells 
the opposite is true for the MET. Plus semi-quantitative evaluation of MSF 
immunolocalisation in the keratinocytes revealed that the highest staining intensity was 
consistently located in the MET cells. In addition, compared to the BEN and MAL 
cultures the MET cells were consistently MSF positive, that is no MSF-negative cells 
were identified. Therefore, this altered balance of MSF and NGAL compared to the 
HaCaT has led to the postulation that of all the tumorigenic keratinocytes, the MET 
would differ from the HaCaT CM and actually display motogenic activity attributable to 
MSF. This prediction, of course, does not take into consideration other motogenic 
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factors which may also be present in the CM, with the potential to affect the CM 
bioactivity of each cell line. 
 
 
6.3 THE ASSESSMENT OF THE BIOACTVITY OF HACAT SERIES  
    CONDITIONED MEDIUM 
 
6.3i The Motogenic Activity of HaCaT Series Conditioned Medium 
 
Serum free (SF) conditioned medium was collected from each HaCaT series cell line 
and tested for motogenic activity in a minimum of five separate 3D collagen gel 
fibroblast migration experiments. The CM was tested alone, at a range of dilutions from 
1/4 to 1/40,000 (all dilutions made with SF MEM). Bioactivity was classified as 
motogenic when fibroblast migration was stimulated to increase by a minimum of 50%, 
as compared to SF MEM control baseline level. 
As discussed previously, when recombinant MSF is tested in the migration assay its 
motogenic activity is characterised by a bell-shaped dose response. Maximal MSF 
stimulation migration occurs at concentrations of 100-500pg/ml, with migration 2-3 
times that of the SF MEM baseline, (Figure 6.1a). When tested, both BEN and MAL 
CM displayed a pattern of motogenic activity similar to rhMSF; a bell shaped dose 
response with peak stimulation at the 1/1000 dilution point, 2-2.5 times that of SF MEM 
baseline level (Figure 6.1b-c). 
MET CM also possessed stimulatory bioactivity, but this activity was not characterised 
by the same response pattern. Every dilution point from 1/40,000 to 1/100 demonstrated 
a similar level in motogenic activity; 2-2.5 times more than SF MEM baseline level. 
(Fig6.1d). Since MET bioactivity did not diminish at the higher dilutions as occurred 
with BEN and MAL, one can conclude that the MET CM possessed the most motogenic 
activity and therefore the motogen responsible must be present at a higher concentration 
in the MET CM. As stated previously, when MET cells are grown on a 90mm culture 
dish fewer cells are present at confluence, when CM is collected, than compared to the 
BEN and MAL lines, (Table 5.2). Hence, a fewer number of MET cells are required to 
condition medium for maximal bioactivity; the motogen expression and secretion must 
consequently be higher.  
The highest dilutions of MET CM tested (1/40,000 and 1/20,000) still displayed 
motogenic activity.  The same dilutions of BEN CM showed no activity, whereas MAL 
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CM appeared to show borderline activity (i.e. MAL CM was motogenic at 1/40,000 in 
2/4 experiments and showed no activity in the rest). Within the range of dilutions tested, 
maximal motogenic activity was obtained at 1/40,000 for the MET CM and 1/4,000 -
1/1,000 for the BEN and MAL CM.   These results indicate that the concentration of a 
putative motogenic factor(s) in the MET CM may be at least 10 fold higher than in the 
BEN CM, with the MAL somewhere in between. Although, at this stage it cannot be 
presumed that the motogenic activity is due to a single factor, the presence and activity 
of other factors cannot be dismissed. 
If the presumption is that MSF is the only motogen responsible for the HaCaT series 
stimulatory bioactivity, then these results are in accord with those gained from MSF 
immunolocalisation experiments; the most tumorigenic cell line, the metastatic MET 
keratinocytes, expresses the most MSF while the MAL and BEN have similar 
expression levels. That is, for the HaCaT series increasing MSF expression levels 
corresponds to increasing motogenic bioactivity present within the CM, which equates 
to the tumourigenic potential of the cell line. 
 
6.3ii  The MSF-Inhibitory Activity of HaCaT Series Conditioned Medium 
 
To assess whether the HaCaT series CM possessed MSF-I bioactivity, CM was tested in 
the 3D collagen gel fibroblast migration assay in the presence of 100pg/ml rhMSF. A 
minimum of three experiments were performed for each cell line, with the CM tested at 
a range of dilutions from 1/4 to 1/40,000 (all dilutions made with SF MEM). 100pg/ml 
of rhMSF reproducibly increases fibroblast migration by at least two fold by 
comparison to the control, SF MEM baseline. Therefore, a dilution was categorised as 
having MSF inhibitory activity if upon addition of 100pg/ml rhMSF it reduced 
migration by at least 50% when compared to the control 100pg/ml rhMSF baseline. 
Experiments with recombinant NGAL have demonstrated its ability to inhibit the 
bioactivity of 100pg/ml rhMSF back to SF MEM baseline levels. NGAL concentrations 
of 1ng/ml and below do not inhibit MSF stimulated migration, while concentrations of 
10ng/ml and above do, returning migration levels back to the SF MEM baseline. NGAL 
does not have the ability to reduce migration to below the SF MEM baseline (maximum 
concentration tested 1 g/ml). (Figure 6.2a).   
In comparison to the effect NGAL has on rhMSF, the HaCaT series BEN and MAL cell 
lines CM also reduces MSF motogenic activity. Overall, as the concentration of BEN 
and MAL CM increased so did their MSF-I bioactivity and similar to rhNGAL, 
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migration was not inhibited below SF MEM baseline. BEN and MAL displayed a 
similar level of MSF-I activity meeting the set criteria of a 50% reduction in migration 
at dilution points 1/1000 to 1/4, (Figure 6.2b and c). These results are in accordance to 
the data gained from the assessment of NGAL in CM by ELISA, where BEN and MAL 
have similar NGAL concentration in un-standardised CM (Table 5.3). 
However, MET CM displayed no MSF-I activity. All dilution points tested failed to 
reduce migration by the set criteria, (Figure 6.2d). NGAL quantification by ELISA 
indicated that MET secreted the least NGAL (or lowest amount).  
 
6.3iii The Motogenic Activity of Recombinant MSF in the  
Presence of HaCaT Series Conditioned Medium. 
 
Each of the HaCaT series cell lines (BEN, MAL and MET) demonstrated the ability to 
stimulate fibroblast migration in the 3D collagen gel assay, possessing an endogenous 
motogenic activity. Therefore, an additional method of analysis was required to 
eliminate the possibility that this activity may mask the effect of any MSF- inhibitor(s) 
present in the CM. Instead of determining an increase or decrease in migration by 
comparison to the positive (rhMSF) or negative (SF MEM) controls, the CM when 
tested alone, at each individual dilution, was considered as the baseline migration. That 
is, MSF-inhibitory bioactivity was defined, upon addition of 100pg/ml rhMSF, as the 
inability to increase CM baseline migration by a minimum of 50%. 
If MSF is responsible for the motogenic activity detected in the CM, the nature of 
MSF’s bioactivity, a bell shaped dose response, may cause misinterpretation of the 
results. For example, if the MSF present in the CM is at a low concentration i.e. below 
10pg/ml, the addition of 100pg/ml rhMSF would result in an increase in migration due 
to “tipping” over of the bell-shaped response to MSF concentrations which give 
maximal migration. Whereas, if the MSF present in the CM is at a concentration above 
500pg/ml, in theory, the addition of 100pg/ml could result in a reduction in migration. 
However, results from the ELISA and immunoblot experiments, to detect MSF, imply 
that the MSF concentrations present in the HaCaT series CM are low and therefore any 
reduction in migration is probably due to the action of a MSF- inhibitor. Finally, if there 
appeared to be no effect upon addition of rhMSF the conclusion was either that it was 
the actions of an inhibitor or that MSF within the CM must be at the concentration of 
peak bioactivity (100-500pg/ml) and therefore the addition of a further 100pg/ml would 
make little or no difference to cell migration. 
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As shown previously, BEN and MAL CM display both endogenous motogenic 
bioactivity, when tested alone, and MSF- inhibitory activity upon addition of rhMSF. 
Now that the baseline migration is taken into account this shows that BEN and MAL 
CM possess a distinct MSF-inhibitory activity, (Figure 6.3 a and b). The addition of 
100pg/ml rhMSF appeared to have no effect on the baseline migration at the majority of 
dilution points tested. A limited increase in migration was noted in the MAL CM at the 
maximal dilutions but this did not reach the set criteria for MSF stimulation.  High 
standard deviations at these dilutions demonstrate the effects such high dilutions have 
on experimental variability and reproducibility. The BEN CM also increased migration, 
which met the set criteria of MSF bioactivity, at 1/20,000 dilution; when previously 
tested alone this dilution point displayed no motogenic activity, (Figure 6.1.b).  
Previously, MET CM displayed motogenic activity (Figure 6.1.d) whilst having no 
ability to inhibit MSF bioactivity, (Figure 6.2.d). However, this analysis has shown the 
addition of rhMSF actually had no effect on increasing cell migration above the baseline 
level at the various dilutions tested, (Figure 6.3.c) suggesting possible MSF inhibitory 
activity. Presuming the motogenic activity of the MET CM is due to the expression of 
endogenous MSF then this “inhibitory activity” could actually be due to the addition of 
excess MSF causing a “tipping” over of the bell shaped dose response, where the higher 
MSF concentration (>500pg/ml) results in a reduction in migration, (Figure 6.3c). 
 
 
6.4      THE CHARACTERISATION OF HACAT SERIES  
ENDOGENOUS MOTOGENIC BIOACTIVITY. 
 
The CM from each HaCaT series cell lines has consistently displayed the ability to 
stimulate the migration of fibroblasts in the migration assay in a similar way to the 
bioactivity of MSF. Testing the CM in the presence of NGAL and the MSF function 
neutralising antibody, PEPQ1.1, should determine whether this endogenous motogenic 
activity could be attributed to the secretion of MSF. Both NGAL and the PEPQ 
antibody inhibit MSF bioactivity back to baseline levels; however they have different 
levels of potency. The maximum MSF concentration that 10ng/ml of NGAL can inhibit 
is 500pg/ml, whereas a 50ng/ml of PEPQ 1.1 can inhibit up to 1ng/ml of MSF. The set 
criteria for NGAL and PEPQ1.1 inhibition was a reduction in CM baseline migration by 
at least 50% and each cell line was tested a minimum of three times.  
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NGAL appeared to have a minimal effect on reducing the motogenic activity of the 
HaCaT series CM. CM only baseline migration was decreased upon addition of NGAL 
at a few dilution points, but for all the cell lines it failed to reach the set criteria of a 
50% reduction. Maximal inhibition by rhNGAL was 38%, 40% and 31% at dilutions 
1/10, 1/4000 and 1/10 for BEN, MAL and MET respectively, (Figure 6.4a-d). 
The PEPQ1.1, MSF function neutralising antibody, appeared to have more of an effect 
in limiting the motogenic activity of the HaCaT series CM. However, in the majority of 
cases, any inhibition which did occur, failed to meet the set criteria of a 50% reduction. 
The maximum level of inhibition by PEPQ 1.1 antibody was 68% at 1/10 dilution of 
BEN CM and 51% for MET CM 1/1000 dilution; other dilution points had borderline 
results, (Figure 6.5a-d). Overall, the level of inhibition by PEPQ 1.1 was greater than 
that of NGAL in both the number of motogenic dilutions with reduced migration and 
the level of inhibition achieved- a foreseeable result knowing the different intensities of 
MSF-I activity displayed by each inhibitor, as discussed earlier. (Table 6.1)  
The inability to achieve the set criteria of a 50% reduction in motogenic bioactivity 
could be due to numerous factors. The most obvious being that too little NGAL and 
PEPQ1.1 were added to the CM which resulted in incomplete inhibition due to the 
discrepancy between inhibitor potency and actual amount of MSF present in the CM. 
However, the level of motogenic activity detected in the HaCaT series CM appeared to 
be below that measured for 100pg/ml rhMSF, which would imply that ample 
concentrations of inhibitors were used since 10ng/ml NGAL and 50ng/ml of PEPQ1.1 
can inhibit the activity of 500pg/ml and 1ng/ml rhMSF respectively. (100pg/ml rhMSF 
= 300% of cells migrated compared to SF MEM baseline, maximal migration achieved 
by HaCaT series CM = 250%).  
The consequences of the nature of MSF bioactivity should be also be considered. By 
adding an inhibitor to the CM was excess MSF being “removed” allowing the bell-
shaped dose response to tip back over into concentrations where upon migration was 
actually stimulated? However, only the addition of NGAL resulted in an increase in 
migration compared to baseline levels and only at a few random dilution points; no 
pattern emerged to support this theory.  
Another reason could be the presence of another motogen(s) in the CM, which would be 
unaffected by the MSF-inhibitors. Therefore, the criteria to determine whether 
inhibition was achieved by NGAL and PEPQ1.1 was maybe set too high and did not 
take this into account. However, since the exact concentration of MSF present within 
the CM was unknown the setting of the criteria was arbitrary and understandably high 
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in order to eliminate false positive results. Nonetheless, from these experiments the 
overall conclusion was that at least a proportion of the motogenic bioactivity present 
within the CM of the HaCaT series could be attributed to MSF.
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Figure 6.1: The motogenic activity of conditioned medium from HaCaT Series 
cells, comparison with rhMSF.   Conditioned medium (CM) from each cell line (BEN, 
MAL and MET) was tested, on its own, at various dilutions in the 3D Collagen gel fibroblast 
migration assay.  The number of cells migrated is expressed as a percentage of the SF MEM 
control baseline migration i.e. SF MEM Baseline = 100 +/- 16.07%, as represented by hatched 
and dotted lines (mean and SD respectively). This was equivalent to 2.8 +/- 0.45 migrated cells. 
(100pg/ml rhMSF only = 8.6 +/- 0.28 migrated cells). The results represent an average of three 
experiments. Dose response to rhMSF is shown for comparison. 
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Figure 6.2: The MSF-inhibitory activity of conditioned medium from HaCaT 
Series cells, comparison with rhNGAL. Conditioned medium (CM) from each cell line 
(BEN, MAL and MET) was tested at various dilutions in the 3D collagen gel fibroblast 
migration assay in the presence of 100pg/ml rhMSF. The number of cells migrated is expressed 
as a percentage of the 100pg/ml rhMSF control baseline migration i.e. MSF Baseline = 100 +/- 
3.26%, as represented by hatched and dotted lines (mean and SD respectively). This was 
equivalent to 8.6 +/- 0.28 migrated cells. The results represent an average of three experiments. 
Dose response to rhNGAL is shown for comparison. 
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Figure 6.3. The motogenic activity of exogenous rhMSF in the presence of 
conditioned medium. Conditioned medium (CM) from each cell line (BEN, MAL and MET) 
was tested, at various dilutions, in the 3D collagen gel fibroblast migration assay with and 
without the presence of 100pg/ml rhMSF.  The number of cells migrated is expressed as a 
percentage of the CM only baseline migration at each individual dilution point. i.e. ¼ dilution 
CM only = 100%, as represented by hatched line. The results represent an average of three 
experiments. 
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Figure 6.4: The effect of NGAL on the endogenous motogenic bioactivity of HaCaT 
Series CM, comparison with rhMSF. Conditioned medium (CM) from each cell line 
(BEN, MAL and MET), at various dilutions, in the 3D collagen gel fibroblast migration assay in 
the presence of 10ng/ml rhNGAL. The number of cells migrated is expressed as a percentage of 
the CM only baseline migration at each individual dilution point. i.e. ¼ dilution CM only = 
100%, as represented by hatched line. CM dilutions which display motogenic activity, when 
tested alone, are identified by a star (*). The results represent an average of three experiments. 
Effect of rhNGAL on the dose response of rhMSF is shown for comparison. 
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Figure 6.5: The effect of MSF-neutralising antibody, PEPQ1.1, on the endogenous 
motogenic bioactivity of HaCaT Series CM, comparison with rhMSF. Conditioned 
medium (CM) from each cell line (BEN, MAL and MET), at various dilutions, in the 3D 
collagen gel fibroblast migration assay in the presence of 50ng/ml PEPQ1.1. The number of 
cells migrated is expressed as a percentage of the CM only baseline migration at each individual 
dilution point. i.e. ¼ dilution CM only = 100%, as represented by hatched line. CM dilutions 
which display motogenic activity, when tested alone, are identified by a star (*). The results 
represent an average of three experiments. Effect of PEPQ1.1 on the dose response of rhMSF is 
shown for comparison. 
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Table 6.1. The Characterisation of HaCaT Series Endogenous Motogenic 
Bioactivity. 
Conditioned medium (CM) from each cell line (BEN, MAL and MET) tested at various 
dilutions, in the 3D collagen gel fibroblast migration assay in the presence of either 10ng/ml 
rhNGAL or 1/180 dilution of PEPQ1.1 antibody.  
 
a. The Effect of NGAL on the Endogenous Motogenic Bioactivity of HaCaT Series 
Conditioned Medium. 
 BEN MAL  MET 
Motogenic Dilutions 
(50% increased migration compared to SF 
MEM baseline) 
1/4000 -1/10 1/20,000 – 1/10 1/40,000 – 1/10 
Dilutions with reduced migration 
upon addition of 10ng/ml rhNGAL. 
1/10, 1/100 1/4000 1/10, 1/100 
Maximal inhibition of migration by 
10ng/ml rhNGAL 
38% @ 1/10 40% @ 1/4000 31% @ 1/10 
NGAL inhibition which met set 
criteria (50% reduction compared to CM 
only baseline). 
None None None 
 
 
b. The Effect of MSF- Neutralising Antibody, PEPQ 1.1, on the Endogenous 
Motogenic Bioactivity of HaCaT Series Conditioned Medium. 
 BEN MAL  MET 
Motogenic Dilutions 
(50% increased migration compared to SF 
MEM baseline) 
1/4000 -1/10 1/20,000 – 1/10 1/40,000 – 1/10 
Dilutions with reduced migration 
upon addition of PEPQ1.1 
antibody. 
ALL 1/20,000 – 1/4 ALL 
Maximal inhibition of migration by 
PEPQ 1.1 antibody 
68% @ 1/1000 31% @ 1/4000 51% @ 1/1000 
PEPQ 1.1 inhibition which met set 
criteria (50% reduction compared to CM 
only baseline). 
1/1000 None 1/1000 
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Table 6.2. Result Summary 1. The Bioactivity of HaCaT Series CM. 
Conditioned medium collected from the HaCaT series cell lines BEN, MAL and MET, were tested at various dilutions in the 3D collagen gel fibroblast migration 
assay with and without the presence of 100pg/ml rhMSF. By comparison to SF MEM or rhMSF baseline controls the nature of each cell line’s bioactivity, at each 
dilution point, was determined. 
 
 Bioactivity in CM 
Compared to SF MEM Baseline 
Response to rhMSF 
Compared to MSF Baseline 
Response to rhMSF 
Compared to CM Baseline 
Cell line None Motogenic None Stimulation Inhibition None Stimulation Inhibition 
 
 
BEN 
1/4 
1/40,000 
1/10 
1/100 
1/1000 
1/4000 
1/4000 
1/20,000 
- 1/4 
1/10 
1/100 
1/1000 
1/40,000 
- 1/20,000 1/4 
1/10 
1/100 
1/1000 
1/4000 
1/40,000 
 
 
MAL 
1/4 
1/40,000 
1/10 
1/100 
1/1000 
1/4000 
1/20,000 
1/1000 
1/4000 
1/20,000 
1/40,000 
- 1/4 
1/10 
1/100 
- 1/20,000 
1/40,000 
1/4 
1/10 
1/100 
1/1000 
1/4000 
1/20,000 
 
 
MET 
1/4 
 
1/10 
1/100 
1/1000 
1/4000 
1/20,000 
1/40,000 
1/4 
1/10 
1/100 
1/1000 
1/4000 
1/20,000 
1/40,000 
- - - 1/4 1/10 
1/100 
1/1000 
1/4000 
1/20,000 
1/40,000 
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Table 6.3. Result Summary 2. The Bioactivity of HaCaT Series CM. 
Conditioned medium collected from the HaCaT series cell lines BEN, MAL and MET, was tested at various dilutions in the 3D collagen gel fibroblast migration 
assay with and without the presence of 100pg/ml rhMSF. By comparison to SF MEM or rhMSF baseline controls the nature of each cell line’s bioactivity, at each 
dilution point, was determined. 
 
 
 
 
 
 
 
 
 
 
Cell Line Motogenic Activity 
Compared to SF MEM Baseline 
(CM tested alone) 
MSF-I Activity 
Compared to MSF Baseline 
(CM + 100pg/ml rhMSF) 
MSF-I Activity Only 
No endogenous 
motogenic activity. 
BEN 
1/10 
1/100 
1/1000 
1/4000 
1/4 
1/10 
1/100 
1/1000 
1/40,000 
1/4 
1/40,000 
MAL 
1/10 
1/100 
1/1000 
1/4000 
1/20,000 
1/4 
1/10 
1/100 
1/4 
 
MET 
1/10 
1/100 
1/1000 
1/4000 
1/20,000 
1/40,000 
none none 
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6.5           THE SUPERDEX FRACTIONATION OF HACAT SERIES  
    CONDITIONED MEDIUM 
 
The analysis of total CM collected from the HaCaT series cell lines revealed the 
presence of both motogenic and MSF-inhibitory bioactivity, the proportion of which 
varied between the cell lines. The next phase was to determine the nature of these 
bioactivities; that is can each bioactivity be separated into a distinct entity? Size 
exclusion chromatography (SEC), as used previously to fractionate the HaCaT 
keratinocyte CM, was selected to separate the proteins by molecular weight. 
The Superdex 75 HiLoad 26/60 (GE Healthcare) column, which has a fractionation 
range of 3-70kDa, was used to fractionate 4ml of ten times Amicon concentrated CM 
(Materials & Methods, Chapter 2). Multiple runs were completed in order to provide 
sufficient material for downstream analysis. For each individual run 100 x 3ml fractions 
were collected (2ml/min) and numbered 1 to 100; the corresponding fractions from the 
duplicate runs were then pooled together, (Figure 6.6). Subsequently the fractions were 
pooled into groups of three; Groups 1 to 33. For each cell line Groups 13 to 23 
(fractions 37-69), equivalent to the main absorbance peak with a molecular weight 
range of approximately >70kDa to 20kDa, were tested at a final dilution of 1/20 for 
bioactivity in the 3D collagen gel fibroblast migration assay, (Figure 6.7, Table 6.4). 
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Table 6.4. The Estimated Molecular Weight of the Size Exclusion 
Chromatography Fractions. The Superdex 75 HiLoad 26/60n column was calibrated prior 
to sample loading with known molecular mass markers (albumin, ovalbumin and 
chymotrypsinogen) thereby permitting an estimated molecular weight for each fraction and 
subsequently each fraction group. The table shows the selected fractions, 37-69, equivalent to 
the main absorbance peak which were pooled into groups of three (fraction groups 13-23) and 
tested for bioactivity in the 3D collagen gel fibroblast migration assay. 
 
Fraction 
Number 
Equivalent 
Fraction 
Group 
Location of 
Calibration Markers 
Estimated 
Molecular Weight 
37, 38, 39 13   
 
>70kDa 
40, 41, 42 14  
43, 44, 45 15  
46, 47, 48 16  
49, 50, 51 17 Albumin MWt = 66kDa >60kDa 
52, 53, 54 18  Approx 50kDa 
55, 56, 57 19 Ovalbumin MWt = 45kDa >40kDa 
58, 59, 60 20  Approx 30-40kDa 
61, 62, 63 21 Chymotrypsinogen MWt = 
25kDa 
>=25kDA 
64, 65, 66 22 
67, 68, 69 23  Approx 20kDa 
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c. MET CM, Superdex 75 Fractions.
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Figure 6.6. The Fractionation of HaCaT Series Conditioned Medium by Size-
Exclusion Chromatography. 4ml of 10x concentrated CM from each HaCaT Series cell line 
(BEN, MAL, MET) was applied to a Superdex 75 HiLoad 26/60n column. 100 x 3ml fractions 
were collected (2ml/min). The eluant was monitored for absorbance at 254nm and 280nm. 
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a. BEN Superdex 75 Fractionated CM.
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b. MAL Superdex 75 Fractionated CM.
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c. MET Superdex 75 Fractionated CM.
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Figure 6.7. The Fractionation of HaCaT Series Conditioned Medium by Size-
Exclusion Chromatography. 4ml of 10x concentrated CM from each cell line (BEN, MAL, 
MET) was applied to a Superdex 75 HiLoad 26/60n column. The eluant was monitored for 
absorbance at 254nm and 280nm. 100 x 3ml fractions were collected (2ml/min). The collected 
fractions were pooled together into groups of three. Fraction groups 13 to 23, equivalent to the 
main absorbance peak, were assayed for biological activity in the 3D collagen fibroblast 
migration assay. 
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6.9 THE ASSESSMENT OF THE BIOACTIVITY OF SEC  
FRACTIONATED HACAT SERIES CONDITIONED MEDIUM 
 
6.6i The Motogenic Activity of  Size- Exclusion Fractionated  
HaCaT Series Conditioned Medium. 
 
As previously performed with the unfractionated HaCaT Series CM, the SEC 
fractionated CM was tested alone in the 3D collagen gel fibroblast migration assay in 
order to determine the presence of motogenic activity. Fraction groups 13 to 23 were 
tested at a final dilution of 1/20 (all dilutions made with SF MEM). Each fraction group 
was considered as motogenic if fibroblast migration was stimulated by at least 50% 
when compared to SF MEM control baseline levels.  
As expected, each cell line exhibited motogenic activity, with bioactivity commonly 
present in the higher molecular weight fraction groups (13-16) (Figure 6.8). The 
majority of stimulatory activity was detected in the MAL fractions; groups 13 to 21 all 
met the set criteria for motogenic activity (approx. >70kDa to 25kDa). Also, compared 
to the BEN and MET results the highest levels of fibroblast migration were measured in 
the MAL experiments; on average twice the SF MEM baseline level. However, as the 
fractions were not standardised by protein concentration and only tested at a single 
dilution, the level of bioactivity of the MAL fractions may merely be a result of a 
greater protein concentration compared to the others as displayed by the absorbance 
readings monitored during fractionation, (Figure 6.7). 
In the BEN experiments, the lowest molecular weight group, 23 (approx. 20kDa), 
displayed motogenic activity twice that of the SF MEM baseline. Suggesting that either 
breakdown products of MSF, namely IGD containing fragments, were responsible for 
this bioactivity or it is due to the presence of another motogen. 
 
6.6ii The MSF-Inhibitory Activity of  Size- Exclusion Fractionated  
HaCaT Series Conditioned Medium. 
 
SEC fraction groups for each cell line were tested in the 3D collagen gel fibroblast 
migration assay in the presence of 100pg/ml rhMSF in order to determine the presence 
of MSF-inhibitor(s) within the fractionated CM. Each group was tested at a final 
dilution of 1/20 and the criteria set for MSF inhibition was the ability to limit fibroblast 
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migration by at least 50% upon addition of 100pg/ml rhMSF, as compared to the MSF 
baseline. 
The addition of 100pg/ml rhMSF should result in a minimal two fold increase in 
fibroblast migration, overall this failed to be achieved when tested with the fraction 
groups of the  HaCaT series fractionated CM. For each cell line, inhibitory activity was 
detected at varying degrees; the majority of fraction groups displaying MSF- inhibition 
although not necessarily reaching the set criteria of 50%. All BEN fraction groups failed 
to have an increase in migration upon addition of MSF but only groups 13, 16, 18, 21, 
23 met the strict criteria. MAL and MET inhibitory groups were 13, 15, 21, 22, 23 and 
17, 18, 19 respectively. (Figure 6.9). This does appear to suggest that if NGAL is solely 
responsible for the MSF inhibitory activity of the CM then it must be present within all 
the fractions implying that either the fractionation process has failed to separate the 
proteins or that NGAL has formed higher molecular weight complexes with other 
molecules. As previously stated NGAL has been described as having a molecular 
weight of 20-25kDa but is also known to form a 46kDa homodimer and a 135kDa 
disulfide linked heterodimer with neutrophil gelatinase. If NGAL has made these 
associations then the results would imply that NGAL still retains its ability to inhibit 
MSF when complexed. Another possibility is that NGAL has formed non-specific 
protein interactions as a consequence of storage conditions, pH and/ or salt 
concentration.  
Unlike the stimulatory activity detected when tested alone, there failed to be a common 
zone of similar molecular weight fractions possessing inhibitory activity. If the nature of 
the MSF bell shaped dose response bioactivity is taken into account  and presume that 
the inhibition displayed by fraction groups which  previously displayed motogenic 
activity when tested alone is actually due to the addition of 100pg/ml rhMSF causing a 
shift in bell- shaped response. Then, it does become apparent that “true” MSF- 
inhibitory activity may reside in the lower molecular weight fractions (<25kDa), with 
MAL and BEN having similar activity in fraction groups 21-23. However, BEN fraction 
group 23 had also displayed motogenic activity when tested alone. 
 
6.6iii     The Motogenic Activity of Recombinant MSF in the Presence of 
HaCaT Series Size- Exclusion Fractionated Conditioned Medium. 
 
This analysis enables the existence of any motogenic activity within the HaCaT series 
CM, which may mask the effect of any MSF-inhibitors also present, to be taken into 
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account.  The baseline is set for each individual fraction group when it is tested alone in 
the assay and MSF –inhibition is determined by a failure of migration to increase by 
50% upon addition of 100pg/ml rhMSF. However, to interpret this analysis the nature of 
MSF’s motogenic activity, which functions in a bell shaped dose-response, must be 
taken into account. That is, any inhibitory activity detected needed to be established as 
genuine and not accumulative effect of endogenous MSF and additional rhMSF causing 
the overall MSF concentration to shift to the level where it has an inhibitory effect. 
By comparison to the baseline levels, a number of the BEN fraction groups appeared to 
possess MSF-I activity; 13, 14, 16, 18, 23. However, when tested alone, stimulatory 
activity had previously been discovered in groups 13, 14, 16 and 23. Only fraction 
group 18 (MW approx. 50kDa) appeared to display a true inhibition of the rhMSF, as no 
stimulatory activity had previously been detected. Similarly, numerous MAL fraction 
groups displayed the ability to inhibit rhMSF (13-17, 21- 23) but once those groups that 
had previous stimulatory activity (13-21) were precluded only two appeared to have 
indisputable MSF-I activity- groups 22 and 23, with MW equivalent to approximately 
25kDa or less. The majority of the MET fraction groups (13-19) also exhibited varying 
levels MSF-I activity. After excluding the higher molecular weight fraction groups 13- 
15 because stimulatory activity was detected previously, only the MSF-I activity of 
groups 17-19 could be considered as genuine (MW approximately >60- 40kDa) (Figure 
6.10). 
In conclusion, these results appear to be ambiguous, as the MSF-I activity of the HaCaT 
series CM does not appear to be located in identical fraction group(s). The inability of 
the cell lines to share similar activities may of course be due to a concentration issue as 
the CM tested was not standardised and only one dilution was tested. However, overall 
there does appear to be a separation between the detected stimulatory and MSF-I 
activity by molecular weight, as the motogenic activity was detected predominantly in 
the higher molecular weight fraction groups (13-16), greater than 70kDa. While MSF-I 
bioactivity appeared to be located in the lower molecular weight fraction groups, but 
over a greater range (groups 17-23).  
Presuming that the two bioactivities detected in the HaCaT series total CM, motogenic 
and MSF-inhibition, were due to MSF and NGAL respectively then one would expect 
to locate them in the fractionated CM in two distinct molecular weight locations of 
approximately 70kDa and 25kDa. A possible explanation why this did not occur would 
be that the Superdex 75 column was overloaded with the 10x concentrated CM resulting 
in an inadequate separation. However, when the OD traces of the fractionated CM were 
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examined, it would appear that the protein concentrations were actually very low. 
(Figure 6.7). Another possibility would be that the NGAL present in the HaCaT series 
CM has formed higher molecular weight associations. Moreover, it may be a 
consequence of concentrating the CM to such a high degree (10 times) that non-specific 
associations have formed, possibly to the point of proteins precipitating out of solution. 
Plus, although repeated freeze/ thaw cycles were kept to a minimum, the impact that 
storage had on the integrity of the CM proteins cannot be overlooked. 
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b. BEN Fractionated CM only.
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c. MAL Fractionated CM only.
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d. MET Fractionated CM Only.
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Figure 6.8: The motogenic activity of Superdex 75 fractionated conditioned 
medium from HaCaT Series cells, comparison with rhMSF.   The fractionated 
conditioned medium (CM), fraction groups 13-23, from each cell line (BEN, MAL and MET) 
was tested, alone in the 3D collagen gel fibroblast migration assay.  The number of cells 
migrated is expressed as a percentage of the SF MEM control baseline migration i.e. SF MEM 
Baseline = 100 +/- 16.07%, as represented by hatched and dotted lines (mean and SD 
respectively). This was equivalent to 2.8 +/- 0.45 migrated cells. (100pg/ml rhMSF only = 8.6 
+/- 0.28 migrated cells). Dose response to rhMSF is shown for comparison. The results 
represent an average of two experiments. 
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a. Recombinant NGAL, Tested with 100pg/ml rhMSF.
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b. BEN Fractioned CM, Tested with 100pg/ml rhMSF.
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c. MAL Fractioned CM, Tested with 100pg/ml rhMSF.
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c. MET Fractioned CM, Tested with 100pg/ml rhMSF.
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Figure 6.9: The MSF-inhibitory activity of Superdex 75 fractionated conditioned 
medium from HaCaT Series cells, comparison with rhNGAL. The fractionated 
conditioned medium (CM), fraction groups 13-23, from each cell line (BEN, MAL and MET), 
was tested in the fibroblast migration assay in the presence of 100pg/ml rhMSF. The number of 
cells migrated is expressed as a percentage of the 100pg/ml rhMSF control baseline migration 
i.e. MSF Baseline = 100 +/- 3.26%, as represented by hatched and dotted lines (mean and SD 
respectively). This was equivalent to 8.6 +/- 0.28 migrated cells. Dose response to rhNGAL is 
shown for comparison. The results represent an average of two experiments. 
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a. BEN Fractionated CM, Tested with 100pg/ml rhMSF.
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b. MAL Fractionated CM, Tested with 100pg/ml rhMSF.
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c. MET Fractionated CM, Tested with 100pg/ml rhMSF.
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Figure 6.10. The motogenic activity of exogenous rhMSF in the presence of 
Superdex 75 fractionated conditioned medium. Fractionated conditioned medium (CM), 
fraction groups 13-23, from each cell line (BEN, MAL and MET) was tested in the fibroblast 
migration assay with and without the presence of 100pg/ml rhMSF.  The number of cells 
migrated is expressed as a percentage of the CM only baseline migration at each individual 
dilution point. i.e. ¼ dilution CM only = 100%, as represented by hatched line. Fraction groups 
which lacked motogenic activity when previously tested alone are identified by a star (*). The 
results represent an average of two experiments. 
 
 
6.7 THE IDENTIFICATION OF NGAL IN THE HACAT SERIES  
SIZE- EXCLUSION FRACTIONATED CONDITIONED MEDIUM. 
 
A colorimetric indirect ELISA with specific anti-NGAL antibody was performed in 
order to detect the presence of NGAL in the fractionated HaCaT series CM. Adopting 
the method as previously described in Materials & Methods, Chapter 2. For each cell 
line 100 l of every fraction group, 13-23, were tested neat in duplicate wells; two 
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separate Superdex 75 runs were analysed. SF MEM and coating buffer were used as 
negative controls.  
The results were assessed in a qualitative manner, to give a yes or no answer as to 
whether NGAL was present in each fraction group, as it was unfeasible to directly 
compare the ELISA results for each cell line. A quantitative analysis was not 
appropriate as firstly, the CM which was fractioned was un-standardised either by 
protein concentration or per cell number. Secondly, the effects of storage and 
concentrating the CM before fractionation, as discussed previously, must be taken in 
account as protein may have been lost due to precipitation and this would not be 
reflected in the ELISA results. Also, there was a very limited amount of sample 
available to test and unfortunately dilutions of the positive fraction groups were unable 
to be performed in order to bring them in line with the range of the rhNGAL standard 
curve. 
A fraction was considered to be positive for the presence of NGAL if the final OD 
reading (minus blanks) was 0.1 or above; comparing to a standard curve of rhNGAL 
this is equivalent to 25ng/ml (Figure 5.3). For BEN and MAL all fraction groups were 
positive for NGAL, with all final ODs well above the cut-off point. For the MET line all 
fraction groups were positive except the higher molecular weight (>70kDa) fraction 
groups 13-14. This result substantiated the reasoning why a clear zone of NGAL 
inhibitory activity was not detected in the 3D collagen gel migration assays; that is 
NGAL was present at a bioactive concentration in the majority of the fraction groups. 
(Figure 6.11). 
Observation of the OD readings measured in the MET fraction groups noted that NGAL 
is present predominately at the lower molecular weight (<25kDa) range. This is also 
true for BEN CM too. However, a similar OD reading was measured for all MAL 
fraction groups. As previously discussed, this was a qualitative assessment so limited 
conclusions can be drawn from these observations. 
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b. MAL Superdex 75 Fractionated CM
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c. METSuperdex Fractionated CM
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Figure 6.11: The NGAL Indirect ELISA analysis of Superdex 75 fractionated 
conditioned medium. Non- standardised fractionated conditioned medium (CM), fraction 
groups 13-23, from each cell line (BEN, MAL and MET) was analysed for the presence of 
NGAL by the indirect ELISA method. The average final OD (minus blanks), from two 
individual Superdex runs, is displayed for each fraction group. A fraction group was defined as 
positive for NGAL if final OD equalled 0.1 or above. 
 
 
6.8 THE IDENTIFICATION OF MSF IN THE HaCaT SERIES  
SIZE-EXCLUSION FRACTIONATED CONDITIONED MEDIUM. 
 
Numerous bioactivity experiments have shown that CM collected from each cell line of 
the HaCaT series possesses a degree of motogenic activity. The ability to stimulate 
fibroblast migration in the 3D collagen gel assay was first noted in dilutions of total CM 
and subsequently in the high molecular weight fractions of the SEC fractionated CM. 
Immunolocalisation experiments using specific anti-MSF antibodies revealed that the 
HaCaT series cell lines all express MSF, at varying extents. However,  difficulty arises 
when trying to prove that endogenous MSF is responsible for the stimulatory activity 
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detected in the CM, as both ELISA and immunoblot analysis of total CM (including 
concentrated CM) using specific anti-MSF antibodies failed to give a positive result. 
Since any MSF present in the total CM is below the detection limits of the ELISA and 
immunoblot assays it would be futile to try to analyse the fractionated CM by these 
methods. Instead, the technique of immunopreciptation with Protein G using MSF- 
specific identification antibody, RpVSI, was selected in order to prove that endogenous 
MSF was responsible for the motogenic bioactivity detected in HaCaT series CM. The 
process involves the binding of MSF, present in the fractionated CM, to a specific anti-
MSF antibody, thereby removing it from solution, after which it could be eluted and 
tested for bioactivity in the 3D collagen gel assay. If the bound elutions possess 
stimulatory bioactivity then it was concluded that MSF is responsible as the rabbit 
polyclonal VSI antibody only recognises the MSF-unique carboxyl terminal 
decapeptide and then consequently the HaCaT series cell lines secrete bioactive MSF 
into their CM. 
Analysis of size exclusion fractionated CM consistently located motogenic bioactivity 
to similarly high molecular weight fractions (F37-48 for BEN, F37-63 for MAL and 
F37-45 for MET). Hence, for each cell line fractions 30-50, equivalent to molecular 
weight of 60kDa and greater, were selected and pooled from two separate SEC runs. 
Following dialysis against distilled water the pooled fractions were concentrated 100 
times by freeze drying (sample now referred to as F-msa; fractions displaying migration 
stimulating activity). 1ml of F-msa, from each cell line, was then incubated with the 
rabbit polyclonal RpVSI antibody followed by immunoprecipation as described in 
Materials & Methods, Chapter 2. The original pooled fractions, 100x concentrated F-
msa sample, unbound material and the elutions of bound material were tested for 
migration stimulating activity in the 3D collagen gel assay. Where possible each test 
sample was analysed in duplicate at a range of dilutions. The same criteria used in 
previous bioactivity experiments to detect motogenic activity was adopted; stimulatory 
activity was defined as an increase in migration of at least 50% when compared to the 
SF control baseline.  
Testing of the pooled fractions 30-50, the original sample, showed as expected, for each 
cell line, the ability to stimulate fibroblast migration, although at different potencies. 
(Figure 6.12). The MET appear to have maximal activity at the highest dilution whilst 
the MAL had a borderline stimulation as poor replicates gave a high standard deviation. 
After dialysis and 100x concentration, sample F-msa, each cell line retains stimulatory 
activity although peak activity was located in the BEN sample. After concentration the 
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MET appeared to loose bioactivity, maybe as a consequence of the concentration 
process whereby protein fails to return to solution or possibly MSF has been 
concentrated to such an extent that it was present at the levels which does not stimulate 
migration. 
It would appear that any MSF present in the F-msa sample for the BEN and MET bound 
to the RpVSI antibody and allowing it to be eluted from the solution; since the unbound 
elution demonstrated a complete lack of motogenic activity. The MAL unbound elution, 
however, did exhibit a borderline stimulatory activity which may mean the presence of a 
motogen other than MSF or that the F-msa sample had  too high a concentration of  
MSF for it all to be successfully bound and removed from solution.  
For each cell line the bound material was eluted five times and each was tested for 
motogenic activity. For BEN the first two elutions caused an increase in migration of 
nearly 3 and 4 times that of the SF baseline levels, although high standard deviations 
highlighted poor reproducibility. All five MET elutions displayed a distinct motogenic 
activity, peaking in elution 3, with 4 times the baseline level of migration. The first 
MAL elute failed to stimulate migration however the four subsequent elutions did, 
peaking with elution 5. 
These results are palpable evidence that each member of the HaCaT series cell lines, 
BEN, MAL and MET, express MSF and that it is responsible for the motogenic activity 
detected in their CM. As the RpVSI antibody used for the immunopreciptation only 
recognises the MSF-unique carboxyl terminal decapeptide. However, in order to further 
substantiate that MSF was responsible for the motogenic activity detected in the bound 
elutions they were tested with NGAL and PEPQ1.1 antibody in the 3D collagen gel 
assay. As previously discussed, both NGAL and the IGD function neutralising antibody, 
PEPQ1.1, are potent inhibitors of MSF bioactivity. 10ng/ml rhNGAL can inhibit up to 
500pg/ml rhMSF, while 1/80 dilution of PEP1.1 antibody has the potential to reduce the 
bioactivity of up to 1ng/ml rhMSF back to SF baseline levels. As the MSF 
concentration within the samples was unknown, the inhibitors were added in excess in 
order to try and completely eliminate any bioactivity. The criteria set for the inhibition 
of motogenic activity was a reduction in migration by at least 50% compared to the 
baseline level. (Bound elutions were pooled in some instances due a shortage material). 
The findings verified that the migration stimulating activity detected in the CM of the 
keratinocyte cell lines BEN, MAL and MET was due to MSF. (Figure 6.13) In all cases 
the motogenic activity of the bound elutions was inhibited by the addition of MSF 
inhibitors NGAL and PEPQ1.1 antibody. It is of interest to note that the level of 
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inhibition by NGAL and PEPQ 1.1 antibody sometimes varied. For example, 100pg/ml 
rhMSF was inhibited to a similar extent by the NGAL and PEPQ1.1, by 70.5% and 
67.2% respectively. However, the inhibition of BEN F-msa bound elutions 1+2 was 
59.6% by NGAL but 75.1% by PEPQ1.1 a difference of 15.5%.  While MET F-msa 
Bound elute 5 had its stimulatory activity inhibited by 85.2% by NGAL but only 68.5% 
by PEPQ, a difference of 16.7%. This variation is difficult to explain as all samples 
were treated in the same manner, plus both NGAL and PEPQ1.1 were used at excess to 
try and eliminate all motogenic activity. There is also no consistency in either NGAL or 
PEPQ having a greater inhibitory effect on the samples. This may imply the presence of 
another motogen but this seems highly unlikely since the samples are the result of 
immunopreciptation for MSF using a specific anti-MSF antibody, which only 
recognises MSF’s unique carboxyl-terminal decapeptide.  
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Figure 6.12: The motogenic activity of the HaCaT Series SEC Fractionated CM 
before and after Immunopreciptation with MSF-specific identification antibody 
RpVSI. For each cell line the motogenic SEC fractions F30-50, molecular weight equivalent to 
greater than 60kDa, were pooled (original) and then concentrated 100x by freeze drying (100x 
F-msa). After which, immunopreciptation with the RpVSI MSF identification antibody was 
performed; unbound and five bound elutions were collected. All variables were tested alone in 
the 3D collagen gel fibroblast migration assay at a final dilution of 1/80 (unless otherwise 
stated). The number of cells migrated is expressed as a percentage of the SF MEM control 
baseline migration i.e. SF MEM Baseline = 100 +/- 17.50 represented by hatched and dotted 
lines (mean and SD respectively). This was equivalent to 2.0 +/- 0.35 migrated cells. (100pg/ml 
rhMSF only = 8.2 +/- 0.78 migrated cells).  
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Figure 6.13: The effect of MSF-Inhibitors, NGAL and function neutralising 
antibody PEPQ1.1, on the endogenous motogenic bioactivity of HaCaT series 
Fractionated CM post Immunopreciptation. For each cell line immunopreciptation for 
MSF, using the MSF specific identification antibody RpVSI, was performed on the SEC 
fractionated CM, F30-50. The motogenic active bound elutions were then tested with both 
10ng/ml rhNGAL and 50ng/ml PEPQ1.1 antibody in the 3D collagen gel fibroblast migration 
assay, at a final dilution of 1/80 (unless otherwise stated). The number of cells migrated is 
expressed as a percentage of the variable only baseline migration i.e. Bound Elution 2 only = 
100%. The effect of rhNGAL and PEPQ1.1 antibody on 100pg/ml rhMSF is shown for 
comparison. (100pg/ml rhMSF only = 8.4 +/- 0.85). 
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6.9      THE SDS POLYACRLAMIDE GEL ELECTROPHORESIS 
OF HaCaT SERIES CONDITIONED MEDIUM.  
 
As SEC fractionation failed to conclusively show that the two bioactivities, of 
motogenicity and MSF-inhibition, detected in the total CM of the HaCaT series could 
be separated into two distinct entities another approach was required. Complications 
had arisen with SEC fractionation with NGAL detected in the majority of fractions, 
possibly due to the formation of high molecular weight associations. By choosing to 
fractionate the CM by SDS PAGE electrophoresis under reducing conditions it was 
hoped that this artefact could be eliminated. By heating the CM briefly with the 
reducing agent 2 -mercaptoethanol the proteins present  were denatured by reducing 
disulfide linkages and then subsequently separated by their electrophoretic mobility, 
which due to the binding of SDS causes an identical charge per unit mass;  therefore 
ultimately separating the proteins by their size. 
Equal volumes of Laemmli loading buffer and 10x Amicon concentrated CM were 
loaded onto a pre-run 12% separating 5% stacking SDS polyacrylamide gel. Following 
electrophoresis each lane was cut into 12 segments, from high to low molecular weight 
(S1-12), and the proteins were eluted from the gel by an overnight incubation in 1ml of 
elution buffer. (Materials & Methods, Chapter 2). After which the bioactivity of each 
gel elution was determined by testing, at a final dilution of 1/1000, in the 3D collagen 
gel assay with and without the presence of 100pg/ml rhMSF. 
 
 
6.10 THE ASSESSMENT OF THE BIOACTIVITY OF  
SDS ELECTROPHOESIS FRACTIONATED HACAT SERIES 
CONDITIONED MEDIUM 
 
6.10i The Motogenic Activity of SDS Electrophoresis Fractionated  
HaCaT Series Conditioned Medium 
 
For each cell line, in order to determine the presence of motogenic activity the proteins 
eluted from each gel segment were tested alone in the 3D collagen gel fibroblast 
migration assay. A gel elution was considered motogenic if it caused fibroblast 
migration to increase by 50% above the baseline level set by the SF MEM control.  
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A similar pattern of activity was detected in the BEN and MAL experiments with a peak 
of motogenic activity in the higher molecular weight segments (BEN S1-2 and MAL 
S1-3) equivalent to 100kDa and above. Activity was also located in lowest molecular 
weight gel elutions; BEN S10 and MAL S10and 12. However, motogenic activity was 
discovered in practically all the MET elutions, with only S11 not showing any 
stimulatory activity. Also, the level of activity of the MET elutions were considerably 
greater than the BEN and MAL with peak levels being equivalent to or more than that 
measured for 500pg/ml of rhMSF. The peak areas of activity appear to be located at the 
higher and lower molecular weight segments. (Figure 6.14). 
 
6.10ii The MSF- Inhibitory Activity of SDS Electrophoresis Fractionated  
HaCaT Series Conditioned Medium 
 
In order to determine which gel elutions contained proteins with the ability to inhibit 
MSF bioactivity, the eluted proteins were tested in the 3D collagen gel assay in the 
presence of 100pg/ml rhMSF. The addition of 100pg/ml rhMSF should cause migration 
to be stimulated by a minimum of 50% therefore a gel elution was determined as 
possessing inhibitory activity if migration failed to increase by this amount.  
For BEN and MAL, a clear result was obtained with peak inhibitory activity of 60% and 
67% respectively , located in S6 which corresponds to a molecular weight of 20-25kDa. 
Immunoblotting of HaCaT series CM with a specific antibody for NGAL identifies a 
positive band at this molecular weight, suggesting that NGAL is responsible for the 
inhibitory bioactivity. Other BEN segments showed potential inhibitory activity but 
failed to reach the set criteria; namely S7-9 with approximately 42% inhibition. For the 
MAL the only other area displaying inhibitory activity was S1, molecular weight 
>100kDa; inhibiting the motogenic activity of 100pg/ml MSF by 62%. This gel elution 
had previously shown borderline stimulatory activity when tested alone. Meanwhile, all 
gel segments of the MET CM failed to reach the criteria for MSF-inhibitory activity 
with maximal inhibition peaking at only 12% (S7). (Figure 6.15). 
 
6.10iii    The Motogenic Activity of Recombinant MSF in the Presence  
of  HaCaT Series SDS Electrophoresis Fractionated Conditioned Medium 
 
Comparison of the effect of the addition of 100pg/ml MSF to the baseline activity of 
each gel elution allows any endogenous stimulatory activity to be taken into account. As 
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inhibitory activity may actually be a consequence of the MSF bell shaped dose response 
bioactivity. Therefore, inhibitory activity was defined as the inability of baseline 
migration to be stimulated by 50%, upon addition of 100pg/ml rhMSF.  
When tested alone proteins eluted from BEN gel segments S1, S2 and S10 all displayed 
stimulatory activity. However, upon addition of exogenous rhMSF all these elutions 
exhibited inhibitory activity. A similar situation occurred with MET and MAL gel 
elutions which possess endogenous stimulatory activity but upon addition of rhMSF 
demonstrate MSF-inhibitory bioactivity. The dilemma is whether this MSF-inhibitory 
activity is actually due to the presence of an inhibitor or is it merely an effect of the 
MSF dose response, whereby the additional MSF has caused a shift into the higher 
concentrations (>500pg/ml) resulting in a reduction in migration. 
However, if the gel elutions with endogenous stimulatory activity are eliminated a 
clearer picture emerges. For the BEN and MAL CM a distinct MSF-inhibitory activity 
is located in S5 and S6 respectively, equivalent to molecular weight of 37-20kDa. 
Applying the same principles to the MET, then all gel elutions, except S11, would have 
to be removed from the analysis as all displayed endogenous stimulatory activity. While 
the MET S11, upon addition of rhMSF showed no MSF-inhibitory activity as migration 
increased by 2.8 fold. Subsequently, the conclusion would be that no MSF-inhibitory 
activity was detected in MET fractionated CM. 
But, by eliminating all gel elutions with endogenous stimulatory activity the 
presumption is that MSF is responsible for all the motogenic activity detected in the 
fractionated CM. This does seem somewhat unrealistic considering the array of proteins 
each cell line expresses, plus the stimulatory activity was detected in a whole range of 
molecular weights (>100 to <20kDa). It could also suggest that the amount of protein 
added to the gel was too great resulting in the inefficient separation. However, clear 
distinct bands were detected when duplicate gels were stained with Coomassie Blue and 
not just a streak of protein as would be expected with an overloaded lane. Biochemical 
characterisation of MSF has shown that it is a 70kDa protein, and that the potent 
motogenic activity of MSF is indistinguishable from its proteolytically generated 43kDa 
Gel-BD functional domain and 21kDa IGD tripepetide. This may explain why the 
motogenic activity is spread over such an array of molecular weights since no protease 
inhibitors were added to the CM.  
Also, if the nature of MSF’s bioactivity is taken into account; a bell shaped dose 
response whereby a threshold concentration is required to initiate cell migration and 
negative feedback mechanism at the higher concentration results in an inhibition of 
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migration. It can be seen that the addition of rhMSF to the MET gel segments which 
possessed maximal stimulatory activity of 3 to 5 times the SF baseline (S1, S2, S6, S7, 
S8 and S10) resulted in maximum inhibition back to the SF MEM control baseline 
level. Thereby suggesting the additional rhMSF had caused a major shift of the bell 
shaped dose response to the higher concentrations of MSF which result in a complete 
inhibition of cell migration. However, those gel elutions that displayed motogenic 
activity on a similar scale to the 100pg/ml rhMSF control (S3, S4 and S5) did exhibit 
inhibition upon addition of exogenous rhMSF but to a far lesser extent. The additional 
rhMSF must have resulted in just a “tipping” over of the bell shaped dose response. 
Finally those segments which displayed borderline or no stimulatory activity (S11, S12) 
were not inhibited by the exogenous rhMSF but migration was actually stimulated to the 
100pg/ml rhMSF control level, (Figure 6.16). 
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d. MET Fractionated CM.
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Figure 6.14: The motogenic activity of the gel elutions from the SDS 
Electrophoresis fractionation of HaCaT Series conditioned medium, comparison 
with rhMSF. After the SDS electrophoresis of CM and segmentation of the gel, the protein 
eluted from each segment (1-12) was tested alone in the 3D collagen gel fibroblast migration 
assay.  The number of cells migrated is expressed as a percentage of the SF MEM control 
baseline migration i.e. SF MEM Baseline = 100 +/- 16.07%, as represented by hatched and 
dotted lines (mean and SD respectively). This was equivalent to 2.8 +/- 0.45 migrated cells. 
(100pg/ml rhMSF only = 8.6 +/- 0.28 migrated cells). Dose response to rhMSF is shown for 
comparison. The results represent an average of two experiments. 
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b. BEN Fractionated CM, Tested with 100pg/ml MSF.
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c. MAL Fractionated CM, Tested with 100pg/ml MSF.
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d. MET Fractionated CM, Tested with 100pg/ml MSF.
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Figure 6.15: The MSF-inhibitory activity of gel elutions from the SDS 
Electrophoresis fractionation of HaCaT Series conditioned medium, comparison 
with rhNGAL. After the SDS electrophoresis of CM and segmentation of the gel, the protein 
eluted from each segment (1-12) was tested in the 3D collagen gel fibroblast migration assay in 
the presence of 100pg/ml rhMSF. The number of cells migrated is expressed as a percentage of 
the 100pg/ml rhMSF control baseline migration i.e. MSF Baseline = 100 +/- 3.26%, as 
represented by hatched and dotted lines (mean and SD respectively). This was equivalent to 8.6 
+/- 0.28 migrated cells. Dose response to rhNGAL is shown for comparison. The results 
represent an average of two experiments. 
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b. MAL Fractionated CM, Tested with 100pg/ml MSF.
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c. MET Fractionated CM, Tested with 100pg/ml MSF.
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Figure 6.16. The motogenic activity of exogenous rhMSF in the presence of gel 
elutions from the SDS Electrophoresis fractionation of HaCaT Series conditioned 
medium. After the SDS electrophoresis of CM and segmentation of the gel, the protein eluted 
from each segment (1-12) was tested in the 3D collagen gel fibroblast migration assay with and 
without the presence of 100pg/ml rhMSF.  The number of cells migrated is expressed as a 
percentage of the CM only baseline migration at each individual dilution point. i.e. ¼ dilution 
CM only = 100%, as represented by hatched line. Elutions which lacked motogenic activity 
when previously tested alone are identified by a star (*). The results represent an average of two 
experiments. 
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Table 6.5. Result Summary. The Bioactivity of Fractionated HaCaT Series Conditioned Medium. 
Conditioned medium (CM) collected from the HaCaT series cell lines BEN, MAL and MET, was fractionated by two methods of size exclusion chromatography 
(SEC) and SDS PAGE electrophoresis with subsequent fractions/ elutions tested in the  fibroblast migration assay with and without the presence of 100pg/ml 
rhMSF. Using 10x Amicon concentrated CM the fractionation conditions were as follows:  
1. SEC performed using Superdex 75 Hiload 26/60 column (GE Healthcare), multiple runs performed with fractions pooled together into groups of three (13-23) 
equivalent to MW >70kDa to 20kDa, and tested at final dilution of 1/20.  
2. Electrophoresis (12% separating, 5% stack SDS polyacrylamide gel) performed under reducing conditions; gel divided into 12 segments (>100kDa to >20kDa) 
and proteins eluted during an overnight incubation in 1ml elution buffer; elutions subsequently tested at a final dilution of 1/1000. By comparison to SF MEM or 
rhMSF baseline controls the nature of each cell line’s bioactivity was determined. 
 
Cell Line Fractionation          
Method 
Motogenic Activity 
Compared to SF MEM Baseline 
(Tested alone) 
MSF-I Activity 
Compared to MSF Baseline 
(Tested with 100pg/ml rhMSF) 
MSF-I Activity Only 
No endogenous motogenic activity. 
  
Fraction 
Group/ Elution 
Equivalent MW Fraction 
Group/ Elution 
Equivalent MW Fraction 
Group/ Elution 
Equivalent MW 
BEN 
SEC 
13, 14, 16 
23 
>70kDa 
Approx 20kDa 
13 
18 
21 
>70kDa 
Approx 50kDa 
>=25kDa 
18 
21 
Approx 50kDa 
>=25kDa 
SDS 
1, 2, 
10 
>=100kDa 
<20kDa 
6 25-20kDa 
 
6 25-20kDa 
 
        
MAL 
SEC 
13-21 >70-25kDa 13,15 
21, 22, 23 
>70kDa 
25-20kDa 
22, 23 25-20kDa 
SDS 
1, 2, 3 
10, 12 
>=100kDa 
<20kDa 
1 
6 
>100kDa 
25-20kDa 
 
6 25-20kDa 
 
        
MET 
SEC 
13, 14, 15 >70kDa 17, 18, 19 60-40kDa 
 
17, 18, 19 
 
60-40kDa 
 
SDS 
1-10, 12 >100kDa- 
<20kDa 
none ----- none ----- 
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6.11 DISCUSSION 
 
The in vitro model system of the HaCaT series keratinocyte cell lines offers the 
potential to investigate the different stages of tumour development and progression.  
The previous chapter described that, during tumour progression from the benign 
condition, malignancy and ultimately metastasis the relative expression of NGAL 
decreases whilst MSF increases. The next stage therefore, was to ascertain the effect an 
alteration in the co-expression levels of MSF and NGAL had on the bioactivity of the 
CM, when tested in the 3D collagen gel fibroblast migration assay. As shown with the 
CM of the normal HaCaT keratinocytes, the prospective motogenic bioactivity of the 
endogenous MSF is rendered functionally inactive by the co-secreted MSF inhibitor, 
NGAL. It could therefore be postulated that any modification to the balance of 
stimulator and inhibitor would be reflected in the bioactivity. Consequently it was of 
interest to discover whether the tumourigenic potential of the HaCaT series 
keratinocytes was mirrored by a reduction in the NGAL inhibition of MSF thereby 
resulting in increased motogenic activity. 
On testing the HaCaT series CM in the migration assay it was soon apparent that the 
bioactivity was indeed different to that of the normal HaCaT keratinocytes. Overall, the 
autogenous bioactivity of BEN, MAL and MET keratinocytes was motogenic; each 
possessing the ability to stimulate fibroblast migration by a minimum of 50% above 
baseline levels. For BEN and MAL the bioactivity exhibited a bell-shaped dose 
response similar to that of rhMSF; maximal stimulation of 2-2.5 times that SF MEM 
baseline at the 1/1000 dilution point, while the highest and lowest dilution points tested 
displayed none or minimal activity. However, MET motogenic activity was the most 
prevalent with maximal stimulation measured at the majority of dilution points tested 
(5/7). (Figure 6.1, Table 6.2) These results correlated with the immunolocalisation data 
whereby the highest intensity of MSF expression was identified in the MET, as 
compared to MAL and BEN. Indeed it would appear that if MSF was solely responsible 
for the increased motogenic activity of MET then, taking into account cell numbers per 
ml of CM, the MSF concentration in its CM must be ten times higher than BEN or 
MAL. 
By using known MSF inhibitors (NGAL and IGD function neutralising PEPQ1.1 
antibody) it was attempted to prove whether this motogenic bioactivity could be 
attributed to the presence of MSF within the CM. Certainly, a proportion of motogenic 
activity could be accredited to MSF, as there was a reduction in the level of CM 
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stimulated migration upon addition of the inhibitors, however it would appear that other 
active motogen(s) must be present in the CM (Figure 6.4 and 6.5, Table 6.1). Both 
inhibitors were added in excess compared to the expected MSF concentration, as 
estimated from the level of cell migration, but still failed to eliminate all activity 
(generally a 2-2.5 times increase in migration requires 100pg/ml rhMSF, while 10ng/ml 
NGAL and 1/80 dilution of PEPQ 1.1 antibody inhibits up to 500pg/ml and 1ng/ml of 
rhMSF respectively). Indeed, it could be  suggested that the criteria to determine an 
inhibition in bioactivity was set too high, at 50% reduction compared to CM only 
baseline level, and did not take into account the effect of other motogens present within 
the CM. But, even raising the criteria to requiring only a 30-40% reduction in migration 
would still not have resolved the issue that NGAL and PEPQ1.1 appear to have 
different inhibitory properties, with PEPQ1.1 being a more potent inhibitor than NGAL.  
The exact mechanism of action of NGAL inhibition of MSF is unknown, but there is 
evidence that direct binding of NGAL to MSF is not required. Pre-incubation 
experiments of fibroblasts with NGAL still resulted in the inhibition of rhMSF 
stimulated migration, suggesting that NGAL may act by blocking an MSF-activated 
signal transduction pathway or indirectly by inducing expression of an intermediate 
inhibitory molecule. (Jones et al., 2007). However, the PEPQ1.1 antibody was raised 
against the 21mer peptide containing the IGDQ sequence present in module 1-7 and has 
the ability to recognise both MSF and the proteolytically generated GBD. Hence, the 
increased inhibitory efficiency maybe due to the ability of PEPQ1.1 to inhibit both MSF 
and the GBD, the bioactivity of which is indistinguishable. Since biological assays were 
being performed with the CM, no protease inhibitors were added and subsequently any 
MSF present would be subject to proteolysis. 
Another point of consideration is the bioactivity characteristics of MSF, whereby a 
threshold concentration (1pg/ml) is required to initiate migration, while a negative 
feedback mechanism operates at high concentrations, above 500pg/ml, to inhibit 
migration. This complicates the issue when estimating the concentration of MSF present 
in CM, because if MSF was solely responsible for the peak motogenic activity (2-2.5 
fold increase compared to SF MEM baseline) this would mean that the concentration 
was either approximately 100pg/ml or 1ng/ml, when compared to similar levels of 
migration for the rhMSF dose response. While PEPQ1.1 can still inhibit 1ng/ml rhMSF, 
10ng/ml NGAL fails, instead causing an increase in migration (Figure 6.4a and 6.5a). A 
similar situation occurs with the 1/4 dilution of MET CM; unlike the other MET 
dilutions no motogenic activity is detected when tested alone, however the addition of 
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10ng/ml NGAL resulted in approximately 50% increased migration compared to the 
baseline whereas PEPQ1.1 antibody caused a slight decrease (Figure 6.1d, 6.4d and 
6.5d). This would imply that NGAL somehow “removes/ deactivates” the inhibitory 
effect of excess MSF into the realms of a concentration which stimulates migration. 
Since it appears that NGAL does not bind directly to MSF the mechanism of how 
NGAL achieves the “removal/ deactivation” of MSF remains a mystery.  
In order to determine whether MSF-I activity was present in the HaCaT series CM, each 
was tested in the migration assay with 100pg/ml rhMSF; which is known to stimulate 
baseline migration by a minimum of 50%. To assess the capacity of the CM to inhibit 
the rhMSF the level of migration was compared to both the rhMSF and CM baseline 
migration. BEN CM was the most effective MSF inhibitor with the majority of dilution 
points preventing any rhMSF stimulated migration. MAL CM followed with the MET 
having the least MSF-I activity (Table 6.2). Considering the ELISA data for the 
assessment of NGAL concentration in total CM these results confirm what was 
expected; NGAL concentration was discovered to be highest in the BEN and MAL CM, 
while MET CM had the lowest. However, it does not explain how the HaCaT series CM 
can stimulate migration but at the same time inhibit the bioactivity of exogenous MSF. 
Although there is proof that the cells express MSF and NGAL, a direct link of these 
proteins to CM bioactivity is required.  
In order to determine the origins of the motogenic and MSF-I bioactivity within the 
HaCaT series CM the route previously described for the HaCaT keratinocytes was 
followed; by fractionating the CM by molecular weight selection using both size 
exclusion chromatography (SEC) and SDS polyacrylamide gel electrophoresis under 
reducing conditions. 
Difficulties arose in trying to separate the two bioactivities into distinct entities. The 
process of concentrating the CM appeared to cause non-specific binding of proteins 
making SEC separation inefficient and some protein was lost due to precipitation, 
making any quantitative assessment meaningless. Also the inability to halt proteolysis 
of proteins within the CM, by the addition protease inhibitors, due to the biological 
assessment of bioactivity resulted in the production of bioactive breakdown products 
which made it difficult to identify a specific location/ molecular weight of protein 
responsible for each bioactivity. 
MSF-I bioactivity was discovered in a number of different SEC fractions with various 
molecular weights (Table 6.5). Subsequent ELISA analysis using NGAL- specific 
antibodies identified a bioactive level of NGAL in all BEN and MAL fractions, and the 
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majority of MET too. Although, the maximal concentrations of NGAL was 
predominantly localised to the lower MW fractions (<25kDa); especially seen in BEN 
and MET CM (Figure 6.11). NGAL can bind to itself and other proteins, it has been 
previously described as having a molecular weight of 20-25kDa, forming a 46kDa 
homodimer and a 135kDa disulfide linked heterodimer with neutrophil gelatinase. 
Therefore, when SDS polyacrylamide gel electrophoresis of the CM was performed 
under reducing conditions a clearer picture emerged with BEN and MAL MSF-I 
activity being localised to 20-25kDa, which was equivalent to a positive band when 
immunoblotting of the CM was performed using a specific anti-NGAL antibody. For 
the MET CM, the presence of NGAL was detected both by ELISA and immunoblotting 
at this MW, although MSF-I bioactivity was the lowest measured of all the cell lines.  
The localisation of motogenic activity in fractionated CM also proved challenging. If 
MSF was indeed responsible it would be bioactive at a molecular weight of 
approximately 70kDa and also in the form of its proteolytically generated breakdown 
products; 43kDa GBD and 21kDa IGD-containing peptide. SDS PAGE separation of 
the CM identified MET CM as possessing the greatest motogenic activity but like BEN 
and MAL it could not be localised to a specific MW, although the majority of 
bioactivity was focused in the highest and lowest molecular weight segments. SEC 
separation confirmed that the higher molecular weight fractions possessed the most 
bioactivity, although MAL appeared to have the largest amount.  
As previously revealed, the sensitivity limits of the ELISA and immunoblot to identify 
MSF are too low to give a positive result for HaCaT series CM. Consequently, using the 
higher molecular weight SEC fractions (>60kDa), immunopreciptation (IP) with 
immobilised Protein G was performed, using the specific MSF identification antibody, 
RpVSI, followed by confirmation of MSF bioactivity in the 3D collagen gel fibroblast 
migration assay. Motogenic activity was present in the bound fractions of BEN, MAL 
and MET, confirming that MSF is indeed present in the HaCaT series CM. It would be 
erroneous to comment on which cell line gave the highest motogenic activity since it 
would be impossible to estimate how much protein was lost due to precipitation during 
the concentration process required for sample preparation and the scarcity of sample did 
not allow for a total protein measurement. The presence of MSF was further 
substantiated, by testing the bound elutions with the known MSF inhibitors, NGAL and 
the IGD function neutralising PEPQ1.1 antibody. Using the inhibitors in excess, the 
motogenic activity of the IP bound samples of each cell line was inhibited confirming 
MSF was responsible for the bioactivity.  
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In conclusion, it has been verified that the HaCaT series keratinocytes (BEN, MAL and 
MET) secrete bioactive forms of both MSF and NGAL. However, unlike the normal 
HaCaT cell line, an alteration in the balance of these pro and anti- motogenic factors 
manifests itself by the CM having an inherent motogenic activity, although with BEN 
and MAL still retaining the capability to inhibit rhMSF. Considering the data from the 
ELISA analysis for NGAL (presented in Chapter 5), where NGAL is present at a higher 
concentration in BEN and MAL CM than in the normal HaCaT, this was an unexpected 
outcome.  
Comparing the bioactivity of BEN, MAL and MET CM with the parental HaCaT, 
where the production of NGAL appeared to obstruct the activity of endogenous MSF, 
there are two possible explanations as to why HaCaT series CM displays an inherent 
motogenic bioactivity. Firstly, the concentration of MSF must be far greater in the 
HaCaT series CM than in normal HaCaT CM to enable motogenic activity to prevail 
over NGAL MSF-I activity. This would be particularly relevant for the BEN and MAL 
as they had the highest levels of NGAL. However, the semi-quantitative evaluation of 
MSF immunolocalisation in the HaCaT series keratinocytes showed that MET had the 
highest intensity of MSF expression, borne out in also possessing the greatest 
motogenic bioactivity in their total CM. BEN cells cultured on plastic dishes, however 
had the least amount of MSF staining and highest NGAL concentration in the ELISA 
analysis but still exhibited an inherent motogenic activity similar to rhMSF, whilst 
retaining the capacity to inhibit rhMSF. Unfortunately the limit of detection of the MSF 
ELISA prevents a direct measurement of MSF concentration in the CM, making the 
migration assay as the only means of detecting the presence of MSF in the CM. As 
discussed earlier the characteristics of MSF bioactivity lead to complications in relating 
the level of migration to MSF concentration. It can also not be discounted that the CM 
contains other motogens, which are unaffected by the inhibitory actions of NGAL, and 
therefore contribute to the motogenic potential of the CM. Since the addition of MSF 
inhibitors, NGAL and PEPQ1.1 antibody, to the total CM failed to eliminate all 
motogenic activity. Possibly by performing MSF immunopreciptation on total CM 
instead of fractionated, MSF contribution to the motogenic activity of HaCaT series CM 
could be conclusively be determined. 
The second possible explanation is that the NGAL produced by the cells is only capable 
of inhibiting rhMSF but not the endogenously produced MSF. This suggests that the 
HaCaT series MSF is somehow different to the normal HaCaT keratinocyte produced 
MSF, making it NGAL resistant. Indeed, when recombinant NGAL was used in attempt 
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to knock-out the motogenic activity in the total CM, it proved to be less effective than 
the PEPQ1.1 antibody. However, MSF semi- purified from the HaCaT series CM 
(RpVSI immunopreciptation of motogenic SEC fractions) did appear to be similarly 
inhibited by NGAL and PEPQ1.1. This implies that other factors in the CM are 
affecting NGAL efficiency in inhibiting endogenous MSF thereby contributing to the 
HaCaT series motogenic activity.  
NGAL is known to have a protective role of MMP-9, safeguarding it from proteolytic 
degradation and is therefore involved in the remodelling of the extracellular matrix a 
precursor to neoplastic diffusion and metastatisation (Yan et al., 2001). Therefore, it is 
possible that the higher concentrations of NGAL expressed by BEN and MAL lead to 
increased migration because of its indirect influence on ECM degradation. NGAL’s 
association with MMP-9 has been linked to promoting breast, gastric and esophageal 
cancer tumourigenesis (Leng et al., 2009, Fernandez et al., 2005, Kubben et al., 2007, 
Zhang et al., 2007). However, many other studies (ovarian , pancreatic and colon) have 
described high levels of NGAL present in well- differentiated neoplasias but then 
almost negative in the high grade ones (Lim et al., 2007, Tong et al., 2008, Lee et al., 
2006). Lim et al., described increased NGAL expression in benign ovarian tumours 
compared to normal tissue, but was then reduced in invasive high-grade carcinomas. 
This reflects the situation of the HaCaT series, with BEN and MAL having higher levels 
of NGAL compared to the normal HaCaT while the metastatic line, MET, has lowest 
NGAL levels with very limited MSF-I activity, therefore resulting in the highest 
motogenic activity. This would be in agreement with the Lee et al., (2006) study 
involving the KM12SM colon cancer cell line, where an inverse correlation between 
NGAL expression and metastatic potential was described. 
Each cell line of the HaCaT series expresses different amounts of MSF and NGAL and 
it has been have shown that an alteration in balance of stimulator and inhibitor appears 
to directly influence the bioactivity of their CM. The results show that as the metastatic 
potential of the keratinocytes increased there was a relative increase in intensity of MSF 
immunolocalisation and motogenic bioactivity. While the expression level of NGAL 
was the lowest in the metastatic cells, peaking in the benign and malignant 
keratinocytes although exhibiting a restricted capacity to inhibit the motogenic 
bioactivity of endogenous MSF. Many questions still require answering and 
considerable further investigation is required to understand the relationship between the 
two proteins and their mechanism of interaction however, it has emerged that NGAL 
and MSF do indeed play a role in tumour growth and metastasis. Ultimately, the genetic 
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modification of NGAL and MSF expression levels and the subsequent use of 
experimental animal models would lead to a greater understanding of their importance 
in tumuoriogenesis and possible clinical relevance.  
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Chapter 7: Results 
 
THE IDENTIFICATION OF MSF-I PRODUCED BY ENDOTHELIAL CELLS 
 
7.1 AIMS 
 
The initial aim was to ascertain whether endothelial cells express MSF and NGAL.  
This was the first step in a process to determine whether  endothelial MSF was the 
source of the motogenic bioactivity present in the conditioned medium collected from 
sprouting endothelial cells and whether an endothelial NGAL was responsible for the 
MSF-I activity present in the conditioned medium of endothelial cells expressing the 
cobblestone phenotype. Consequently, these findings should help to establish if the 
phenotype of an endothelial cell can be defined by the expression of either MSF or a 
MSF-inhibitor. However, the situation may be similar to the keratinocyte HaCaT series 
where both MSF and the MSF-inhibitor NGAL are expressed, but at varying levels. 
An additional aim was to ascertain what effect NGAL and MSF have on the 
morphology of endothelial cells, specifically focusing on the consequence MSF 
inhibition has on endothelial sprouting cells.  
 
 
7.2 BACKGROUND 
 
Previous investigations revealed that the bioactivity of conditioned medium (CM) 
collected from endothelial cells in vitro was determined by endothelial phenotype. In 
vitro, endothelial cells retain the phenotypic plasticity observed in vivo. A reversible 
phenotypic conversion enables expression of two distinctive cell morphologies, 
described as cobblestone and sprouting, which are considered to be comparable to the 
resting and angiogenic endothelial cells observed in vivo (Schor et al., 1983). The CM 
collected from the sprouting endothelial cells exhibited an endogenous motogenic 
activity. Conversely, CM from the cobblestone phenotype had the ability to inhibit the 
motogenic activity of rhMSF in the 3D collagen gel fibroblast migration assay.  
A similar MSF- inhibitory bioactivity was discovered in the CM of the immortalised 
human keratinocyte cell line, HaCaT, and subsequently identified as Neutrophil 
Gelatinase Associated Lipocalin (NGAL). In addition, upon fractionation of the HaCaT 
252 
 
CM the existence of a previously obscured motogenic activity was discovered, which 
was identified as MSF. It therefore transpired that the HaCaT keratinocytes express 
MSF but its motogenic activity was inactivated by the co-expression of NGAL.  
Subsequent investigation of the HaCaT series cell lines, which represent the progressive 
stages of tumour development from benign, malignant to metastatic, showed that each 
cell line expressed a differing amount of MSF and NGAL and that the alteration in the 
balance of stimulator and inhibitor had a direct influence on the bioactivity of their CM. 
In both in vitro and in vivo models MSF and NGAL are reported to have opposing 
effects on angiogenesis. An in vitro application of rhMSF to an endothelial cobblestone 
monolayer, under serum free culture conditions, will induce a greater number of 
sprouting cells compared to a serum free only control (Schor and Schor, 2010). MSF 
also stimulates angiogenesis in vivo in the chicken yolk-sac membrane assay (Schor and 
Schor, 2010, unpublished observations). Meanwhile, NGAL significantly reduces the 
tube formation of HUVEC endothelial cells and over-expression of NGAL has been 
shown to mediate a reduction in angiogenesis in an orthotopic mouse model of 
pancreatic cancer and an intradermal tumour angiogenesis assay (Venekatesha et al., 
2006, Tong et al., 2008). 
The first line of investigation was therefore to determine whether MSF and NGAL were 
expressed by the cultured endothelial cells and whether there were phenotypic 
differences in expression. Since endothelial cell morphology appears to determine CM 
bioactivity, it will be interesting to discover if both factors are expressed together and 
whether the relative expression levels determine bioactivity and possibly morphology.  
 
7.3  THE IDENTIFICATION OF NGAL EXPRESSION IN  
ENDOTHELIAL CELL LINES 
 
7.3.i Western Blot Identification of NGAL  
 
To determine whether NGAL was present in endothelial cell conditioned medium (CM) 
the immunoblot method previously optimised for the HaCaT series study was 
performed using a specific anti-NGAL antibody, Mab1757 (Materials & Methods, 
Chapter 2). A variety of endothelial cell lines, of both human and bovine origin were 
cultured on a 2D surface of 0.1% (w/v) gelatin coated plastic cell cultures dishes and 
CM was collected when cells had reached confluence and displayed the cobblestone 
phenotype. In addition, CM was collected from ENDO 742 and BAEC cells plated 
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either on or within a 3D type I collagen matrix; the cells displaying a cobblestone and 
sprouting phenotype respectively. CM collected from a blank type I collagen gel (no 
cells) acted as a control. The CM was tested both neat and at various concentrations 
(Amicon method). A control sample of rhNGAL (300ng) was always included as a 
positive control. 
The unfractionated CM was separated by 12% SDS PAGE under reducing conditions, 
followed by immunoblotting with the anti-NGAL antibody (Chapter2, Materials & 
Methods).Visualisation by chemiluminescence identified a clear band of approximately 
20-25kDa in the rhNGAL control lane, however no positive bands was observed in the 
any of endothelial CM lanes. Irrespective of endothelial cell origin (human or bovine), 
cell phenotype (cobblestone or sprouting) or CM concentration (tested neat and 
maximum concentration x50) the result was consistently negative for the presence of 
NGAL. (Figure 7.1). 
The immunoblot experiments were repeated using a different anti-NGAL antibody, 
polyclonal AF1757. The results confirmed that either NGAL was not present in the 
endothelial CM or if present it was at a concentration below the sensitivity of the assay. 
 
 
 
 
 
254 
 
 
Figure 7.1.  
A. The Separation of endothelial conditioned medium by SDS PAGE. 
Endothelial CM collected from cultures displaying either cobblestone or sprouting phenotype 
was separated by 12% SDS PAGE under reducing conditions. Protein bands were visualised by 
Coomassie Blue. 
B. The identification of NGAL in endothelial cell lines by immunoblotting. 
Immunoblot of 12% SDS PAGE separation of endothelial cell CM, under reducing conditions, 
with specific anti-NGAL antibody, Mab1757. A distinct band was seen at 20-25kDa in the 
rhNGAL lane. No correspondingly sized bands were located in any of the endothelial CM. 
Diffuse bands were observed in Lanes 6 and 7 but were located at the wrong molecular weight 
and considered an artefact due to the high concentration of protein present in the sample; 
especially, since no bands were ever detected in un-concentrated or less concentrated CM. In 
conclusion, by this method, the endothelial CM of both bovine and human origin, whether 
displaying the cobblestone and sprouting phenotype were negative for NGAL. 
 
7.3.ii Immunolocalisation of NGAL in Endothelial Cell Lines  
 
In order to confirm the results achieved by the immunoblot experiments, 
immunolocalisation of NGAL in cultured endothelial cell lines was performed. 
Endothelial cell lines of both human and bovine origin were plated on either the surface 
25kDa► 
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37kDa► 
50kDa► 
75kDa► 
LANE 1 2 3 5 4 6 7 
25kDa► 
20kDa► 
Lane 1: Broad Range Ladder (BioRad) 
Lane 2: Recombinant NGAL, 300ng  
Lane 3: Blank Gel CM, neat 
Lane 4: Endo 742 Cobblestone CM, neat 
Lane 5: ENDO 742 Sprouting CM, neat 
Lane 6: BAEC Cobblestone CM,  
              20x concentrated 
Lane 7: BAEC Sprouting CM ,  
              20x concentrated 
A  
B  
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of a 2D 0.1% (w/v) gelatin coated plastic cell cultures dish or a 3D type I collagen 
matrix and also within a 3D type I collagen matrix; thereby insuring both endothelial 
phenotypes, cobblestone and sprouting, were screened.  
The method optimised for HaCaT experiments using the NGAL specific antibody, anti-
NGAL goat polyclonal AF1757, was adopted (Materials & Methods, Chapter 2). Each 
immunolocalisation experiment included an internal control of normal serum goat IgG, 
(used at same concentration as anti-NGAL antibody) and secondary antibody only 
(biotinylated polyclonal swine anti-goat IgG). In addition, known NGAL positive and 
negative cell lines HaCaT and FSF44, respectively, were included as an additional 
check. 
The results obtained corroborated those gained by immunoblot with all endothelial cell 
lines negative for the presence of NGAL, irrespective of species type, phenotype and 
plating matrix (Figure 7.2). 
 
 
Figure 7.2: Immunolocalisation of NGAL in endothelial cells. Endothelial cells of both 
human and bovine origin, ENDO 742 and BAEC respectively, were plated on and within a 3D 
collagen type I matrix. Thereby, insuring both endothelial phenotypes, cobblestone and 
sprouting, were exhibited. The presence of NGAL was assessed by immunocytochemistry using 
the specific anti-NGAL goat polyclonal AF1757 (0.5µg/ml); Image A. NGAL positive 
expression resulted in a brown colour staining. Control cultures were incubated with normal 
goat IgG at the same concentration as the NGAL specific antibody (0.5µg/ml); Image B.  
Images and observations were made at x20 magnification.   
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7.4  THE IDENTIFICATION OF MSF EXPRESSION  
 IN ENDOTHELIAL CELL LINES 
 
7.4.i Western Blot Identification of MSF 
 
In a repeat of the immunoblot performed to determine endothelial expression of NGAL, 
a variety of CM collected from various human and bovine endothelial cells were tested 
for the presence of MSF. As previously described, CM was collected from endothelial 
cells expressing either the cobblestone and sprouting endothelial cells, when cultured on 
a 2D (0.1% (w/v) gelatin coated plastic) and on or within a 3D matrix (type I collagen 
gel).  
The un-fractionated CM was separated by 12% SDS PAGE under reducing conditions 
followed by immunoblotting with a specific anti-MSF antibody, RpVSI (Materials & 
Methods, Chapter 2). A control sample of rhMSF (250pg) consistently resulted in a 
main band of approximately 77kDa on the immunoblot. However, no bands were 
observed in any of the lanes containing the variety of endothelial CM tested. A selection 
of concentrated endothelial CM (maximum concentration x50) was tested but all 
yielded a negative result. (Figure 7.3). 
 
 
Figure 7.3. The identification of MSF in endothelial cell lines by immunoblotting. 
Immunoblot of 12% SDS PAGE separation of endothelial cell CM, under reducing conditions, 
with specific anti-MSF antibody, RpVSI. A distinct band was seen at approximately 75-80kDa 
in the rhMSF lane, however all endothelial CM tested was negative.  
1 2 3 4 5 
Lane 1: Broad Range Ladder (BioRad) 
 
Lane 2: Recombinant MSF, 25ng 
 
Lane 3: Blank Gel Cm,  
             10x concentrated 
 
Lane 4: ENDO 742 Cobblestone,  
             10x concentrated 
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7.4.ii Immunolocalisation of MSF in Endothelial Cell Lines 
 
In a direct repeat of experiments performed for the NGAL immunolocalisation in 
endothelial cell lines the same set of samples were screened for the presence of MSF. A 
rabbit polyclonal anti-VSI antibody (Rp2), raised against the MSF unique carboxyl 
terminal decapeptide was employed for MSF identification. Two negative controls were 
included in every experiment; the secondary antibody (biotinylated goat anti-rabbit IgG) 
tested alone and normal rabbit IgG used at the same concentration as the anti-VSI 
antibody (Materials & Methods, Chapter 2). In addition the FSF44 and HaCaT cell lines 
were included as internal controls since they had previously been shown to be MSF 
negative and positive, respectively.  
In contrast to the MSF immunoblot results, both bovine (BAEC Clone 2 and Clone 2-2 
U7) and human (ENDO 742, HUVEC) cell lines were shown to express MSF. 
However, MSF expression appeared to be dependent upon the endothelial phenotype. In 
the majority of experiments (4/5), endothelial cells (BAEC, HUVEC and ENDO 742) 
plated on a 2D surface (0.1% (w/v) gelatin coated plastic) and displaying the 
cobblestone phenotype were negative for MSF. Yet, when the same cells were cultured 
to post-confluence, forming sprouting networks, the highest intensity of MSF positive 
staining appeared to be specifically localised to the sprouting cells whilst areas of 
cobblestone remained negative or very weak positive.  
The phenotypic-specific expression of MSF was also seen when the endothelial cells 
(BAEC, ENDO 742, HUVEC) were plated either on the surface of or within a 3D 
collagen type I matrix. Endothelial cells plated within a 3D matrix spontaneously adopt 
a sprouting phenotype which, in time, develop into sprouting networks however when 
endothelial cells are plated on a gel surface they form a typical cobblestone appearance. 
Again, the sprouts consistently stained positive with intensity ranging from weak to 
strong, whereas the cobblestone endothelial cells were either completely negative or 
very weakly positive. However, in a minority of cases (2/7 experiments) a few strong 
positive cells were noted on the gel surface. From the observations of these MSF 
positive cells it would appear that they did not have a free apical surface but were in fact 
plated underneath other endothelial cells. As seen in the HaCaT series study, the 
background staining of the type I collagen gel pellet was itself scoring (weakly) 
positive. (Figure 7.4). 
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These results seem to imply that MSF expression in endothelial cells is dependent on 
the loss of apical-basal polarity, irrespective of whether that is achieved by plating the 
cells within a 3D environment or cells growing beneath a cobblestone monolayer. 
However, the discovery of positive MSF expression is at odds with the immunoblot 
results where both cobblestone and sprouting CM were MSF negative. As previously 
discussed for the HaCaT CM immunoblot experiments to identify MSF; the conclusion 
was that endothelial cells do express MSF but that it must be present in the CM at 
concentrations below the limits of sensitivity of the immunoblot assay (25ng/ml). 
 
 
 
Figure 7.4: Immunolocalisation of MSF in endothelial cells. Endothelial cells of both 
human and bovine origin, ENDO 742 and BAEC respectively, were plated on and within a 3D 
collagen type I matrix. Thereby, ensuring both endothelial phenotypes, cobblestone and 
sprouting, were exhibited. The presence of MSF was assessed by immunocytochemistry using 
the specific anti-MSF antibody, Rp2 (5µg/ml); Image A. MSF positive expression resulted in a 
brown colour staining. Control cultures were incubated with normal rabbit IgG at the same 
concentration as the MSF specific antibody (5µg/ml); Image B.  Images and observations were 
made at x20 magnification. 
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7.5 THE CHARACTERISATION OF ENDOTHELIAL  
ENDOGENOUS MOTOGENIC BIOACTIVITY. 
 
During the initial screening, the bioactivity of endothelial conditioned medium was 
assessed by testing in the 3D collagen gel fibroblast migration assay. Bioactivity was 
discovered to be phenotype dependent; cobblestone CM possessed the ability to inhibit 
rhMSF stimulated fibroblast migration whilst it emerged that the sprouting CM had 
endogenous motogenic activity. Immunolocalisation experiments have detected MSF in 
sprouting endothelial cells, however immunoblot analysis of endothelial CM failed to 
identify any MSF present. Consequentially by characterising the endothelial CM 
motogenic bioactivity it should be possible to determine whether an endothelial 
expressed MSF is indeed responsible for this motogenic bioactivity. 
Taking direction from the HaCaT study, endothelial CM was fractionated and the 
subsequent fractions tested for bioactivity in the 3D collagen gel fibroblast migration 
assay. The motogenic active fractions were then characterised by testing with known 
MSF inhibitors, NGAL and PEPQ 1.1. If endothelial MSF was present then all 
motogenic activity would be neutralised by addition of the MSF-inhibitors. Two 
methods of fractionation were adopted, size exclusion chromatography and SDS 
electrophoresis. Although both methods separate proteins according to their molecular 
weight by performing the SDS PAGE under reducing conditions some higher molecular 
weight associations between proteins would be eliminated. Thereby, diminishing the 
possibility of concealment of bioactivity due to associations between proteins; a 
possible result of an artefact of the CM collection and concentration process. 
In order to ensure that the CM was collected from a specific phenotype of endothelial 
cells CM was collected from ENDO 742 cells plated either within or upon a type I 
collagen gel; sprouting and cobblestone phenotype respectively. Although motogenic 
activity was only detected in the sprouting CM, the cobblestone CM was also 
fractionated since, as seen with the HaCaT study, motogenic activity may be undetected 
in the total CM due to inactivation by a co-secreted inhibitor. CM collected from a 
blank collagen gel was used as a control. For ease of discussion, the CM was classified 
as Blank (gel only no cells), Sprouting (ENDO 742 plated within gel exhibiting 
spontaneous sprout phenotype) and Cobblestone (ENDO 742 plated upon a gel 
exhibiting cobblestone phenotype). 
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7.5i The Motogenic Activity of  Size- Exclusion Fractionated ENDO 742  
 Conditioned Medium. 
 
As previously used for the HaCaT study, the Superdex 75 HiLoad 26/60 (GE 
Healthcare) column, which has a fractionation range of 3-70kDa, was used to 
fractionate 4ml of ten times Amicon concentrated CM (Materials & Methods, Chapter 
2). Multiple runs were completed in order to provide sufficient material for downstream 
analysis. For each individual run 100 x 3ml fractions were collected (2ml/min) and 
numbered 1 to 100; the corresponding fractions from the duplicate runs were then 
pooled together. Subsequently the fractions were pooled into groups of three; Groups 1 
to 33.  Groups 11 to 23 (fractions 31-69), equivalent to the main absorbance peak with a 
molecular weight range of approximately >70kDa to 20kDa were selected for analysis. 
The SEC fractionated CM of each variable (sprout, cobblestone and blank) was tested 
alone in the 3D collagen gel fibroblast migration assay in order to determine the 
presence of motogenic activity. Fraction groups 11 to 23 were tested at a final dilution 
of 1/20 (all dilutions made with SF MEM). Each fraction group was considered as 
motogenic if fibroblast migration was stimulated by at least 50% when compared to SF 
MEM control baseline levels (100 +/- 12.22%).  
As expected, the Blank CM displayed a complete absence of motogenic activity in all 
fraction groups tested (11-23) with migration levels comparable to the SF MEM 
baseline. For both Cobblestone and Sprout CM motogenic activity was located within 
the higher molecular weight fraction groups (>70kDa). (Figure 7.5b).  
The fraction groups 11-14 of the Cobblestone CM had an average migration of 183.0 
+/- 32.16% compared to the SF MEM baseline migration. Maximum migration of twice 
baseline level was achieved by fraction groups 13 and 14. Group 15 displayed 
motogenic activity but results were inconsistent between experiments resulting in a high 
standard deviation. Lower molecular weight fraction groups exhibited no motogenic 
activity which met the criteria of 50% above SF MEM baseline. (Figure 7.5c). The 
discovery of motogenic activity is at odds with the result achieved from the 
unfractionated CM collected from cobblestone endothelial cells where no motogenic 
activity was measured. However, it is similar to the masked motogenic activity, 
attributed to MSF, present in total HaCaT CM. 
The motogenic activity of the Sprout CM was located in fraction groups 11-15 with an 
average migration of 212.7 +/- 24.59% compared to SF MEM baseline. Overall, the 
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level of migration was greater than that of the Cobblestone CM, peaking at 2.4 times SF 
MEM baseline in Fraction group 12. No motogenic activity was detected in the lower 
molecular weight fraction groups. (Figure 7.5d). 
 
7.5ii The Effect of MSF-Inhibitors on the ENDO742 Motogenic SEC 
 Fractionated Conditioned Medium. 
 
The motogenic active SEC fractions of each ENDO 742 CM type were pooled together 
(Cobblestone CM fraction groups 11-14 and Sprout CM fraction groups 11-15). 
Dilutions 1/20 to 1/1000 were made with SF MEM and then tested alone in the 3D 
collagen gel fibroblast migration assay.  
A similar level of motogenic activity was measured in pooled samples as compared to 
those previously found in the individual fraction groups for both the Cobblestone and 
Sprout CM. For both CM types, maximum motogenic activity was present in the 1/200 
dilution; 213.9 +/- 39.17 and 210.0 +/-31.43 for Cobblestone and Sprout CM 
respectively. The dilutions 1/400 and 1/1000, for both CM types, failed to increase 
migration by 50% above the SF MEM baseline. Overall, the motogenic activity 
appeared to adopt a bell-shaped dose response with the lowest and highest dilutions 
displaying less activity than the mid-range dilution which possessed maximal activity 
(Figure 7.6b and c). However, the activity is certainly not as distinct as compared to the 
dose response of rhMSF (Figure 7.6a). 
In order to determine whether this endogenous motogenic activity of the endothelial 
CM could be attributed to the expression of MSF, the pooled SEC fractions were tested 
in the presence of NGAL and the MSF function neutralising antibody, PEPQ 1.1. Both 
NGAL and the PEPQ 1.1 antibody possess the ability to inhibit MSF bioactivity back to 
baseline levels; but at different levels of potency. The maximum MSF concentration 
that 10ng/ml of NGAL can inhibit is 500pg/ml while a 50ng/ml of PEPQ 1.1 can inhibit 
up to 1ng/ml of MSF. The set criterion for NGAL and PEPQ1.1 inhibition was a 
reduction in baseline migration by at least 50%. The SEC fractions were again tested at 
a range of dilutions, 1/20 to 1/1000. 
In the two experiments performed, the effect of the MSF inhibitors on the endothelial 
SEC motogenic fractions was ambiguous. For the Cobblestone SEC motogenic 
fractions, the criteria for inhibition by NGAL was only achieved in dilutions 1/20 and 
1/40 (average 64.4 +/- 6.65% inhibition) and by PEPQ 1.1 in dilution 1/40 (53.5% 
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inhibition). The motogenic activity of the Sprout SEC fractions was only inhibited by 
PEPQ1.1 at the 1/20 dilution (51.4% inhibition) (Figure 7.7). 
However, if the dilution 1/200 which achieved maximal motogenic activity was 
analysed in isolation, the effect of the addition of NGAL and PEPQ 1.1 was similar for 
both Sprout and Cobblestone SEC fractions. Although the level of inhibition failed to 
reach the set criteria it was apparent that PEPQ 1.1 had nearly twice the inhibitory 
ability than NGAL: with an average 46.0 +/- 4.24% inhibition compared to 26.0 +/- 
2.83%, respectively. Overall, PEPQ 1.1 showed the greater ability to inhibit the 
motogenic activity than NGAL; particularly for the Sprout SEC fractions.  
From the analysis of the level of motogenic activity measured for both Cobblestone and 
Sprout CM, compared to a rhMSF dose response curve, both NGAL and PEPQ 1.1 were 
added in excess and should have neutralised all migration if MSF-induced migration. 
Since motogenic activity was inhibited to some degree, a plausible conclusion would be 
that MSF was present in both ENDO 742 Cobblestone and Sprout CM in addition to 
another motogen. However, the indeterminate results may also have arisen because the 
MSF inhibitors were not functioning efficiently possibly due to the formation of non-
specific protein associations; as an artefact of the sample preparation process. 
  
263 
 
 
a. Recombinant MSF.
0 1 10 10
0
50
0
10
00
10
,0
00
0
100
200
300
400
500
SF MEM
Baseline
rhMSF (pg/ml)
C
e
ll
s
 M
ig
ra
te
d
(%
 o
f 
 B
a
s
e
li
n
e
 M
ig
ra
ti
o
n
)
b. Blank Gel, Fractionated CM
11 12 13 14 15 16 17 18 19 20 21 22 23
0
100
200
300
SF MEM
Baseline
>70kDa <25kDa
Fraction Group
C
e
ll
s
 M
ig
ra
te
d
(%
 o
f 
 b
a
s
e
li
n
e
 m
ig
ra
ti
o
n
)
c. Cobblestone Transformed Human Endothelial,
ENDO 742, Fractionated CM.
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d. Sprouting Transformed Human Endothelial,
ENDO 742,  Fractionated CM.
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Figure 7.5: The motogenic activity of Superdex 75 fractionated conditioned 
medium from ENDO 742 cells. Comparison with rhMSF. Conditioned medium was 
collected from ENDO 742 cells grown either on or within a collagen gel matrix; thereby 
displaying either a cobblestone or sprouting phenotype respectively. As a control, conditioned 
medium was also collected from a blank collagen gel (no cells). The Superdex 75 fractionated 
conditioned medium (CM), fraction groups 11-23, was tested, alone in 3D collagen gel 
fibroblast migration assay. The number of cells migrated is expressed as a percentage of SF 
MEM control baseline migration i.e. SF MEM Baseline = 100 +/- 12.22%, as represented by the 
hatched and dotted lines (mean and SD respectively). This was equivalent to 2.7 +/- 0.33 
migrated cells. (100pg/ml rhMSF only = 7.8 +/- 0.32 migrated cells). Dose response to rhMSF 
is shown for comparison. The results represent an average of two experiments.       
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b. Cobblestone Transformed Human Endothelial,
ENDO 742, Fractionated CM.
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c. Sprouting Transformed Human Endothelial,
ENDO 742, Fractionated CM.
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Figure 7.6: The motogenic bioactivity of Superdex 75 fractionated ENDO 742 
conditioned medium. Comparison with rhMSF. Conditioned medium was collected 
from ENDO 742 cells grown either on or within a collagen gel matrix; thereby displaying either 
a cobblestone or sprouting phenotype respectively. The Superdex 75 fractionated conditioned 
medium (CM), fraction groups 11-23, was previously tested, alone in 3D collagen gel fibroblast 
migration assay. For cobblestone and sprouting CM fraction groups 11-14 and 11-15, 
respectively were shown to possess motogenic activity. Following pooling, the motogenic 
fraction groups were then tested alone in the 3D collagen gel fibroblast migration assay, at a 
range of dilutions. The number of cells migrated is expressed as a percentage of SF MEM 
control baseline migration i.e. SF MEM Baseline = 100 +/- 8.28%, as represented by the 
hatched and dotted lines (mean and SD respectively). This was equivalent to 3.5+/- 0.29 
migrated cells. (100pg/ml rhMSF only = 8.2 +/- 0.63 migrated cells). Dose response to rhMSF 
is shown for comparison. The results represent an average of two experiments.       
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b. Sprouting Transformed Human Endothelial,
ENDO 742, Fractionated CM.
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Figure 7.7: The effect of MSF-Inhibitors, NGAL and function neutralising 
antibody PEPQ1.1, on the endogenous motogenic bioactivity of Superdex 75 
fractionated ENDO 742 conditioned medium. Conditioned medium was collected from 
ENDO 742 cells grown either on or within a collagen gel matrix; thereby displaying either a 
cobblestone or sprouting phenotype respectively. The Superdex 75 fractionated conditioned 
medium (CM), fraction groups 11-23, was tested, alone in the 3D collagen gel fibroblast 
migration assay. For cobblestone and sprouting CM fraction groups 11-14 and 11-15, 
respectively were shown to possess motogenic activity. Following pooling the motogenic 
fraction groups were then tested with both 10ng/ml rhNGAL and 50ng/ml PEPQ1.1 antibody in 
the 3D collagen gel fibroblast migration assay, at a range of dilutions. The number of cells 
migrated is expressed as a percentage of the variable only baseline migration i.e. Cobblestone 
ENDO 742 groups 11-14 diluted 1/20 only = 100 +/- 16.47. The effect of rhNGAL and 
PEPQ1.1 antibody on 100pg/ml rhMSF is shown for comparison (100pg/ml rhMSF only = 8.4 
+/- 0.49).           
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7.5iii The Motogenic Ativity of SDS PAGE Fractionated  
 ENDO 742 Conditioned Medium 
 
The same ten times concentrated CM used for the SEC fractionation (ENDO 742 
Cobblestone and Sprout plus Blank CM) was fractionated by SDS PAGE under 
reducing conditions. Equal volumes of the 10x Amicon concentrated CM and Laemmli 
loading buffer, containing the reducing agent 2 -mercaptoethanol, was heated for five 
minutes thereby denaturing the proteins present by reducing the disulfide linkages. The 
samples were then loaded onto a pre-run 12% separating 5% stacking SDS 
polyacrylamide gel. Following electrophoresis each lane was cut into 12 segments, from 
high to low molecular weight (1-12), and the proteins were eluted from the gel segments 
by an overnight incubation in 1ml of elution buffer. (Materials & Methods, Chapter 2). 
To determine the presence of motogenic activity, the proteins eluted from each gel 
segment were tested alone, at a final dilution of 1/1000, in the 3D collagen gel fibroblast 
migration assay. A protein elution was considered motogenic if it caused fibroblast 
migration to increase by 50% above the baseline level set by the SF MEM control.  
Once again, the Blank CM showed no bioactivity in any of the protein elutions with 
migration equivalent to the SF MEM baseline level (Figure 7.8a). Comparable to the 
results from the SEC fractionated endothelial CM, the higher molecular weight protein 
elutions of both cobblestone and sprout CM exhibited maximal motogenic activity. 
Motogenic activity was restricted to elutions 3 and 4 of the Cobblestone CM (37-
100kDa) with an average migration of 169.7 +/- 4.17% compared to the SF MEM 
baseline (Figure 7.8b). Sprout CM elutions 2 and 3, corresponding to 75-100kDa, 
exhibited an average migration of 161.95 +/- 14.21 (Figure 7.8c). For both Cobblestone 
and Sprout no other protein elution displayed the ability to stimulate migration above 
50% of the SF MEM baseline. 
 
 
7.5iv The Effect of MSF-Inhibitors on the ENDO742 Motogenic SDS PAGE 
 Fractionated Conditioned Medium. 
 
The next stage was to pool the migration stimulatory gel elutions and to test then with 
NGAL and PEPQ1.1 antibody in the 3D collagen gel assay. In order to ensure the 
complete neutralisation of any MSF-induced motogenic activity the inhibitors were 
added in excess. The criteria set for the inhibition of motogenic activity was a reduction 
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in migration by at least 50% compared to the baseline level. The pooled elutions were 
only tested at a final dilution of 1/1000. 
In an average of two experiments, the pooled elutions 3-4 of the Cobblestone CM 
showed increased migration by 1.7 times that of SF MEM baseline. The addition of 
NGAL and PEPQ 1.1 inhibited this activity by 40.8 +/- 7.24% and 46.9 +/- 9.63% 
respectively. Sprout CM pooled elutions 2-3 stimulated migration by a similar level, 
which was reduced by 34.0 +/- 5.96% with addition of NGAL and 40.4 +/- 4.47% by 
PEPQ 1.1. (Figure 7.9). Although inhibition of motogenic activity was achieved it failed 
to reach the set criteria of at least 50% compared to the baseline level. 
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d. Sprouting Transformed Human Endothelial,
ENDO 742,  Fractionated CM.
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Figure 7.8: The motogenic activity of the gel elutions from the SDS electrophoresis 
fractionation of ENDO 742 conditioned medium. Comparison with rhMSF.  
Conditioned medium was collected from ENDO 742 cells grown either on or within a collagen 
gel matrix; thereby displaying either a cobblestone or sprouting phenotype respectively. As a 
control conditioned media was also collected from a blank collagen gel (no cells). After 
electrophoresis of the CM and segmentation of the gel, the protein eluted from each segment (1-
12) was tested alone in the 3D collagen gel fibroblast migration assay (final concentration 
1/1000). The number of cells migrated is expressed as a percentage of the SF MEM control 
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baseline migration i.e. SF MEM Baseline = 100 +/- 15.64%, as represented by the hatched and 
dotted lines (mean and SD respectively). This was equivalent to 3.9+/- 0.61 migrated cells. 
(100pg/ml rhMSF only = 11.7 +/- 0.40 migrated cells). Dose response to rhMSF is shown for 
comparison. The results represent an average of two experiments. 
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Figure 7.9: The effect of MSF-Inhibitors, NGAL and function neutralising 
antibody PEPQ1.1, on the endogenous motogenic bioactivity of the gel elutions 
from the SDS electrophoresis fractionation of ENDO 742 conditioned medium. 
Conditioned medium was collected from ENDO 742 cells grown either on or within a collagen 
gel matrix; thereby displaying either a cobblestone or sprouting phenotype respectively. After 
electrophoresis of the CM and segmentation of the gel, the protein eluted from each segment (1-
12) was tested alone in the 3D collagen gel fibroblast migration assay. The following gel 
elutions were shown to possess motogenic activity; ENDO 742 On Gel elutions 3- 4 and ENDO 
742 In Gel elutions 2- 3.The motogenic active gel elutions were pooled and then tested with 
both 10ng/ml rhNGAL and 50ng/ml PEPQ1.1 antibody in the 3D collagen gel fibroblast 
migration assay, at a final dilution of 1/1000. The number of cells migrated is expressed as a 
percentage of the variable only baseline migration i.e ENDO 742 gel elutions 9-10 only = 100 
+/- 10.00. The effect of rhNGAL and PEPQ1.1 antibody on 100pg/ml rhMSF is shown for 
comparison (100pg/ml rhMSF only = 11.4 +/- 0.95).             
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7.6 THE CHARACTERISATION OF ENDOTHELIAL  
 MSF-INHIBITORY BIOACTIVITY. 
 
The preliminary experiments where conditioned medium (CM) from various cell lines 
was assessed for bioactivity in the 3D collagen gel fibroblast migration assay, revealed 
that endothelial cells exhibiting the cobblestone phenotype expressed a factor that had 
the ability to inhibit rhMSF. That is, endothelial cobblestone CM impeded rhMSF from 
stimulating fibroblast migration. A similar ability to inhibit rhMSF was detected in 
HaCaT keratinocyte CM and after a purification process NGAL was subsequently 
identified as the protein responsible. Immunolocalisation and immunoblot experiments 
disclosed that endothelial cells, in vitro, do not express NGAL and therefore it cannot 
be accountable for the endothelial MSF- inhibitory bioactivity.  Consequently, the next 
stage was to characterise the endothelial MSF inhibitory bioactivity.  
As described previously, for the characterisation of endogenous endothelial motogenic 
bioactivity, the endothelial CM underwent a process of fractionation by two methods; 
size exclusion chromatography and SDS PAGE. Then, in order to determine the 
presence of endothelial MSF-inhibitory activity the fractionated CM was again tested in 
the 3D collagen gel fibroblast migration assay but this time in the presence of 100pg/ml 
rhMSF.  Both cobblestone and sprouting fractionated ENDO 742 CM were tested, plus 
the Blank gel CM was included as a control. 
Two means of analysis were employed to determine whether MSF inhibition had 
occurred. Firstly, the criteria set for MSF inhibition was the ability to limit fibroblast 
migration by at least 50% upon addition of 100pg/ml rhMSF, as compared to the rhMSF 
baseline. Secondly, since motogenic activity had been identified in both sprouting and 
cobblestone fractionated CM, this activity was taken into account during analysis of the 
results in order to reduce any masking effect of MSF-inhibitory activity present by the 
endogenous motogenic bioactivity.  Therefore, baseline migration was set for each 
individual fraction group (or elution) when tested alone in the assay and MSF inhibition 
was determined by a failure of migration to increase by 50% upon addition of 100pg/ml 
rhMSF.  In addition, since an endothelial expressed MSF had been attributed for at least 
a portion of this endogenous motogenic activity then the nature of MSF motogenic 
activity, which displays a bell-shaped dose-response, needed to be reflected in the 
interpretation of the results. That is, to define the MSF-inhibitory activity as either 
genuine or simply due to the accumulative effect of the endogenous MSF and additional 
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rhMSF causing the overall MSF concentration to shift to the level where upon it has an 
inhibitory effect. 
 
7.6i The MSF-Inhibitory Activity of Size- Exclusion Fractionated  
 ENDO 742 Conditioned Medium. 
 
The pooled SEC fraction groups 11 to 23 which had been previously generated for the 
characterisation of motogenic activity (Chapter 7.5i) and corresponding to a molecular 
weight range of approximately >70kDa to 20kDa, were selected for analysis. Each 
group was tested in the 3D collagen gel fibroblast migration assay, at a final dilution of 
1/20 in the presence of 100pg/ml rhMSF and the level of fibroblast migration was 
assessed. Normally, the addition of 100pg/ml rhMSF should result in a minimal two 
fold increase in fibroblast migration. The fibroblast migration measured in presence of 
the SEC fraction groups was therefore labelled as MSF-inhibitory when migration was 
restricted by at least 50% upon addition of 100pg/ml rhMSF, as compared to the rhMSF 
baseline.  
As expected the control CM, from a Blank gel, displayed no ability to inhibit rhMSF 
bioactivity. The average migration level for all the fraction groups was 96.1 +/- 9.40% 
as compared to the 100pg/ml rhMSF only baseline migration of 100 +/- 14.13%. (Figure 
7.10b). 
The fractionated Cobblestone CM had the greatest number of fraction groups which 
meet the criteria for MSF-inhibitory activity; groups 16, 17, 21 and 22. Maximal 
inhibition could be categorised as either having a molecular weight (MW) of 
approximately 70kDa, groups 16 and 17, or a MW of <25kDa, groups 21 and 22. 
Compared to the MSF baseline (100% migration) groups 16 and 17 reduced rhMSF 
stimulated fibroblast migration by 49.4 +/- 7.44% and 60.5 +/- 8.26% respectively; an 
average of 54.95 +/- 7.85%.  Migration was reduced by the lower MW fraction groups 
21 and 22 by 63.9 +/- 0.00% and 59.8 +/- 10.83% respectively; an average of 61.85 +/- 
2.90%. (Figure 7.10c). 
When the un-fractionated Sprout CM was analysed the only bioactivity observed was 
motogenic; that is when tested alone the CM stimulated fibroblast migration. However, 
upon fractionation the Sprout CM also exhibited MSF-inhibitory activity; fraction 
groups 19, 20 and 23 all met the set criteria. Akin to the Cobblestone fractionated CM, 
maximal activity was found in the lower MW fraction groups of 25kDa and less. 
Fraction groups 19, 20 and 23 reduced rhMSF stimulated migration by 56.3 +/- 0.00%, 
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64.9 +/- 6.62% and 57.6 +/- 2.48% respectively. (Figure 7.10d). It was noted that 
although the Cobblestone CM MSF-inhibitory activity was present in a larger range of 
fraction groups compared to the Sprout CM, the actual level of inhibition achieved was 
similar. 
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Figure 7.10 : The MSF-inhibitory activity of Superdex 75 fractionated conditioned 
medium from ENDO 742 cells. Comparison with rhNGAL.  Conditioned medium 
(CM) was collected from ENDO 742 cells grown either on or within a collagen gel matrix; 
thereby displaying either a cobblestone or sprouting phenotype respectively. As a control 
conditioned medium was also collected from a blank collagen gels (no cells). The Superdex 75 
fractionated conditioned medium, fraction groups 11-23, was tested in the 3D collagen gel 
fibroblast migration assay with 100pg/ml rhMSF. The number of cells migrated is expressed as 
a percentage of the 100pg/ml rhMSF control baseline migration i.e. MSF Baseline = 100 +/- 
4.10%, as represented by hatched and dotted lines (mean and SD respectively). This was 
equivalent to 7.8 +/- 0.32 migrated cells. Dose response to rhNGAL, a known MSF-inhibitor, is 
shown for comparison. The results represent an average of two experiments. 
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7.6ii     The Motogenic Activity of Recombinant MSF in the Presence of ENDO 742 
Size- Exclusion Fractionated Conditioned Medium. 
 
The motogenic activity of the fractionated Cobblestone and Sprout CM was detected in 
the higher MW fraction groups. Subsequent analysis with known MSF inhibitors, 
NGAL and PEPQ 1.1 antibody, partly attributed this motogenic bioactivity to an 
endothelial expressed MSF. Therefore this method of analysis enabled the existence of 
the endogenous motogenic activity present in the endothelial CM, which may mask the 
effect of any MSF-inhibitors also present, to be taken into account. The baseline was set 
for each individual fraction group when it was tested alone in the assay and the 
inhibition of rhMSF was determined by a failure of migration to increase by 50% upon 
addition of 100pg/ml rhMSF.  
When tested alone the fraction groups of the control, Blank gel fractionated CM, 
displayed no motogenic activity and subsequently when tested with the addition of 
100pg/ml rhMSF no MSF-inhibitory was detected either. On average, the addition of 
100pg/ml rhMSF increased migration by 2.6 +/-0.31 fold (Figure 7.11a). 
Compared to the baseline level of migration for each of the Cobblestone CM fraction 
groups rhMSF appeared to be inhibited by the majority of fraction groups; 11-17, 19, 
21, 22 and 24 all displayed MSF-inhibitory activity (Figure 7.11b). A similar situation 
occurred for the Sprout CM; 12-16, 19, 20, 23 fraction groups all inhibited rhMSF 
stimulated migration (Figure 7.11c). However, since these higher MW fraction groups 
(Cobblestone CM groups 11-14 and Sprout CM groups 11-15) have been shown to 
contain MSF then the MSF-inhibitory displayed could potentially be due to the 
accumulation effect of endogenous MSF and additional rhMSF causing a shift to MSF 
concentrations that cause inhibition of fibroblast migration instead of stimulation. The 
lower MW (25kDa and lower) fraction groups had shown no endogenous motogenic 
activity and were therefore considered to contain a genuine inhibitor(s) of MSF.  
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Figure 7.11. The motogenic activity of exogenous rhMSF in the presence of 
Superdex 75 fractionated ENDO 742 conditioned medium. Conditioned medium (CM) 
was collected from ENDO 742 cells grown either on or within a collagen gel matrix; thereby 
displaying either a cobblestone or sprouting phenotype respectively. As a control, conditioned 
medium was also collected from a blank collagen gels (no cells). The Superdex 75 fractionated 
conditioned medium, fraction groups 11-23, was tested in the 3D collagen gel fibroblast 
migration assay (final dilution 1/20), with and without the presence of 100pg/ml rhMSF. The 
number of cells migrated is expressed as a percentage of each individual fraction group only 
baseline migration i.e. Fraction group 11 = 100%, as represented by the hatched line. Fraction 
groups which lacked motogenic activity when previously tested alone are identified by a star 
(*). The results represent an average of two experiments. 
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7.6iii The MSF- Inhibitory Activity of SDS PAGE Fractionated ENDO 742  
Conditioned Medium 
 
The protein elutions of SDS PAGE fractionated ENDO 742 CM previously tested for 
motogenic activity were also analysed for the presence MSF-inhibitory activity. The 
protein elutions (1-12) of SDS PAGE fractionated cobblestone and sprout ENDO 742 
CM plus the control CM (collected from a blank gel) were tested at a final dilution of 
1/1000 in the 3D collagen gel fibroblast migration assay with the addition of 100pg/ml 
rhMSF. The level of migration achieved was analysed by the same techniques as 
described for the SEC fractionated CM. Firstly, the level of migration attained for each 
elution when in the presence of 100pg/ml rhMSF was compared to the rhMSF baseline 
level. An elution was considered to be displaying MSF- inhibitory activity if migration 
was restricted by at least 50% upon addition of 100pg/ml rhMSF, as compared to the 
rhMSF baseline. 
No MSF inhibitory activity was detected in any of the protein elutions of the control 
CM. The average migration of the elutions 1-12 was 93.0 +/- 6.80%, whilst the rhMSF 
baseline migration was 100+/- 9.08%. These results were analogous to the results 
gained from the SEC fractionated control CM.  
Although not reaching the set criteria of a 50% reduction in rhMSF stimulated 
migration, two elutions of cobblestone CM did show a distinct MSF-inhibitory activity. 
Elution 3 (MW approximately 75kDa) and Elution 8 (MW approximately 20kDa) were 
able to reduce rhMSF stimulated migration by 49.05 +/- 8.93% and 46.5 +/- 1.77%, 
respectively. It should be noted that Elution 3 had previously displayed motogenic 
activity when tested alone in the assay. Elutions 6 and 9 (MW 25kDa and less) also 
displayed an ability to inhibit rhMSF activity but level was far below the set criteria; 
39.2 +/-10.44% and 33.05 +/-10.10% reduction in migration, respectively. 
As seen with the SEC fractionated CM, the MSF-inhibitory activity of the sprout CM 
elutions could be classified as having either a high or low molecular weight. Of the 
higher MW protein elutions, the maximum reduction in migration was achieved by 
elution 4 (50-75kDa); rhMSF motogenic activity was restricted by 70.5 +/- 3.75%.  
Meanwhile elution 5 (25-50kDa) limited migration by 54.2 +/- 11.07%. The lower MW 
elutions (<20kDa) 8 and 10 displayed an ability to reduce MSF bioactivity by 49.8 +/- 
5.98% and 56.0 +/- 8.57% respectively. Borderline MSF-inhibitory activity was noted 
in elutions 2 and 11. 
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 Figure 7.12: The MSF-inhibitory activity of gel elutions from the SDS PAGE 
fractionation of ENDO 742 conditioned medium. Comparison with rhNGAL. 
Conditioned medium (CM) was collected from ENDO 742 cells grown either on or within a 
collagen gel matrix; thereby displaying either a cobblestone or sprouting phenotype 
respectively. As a control conditioned medium was also collected from a blank collagen gels 
(no cells). After SDS PAGE of the CM and segmentation of the gel, the protein eluted from 
each segment (1-12) was tested in the 3D collagen gel fibroblast migration assay in the presence 
of 100pg/ml rhMSF. The number of cells migrated is expressed as a percentage of the 100pg/ml 
rhMSF control baseline migration i.e. MSF Baseline = 100 +/- 9.08%, as represented by hatched 
and dotted lines (mean and SD respectively). This was equivalent to 10.9 +/- 0.99 migrated 
cells. Dose response to rhNGAL, a known MSF-inhibitor, is shown for comparison. The results 
represent an average of two experiments. 
 
 
 
 
276 
 
7.6 iv    The Motogenic Activity of Recombinant MSF in the Presence of  
 ENDO 742 SDS PAGE Fractionated Conditioned Medium 
 
The second method of data analysis enabled the presence of endogenous motogenic 
activity within the protein elutions of the fractionated CM to taken into account. As 
discussed previously, the protein elutions of fractionated control CM from a blank gel 
(no cells) showed no motogenic activity. Compared to the baseline level of migration 
achieved for each elution the addition of 100pg/ml rhMSF increased migration by a 
minimum of 51.9 +/- 6.32% (elution 7) and a maximum of 90.6 +/-14.87% (elution 8). 
For all the elutions migration was on average increased by 63.0 +/- 13.14% with 
addition of rhMSF (Figure 7.13a). 
For the cobblestone CM, by comparison to the ‘elution only’ baseline migration the 
addition of 100pg/ml rhMSF failed to increase migration by at least 50% in a total of 8 
elutions (2, 3, 4, 6, 7, 8, 9 and 12). Elutions 3 and 4 had previously shown a distinct 
motogenic activity; when pooled together migration was stimulated by factor of 1.7 
compared to the SF MEM baseline. In addition this stimulatory activity could be 
markedly inhibited by MSF inhibitors NGAL and PEPQ 1.1 antibody, thereby 
prompting the supposition that an endothelial MSF was present in these elutions. 
Therefore the inhibition of migration seen with the addition of exogenous rhMSF was 
probably an effect of the nature of the MSF bell-shaped dose-response bioactivity. 
However, the other elutions had not shown any motogenic activity when tested alone so 
the inhibitory activity was considered to be due to the presence of an MSF-inhibitor(s). 
Of these, protein elutions 6 and 8 (MW 20-25kDa) showed maximal inhibitory activity 
(Figure 7.13b). 
The sprout CM also had a number of elutions which prevented the level of migration 
increasing by 50% upon addition of 100pg/ml rhMSF (2, 3, 4, 5, 8, 10 and 11). 
Motogenic activity, presumed to be endothelial MSF had been previously detected in 
elutions 2 and 3. However, none of the other elutions had displayed the ability to meet 
the criteria for the presence of motogenic activity; the ability to increase migration by at 
least 50% compared to the SF MEM baseline. As described before, the MSF inhibitory 
activity could be categorised by the elutions having a high or low MW; elutions 4 and 5 
have a molecular weight of 50-25kDa and elutions 8, 10 and 11 have a MW of 20kDa 
and less (Figure 7.13c). The maximal level of rhMSF inhibition achieved was by elution 
4. The effect of the rhMSF upon elution 9 should also be noted; compared to when 
elution 9 was tested alone migration increased by 2.75 fold upon addition of 100pg/ml 
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rhMSF. This increase in migration was far greater than the rhMSF control, which had 
increased migration by 1.9 fold compared to the SF MEM baseline. 
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Figure 7.13: The motogenic activity of exogenous rhMSF in the presence of gel 
elutions from the SDS PAGE fractionation of ENDO 742 conditioned medium. 
Conditioned medium (CM) was collected from ENDO 742 cells grown either on or within a collagen gel 
matrix; thereby displaying either a cobblestone or sprouting phenotype respectively. As a control, 
conditioned medium was also collected from a blank collagen gels (no cells). After SDS PAGE of the 
CM and segmentation of the gel, the protein eluted from each segment (1-12) was tested in the 3D 
collagen gel fibroblast migration assay in the presence of 100pg/ml rhMSF. The number of cells migrated 
is expressed as a percentage of each individual gel elution only baseline migration i.e.  gel elution 1 = 
100%, as represented by hatched line. Elutions which lacked motogenic activity when previously tested 
alone are identified by a star (*). The results represent an average of two experiments. 
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7.7 THE EFFECT OF MSF ON ENDOTHELIAL MORPHOLOGY. 
 
As discussed previously, MSF has been shown to induce angiogenesis in both in vivo 
and in vitro models. In vivo examples include the stimulation of angiogenesis when 
MSF was applied to chicken yolk-sac membranes and when included in subcutaneous 
implants placed in rat and pig models (Schor 2010, unpublished data). In vitro 
angiogenesis assays have also shown that the addition of MSF to a monolayer of resting 
cobblestone endothelial cells causes a dramatic induction of the endothelial cells to 
exhibit the sprouting phenotype; sprouts which progressively form an interconnected 
sprout network.  
Endothelial cells plated on a 2D surface (plastic, gelatin, collagen) typically form a 
cobblestone monolayer which is stable under serum free conditions. Sprouting is only 
induced either by culture in high serum concentrations or by the addition of specific 
angiogenic factors (for example MSF, FGF, VEGF). However, endothelial cells 
spontaneously form sprouts when plated within a 3D type I collagen gel suggesting that 
the cells must produce an endogenous angiogenic factor(s). Analysis of un-fractionated 
endothelial conditioned medium has indeed shown that an endogenous motogenic 
activity is present in the sprouting endothelial CM but is absent from cobblestone 
endothelial CM. Plus, the addition of MSF-inhibitors reduced this motogenic activity 
thereby implying the expression of an endothelial MSF.  
In order to determine whether endothelial morphology can be altered by MSF a series of 
sprouting assays were performed. Aims were firstly, to corroborate the reported findings 
and secondly to investigate what effect known MSF-inhibitors, PEPQ 1.1 antibody and 
NGAL, have on endothelial morphology; specifically to determine whether MSF is 
accountable for the spontaneously sprouting morphology of endothelial cells plated in a 
3D matrix.  
 
7.7i The Induction of Endothelial Sprouting Phenotype by rhMSF. 
 
A variety of in vitro angiogenesis assays were performed to show the effect rhMSF has 
on endothelial morphology. The common denominator was that the endothelial cells 
were plated onto a 2D surface and cultured in high serum conditions (15%DCS) until 
they achieved confluence, forming a cobblestone monolayer. Conditions were then 
changed to low serum with and without the addition of rhMSF; range tested 0.1-
100ng/ml. All test variables were performed in either duplicate or triplicate. The 
279 
 
cultures were then observed microscopically over the subsequent days to determine any 
changes in endothelial morphology.  
Differences between assays included the 2D plating surface, the serum concentration of 
the test conditions and the method adopted to determine the level of sprouting activity. 
The 2D surfaces tested, included the untreated plastic surfaces of cell cultures dishes 
and the same dishes coated with either 0.1% (w/v) gelatin or native type I collagen. The 
serum concentration of the test conditions ranged from zero to a maximum of 5%DCS. 
Whilst the degree of sprouting activity was determined by observations over an 
incubation period ranging from one to five days by either simply determining whether 
sprouts were present, counting the number of sprouts present whether as single cells or 
in groups/ associations or by performing a 40 point count. Irrespective of the method 
used, data was collected from ten fields of view per dish. 
Of the various experiments performed, the data collected led to the same conclusion and 
verified previous findings that rhMSF stimulated cobblestone endothelial cells to 
exhibit a sprouting morphology (Figure 7.14). Dissimilarity to the control cultures was 
seen within 24 hours of incubation with MSF and the effect was identical irrespective of 
the 2D plating surface. 
The angiogenic effect of MSF was shown to increase with increasing concentration. In 
comparison to the control cultures, 0.1-1ng/ml rhMSF displayed no effect. 10ng/ml 
rhMSF was the minimal rhMSF concentration that could induce the sprouting 
phenotype.  The maximum concentration of rhMSF tested, 100ng/ml, on average 
increased the number of sprouts present by at least three fold. Two representative 
experiments are shown in Tables 7.1 and 7.2. In addition, to showing the angiogenic 
effect of rhMSF, the results also reveal that rhMSF appears to stimulate the sprouts to 
gather together to form groups/ associations which eventually establish an 
interconnecting sprout network over the entire surface of the dish. 
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Figure 7.14: The effect of MSF on endothelial morphology. Bovine aortic endothelial 
cells (BAEC) were plated on to a 2D surface of 0.1% (w/v) gelatin coated plastic cell culture 
35mm dish and cultured in the presence of 15% DCS MEM until confluence was achieved and 
a cobblestone monolayer was formed (A). Conditions were then changed to 1%DCS with 
addition of 100ng/ml rhMSF. After a three day incubation the endothelial cells had been 
induced to change morphology, to the sprouting phenotype, forming a network underneath the 
cobblestone monolayer (B). Observations made at 10x magnification.  
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Variable 
Average number of 
Sprouts per Field 
(Aver/Stdev) 
% of Fields Containing 
                                                         (Aver/Stdev) 
No Sprouts Single Sprouts Sprouts Associations 
2-3cells 
Sprout Associations  
3+ cells 
      
5% DCS MEM 1.6 +/- 0.17 36.25 +/- 9.57 48.75 +/- 19.45 15.0 +/- 9.57 - 
      
0.1ng/ml rhMSF 1.625 +/- 0.11 30.0 +/- 14.14 50.0 +/- 14.14 15.0 +/- 7.07 5.0 +/-1.15 
1ng/ml rhMSF 1.42 +/- 0.16 16.7 +/- 7.07 60.2 +/- 5.13 18.3 +/- 7.64         4.8 +/- 7.07 
10ng/ml rhMSF 3.4 +/-0.70 12.8 +/- 12.51 47.2 +/- 16.07 27.7 +/- 2.51 12.3 +/- 2.52 
100ng/ml rhMSF 4.6 +/- 0.20 8.7 +/- 2.89 35.0 +/- 3.61 28.0 +/- 5.29 28.3 +/- 7.51 
      
Table 7.1: The effects of rhMSF on endothelial morphology. Bovine aortic endothelial cells (BAEC) cultured on a 2D surface of 0.1% (w/v) gelatin coated 
plastic cell culture 35mm dishes, in the presence of 15%DCS MEM were grown to confluence and displayed a typical cobblestone morphology. The conditions were 
then changed to 5% DCS MEM with and without the addition of rhMSF (0.1- 100ng/ml); each variable tested in triplicate. Changes in the endothelial morphology 
were observed, especially the emergence of sprouting endothelial cells. After three days in the test conditions the following observations were noted in ten separate 
fields of view per dish- the number of fields with exhibiting sprouting endothelial cells, if present the total number of sprouts and whether these sprouts were present 
as either single or integrated to form groups of sprouts of either 2-3 cells and 3+ cells (termed sprout associations). The data shown is an average of three 
experiments.  
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 DAY ONE DAY THREE 
 
Variable ALL AREAS 
AREAS OF HIGH 
SPROUTING  
DENSITY 
ALL AREAS 
AREAS OF HIGH 
SPROUTING  
DENSITY 
No. of Fields 
with Sprouts 
Present 
Average  
Point Count 
Average Point Count 
No. of Fields 
with Sprouts 
Present 
Average  
Point Count 
Average Point 
Count 
2.5% DCS 6/30 0.4 +/- 0.83 5.0 +/- 2.0 18/30 1.1 +/- 1.10 1.7 +/- 0.58 
1ng/ml rhMSF 6/30 0.3 +/-0.68 3.0 +/- 1.0 15/30 0.4 +/- 0.70 4.0 +/- 1.52 
10ng/ml rhMSF 18/30 0.9 +/- 1.29 6.3 +/- 0.58 30/30 3.4 +/- 2.32 9.3 +/- 1.16 
100ng/ml rhMSF 27/30 2.8 +/- 0.99 15.7 +/- 3.06 30/30 15.7 +/- 6.18 22.3 +/- 1.53 
       
Table 7.2: The effects of rhMSF on endothelial morphology. Bovine aortic endothelial cells (BAEC) cultured on a 2D surface of native collagen coated 
plastic cell culture 35mm dishes, in the presence of 15%DCS MEM were grown to confluence and displayed a typical cobblestone morphology. Conditions were 
then changed to 2.5% DCS MEM with and without the addition of rhMSF (1- 100ng/ml); each variable tested in triplicate. Observations were made after one and 
three day exposure to the test conditions. In ten random fields of view per dish the presence of sprouts was noted followed by a 40 point count (the number of points 
were sprouts present). In addition, where possible, a 40 point count was performed in the areas where sprouts were present in the highest density. The data shown is 
a representative example of the three experiments performed
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7.7ii The Effect of MSF Inhibitor, PEPQ 1.1 Antibody, on  
Spontaneous Endothelial Sprouts 
 
In order to achieve a homologous spontaneous sprouting phenotype, bovine aortic 
endothelial cells (BAEC) were cultured within a 0.5ml type I collagen gel (plating 
density 6.5 x 10
5 
per ml). The gels were plated into 24 well tissue culture plates to set 
and then over-laid with 0.5ml 20% DCS. After a three day incubation, only the healthy 
cultures displaying a typical sprout morphology, with single sprouts and small 
associations present, were selected. The media was then changed to 1% DCS MEM 
with and without the addition of the PEPQ 1.1 antibody. The antibody was tested at the 
range 10-30µg/ml. To rule out a potential dilution effect of the final serum 
concentration by the addition of the antibody, a series of controls were included, 
whereby for each antibody concentration the equivalent volume of serum free MEM 
was added instead. Each control and test overlay was performed in triplicate. Analysis 
of the effect of PEPQ 1.1 antibody consisted of performing a 40 point count in ten fields 
per gel after a 24 hour and 48 hour incubation period. The total number of sprouts 
counted was then calculated for each variable.  
Three experiments were performed with similar results. Initially, when the total number 
of sprouts counted after a 24 and 48 hour incubation were compared, it appeared that the 
number of sprouts was decreasing in 1% DCS MEM control. However, the counts were 
not reflecting the true situation within the gel. Although the number of individual 
sprouts did decrease, the reason was not due to the loss of sprouts but due to the 
formation of sprout associations. Owing to the density and complexity of these 
associations, which eventually form a whole network of interconnecting sprouts within 
the gel, it was incredibly difficult to count the number of individual sprouts present.  
This however, did not explain the dramatic decrease in the number of sprouts counted in 
the wells exposed to the PEPQ 1.1 antibody. The effects of PEPQ 1.1 antibody 
increased with increasing concentration, with sprouting cells practically annihilated on 
addition of 30µg/ml. A 24 hour exposure to 30µg/ml resulted in an average 67.9 +/- 
19.31% reduction in the number of sprouts as compared to the 1%DCS MEM control. 
By 48 hours the vast majority of endothelial sprouts were dead; only 2.1 +/- 1.80% 
remained (as compared to control). Whilst 24 and 48 hour incubation with 20µg/ml 
PEPQ 1.1 caused 42.6 +/-23.99% and 80.5 +/- 5.99% reductions in sprouts, 
respectively, as compared to the control. The lowest PEPQ 1.1 antibody concentration 
tested, 10µg/ml, displayed the greatest similarity to the 1% DCS MEM control. (Figure 
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7.15, Table 7.3). Any dilution effect on final serum concentration due to the antibody 
volume was dismissed as the addition of the equivalent volume of SF MEM showed no 
adverse effect on sprout numbers; comparable to the 1% DCS MEM control. 
The results therefore show that MSF must be expressed by the spontaneous sprouts. 
Plus, as well as influencing endothelial morphology, MSF must also act as an 
endothelial survival factor since neutralisation of MSF compromises the viability of 
sprouts. However, the role of MSF as a survival factor appears to be specific to 
endothelial sprouts, as previously reported results on the effect of MSF neutralising 
antibodies on a mixed population of sprouting and cobblestone endothelial cells showed 
that apoptotic death was only induced in sprouting cells whilst the co-cultured 
cobblestone cells was unaffected (Schor 2010, Schor et al., 2003).  
 
 
Figure 7.15. The effect of MSF-Inhibitor PEPQ1.1 antibody on endothelial cells 
exhibiting the spontaneous sprouting phenotype. Endothelial cells (BAEC) were plated 
within a 0.5ml type I collagen gel at a plating density of 6.5 x 10
5 
per ml. After a three day 
incubation in the presence of 20% DCS MEM the endothelial cells spontaneously formed 
sprouts within the gel.  Conditions were then changed to the 1% DCS MEM with and without 
the addition of PEPQ 1.1 antibody (10-30µg/ml).The images display the effect seen on the 
endothelial sprouts after a 48hour incubation with either: 
A. 1% DCS MEM    B. 10µg/ml PEPQ 1.1 Antibody 
C. 20µg/ml PEPQ 1.1 Antibody   D. 30µg/ml PEPQ 1.1 Antibody 
Images were taken at 10x magnification. 
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Variable Average Number of Sprouts  
 Post 24hr Post 48hr 
CONTROLS:   
1. 1% DCS MEM 124.5 +/- 19.62 118.0 +/- 15.03 
2. SF MEM equivalent to 
10µg/ml PEPQ 1.1 
133.5 +/- 13.43 122 +/- 15.56 
3. SF MEM equivalent to 
20µg/ml PEPQ 1.1 
143.0 +/- 12.73 117.0 +/- 14.14 
4. SF MEM equivalent to 
30µg/ml PEPQ 1.1 
142.5 +/- 14.85 115.5 +/- 17.68 
   
PEPQ 1.1 Antibody:   
1. 10µg/ml 134.0 +/-22.63 81.5 +/- 10.61 
2. 20µg/ml 71.5 +/-28.99 23.0 +/- 7.07 
3. 30µg/ml 40.0 +/-24.04 2.5 +/-2.12 
   
Table 7.3:  The effect of MSF inhibitor PEPQ1.1 on the number of spontaneous 
endothelial sprouts present in a Type I collagen gel. Endothelial cells (BAEC) were 
plated within a 0.5ml type I collagen gel at a plating density of 6.5 x 10
5
. After a three day 
incubation in the presence of 20% DCS MEM the endothelial cells spontaneously formed 
sprouts within the gel.  Conditions were then changed to the 1% DCS MEM with and without 
the addition of PEPQ 1.1 antibody (10-30µg/ml) or the equivalent volume of serum free MEM. 
Each variable was tested in duplicate. A 40 point count was performed in 10 fields per variable 
and the total number of sprouts was calculated. The results shown are an average of two 
experiments. 
 
 
7.7iii The Effect of MSF Inhibitor, NGAL, on Spontaneous Endothelial Sprouts 
 
The spontaneous sprouting experiments performed to investigate the effect of MSF- 
inhibitor PEPQ 1.1 antibody were repeated in order to determine the effect of the other 
known MSF inhibitor, NGAL. Three different sources of NGAL were tested; NGAL 
isolated from a MMP-9/ NGAL complex isolated from activated neutrophils (complex 
purchased from Calbiochem), free NGAL purified from the complex by SDS PAGE 
separation followed by gel elution (Chapter 4, Results)), eukaryotic rhNGAL 
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(purchased from R&D Systems, 1757-LC) and prokaryotic rhNGAL (in-house 
preparation). 
Preliminary experiments were performed using the NGAL purified from MMP-
9/NGAL complex at a range of dilutions (1/100,000 to 1/5000) equivalent to an 
estimated NGAL concentration range of 1- 40ng/ml (15%DCS MEM diluent). Over a 3 
day observation period no obvious differences to the 15% DCS MEM only control was 
noted. However on day 4, in 2/3 experiments, a transient effect was seen with a 
minority of  sprouts developing vacuoles but by day 5 they had recovered and were akin 
to the controls.  
The prokaryotic NGAL was tested at a concentration range of 1ng/ml-1µg/ml. A lower 
serum concentration was used in order to minimise any antagonistic effect by factors 
present with the serum. A total of four experiments were performed, two using 1%DCS 
MEM and the other two with 5%DCS MEM. As seen previously with NGAL gel 
elution, the sprouts appeared to be unaffected by the lower concentrations 1-100ng/ml 
of prokaryotic NGAL; typically displaying healthy sprouts which formed associations 
of 10+ cells by day 6. However, adverse effects of 500ng/ml and 1µg/ml NGAL were 
initially noted on day 2 (Figure 7.16). Compared to the controls the sprouts were less 
numerous, of poor quality and smaller; there was also an increase the amount of debris 
present. By day 5 this had progressed severely, with the majority of sprouts having died 
and those which did remain were in a poor condition with vacuoles present and 
surrounded by debris. The serum concentration did not appear to affect the outcome 
with the same results achieved at 1% and 5%DCS. 
The eukaryotic NGAL was tested at a more limited range of concentrations, 100ng/ml 
to 1µg/ml and a similar effect was observed. 100ng/ml was indistinguishable from the 
1% DCS MEM control. Whilst by day 2 the majority of sprouts had rounded up when 
exposed to 500ng/ml and 1µg/ml NGAL, progressing to cell death by day 3. Very few 
sprouts remained by day 4 and those that did were of poor quality. 
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Figure 7.16: The effect of MSF-Inhibitor, NGAL on endothelial cells exhibiting the 
spontaneous sprouting phenotype. Endothelial cells (BAEC) were plated within a 0.5ml 
Type I collagen gel at a plating density of 6.5 x 10
5 
per ml. After a three day incubation in the 
presence of 20% DCS MEM the endothelial cells spontaneously formed sprouts within the gel.  
Conditions were then changed to the 1% DCS MEM with and without the addition of 500ng/ml 
prokaryotic rhNGAL (in-house preparation). The images display the effect seen of incubating 
the endothelial sprouts with 500ng/ml prokaryotic rhNGAL over three day incubation period. 
Images were taken at 10x (A and B) and x20 magnification (C). 
 
7.7iv The Effect of MSF Inhibitor, NGAL, on Post- Confluent  
 Endothelial Sprouts 
 
The effect of rhNGAL on spontaneous endothelial sprouts was similar to that of the 
PEPQ 1.1 antibody. The next stage was to determine what effect NGAL had on a mixed 
population of endothelial cells, expressing both the cobblestone and sprouting 
phenotype.  
Endothelial cells (BAEC) were plated onto the 2D surface of a 0.5ml type I collagen gel 
in the presence of 15%DCS MEM.  Once a confluent cobblestone monolayer had 
formed across the entire surface of the gel (typically after a 3 day incubation period) the 
overlays were changed to the test conditions. In order to induce sprouting, a high serum 
dilution of 15%DCS was used. Initially experiments were performed with NGAL 
isolated from a MMP-9/ NGAL complex isolated from activated neutrophils (NGAL gel 
elution) and repeated with prokaryotic rhNGAL. Observations were made regarding the 
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health and appearance of the cobblestone monolayer, the development of sprouts and 
the migration of sprouts into the underlying collagen gel. 
Four separate experiments were performed using the NGAL gel elution, tested (in 
triplicate) at a dilution range of 1/100,000 to 1/500, equivalent to approximately 1-
400ng/ml. In the controls, 15%DCS MEM only, sprouting was not observed until 
around day 2-3. By day 5 single sprouts had formed small associations of 5+ cells 
beneath the cobblestone monolayer and a few had started to migrate into the collagen 
gel. By day 8 sprouting networks had formed over the surface of the gel and within the 
gel the numerous single sprouts had started to form associations. Meanwhile, 
throughout the incubation period, the cobblestone monolayer kept intact and healthy.  
In the higher dilutions of the NGAL gel elution tested, 1/100,000 to 1/20,000 (est.1-
10ng/ml), cultures were indistinguishable from the controls. The mid-range dilutions 
1/10,000 to 1/500 (est.10-40ng/ml) showed slightly reduced sprouting activity 
compared to the controls; with surface sprouting activity confined until day 4 and 
sprouts only appearing in the gel by day 7-8. Eventually a sprouting network did form 
underneath the cobblestone by day 9-10, although in the majority of cases it failed to 
extend across the entire gel surface.  
No sprouts were observed within the collagen gels that were exposed to the highest 
dilutions of the NGAL gel elution, 1/1000 and 1/500 (est. 200-400ng/ml). Only a 
limited number of sprouts were seen on the surface by day 5, which eventually 
progressed to form restricted areas of sprout associations (10-15 cells). The cobblestone 
monolayer also appeared to be have been affected; although still intact over the gel 
surface the endothelial cells were less healthy and the cobblestone looked disorganised 
plus there was distinctly more debris than the controls. 
Using the same protocol, prokaryotic rhNGAL was tested at a concentration range of 
1ng/ml -1µg/ml (2 experiments) and similar observations to the NGAL gel elution were 
noted. The lower concentrations 1-100ng/ml showed no difference to the 15% DCS 
MEM control. No sprouts were observed in cultures exposed to the higher 
concentrations of 500ng and 1µg/ml. The higher concentrations of rhNGAL had a very 
apparent adverse effect on the cobblestone monolayer; vacuoles developed within the 
cells by day 4 and by day 5, 1µg/ml rhNGAL induced the complete disruption of the 
cobblestone monolayer with loss of typical morphology, increased cell death and debris. 
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7.7v The Effect of NGAL on Endothelial Proliferation and Viability. 
 
It has been reported that when PEPQ 1.1 antibody was tested in a mixed endothelial cell 
population it had the selective ability to eliminate cells exhibiting the sprouting 
phenotype whilst appearing to leave the underlying cobblestone monolayer unaffected 
(Schor et al., 2010). However, in a mixed culture rhNGAL displayed an adverse effect 
on both endothelial phenotypes, especially when tested at the higher concentrations 
(500ng- 1µg/ml). In order to eliminate the possibility that the effect of rhNGAL was due 
to toxicity, viability and proliferation assays were performed with both prokaryotic and 
eukaryotic rhNGAL. 
The bovine endothelial cells (BAEC) were plated on a 2D surface of a 0.1% (w/v) 
gelatin coated 35mm plastic cell culture dish at a concentration of 1 x 10
5
 per dish in 
15%DCS and incubated overnight to allow the cells to attach. The next day a baseline 
count and viability was measured. Before changing to the test conditions, all dishes 
were washed twice with Hanks solution. Both source of rhNGAL were tested at 
10ng/ml, 100ng/ml and 1µg/ml in a final serum concentration of 5% DCS. The control 
(5%DCS MEM only) and variables were tested in duplicate in two separate 
experiments. Over a 5 day period cell counts and viability were measured by the Coulter 
Counter Z1 Series (Beckmann Coulter) and the trypan blue assay, respectively (Chapter 
2, Materials & Methods). 
Both prokaryotic and eukaryotic rhNGAL affected the endothelial cells in the same 
manner. As expected from the sprout assay(s) observations, the lower rhNGAL 
concentrations of 10ng/ml and 100ng/ml had no adverse effects on endothelial cell 
proliferation or viability. However, 1µg/ml rhNGAL over the 5 day course of the 
experiment when compared to the 5%DCS control decreased endothelial proliferation 
on average by 20.5 +/-5.14% and 23.2 +/- 5.49%, prokaryotic and eukaryotic 
respectively. Yet, it had no effect on endothelial cell viability. 5% DCS MEM had an 
average cell viability of 94.4 +/-3.19%, whilst 1µg/ml prokaryotic and eukaryotic 
rhNGAL had an average cell viability of 91.6 +/- 2.76% and 90.85 +/- 3.16%, 
respectively. 
It should be noted that the same sources of rhNGAL, at a range of concentrations 0.01-
1µg/ml, had been extensively tested on fibroblasts (FSF44) in the 3D collagen migration 
assay and no toxic effects were ever observed. Indeed, fibroblast viability and 
proliferation assays performed with prokaryotic rhNGAL, 0.01-1µg/ml, showed 
290 
 
rhNGAL had no effect on fibroblast morphology, viability and proliferation when 
compared to the control. 
 
 
 
Table 7.4: The effect of NGAL on endothelial viability and proliferation. 
Endothelial cells, BAEC, were plated at a density of 1 x 10
5
 per 35mm dish, in the presence of 
15%DCS MEM. After a 24 hour attachment period, conditions were changed to 5% DCS MEM 
with and without the addition of rhNGAL. Both prokaryotic and eukaryotic sources of rhNGAL 
were tested, in duplicate, at a range of concentrations (1ng/ml, 100ng/ml and 1µg/ml). Cell 
viability and cell counts were taken over a 1-5 day incubation period. The percentage of cell 
viability for each variable was measured by the trypan blue assay. The average cell count at 
each time point, for each variable was measured with the Coulter Counter Z1 Series (Beckmann 
Coulter). The results shown are an average of two experiments. 
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A. Prokaryotic rhNGAL 
Variable Baseline Post 24hrs Post 3days Post 5days 
 % Viability Cell Count 
(x 10
5
) 
% Viability Cell Count 
(x 10
5
) 
% Viability Cell Count 
(x 10
5
) 
% Viability Cell Count 
(x 10
5
) 
5% DCS MEM 
Control 
88.25 +/- 1.06 1.43  +/- 0.15 95.85 +/- 3.04 2.0 +/- 0.45 87.8 +/- 8.06 3.25 +/- 1.27 92.08 +/- 4.05 4.325 +/- 0.18 
1ng/ml NGAL - - 92.95 +/- 0.64 1.675 +/-0.51 86.15 +/- 5.02 3.325 +/- 0.98 91.7 +/- 4.07 4.4 +/-0.72 
100ng/ml NGAL - - 92.85 +/- 3.75 1.975 +/-0.40 82.1 +/- 5.52 2.95 +/-0.96 87.4 +/- 6.74 4.025 +/-1.06 
1µg/ml NGAL - - 94.65 +/- 4.60 1.675 +/- 0.22 90.8 +/- 0.42 2.4 +/- 0.75 92.6 +/- 2.76 3.5 +/- 0.98 
         
 
B. Eukaryotic rhNGAL 
Variable Baseline Post 24hrs Post 3days Post 5days 
 % Viability Cell Count 
(x 10
5
) 
% Viability Cell Count 
(x 10
5
) 
% Viability Cell Count 
(x 10
5
) 
% Viability Cell Count 
(x 10
5
) 
5% DCS MEM 
Control 
90.5 +/- 0.89 1.56 +/-0.25 96.85 +/- 2.65 1.95 +/- 0.57 95.6 +/-3.65 3.3 +/- 0.75 90.8 +/- 5.07 4.5 +/- 0.58 
1ng/ml NGAL - - 94.2 +/-1.07 1.8 +/- 0.40 93.4 +/- 4.42 3.45 +/- 0.81 92.6 +/- 3.56 4.45 +/- 0.92 
100ng/ml NGAL - - 95.6 +/- 0.74 1.8 +/- 0.75 90.4 +/- 5.75 2.95 +/-0.52 94.75 +/- 5.67 4.05 +/- 0.98 
1µg/ml NGAL - - 93.7 +/- 0.46 1.6 +/- 0.35 91.4 +/- 6.75 2.55 +/- 0.81 90.85 +/- 3.16 3.2 +/- 1.01 
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7.8 DISCUSSION 
 
The ability to inhibit the motogenic activity of MSF has been discovered in the 
conditioned medium of both the keratinocyte HaCaT cell line and endothelial cell lines 
specifically displaying a cobblestone phenotype. Neutrophil gelatinase associated 
lipocalin (NGAL) has subsequently been identified as the keratinocyte expressed MSF- 
inhibitor. By performing immunoblot and IHC experiments, using specific anti-NGAL 
antibodies, it has emerged that endothelial cells in vitro do not express NGAL. 
CM from various endothelial cell lines, of both bovine and human origin, were tested in 
the immunoblot assays at a range of concentrations (neat to 50x concentrated) using 
both monoclonal and polyclonal specific anti-NGAL antibodies. Despite all the 
experimental variations performed no band(s) of the appropriate molecular weight for 
NGAL were identified. Negative results were also achieved in the 
immunohistochemistry experiments, irrespective of whether the cells displayed a 
cobblestone or sprouting morphology and regardless of the plating matrix. The 
conclusion was drawn that the cultured endothelial cells were not expressing NGAL, 
although it could be suggested that NGAL may have been present but at concentrations 
below the detection limits of the assays. 
A literature search of the reported expression of NGAL by endothelial cells is limited 
and generally endothelial expression of NGAL is associated with disease states. 
Furthermore, an analysis of NGAL expression by endothelial cells in vitro has not 
previously been performed. Limited expression of NGAL has been identified in 
endothelial cells present within atherosclerotic plaques (Boekhorst et al., 2011). A study 
of human and experimental rat heart failure, where immunostaining for NGAL was 
performed on the myocardium, revealed some immunoreactivity in endothelial cells; 
especially those endothelial cells within the microvascular at the border zone between 
ischaemic and non-ischaemic regions in post-myocardial infarction rats (Yndestad et al., 
2009, Ding et al 2010). Induction of NGAL expression was also reported to be 
associated with an inflammatory response in endothelial cells of mice, eight hours after 
a sublethal intra-peritoneal infection with E.coli H9049 (Flo et al., 2004).  
In actuality the discovery of an absence of NGAL expression by cultured endothelial 
cells may not reflect the in vivo situation. The isolation of endothelial cells from their 
natural tissue microenvironment has been reported to generate alterations in endothelial 
gene expression and can result in a phenotypic drift (Lacorre et al., 2004). Because 
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endothelial cells sense and react to their environment, changes occur in their messenger 
RNA and protein expression when they become separated from crucial extracellular 
signals (Aird et al., 2013).  Yet, the endothelial cells analysed for NGAL expression 
were plated on and within various different matrices (plastic, gelatin, type I collagen) 
and all were consistently negative. However, the limitations of in vitro studies should 
always be considered. 
In addition to CM from cobblestone endothelial cells possessing MSF-inhibitory 
activity, the other bioactivity detected in endothelial CM appeared to be specific to the 
sprouting phenotype. Endothelial cells exhibiting the sprouting phenotype were shown 
to possess a motogenic bioactivity which resulted in the increased migration of 
fibroblasts in the 3D collagen gel assay. Due to the nature of this stimulatory activity it 
was proposed that an endothelial MSF was responsible. Initial investigations adopting 
immunoblot and immunohistochemistry analysis produced conflicting results.  
Conditioned medium collected from a variety of endothelial lines, expressing 
cobblestone and/ or sprouting phenotypes, on/ within numerous different matrices when 
tested by immunoblot, using anti-MSF RpVSI antibody, constantly resulted in no bands 
being identified as MSF. Immunostaining experiments however, identified a MSF 
expression located within the endothelial cells specifically displaying the sprouting 
phenotype. The cobblestone phenotype was negative for MSF in the majority of 
experiments (9/12). It was suggested that the disparity in results between the 
immunoblot and IHC methods for the sprouting endothelial was due to MSF being 
present in the CM at concentrations below the sensitivity limits of the immunoblot 
assay, namely 25ng/ml. 
In order to further characterise the motogenic activity of the endothelial sprouting CM, 
direction was taken from the HaCaT series study. Conditioned medium was collected 
from homogenous cultures of sprouting endothelial cells, ENDO 742, plated within a 
type I collagen gel. To provide a comparison and a relevant control, CM was also 
collected from cobblestone endothelial cells (plated on the surface of the collagen gels) 
and from a blank gel (no cells), respectively.  Firstly, CM was fractionated by both size 
exclusion chromatography and SDS electrophoresis, and then the subsequent 
fractions/elutions tested for bioactivity in the 3D collagen gel fibroblast migration 
assay. The motogenic active fractions were then tested with known MSF inhibitors, 
NGAL and PEPQ 1.1.  
From analysis of un-fractionated endothelial CM, bioactivity was considered to be 
phenotype specific yet upon fractionation previously masked activities were revealed.  
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As opposed to possessing either motogenic or MSF- inhibitory bioactivity it appears 
that the cobblestone and sprouting endothelial cells simultaneously express both. This is 
similar to the discovery for the HaCaT series keratinocytes whereby both MSF and it 
inhibitor, NGAL, are expressed; although at varying rates which then determines the 
overall bioactivity exhibited by the unfractionated CM. 
Unfortunately, the results are inconclusive as to whether an endothelial expressed MSF 
is solely responsible for the migration stimulatory activity detected in the sprout and 
cobblestone CM. Yet, there is evidence to support the presence of an endothelial MSF 
(Table 7.5). Firstly, the motogenic active fractions of both SEC and SDS PAGE 
fractionated endothelial CM was within the molecular weight range for MSF. Secondly, 
although the addition of MSF inhibitors did not completely neutralise the motogenic 
activity migration was reduced by a significant degree. Finally, immunolocalisation 
experiments also identified MSF expression by endothelial cells.   
However, an anomaly arises when comparing MSF immunolocalisation results with 
fractionated CM bioactivity experiments. In the majority of immunolocalisation 
experiments (5/7) cobblestone endothelial cells were negative for MSF. Whilst in the 
3D collagen gel assay the ability of the fractionated cobblestone CM (SEC and SDS 
PAGE) to stimulate fibroblasts migration was measured at a similar level to the activity 
of the fractionated sprout CM, suggesting the motogen present was at a comparable 
concentration. The NGAL and PEPQ 1.1 inhibition experiments also imply that MSF 
was present in similar quantities in both cobblestone and sprout CM. 
If MSF is responsible for the motogenic activity detected in fractionated Cobblestone 
CM then MSF present in cobblestone endothelial cells must be associated with another 
protein(s) which not only inhibits its bioactivity in the total CM but also masks it from 
identification by the anti-MSF Rp2 antibody. Therefore, both the MSF unique carboxyl 
terminal decapeptide, which the Rp2 antibody has been raised against, and the IGD 
motif, which is responsible for MSF bioactivity, would have to be concealed. Yet, this 
interaction with another protein(s) must be weak since fractionation of the cobblestone 
CM by SEC appears to be enough to unmask the motogenic activity previously hidden 
in the total cobblestone CM.   
However, the method used to collect CM may be somewhat accountable for the 
anomaly in the levels of bioactivity of the cobblestone and sprout CM. In order to insure 
a single population of sprouting cells the ENDO 742 cells were plated within a type I 
collagen gel matrix, whilst the cobblestone CM was collected from the cells plated on 
the surface of the gel. Obviously, any proteins expressed and released by the endothelial 
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cells on the gel surface will enter the overlying media more efficiently than those 
secreted by the cells within the gel. As already discussed in MSF immunolocalisation 
experiments, when cells are plated within a collagen gel matrix (keratinocytes, foetal 
fibroblasts and endothelial cells) a high background staining of collagen gel occurs. 
Therefore, it could be possible that the MSF expressed by the sprouting endothelial cells 
is becoming trapped within the collagen matrix resulting in only a small percentage ever 
reaching the overlaying media. In retrospect, total protein levels of the cobblestone and 
sprout CM should have been measured to insure an accurate comparison of motogen 
concentration and bioactivity.  
Since the evidence from immunoblot and immunostaining experiments implied NGAL 
was not the source of MSF-inhibitory bioactivity present in cobblestone CM further 
characterisation of the inhibitory bioactivity was required. The fractions/elutions of the 
fractionated CM (cobblestone, sprouting and blank) were tested for the ability to inhibit 
the bioactivity of rhMSF in the 3D collagen gel fibroblast migration assay. This testing 
process confirmed the presence of an endothelial MSF-I in the cobblestone CM but also 
revealed a previously hidden MSF-inhibitory activity present within the sprouting CM 
(Table 7.6). 
The MSF-I activity in both the cobblestone and sprouting CM appears to share a similar 
molecular weight and unexpectedly a comparable level of activity (Table 7.7). The 
bioactivity was located to three molecular weight zones of approximately 70kDa, 40kDa 
and ≤25kDa. As seen previously with the HaCaT series experiments the fractionation 
process, by both SEC and SDS PAGE, failed to pin-point the MSF-I activity to a 
specific molecular weight region.  
Since the MSF-I bioactivity of the sprout CM is normally masked in un-fractionated 
CM it was surprising to discover that it shared a similar capability to inhibit rhMSF as 
the cobblestone CM did (Table 7.7). However, any comparisons should be restrained 
due to the lack of total protein concentrations of the two CM types. Nevertheless, 
although the endothelial cells were expressing different phenotypes the CM was 
collected from cultures of the same number of cells and then subsequently underwent 
the same concentration and fractionation processes.  
Obviously, this analysis was the first stage in a process to identify the protein 
responsible for endothelial MSF-I bioactivity, however from these initial results the 
presumption was that the same protein would be accountable in both the cobblestone 
and sprouting endothelial cell cultures. However, a difference between cobblestone and 
sprouting CM was noted by a variation in activity levels of fractions/elutions at an 
296 
 
approximate molecular weight of 40kDa; more MSF-inhibitory was present in the 
sprout fractionated CM than the cobblestone.  
As seen with the discovery of motogenic activity in the cobblestone CM the 
concealment of the MSF-I in the sprouting CM is highly efficient, although any 
association must be weak as it is easily separated by SEC fractionation. Possibly, the 
method of inhibition is via a method other than direct interaction. Further investigation 
is required to identify the protein responsible for endothelial MSF-I activity.  
It has previously been reported that MSF has pro-angiogenic bioactivities in vitro due to 
its capacity to induce endothelial cells to undertake a phenotypic change from the 
cobblestone to the sprouting phenotype. It was also suggested that MSF is accountable 
for the spontaneous sprouting morphology endothelial cells adopt when plated in a 3D 
matrix (Schor, 2010). Although, it was discovered that NGAL was not expressed by the 
endothelial cells an investigation was undertaken to determine its effect on endothelial 
cells; specifically to ascertain whether NGAL can inhibit MSF pro-angiogenic 
bioactivity in addition to inhibiting MSF ability to stimulate fibroblast migration.  
MSF ability to induce a sprouting phenotype in homogenous cobblestone endothelial 
cell culture was easily reproduced in in vitro angiogenesis assays. The effect of 
stimulating phenotypic change by MSF was identical irrespective of the 2D plating 
surface (plastic, 0.1%w/v gelatin, native type I collagen) or endothelial cell line (BAEC, 
HUVEC, ENDO 742). The minimum concentration of rhMSF to initiate sprouting was 
10ng/ml; whilst 48 hour incubation with 100ng/ml rhMSF increased sprout numbers 
three fold compared to the control (1% DCS MEM). 
It has previously been reported that treatment of heterogeneous cultures displaying both 
cobblestone and sprouting endothelial cells with the IGD function neutralising 
monoclonal antibody, PEPQ 1.1, resulted in the apoptotic death of the sprouting cells 
whilst the cobblestone cells remained unaffected (Schor, 2010). Unsurprisingly, the 
exposure of a homogenous culture of spontaneous endothelial sprouts (cells plated 
within a 3D collagen gel) to the PEPQ1.1 also resulted in programmed cell death. A 
minimal PEPQ 1.1 concentration of 20µg/ml caused a significant reduction in sprout 
numbers within 24 hours: average decrease of 42.6+/- 28.99% compared to control 
cultures. The death of practically all sprouts was observed after a 48 hour incubation 
with 30µg/ml PEPQ 1.1.  
As MSF has been proven to induce the sprouting phenotype, it was conceivable to 
predict that treatment with MSF-inhibitors may have caused a reversal of phenotype 
from sprout to the cobblestone. However, the apoptotic cell death that was evoked 
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implies that in addition to stimulating angiogenesis, MSF must also play the role as a 
survival factor for the sprouting cells. The predominant bioactivity of the total CM of 
sprouting and cobblestone cells is motogenic or MSF-inhibitory, respectively. These 
initial investigations insinuated that sprouting cells expressed MSF while the 
cobblestone cells expressed a MSF-inhibitor. However, upon fractionation of the CM it 
was discovered that both endothelial phenotypes expressed both MSF and a MSF-
inhibitor. Therefore, MSF role as a survival factor is unique to the sprout phenotype as 
the cobblestone endothelium appears to remain unaffected by exposure to PEPQ 1.1 
antibody.  It will be interesting to discover what role the masking of cobblestone MSF 
bioactivity has on its ability to be resistant to the PEPQ 1.1. Since PEPQ 1.1 neutralises 
the function of the IGD motif it would imply that this motif is implicated in MSF role as 
a sprout survival factor.    
NGAL has been proven to be an inhibitor of MSF stimulation of fibroblast migration in 
the 3D collagen gel assay. Although NGAL was shown not to be responsible for the 
endothelial expressed MSF-inhibitory activity its effect on endothelial morphology was 
investigated. Initially, NGAL was shown to have a similar effect on spontaneous 
sprouts as the PEPQ 1.1 antibody; 500ng-1µg/ml reduced sprout numbers by day 2, 
with the majority of sprouts undergoing apoptosis by day 5 (lower concentrations 1-
100ng/ml had no effect). However, as opposed to PEPQ 1.1 selective effect on only 
sprouts in a heterogeneous culture of cobblestone and sprouts cells, NGAL was found to 
target both. Although 1-100ng/ml rhNGAL had no effect on either the cobblestone or 
the formation of sprouts in post-confluent cultures the higher concentrations of 400ng-
1µg/ml inhibited all sprout development plus adversely affected the cobblestone. 
Initially NGAL caused disorganisation of the uniform cobblestone monolayer, but with 
longer incubation cell death started to occur. Irrespective of the source of NGAL tested 
(prokaryotic and eukaryotic) the effect was the same.  
Growth and viability studies revealed that the NGAL had the ability to reduce 
proliferation of endothelial cells, although did not affect cell viability. As expected the 
lower NGAL concentrations, 10-100ng/ml, had no effect. Yet 1µg/ml which induced 
sprout and cobblestone apoptosis in the sprout assays caused a significant reduction in 
endothelial proliferation; decreased by 20.5 +/-5.14% and 23.2 +/- 5.49% with 1µg/ml 
prokaryotic and eukaryotic rhNGAL respectively. Yet the same rhNGAL concentrations 
used in growth and viability assays performed with fibroblasts had no effect. It would 
appear therefore the effect of NGAL is cell type dependent. 
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It is questionable whether the effect of NGAL on endothelial cells is solely due to 
inhibition of endothelial expressed MSF since NGAL is known to induce apoptosis, 
mainly through its ability to chelate iron from cells; cellular iron deprivation triggers 
programmed cell death (Devireddy et al., 2005, Virzi et al., 2013). Therefore future 
sprout assays should include analysing the effect of the iron chelator DFOM. Yet, 
NGAL from both prokaryotic and eukaryotic sources, which will have varying amounts 
of bound iron, both display the same effect on endothelial cells. Plus, in the spontaneous 
sprout assays both PEPQ 1.1 and NGAL display the same effect on the sprouts; the 
actions of PEPQ 1.1 antibody is achieved by neutralising the function of the IGD motif 
of MSF. Finally, the capability of NGAL to transport iron has been shown not to be 
relevant to its ability to inhibit MSF stimulated fibroblast migration.  
A role for NGAL as an angiogenesis inhibitor has been previously reported in breast 
and pancreatic cancer studies; its effects have been implicated with VEGF expression. 
Ras-induced tumour angiogenesis in 4T1 mouse breast cancer model was shown to be 
inhibited by NGAL via down-regulation of VEGF expression and an up-regulation of 
TSP-1 expression (Venkatesha et al., 2006). Later Tong et al., 2008, reported NGAL 
could inhibit angiogenesis in in vitro and in vivo models of pancreatic cancer. The 
formation of endothelial tubes by sprouting HUVEC cells was shown to be inhibited by 
NGAL possibly through decreased VEGF production or a blockade of the VEGF 
receptor. NGAL induced reduction in endothelial tube formation was also suggested to 
occur through perturbations of FAK-integrin mediated signalling events (Tong et al., 
2008).  
It would therefore be interesting to investigate whether MSF stimulation of sprout 
formation entails an up-regulation of VEGF expression. 
It should be noted that different concentrations of both of the MSF-inhibitors, NGAL 
and PEPQ1.1 are required to generate an effect in the fibroblast and endothelial assays.  
In the 3D fibroblast migration assays, MSF- inhibition is achieved by minimal 
concentrations of 1-10ng/ml and 50ng/ml of rhNGAL and PEPQ 1.1 antibody, 
respectively. However, minimum concentrations of 400ng/ml rhNGAL and 20µg/ml 
PEPQ 1.1 are required to induce an effect in the endothelial sprout assays. Another, 
main difference in assays is the source of MSF to be inhibited; exogenous or 
endogenous. In the 3D collagen gel assay, an exogenous source of MSF (rhMSF, total 
CM, fractionated CM) is applied to the fibroblasts and the actions of the inhibitors 
observed. Whilst in the sprouting assays it is endogenous endothelial expressed MSF 
which is attempted to be inhibited by the addition of rhNGAL and PEPQ 1.1.  
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These initial experiments have revealed some interesting starting points for future work. 
Obviously, further purification of the endothelial CM is required to identify the protein 
responsible for endothelial MSF-I activity. The identification of the endothelial MSF 
inhibitor will therefore initiate a whole plethora of experiments to determine its 
relationship with MSF and its involvement in regulating endothelial cell morphology 
and bioactivity. In addition, further work is required to understand the nature of MSF 
angiogenic capabilities and the ability of NGAL to inhibit angiogenesis.
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Table 7.5: Summary of experimental data providing evidence that cultured ENDO 742 endothelial cells displaying both the cobblestone and 
sprouting phenotype express MSF. 
TECHNIQUE EXPERIMENTAL  
DETAILS 
ENDOTHELIAL CELLS, ENDO 742 
COBBLESTONE  SPROUTING 
Western Blot 
Identification of 
MSF 
Anti-MSF Antibody, RpVSI. 
10x Amicon concentrated CM tested. 
 
negative 
 
negative 
Immunolocalisation 
of MSF. 
Anti-MSF antibody, Rp2/98pFA2pFn1. 
Cells plated on 2D surface; tested at 
confluence (cobblestone) and post-
confluence (sprouting). 
Cells plated on (cobblestone) and within 
3D collagen gel (sprouting). 
      2D surface: 
 
4/5 expts- negative 
 
1/5 expts -strong                                                         
                 positive 
       3D surface: 
 
5/7 expts- negative 
 
2/7 expts- strong                                         
                 positive 
  2D surface post- 
      confluence: 
 
5/5 expts- positive 
  Within 3D gel: 
 
 
7/7 expts- weak to                         
strong positive 
 
Motogenic Activity 
of Fractionated CM 
10x concentrated CM fractionated by 2 
methods; SEC and SDS electrophoresis. 
Subsequent fractions/elutions tested in 3D 
collagen gel fibroblast migration assay for 
motogenic activity.  Level of migration 
compared to SF MEM baseline.  
SEC 
     Fractions 11-14 
(> 70kDa) 
1/200 dilution  
- 2 fold increase in 
migration  
SDS PAGE 
       Elutions 3-4 
(37-100kDa) 
1/1000 dilution  
-1.7 fold increase in 
migration  
SEC 
    Fractions 11-15 
(>70kDa) 
1/200 dilution  
-2 fold increase in 
migration 
SDS PAGE 
       Elutions 2-3 
(75-100kDa) 
1/1000 dilution  
-1.6 fold increase in 
migration  
IGD Function 
Neutralisation of 
Motogenic Activity. 
Motogenic active ENDO 742 cobblestone 
and sprouting CM fractions/elutions 
pooled and tested in the 3D collagen gel 
fibroblast migration assay with addition of 
50ng/ml Pep Q 1.1- IGD function 
neutralising antibody. Effect on migration 
compared to baseline levels. 
SEC 
 
Migration decreased 
by 
48.7 +/- 8.31% 
 
SDS PAGE 
 
Migration decreased 
by 
40.8 +/- 7.24% 
SEC 
 
Migration decreased 
by 
42.9 +/- 20.54% 
SDS PAGE 
 
Migration decreased 
by 
34.0 +/- 5.96% 
NGAL inhibition of 
Motogenic activity. 
Motogenic active ENDO 742 cobblestone 
and sprouting CM fractions/elutions 
pooled and tested in the 3D collagen gel 
fibroblast migration assay with addition of 
10ng/ml rhNGAL. Effect on migration 
compared to baseline levels. 
SEC 
 
Migration decreased 
by 
27.9 +/- 16.62% 
SDS PAGE 
 
Migration decreased 
by 
46.9 +/- 9.63% 
SEC 
 
Migration decreased 
by 
13.9 +/-17.69% 
SDS PAGE 
 
Migration decreased 
by 
40.4 +/- 4.47% 
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Table 7.6: Result Summary. The bioactivity of fractionated ENDO 742 conditioned medium. Conditioned medium (CM) was collected from ENDO 
742 cells grown either on or within a collagen gel matrix; thereby displaying either a cobblestone or sprouting phenotype respectively. As a control, conditioned 
medium was also collected from a blank collagen gels (no cells). After concentration each type of CM was fractionated by two methods, size exclusion 
chromatography (SEC) and SDS electrophoresis. The subsequent fractions/ elutions were tested in the 3D collagen gel fibroblast migration assay; with and without 
the presence of 100pg/ml rhMSF. By comparison to SF MEM or rhMSF baseline controls the nature of each cell line’s bioactivity was determined. The conditions 
for fractionation of the 10x Amicon concentrated CM was as follows:  
1. SEC performed using Superdex 75 Hiload 26/60 column (GE Healthcare), multiple runs performed with fractions pooled together into groups of three (13-23) 
equivalent to MW >70kDa to 20kDa, and tested at final dilution of 1/20.  
2. Electrophoresis (12% separating, 5% stack SDS polyacrylamide gel) performed under reducing conditions; gel divided into 12 segments (>100kDa to >20kDa) 
and proteins eluted during an overnight incubation in 1ml elution buffer; elutions subsequently tested at a final dilution of 1/1000.  
Cell Line Fractionation          
Method 
Motogenic Activity 
Compared to SF MEM Baseline 
(Tested alone) 
MSF-I Activity 
Compared to MSF Baseline 
(Tested with 100pg/ml rhMSF) 
MSF-I Activity Only 
No endogenous motogenic activity. 
  
Fraction 
Group/ Elution 
Equivalent MW Fraction 
Group/ Elution 
Equivalent MW Fraction Group/ 
Elution 
Equivalent MW 
BLANK GEL  
SEC none - none - - - 
SDS none - none - - - 
        
COBBLESTONE 
ENDO 742 
SEC 11-14 ≥70kDa 16,17 
21, 22 
70-60kDa 
≤25kDa 
15-17 
19 
21, 22 
70-60kDa 
>40kDa 
≤25kDa 
SDS 3-4 100-37kDa 3 
 
8 
approx. 75kDa 
approx. 20kDa 
6, 7, 8, 9, 12 
(maximum activity 6 + 
8) 
         ≤25kDa 
        
SPROUTING  
ENDO 742 
SEC 11-15 ≥70kDa 19, 20, 23 ≤25kDa 16, 
 19 
20, 23 
>70kDa 
>40kDa 
≤25kDa 
SDS 2-3 75-100kDa 4 
5 
50-75kDa 
25-50kDa 
5, 4 
8, 10, 11 
(maximum activity 4) 
25-75kDa 
≤ 20kDa 
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Table 7.7: A comparison of MSF-Inhibitory bioactivity present detected in the 
fractionated conditioned medium of endothelial cells exhibiting either the 
cobblestone or sprouting phenotype. 
Conditioned medium (CM) was collected from ENDO 742 cells grown either on or within a 
type I collagen gel matrix; thereby displaying either a cobblestone or sprouting phenotype 
respectively. After concentration each type of CM was fractionated by two methods, size 
exclusion chromatography (SEC) and SDS electrophoresis. The subsequent fractions/ elutions 
were tested in the 3D collagen gel fibroblast migration assay with addition of 100pg/ml rhMSF. 
The level of inhibition of MSF motogenic activity was calculated by comparison to MSF 
baseline levels and elution/fraction only baseline levels. 
The conditions for fractionation of the 10x Amicon concentrated CM was as follows:  
1. SEC performed using Superdex 75 Hiload 26/60 column (GE Healthcare), multiple runs 
performed with fractions pooled together into groups of three (13-23) equivalent to MW 
>70kDa to 20kDa, and tested at final dilution of 1/20.  
2. Electrophoresis (12% separating, 5% stack SDS polyacrylamide gel) performed under 
reducing conditions; gel divided into 12 segments (>100kDa to >20kDa) and proteins eluted 
during an overnight incubation in 1ml elution buffer; elutions subsequently tested at a final 
dilution of 1/1000.  
 
1. Fractionation by Size Exclusion Chromatography. 
Cobblestone Phenotype Sprouting Phenotype 
Molecular 
Weight 
% of MSF Inhibition Molecular Weight % of MSF 
Inhibition 
70-60kDa 41.6 +/- 18.92 >70kDa 46.9 +/- 5.77 
>40kDa 9.7 +/- 2.26 >40kDa 65.4 +/- 0.00 
≤25kDa 38.15 +/- 2.90 ≤25kDa 45.1 +/- 20.51 
 
2. Fractionation by SDS Electrophoresis. 
Cobblestone Phenotype Sprouting Phenotype 
Molecular Weight % of MSF 
Inhibition 
Molecular Weight % of MSF 
Inhibition 
75kDa 49.05 +/- 8.93 50-75kDa 87.4 +/- 23.83 
- - 25-50kDa 61.1 +/- 9.76 
≤25kDa 41.19 +/- 7.51 ≤20kDa 40.5 +/- 10.40 
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      Chapter 8 
 
                              CONCLUDING DISCUSSION 
 
Migration Stimulating Factor is a potent oncofetal protein which has numerous 
bioactivities pertinent to cancer progression including stimulating motogenesis and 
angiogenesis (Schor et al., 2003, Schor, 2010). Only fetomolar concentrations of MSF 
are required to produce half-maximal motogenic activity. Plus the proteolytic 
degradation of MSF results in the release of bioactive IGD domains. Consequently, 
there appears to be a necessary requirement to limit unrestricted MSF bioactivity. A 
mRNA cleavage event within the nucleus is known to control MSF expression but it is 
unknown whether there is a mechanism to regulate the bioactivity of the actual MSF 
protein (Schor et al., 2003). It was the primary objective of this project to discover a 
source and then ultimately identify potential MSF inhibitor(s). However, as the project 
progressed and novel discoveries were made, further aims were subsequently proposed 
(Table 8.1). 
Motogenesis, matrix remodelling via proteolytic activity, hyaluronan biosysnthesis and 
angiogenesis are all bioactivities exhibited by MSF (Schor et al., 1988, 1989, 1990, Kay 
et al., 2005, Ellis et al., 1992, Houvard et al., 2005). It is the ability of MSF to stimulate 
the migration of various cell types (fibroblast, epithelial and endothelial cells) which 
appears to be pivotal to its contribution to carcinogenesis (Schor et al., 2003). 
Therefore, the sensitive in vitro bioassay for assessing the motogenic bioactivity of 
MSF, the 3D type I collagen gel fibroblast migration assay, was selected to be the 
principal assay for the identification of potential MSF-I activity.  
After a rudimentary screening process of the conditioned medium (CM) from various 
cell lines, two sources of MSF- inhibitory activity were discovered; keratinocytes and 
endothelial cells specifically those exhibiting the cobblestone phenotype. Due to ease of 
culture and subsequent collection of CM, the keratinocyte MSF-I activity was 
investigated first. The CM from the HaCaT cell line, a spontaneously immortalised 
human keratinocyte line, underwent a process of fractionation, by both molecular 
weight and ionic charge, followed by sequence analysis to ultimately identify the 
protein responsible for the  MSF-I bioactivity as Neutrophil Gelatinase Associated 
Lipocalin (Figure 4.19, Table 8.1).  
Unexpectedly, the fractionation process of HaCaT CM also revealed the presence of 
motogenic bioactivity, which was normally obscured within the total HaCaT CM. The 
304 
 
protein responsible for this motogenic bioactivity was subsequently identified as MSF 
(Table 4.3, 8.1). It therefore transpired that cultured HaCaT keratinocytes express MSF 
but its motogenic bioactivity appears to be inactivated (or masked) by the co-expression 
of an inhibitor, NGAL.  
The inhibition of MSF by NGAL is a novel discovery. A member of the lipocalin 
family, NGAL is a multifunctional protein although its exact pathophysiological roles 
are not entirely understood. Numerous functions have been ascribed to NGAL; 
bacteriostatic agent, iron transportation, induction of apoptosis, modulation of 
inflammatory response, fatty acid transportation and protecting cells against thermal and 
oxidative stress conditions (Strong et al., 1998, Goetz et al., 2002, Flo et al., 2004, 
Weng et al., 2012).  
NGAL has the ability to bind to the matrix metalloproteinase MMP-9, protecting it from 
proteolytic degradation. As MSF and MMP-9 share some structurally similarity, with 
both molecules containing fibronectin type II domains and zinc-binding motifs, it was 
initially supposed that NGAL would also bind directly to MSF in order to exert its 
effect. Yet, pre-incubation experiments revealed that NGAL does not require direct 
contact with MSF in order to exert an inhibitory effect; fibroblasts pre-incubated with 
NGAL for 24 hours were shown to become unresponsive to MSF. This result inferred 
that NGAL inhibits MSF either by blocking an MSF-activated signal transduction 
pathway or indirectly via an intermediate molecule.  
Further investigation into the nature of NGAL ability to inhibit MSF revealed that it is 
not dependent upon its iron transportation capability. Testing NGAL in the presence of 
the iron chelator DFOM had no effect its MSF-I activity.  Plus, threes sources of NGAL 
(purified from HaCaT CM, prokaryotic and eukaryotic rhNGAL) possessing varying 
amounts of bound iron were found to exhibit an identical MSF-I activity. 
NGAL has been implicated in cancer progression due to its capacity to affect two 
critical processes; cell survival via apoptosis and cell migration preceding tumour 
invasion and metastasis (Yang and Moses, 2009, Chen and Chan, 2011). However, the 
conclusion from a literature review of NGAL was that a pro or anti- tumourigenic role 
for NGAL is neoplasia-specific and also varies with the different stages of cancer 
progression and degree of tumour differentiation. In addition, NGAL is considered to 
play a role in epithelial differentiation due to its embryonic-spatial expression pattern 
and increased expression in skin disorders characterised by dysregulated epithelial 
differentiation (psoriasis, pityriasis rubra and squamous cell carcinoma) (Malbris et al., 
2002). Therefore, in common with MSF, NGAL has been implicated in various benign 
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and malignant diseases (Schor et al., 2003 and 2005, Hu et al., 2009, Charkraborty et 
al., 2012).  
Consequently, the relationship of these pro- and anti-motogenic factors, MSF and 
NGAL respectively, during cancer progression was investigated using the in vitro 
model for human skin carcinogenesis developed by Fusenig and Boukamp. Developed 
from the non- tumourigenic transformed HaCaT keratinocyte cell line, the HaCaT-ras 
clones (BEN, MAL and MET- the HaCaT series) represent a shift in tumourigenic 
potential from the benign to malignant to metastatic (Fusenig and Boukamp, 1998). For 
ease of the discussion the BEN, MAL and MET keratinocytes were referred to as the 
HaCaT series cell lines. 
Various techniques (IHC, immunoblotting, ELISA) were employed to determine the 
expression levels of MSF and NGAL by each of the HaCaT-ras clones. Similar to the 
HaCaT keratinocytes all members of the HaCaT series expressed both MSF and NGAL, 
but as the tumourigenic potential of the cell lines increased there was a distinctive 
variation in the expression level of each protein. NGAL expression, from lowest to 
highest, was discovered to be MET, MAL, BEN. The reverse situation was found for 
MSF (BEN, MAL, MET); the highest intensity of MSF immunolocalisation was 
detected in MET cultures, especially when grown within a 3D type I collagen matrix. 
Overall, during tumour progression the expression level of NGAL decreases whilst that 
of MSF increases. 
These findings correlated with reported data. A grade specific pattern of NGAL 
expression has been described in pancreatic tumours and oral squamous cell carcinoma 
(Hana et al., 2005, Moniaux et al., 2008, Lin et al., 2012). Furthermore, NGAL 
expression has been shown to increase during the benign and low-grade malignancy 
phases of tumour progression but then drastically reduced at the advanced metastatic 
stage in ovarian, pancreatic and colon carcinoma. These findings have led to NGAL 
being currently considered as a potential early stage biomarker for a variety of cancers 
(Lim et al., 2007, Tong et al., 2008, Lee et al., 2006, Yang and Moses, 2009). Whereas, 
MSF expression is habitually low in normal breast tissue but becomes elevated in breast 
tumours; a poor prognosis associated with an increased expression of MSF. Over-
expression of MSF is also a characteristic of both epithelial and stromal cells of 
malignant salivary gland tumours (Aljorani et al., 2011) 
The presence of MSF in the HaCaT CM was not revealed in the initial analysis of the 
total CM, as the co-expressed NGAL inactivated any motogenic bioactivity. Therefore, 
the objective was set to ascertain what effect the altering co-expression levels of MSF 
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and NGAL exhibited by the HaCaT series cell lines had on the bioactivity present in 
CM. It was subsequently discovered that unlike the HaCaT keratinocytes the 
autogenous bioactivity of BEN, MAL and MET was motogenic. For BEN and MAL 
CM, the motogenic bioactivity adopted a bell-shaped dose response similar to that of 
rhMSF. Maximal motogenic bioactivity was detected in MET CM, which correlated 
with the MET cells having the highest MSF expression levels. However, fractionation 
of the HaCaT series CM revealed that BEN and MAL CM still retained the ability to 
inhibit rhMSF. This implied that the HaCaT series keratinocytes did secrete bioactive 
forms of both MSF and NGAL, and it was the balance of these pro and anti-motogenic 
factors which determined the inherent bioactivity present in the CM.   
Yet, the ELISA analysis for NGAL in the HaCaT series CM revealed that NGAL was 
present in a higher concentration in BEN and MAL CM than in the normal HaCaT CM. 
This data therefore inferred that BEN and MAL unfractionated CM should be exhibiting 
MSF inhibitory bioactivity rather than motogenic bioactivity. Thus it was concluded 
that the MSF concentration must be far greater in the HaCaT series CM than in the 
normal HaCaT CM to enable motogenic activity to prevail over NGAL MSF-I activity. 
Unfortunately, due to limitations of the MSF ELISA assay, only a semi-quantitative 
immunohistochemical analysis of MSF expression levels was available. Consequently, 
there was inadequate proof to determine the relative concentration of MSF compared to 
NGAL. 
In addition, the failure of MSF inhibitors, NGAL and IGD function neutralising PEPQ 
1.1 antibody, when added in excess to achieve complete inhibition of the motogenic 
bioactivity also insinuated the presence of another motogen in the HaCaT series CM. 
Yet, when MSF was semi-purified from the fractionated HaCaT series CM (RpVSI 
immunopreciptation of motogenic SEC fractions) its motogenic activity was inhibited 
by NGAL and PEPQ1.1 antibody. Perhaps, more information regarding the presence of 
other motogen(s) could have been achieved if MSF immunopreciptation had been 
performed on total HaCaT series CM rather than selected motogenic SEC fractions. 
Another obstacle encountered was the failure of the fractionation process to achieve a 
good separation of the two opposing factors. This was considered to be a result of 
concentrating the CM excessively which caused the formation of non-specific 
associations between proteins. Also, due to the biological assessment of bioactivity, 
protease inhibitors could not be added to the CM to halt proteolysis. It was supposed 
that the production of bioactive breakdown products contributed to the difficulty 
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encountered when trying to localise each bioactivity to fractions of a specific molecular 
weight.  
Furthermore, the nature of MSF bioactivity contributed to difficulties in isolating the 
presence of genuine MSF-I bioactivity. MSF acts in a bell-shaped dose response 
manner, whereby motogenic activity increases steadily with increasing concentration 
peaking at a maximum (500pg/ml) followed by a mirror-image decrease in activity 
towards the baseline level as the concentration increases further. That is, the addition of 
100pg/ml rhMSF, used to determine the MSF-I activity, could combine with MSF and 
its IGD bioactive breakdown products present in the CM, to give a final concentration 
that would actually result in a reduction in motogenic activity.  Biochemical 
characterisation of MSF has revealed that the potent motogenic activity of the MSF 
protein is indistinguishable from its proteolytically generated Gel-BD functional domain 
and IGD tripeptide, therefore motogenic activity could be present in fractions of MW 
70kDa, 43kDa and 21kDa, respectively. 
Once NGAL was identified as the source of MSF inhibitory activity in the HaCaT 
keratinocyte CM, the next stage was to determine whether NGAL was also responsible 
for the MSF-I activity detected in the CM collected from endothelial cells specifically 
exhibiting a cobblestone phenotype. By performing immunoblot and IHC experiments, 
using specific anti-NGAL antibodies, it emerged that endothelial cells, in vitro, do not 
express NGAL. This finding was irrespective of the endothelial cell line, phenotype, 
and species of origin. However, the possibility than NGAL was present but at levels 
below the detection limits of the assays cannot be discounted. 
In the initial analysis of conditioned medium for the presence of MSF-I activity the 
bioactivity of endothelial CM appeared to be determined by the phenotype exhibited by 
the cells. Conditioned medium collected from a homogenous population of cobblestone 
endothelial cells specifically displayed the ability to inhibit MSF bioactivity, while the 
CM from a homogenous population of sprouting endothelial cells distinctly exhibited a 
motogenic activity. Having established a protocol for the identification of the source of 
MSF-I activity in HaCaT CM the same procedure of fractionating the CM (SEC and 
SDS PAGE) was followed with the purpose of localising the bioactivity to a specific 
MW. Both cobblestone and sprouting ENDO 742 CM was analysed for the presence of 
MSF-I and motogenic bioactivity. 
Comparable to the analysis of HaCaT fractionated CM, the fractionation of endothelial 
ENDO 742 CM revealed previously masked bioactivities. Previously, the bioactivity of 
endothelial CM was considered to be the phenotypic specific however it would appear 
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that both phenotypes secrete bioactive forms of both motogenic and MSF-I bioactivity. 
Although not conclusive, evidence was gained to suggest that an endothelial MSF was 
at least partially responsible for the motogenic activity detected in both sprouting and 
cobblestone CM. That is, the fractions displaying motogenic bioactivity were within the  
MW range for MSF and although the addition of MSF-inhibitors, NGAL and PEPQ 1.1 
antibody, didn’t completely abolished all activity it was diminished by significant 
degree.  
However, it transpired that an anomaly existed when comparing the results from 
immunohistochemical analysis of MSF expression by the two endothelial phenotypes 
and the level of motogenic bioactivity in the fractionated CM. In 5/7 IHC experiments 
the endothelial cells exhibiting the cobblestone phenotype on the surface of a 3D type I 
collagen gel were negative for MSF whereas in 7/7 IHC experiments the sprouting 
endothelial cells were MSF positive. Yet the motogenic fractions of cobblestone CM 
share a similar MW and level of bioactivity as the sprouting CM, which would imply 
that the motogen responsible was present at a comparable concentration. The NGAL 
and PEPQ 1.1 inhibition experiments also suggested that MSF was present in similar 
quantities in both cobblestone and sprout CM.   
A possible explanation for this anomaly was the CM collection method. In order to 
collect CM from a homogenous population of sprouting endothelial cells the ENDO742 
cells were plated within a 3D type I collagen gel whereas the cobblestone CM was 
collected from cells plated on the surface of a gel. Obviously, any proteins secreted by 
the cells would enter the overlaying media more efficiently from the cobblestone cells 
than the sprouting cells. Due to the high background staining of the collagen gel in the 
IHC experiments it was suggested that MSF expressed by the sprouting cells was 
becoming entrapped within the collagen gel, thereby resulting in only a small 
percentage reaching the overlying media. 
An alternative explanation was that MSF present within the cobblestone cells was 
associated with another protein which has the ability to inhibit its bioactivity in the total 
CM but also masks it from identification by the anti-MSF Rp2 antibody. This would 
therefore require concealment of both the unique MSF carboxyl terminal decapeptide, 
which is the epitope of the Rp2 antibody, and the IGD motif, which is responsible for 
the MSF bioactivity. However, this interaction must be weak since SEC fractionation of 
the cobblestone CM appears to be enough to unmask the motogenic activity previously 
hidden in the total cobblestone CM.  
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As well as, having similar motogenic activity the fractionated cobblestone and sprouting 
endothelial CM also had comparable levels of MSF inhibitory activity. The MSF-I 
activity of both phenotypes could be located in fractions of MW 70kDa, 40kDa and 
≤25kDa which implied that the protein responsible could possibly be forming 
complexes with itself or with other protein(s); a situation similar to that of NGAL. 
Alternatively, maybe more than one MSF inhibitor is present. It is still presumptuous at 
this stage, to suggest that the same protein is responsible for the MSF-I activity in both 
cobblestone and sprout CM. Future work will clearly require further purification of the 
CM to enable the subsequent identification of the protein responsible for the endothelial 
MSF-I activity.  Since there was an obvious difficulty in pinpointing the MSF-I activity 
to a specific MW it may be more efficient to choose another fractionation method. Ion 
exchange chromatography, for example where proteins are separated according to their 
net charge, may prove more efficient. Also, using less extensively concentrated CM 
should help to reduce the formation of non-specific protein associations. 
Although it was concluded that NGAL was not responsible for endothelial MSF-I 
activity, it was relevant to determine what effect NGAL would have on the endothelial 
phenotype especially since MSF was known to induce the development of sprouting 
endothelial cells when applied to a cobblestone monolayer (Schor et al., 2003, Schor, 
2010). Comparing previously reported data, in both in vitro and in vivo models, it 
emerged that NGAL and MSF exhibit opposing effects on angiogenesis. Over-
expression of NGAL has been shown to facilitate a reduction in angiogenesis in an 
orthotopic mouse model of pancreatic cancer plus it significantly reduces the tube 
formation of HUVEC endothelial cells (Venekatesha et al., 2006, Tong et al., 2008).  
Whereas MSF stimulates angiogenesis in vivo in the chicken yolk sac membrane assay 
and in vitro sprouting assays (Schor 2010).   
In addition to pro-angiogenic role, it has been suggested that MSF also plays a role in 
promoting the survival of sprouting endothelial cells. The foundation of the spontaneous 
sprouting assay is the capability of endothelial cells, when cultured within a 3D type I 
collagen matrix, to automatically establish a homogenous population exhibiting the 
sprouting phenotype. Exposure of these sprouts to the IGD function neutralising 
antibody, PEPQ 1.1, resulted in all of the sprouts undergoing apoptosis. Yet when a 
cobblestone monolayer is exposed, at the same concentration, to the PEPQ 1.1 antibody 
no adverse effects on the monolayer are observed. In addition, the antibody exhibits a 
selective ability to restrict the development of post-confluent sprouts on the endothelial 
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monolayer (Schor 2010). These results therefore propose that MSF, specifically the IGD 
motif, is implicated in the process of endothelial sprout formation and survival.  
The effect of rhNGAL on the endothelial morphology was also tested in the in vitro 
post-confluent and spontaneous sprouting assays. Comparable to the PEPQ 1.1 
antibody, incubation with rhNGAL in the spontaneous sprouting assay resulted in 
apoptotic death of the homogenous sprout population. In the post-confluent sprouting 
assay, NGAL initially inhibited the development of any sprouting activity but also 
initiated disruption to the normally uniform cobblestone monolayer. The continued 
incubation with rhNGAL resulted in the induction of apoptotic cell death in all the 
endothelial cells. This result was irrespective of the source of NGAL tested (prokaryotic 
and eukaryotic). It therefore emerges, that unlike PEPQ 1.1, the effect NGAL has on 
endothelial cells is not phenotype specific.  Subsequent growth assays revealed that 
NGAL also acts to reduce the rate of endothelial cell proliferation; at the same 
concentrations previously shown to have no effect on fibroblast growth.  
As discussed, analysis of the fractionated endothelial CM revealed that both 
cobblestone and sprouting endothelial cells express a bioactive motogen that shares 
many characteristics to MSF. Therefore, if the effect on endothelial cells by NGAL was 
due to it inhibiting endogenous MSF then it is not too unexpected that NGAL would 
have a similar effect on both phenotypes.  Yet, the phenotype selective effect of the 
PEPQ 1.1 antibody would concur with previous statements suggesting that MSF, 
specifically its IGD motif, expressed by cobblestone endothelial cells is somehow 
masked; possibly by the protein responsible for endothelial MSF-I activity. Since this 
“masking” does occur with sprouting MSF it is vulnerable to the actions of the PEPQ 
1.1 antibody. Thus the proposition is that a similar situation occurs in cobblestone 
endothelial cells as was discovered in the HaCaT keratinocytes; that is MSF is 
expressed by the cobblestone endothelial cells but its bioactivity is inactivated by the 
co-expression of an inhibitor. However, NGAL is known to induce apopotosis, mainly 
through its ability to chelate iron from cells: this cellular iron deprivation triggers 
programmed cell death (Devireddy et al., 2005, Virzi et al., 2013). Therefore, further 
investigation is required before any definitive statements can be made.  
In conclusion, both keratinocytes and endothelial cells in vitro express MSF, the 
bioactivity of which is regulated by the co-expression of an inhibitor. The protein 
responsible for the MSF inhibitory activity is cell- type specific.  Neutrophil gelatinase 
associated lipocalin, NGAL, was identified as the source of keratinocyte MSF-I activity. 
Using an in vitro model for human skin carcinogenesis, the HaCaT –ras clones, the 
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relative expression levels of the pro and anti-motogenic factors, MSF and NGAL 
respectively, have been implicated in playing a role during tumour progression. 
 
 
312 
 
Table 8.1: Summary of project aims and results. 
CHAPTER 3: ASSESSMENT OF THE BIOACTIVITY OF CONDITIONED MEDIUM. 
Aims Assay Result 
1. Primary screen of total CM collected    
            from various cell lines for the    
            presence of motogenic activity. 
 3D collagen gel fibroblast 
migration assay 
Motogenic detected in the CM of: 
 Human foetal fibroblast (FFD4, F110a) 
 Human and bovine endothelial cell lines, specifically 
expressing sprouting phenotype (BAEC, ENDO742, 
HAEC, HOEC, HUVEC). 
2.  Primary screen of total CM    
 collected from various cell lines for      
 the presence of MSF-inhibitory   
 bioactivity.  
 3D collagen gel fibroblast 
migration assay 
MSF-inhibitory activity detected in the CM of: 
 HaCaT, transformed human keratinocyte 
 Human and bovine endothelial cell lines, specifically 
expressing cobblestone phenotype (BAEC, 
ENDO742, HAEC, HOEC, HUVEC). 
 
CHAPTER 4: THE IDENTIFICATION OF MSF-I PRODUCED BY KERATINOCYTES. 
Aims Assay Result 
1. To isolate the factor responsible for  
            MSF-inhibitory activity detected                  
            in HaCaT CM. 
 Size exclusion chromatography 
(Superdex) of HaCaT total CM. 
* 
 
 Ion exchange chromatography 
(ANX) of SEC fractions MW 
16-27kDa.* 
 
 SDS Electrophoresis of ANX 
unbound fraction. * 
 MSF-I activity detected in fractions of MW 16-27kDa. 
(Motogenic activity detected, fractions of MW 63-
84kDa). 
 
 MSF-I activity detected in unbound fraction, equivalent 
to 32% of total protein. 
 
 
 MSF-I activity detected in gel elutions of MW 20-
25kDa.  
313 
 
2. To identify the factor responsible 
for MSF-inhibitory activity 
detected in HaCaT CM. 
 Sequence analysis (tryptic 
digest, mass spectrometry) of 
SDS electrophoresis elution of 
MW 20-25kDa. 
 
 Immunolocalisation of NGAL 
(Anti-NGAL antibody, 
AF1757). 
 
 Immunoblot for NGAL (Anti-
NGAL antibody, MAB1757). 
 
 Colorimetric Indirect ELISA 
for NGAL (Anti-NGAL 
antibody, AF1757) 
 Neutrophil Gelatinase Associated Lipocalin (NGAL) 
identified. 
 
 
 
 Heterogeneous staining for NGAL in HaCaT cells. 
 
 
 
 Clear band identified at MW 20-25kDa in both neat and 
concentrated HaCaT CM. 
 
 
 NGAL concentrated per ml of unstandardised NGAL 
CM measured as 1.77 +/-0.05µg/ml. 
3. To verify the ability of NGAL to 
inhibit the motogenic bioactivity of 
MSF.  
NGAL from three sources tested 
for MSF-I activity: 
 NGAL isolated from 
NGAL/MMP-9 Complex 
(Calbiochem), 20-25kDa Gel 
elution 3. * 
 
 Eukaryotic NGAL (R&D 
Systems). * 
 
 Prokaryotic NGAL (In-house 
Prep). * 
 
 
 Peak MSF-I activity at est. 5-10ng/ml. 
 
 
 
 
 Peak MSF-I activity at 1ng/ml. 
 
 
 Peak MSF-I activity at 1ng/ml. 
4. To characterise the nature the 
MSF-inhibitory activity of NGAL.  
 NGAL from three sources 
tested for MSF-I activity.* 
 
 Implies MSF-I activity of NGAL is independent of 
ability to transport iron, as all three sources have 
different amounts of bound iron but share identical MSF-
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 Effect of iron chelator, DFOM, 
on NGAL ability to inhibit 
rhMSF. * 
 
 NGAL pre-incubation 3D Type 
I collagen gel fibroblast 
migration experiments. 
I activity.  
 
 Addition of DFOM had no effect on NGAL inhibition of 
MSF. 
 
 
 Fibroblast pre-incubated with NGAL for 24 hours 
become unresponsive to MSF. Imply direct interaction 
with MSF not required for NGAL to exert an inhibitory 
effect. 
5. To verify MSF as the factor 
responsible for the motogenic 
bioactivity detected in fractionated 
HaCaT CM.  
 Immunoblot for MSF (Anti-
MSF antibody, RpVSI). 
 
 
 
 Immunolocalisation of MSF 
(Anti-MSF antibody, 
Rp2/98pFA2pFn1). 
 
 IGD Function Neutralisation of 
Motogenic Activity (Pep Q 1.1 
antibody). * 
 
 Immunopreciptation for MSF 
(Protein G coupled to RpVSI 
antibody).* 
 
 
 NGAL inhibition of motogenic 
activity. * 
 No bands identified in HaCaT CM, irrespective of CM 
concentration (neat to 50x concentrated tested). If MSF 
present in HaCaT CM, is at concentration below limits of 
the assay, <25ng/ml. 
 
 Heterogeneous staining for MSF in HaCaT cells. 
 
 
 
 Motogenic SEC fractions, MW 63-84kDa, alone 
stimulated fibroblast migration by 3.7 fold. Addition of 
PepQ1.1 inhibited motogenic activity by 60-70%. 
 
 Motogenic SEC fractions, MW 63-84kDa, immobilised 
on RpVSI coupled Protein G. No motogenic activity 
present in unbound sample. Motogenic activity present in 
elutions; 2.8 fold increase in fibroblast migration. 
 
 Peak motogenic activity of motogenic SEC fractions, 
MW 63-84kDa, at 1/250 dilution inhibited by 60% by 
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addition of NGAL. 
*bioactivity confirmed by testing in the 3D collagen gel fibroblast migration assay.  
 
CHAPTER 5: THE EXPRESSION OF MSF AND NGAL IN RELATION TO TUMOUR PROGRESSION. 
Aims Assay Result 
1. To establish whether MSF was 
expressed by the other cell lines of 
the HaCaT series (BEN, MAL and 
MET), which displayed an 
increasing tumorigenic potential.  
 Immunoblot for MSF (Anti-
MSF antibody, RpVSI). 
 
 
 
 
 Immunolocalisation of MSF 
(Anti-MSF antibody, 
Rp2/98pFA2pFn1). 
 No bands identified in CM of either BEN, MAL and 
MET, irrespective of CM concentration (neat to 1000x 
concentrated tested). If MSF present in HaCaT series 
CM, it is at concentration below the limits of the assay, 
>25ng/ml. 
 
 Heterogeneous staining for MSF in BEN, MAL and 
MET keratinocytes. Staining intensity highest in MET, 
decreasing in MAL, and lowest in BEN. 
2. To establish whether NGALwas 
expressed by the other cell lines of 
the HaCaT series (BEN, MAL and 
MET), which displayed an 
increasing tumorigenic potential. 
 Immunoblot for NGAL (Anti-
NGAL antibody, MAB1757). 
 
 Immunolocalisation of NGAL 
(Anti-NGAL antibody, 
AF1757). 
 
 Colorimetric Indirect ELISA 
for NGAL (Anti-NGAL 
antibody, AF1757). 
 Clear band identified at MW 20-25kDa in both neat and 
concentrated BEN, MAL and MET CM. 
 
 Heterogeneous staining for NGAL in BEN, MAL and 
MET keratinocytes.  Staining intensity highest in BEN, 
decreasing in MAL, and lowest in MET. 
 
 NGAL detected in CM (neat and concentrated) of BEN, 
MAL and MET. NGAL concentration highest in BEN, 
decreasing in MAL and lowest in MET. 
 
3. To determine whether NGAL and 
MSF expression levels could be 
 Assays as above.  As the tumorigenic potential of the HaCaT series 
keratinocytes increases then expression level of 
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related to tumorigenic potential.  NGAL decreases whilst expression level of MSF 
increases.  
 The NGAL pattern of expression from highest to 
lowest is BEN/MAL> HaCaT> MET. 
 The MSF pattern of expression from highest intensity 
to lowest is MET> MAL> BEN. 
 
 
CHAPTER 6: THE EXPRESSION OF PRO- AND ANTI- MOTOGENIC BIOACTIVITY BY THE HACAT-RAS CLONES. 
Aims Assay Result 
1. To ascertain bioactivity of total CM 
of the HaCaT series cell lines. 
 3D collagen gel fibroblast 
migration assay 
 Motogenic bioactivity detected in BEN, MAL and MET 
CM. BEN and MAL display bell shaped dose response; 
peak stimulation of 2-2.5 fold increase in migration at 
1/1000 dilution point. Maximal motogenic activity 
displayed by MET CM; majority of dilution points 
(1/40,000- 1/10) stimulated a 2-2.5 fold increase in 
migration.  
MSF-inhibitory activity detected in BEN and MAL CM 
at dilution points 1/1000- 1/4. No MSF-I activity 
detected in MET CM.  
2. To ascertain whether the 
fractionated CM of the HaCaT series 
cell lines exhibited motogenic 
activity. 
 Size exclusion 
chromatography (Superdex) of 
HaCaT series total CM.* 
 
 SDS Electrophoresis of 
HaCaT series total CM.* 
 Majority of motogenic activity located in higher 
molecular weight fractions, ≥60kDa; F37-48 for BEN, 
F37-63 for MAL and F37-45 for MET.  
 
 Motogenic activity located in either higher or lower MW 
gel elutions. BEN- elutions 1-2 and 10.MAL- elutions 1-
3 and 10-12. MET- elutions 1-10 and 12. Equivalent to 
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MW ≥100kDa and <20kDa. 
3. To ascertain whether MSF was 
responsible for the motogenic 
activity of HaCaT series CM. 
 Immunopreciptation for MSF 
(Protein G coupled to RpVSI 
antibody).* 
 
 
 
 IGD Function Neutralisation 
of Motogenic Activity (Pep Q 
1.1 antibody). * 
 
 NGAL inhibition of 
motogenic activity.* 
 Motogenic fractions F30-50, equivalent to MW ≥60kDa, 
for BEN, MAL and MET, immobilised on RpVSI 
coupled Protein G. Motogenic activity present in bound 
elutions: BEN elutions 1-2, MAL elutions 2-5, MET 
elutions 1-5. 
 
 BEN, MAL and MET motogenic active IP bound 
elutions inhibited by addition of PEPQ1.1 
 
 
 BEN, MAL and MET motogenic active IP bound 
elutions inhibited by addition of NGAL. 
4. To ascertain whether the 
fractionated CM of the HaCaT series 
cell lines exhibited MSF-inhibitory 
activity. 
 Size exclusion 
chromatography (Superdex) of 
HaCaT series total CM.* 
 
 SDS Electrophoresis of 
HaCaT series total CM.* 
 MSF-inhibitory exhibited by BEN, MAL and MET but 
unable to locate activity to any specific area, activity 
distributed in a variety of fractions/ MW. 
 
 MSF-inhibitory activity specifically located to elution 6, 
MW 20-25kDa, for BEN and MAL. No MSF-I activity 
detected in MET elutions. 
5. To ascertain whether NGAL was 
responsible for the MSF-I inhibitory 
activity of HaCaT series CM. 
 Colorimetric Indirect 
ELISA for NGAL (Anti-
NGAL antibody, 
AF1757). 
 
 Immunoblot for NGAL 
(Anti NGAL antibody, 
MAB1757). 
 NGAL detected in every SEC fraction group of BEN 
and MAL CM, and in the majority of MET too. 
Fractionated CM un-standardised therefore limited 
analysis possible. 
 
 Clear band identified at MW 20-25kDa in both neat 
and concentrated BEN, MAL and MET CM. 
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CHAPTER 7: THE IDENTIFICATION OF MSF-I PRODUCED BY ENDOTHELIAL CELLS 
Aims Assay Result 
1. To determine whether endothelial 
cells express NGAL. 
 Immunoblot for NGAL (Anti-
NGAL antibody, MAB1757). 
 
 
 
 Immunolocalisation of NGAL 
(Anti-NGAL antibody, 
AF1757). 
 Consistently negative for NGAL, irrespective of 
endothelial cell line (human and bovine), phenotype 
exhibited by the endothelial cells (cobblestone or 
sprouting) or concentration of the CM tested. 
 
 Consistently negative for NGAL, irrespective of 
endothelial cell line (human and bovine), phenotype 
exhibited by the endothelial cells (cobblestone or 
sprouting) or plating matrix (3D collagen gel, 2D surface 
coated with 1% (w/v) gelatin). 
2. To determine whether endothelial 
cells express MSF.  
 Immunolocalisation of MSF 
(Anti-MSF antibody, 
Rp2/98pFA2pFn1). 
 Cobblestone endothelial cells negative for MSF in 4/5 
experiments when plated on 2D surface and 5/7 
experiments when plated on 3D surface. 
      Sprouting endothelial cells consistently positive for MSF    
      irrespective of plating matrix (within a 3D collagen gel  
      or post-confluent sprouting on 2D surface coated with  
      0.1% (w/v) gelatin). 
3. To characterise the bioactivity of 
endothelial cells expressing a 
sprouting phenotype. 
 Size exclusion 
chromatography (Superdex).* 
 
 
 
 SDS Electrophoresis.* 
 Motogenic bioactivity detected in fraction groups 11-15, 
equivalent to a MW >70kDa. 
      MSF- inhibitory activity detected in fraction groups 19,    
      20, and 23, equivalent to a MW ≤ 25kDa. 
 
 Motogenic bioactivity detected in gel elutions 2-3, 
equivalent to a MW 75-100kDa.  
      MSF- inhibitory activity detected in gel elutions 4-5    
      equivalent to a MW 25-75kDa. 
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4. To characterise the bioactivity of 
endothelial cells expressing a 
cobblestone phenotype.  
 Size exclusion 
chromatography (Superdex).* 
 
 
 
 SDS Electrophoresis.* 
 Motogenic bioactivity detected in fraction groups 11-14, 
equivalent to a MW >70kDa. 
      MSF- inhibitory activity detected in fraction groups 19,   
      21, 22-24, equivalent to a MW ≤ 25kDa. 
 
 Motogenic bioactivity detected in gel elutions 3-4, 
equivalent to a MW 37-100kDa. 
MSF- inhibitory activity detected in gel elution 8 
equivalent to a MW approximately 20kDa. 
5. To determine whether MSF was 
responsible for the motogenic 
activity detected in fractionated 
endothelial CM.  
 IGD Function Neutralisation 
of Motogenic Activity (Pep Q 
1.1 antibody). * 
 
 NGAL inhibition of 
motogenic activity.* 
 Motogenic active fractionated sprout and cobblestone 
CM (SEC and SDS PAGE) showed only partial 
inhibition, failing to reach set criteria of 50% inhibition. 
 
 Motogenic active fractionated sprout and cobblestone 
CM (SEC and SDS PAGE) showed only partial 
inhibition, failing to reach set criteria of 50% inhibition. 
6. To determine what effect MSF had 
on endothelial morphology. 
 2D Post-confluent endothelial 
sprouting assay. 
 rhMSF stimulated cobblestone endothelial cells to 
exhibit a sprouting morphology. 100ng/ml rhMSF 
increased number of sprouts 3 fold compared to control. 
rhMSF appears to stimulate formation of sprout 
associations. 
7. To determine the effect IGD 
Function Neutralisation, PEPQ 1.1 
antibody had on endothelial 
morphology. 
 3D Spontaneous endothelial 
sprouting assay. 
 
 
 24 hour exposure to 20-30µg/ml PEPQ 1.1 antibody 
decreased sprout numbers. By 48hours majority of 
sprouts underwent apoptosis.  
8. To determine the effect MSF 
inhibitor, NGAL had on endothelial 
morphology. 
 2D Post-confluent endothelial 
sprouting assay. 
 
 
 
 NGAL from three sources tested with similar results. 
1-100ng/ml rhNGAL, no effect. 500ng-1µg/ml rhNGAL 
inhibited sprout development and disruption of 
cobblestone monolayer (vacuole formation and cell 
death). 
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 3D Spontaneous endothelial 
sprouting assay. 
 
 
 
 Endothelial proliferation and 
viability assay. 
 
 NGAL from three sources tested with similar results. 
1-100ng/ml rhNGAL, no effect. 500ng-1µg/ml rhNGAL 
decreased sprout numbers within 48 hours, majority of 
sprout undergoing apoptosis by Day 5. 
 
 Prokaryotic and eukaryotic rhNGAL tested with similar 
results. 10-100ng/ml rhNGAL, no effect. 1µg/ml 
rhNGAL decreased proliferation by 20.5 +/- 5.14% and 
23.2 +/- 5.49% with prokaryotic and eukaryotic 
rhNGAL, respectively. rhNGAL had no effect on  
endothelial cell viability. 
*bioactivity confirmed by testing in the 3D collagen gel fibroblast migration assay.  
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CHAPTER 9 
 
                  FUTURE WORK 
 
Although this project has achieved its original aim and identified an inhibitor of MSF, 
new discoveries have unleashed a plethora of questions and potential routes of 
investigation.  Prospective future studies could include the following:  
 
 A major obstacle encountered during this project was the inability to identify 
and quantify MSF in CM by immunoblot and ELISA techniques, respectively. 
The antibodies used in the identification assays recognised the unique 
decapeptide sequence of MSF which may have no longer be recognisable when 
MSF is secreted into CM either due to conformational change, masking due to 
association with an accessory protein(s) or  degradation by proteolytic enzymes 
(the VSI sequence is vulnerable to proteolysis due to its C-terminus location).  
The addition of protease inhibitors to the CM upon collection would have 
reduced proteolysis but this may have limited any subsequent in vitro analysis of 
bioactivity.  
The suitability of the Rp VSI antibody for use in the immunoblot and ELISA 
assay was also questioned.  A frequent obstacle was poor reproducibility and an 
inadequate rhMSF standard curve in the ELISA assay. However, the same 
antibody was successfully used in both immunohistochemical and 
immunoprecipitation assays; implying its use is limited to specific applications.  
Therefore, the development of improved specific anti-MSF antibodies is 
required. Yet, as MSF is a truncated form of fibronectin, identical to the N-
terminus of fibronectin, the choice of a specific epitope will be restricted to the 
unique decapeptide sequence. 
 
 It was the original observations of the disparity in migratory potential between 
adult and foetal fibroblasts (Schor et al., 1985) that eventually led to the 
discovery of MSF. MSF was subsequently shown to be responsible for the 
greater migratory activity of the foetal fibroblasts. It will, therefore be of interest 
to determine whether NGAL can directly affect the migratory activity of the 
foetal fibroblasts; that is, can NGAL inhibit endogenous MSF activity as well as 
the activity of exogenous MSF? 
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Pre-incubating adult fibroblasts with NGAL resulted in the cells becoming 
unresponsive to MSF, implying that NGAL does not require direct association 
with MSF in order to exert its inhibitory effect. Consequently, what is the effect 
on the migratory activity of foetal fibroblasts if they are pre-exposed to NGAL 
before assessment in a migratory assay? The 3D type I collagen gel assay will be 
invaluable in this investigation, although it would be interesting to determine 
whether the same result is achieved in the Boyden chamber migration assay too.  
 
 The mechanism NGAL uses to inhibit MSF clearly requires further exploration. 
Preliminary experiments revealed that direct association between NGAL and 
MSF is not required and that MSF-I activity of NGAL is not reliant upon its 
ability to transport iron. Numerous functions have been attributed to NGAL; of 
particular interest is the ability to preserve the enzymatic activity of MMP-9 by 
protecting it from proteolytic degradation (Yan et al., 2001). Matrix 
metalloproteinases are capable of degrading all of the molecular components of 
the ECM, including fibronectin (Fn).  A study of monocytes has revealed a 
feedback loop exists between MMP-9 and fibronectin; as MMP-9 degrades Fn 
and binding of Fn upregulates the expression of MMP-9 (Marom et al., 2007).  
It will therefore be of interest to determine whether MMP-9 is implicated in the 
process of NGAL inhibition of MSF. That is, is the MSF-I activity of NGAL 
actually a consequence of its protective role of MMP-9? Knowing the 
characteristic bell-shaped dose- response behaviour of MSF bioactivity is the 
reduction in MSF bioactivity actually a consequence of the production of Fn 
breakdown fragments containing the GBD sequence which contribute to a shift 
in concentration levels to those which actually inhibit cell migration. Or does 
MSF inhibition by NGAL actually result from NGAL protecting MSF from 
degradation, therefore leading to an accumulation of MSF to concentrations 
where cell migration is inhibited rather than stimulated? 
 
 Through a series of bioactivity and identification techniques the variation in the 
expression of NGAL and MSF by the HaCaT series cell lines was revealed. 
However, this data could be further validated by measuring MSF and NGAL 
gene expression levels by reverse transcription polymerase chain reaction (RT-
PCR).   
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 The HaCaT series of cell lines were originally classified by their growth 
behaviour and histological phenotype when subcutaneously injected into nude 
mice. That is, the HaCaT keratinocytes were non-tumourigenic, the BEN 
keratinocytes formed epidermoid cysts, MAL formed well-differentiated 
squamous cell carcinomas and MET exhibited a metastatic phenotype spreading 
to the lung and lymph nodes (Mueller et al., 2001). By genetically modifying the 
expression levels of NGAL and MSF in the HaCaT series cell lines the effect on 
the tumourigenic potential could be investigated; to determine whether an 
alteration in the ratio of NGAL and MSF expression would result in a change in 
the cell lines ability to form tumours in nude mice. This could lead to a greater 
understanding of the roles NGAL and MSF play during epithelial- mesenchymal 
transition and possible clinical relevance of NGAL and MSF as biomarkers of 
EMT. For this investigation the technique of gene silencing using small 
interfering RNAs (siRNA) could be employed to reduce and potentially 
eliminate NGAL and MSF protein production. 
 
 Although MSF-I activity was detected in endothelial CM, further work is still 
required to identify the factor responsible. Preliminary experiments to 
fractionate the endothelial CM by size-exclusion chromatography and SDS 
electrophoresis failed to pinpoint a specific MW where MSF-I activity could be 
located. In addition, the HaCaT series experiments also revealed that the CM 
concentration process may result in non-specific binding of proteins and proteins 
precipitating out of solution. Therefore, a more efficient approach to identify 
endothelial MSF-I should adopt a different fractionation process, for example 
ion-exchange chromatography and use less concentrated CM.   
Once the source of endothelial MSF-I activity has been identified it will be of 
interest to determine the relationship it has with the co- expressed MSF and 
whether it plays a role in regulating endothelial phenotype.  In addition, do 
endothelial MSF-I and the keratinocyte MSF-I, NGAL, act in a similar manner 
to inhibit MSF and are they substitutable? 
 
 In vitro endothelial sprouting assays testing the effect of NGAL on both sprout 
and cobblestone phenotypes, revealed its ability to induce programmed cell 
death. NGAL is known to induce apoptosis due to its ability to chelate iron 
triggering cellular iron deprivation (Tong et al., 2008). Therefore, future 
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sprouting assays should include the iron chelator, DFOM, in order to determine 
whether NGAL anti-angiogenic activity is due to its ability to transport iron. 
However, since different sources of NGAL (prokaryotic and eukaryotic) 
achieved similar results it would imply that iron transportation is not involved, 
as each source would possess varying amounts of bound iron.  
Other studies have reported the anti-angiogenic activity of NGAL is associated 
with either a decrease in VEGF production or a blockade of VEGF receptor 
(Tong et al., 2008). Consequently, the relationship between NGAL and VEGF is 
also another avenue for investigation. In addition, the in vivo anti-angiogenic 
activity of NGAL should be investigated.   
 
 Further investigation is required to understand the role MSF plays during 
angiogenesis. This project has shown that MSF pro-angiogenic bioactivities 
include its ability to induce endothelial cells, in vitro, to undertake a phenotypic 
change from the cobblestone to the sprouting phenotype and its role as a survival 
factor for sprouting endothelial cells. The ability of the IGD function 
neutralising monoclonal antibody, PEPQ 1.1 to specifically induce apoptosis of 
endothelial sprouts implies that the IGD motif must be implicated in the role of 
MSF as a sprout survival factor. The development of mutant forms of MSF, by 
site- directed mutagenesis and their subsequent testing in in vitro and in vivo 
angiogenic assays should reveal which MSF domains are responsible for its pro-
angiogenic bioactivities.
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Chapter 11 
 
                    APPENDICES 
 
Appendix 2.1a: The Preparation Methods of Cell Culture Reagents 
 
Hanks Solution 
3x 500ml 10x HBSS without Calcium and Magnesium 
13.5ltr. Distilled water 
5.25g Sodium Bicarbonate 
0.2µm filter sterilised before aliquoting (30 x 500ml). Stored at room temperature. 
 
MEM 
3x 500ml 10x Minimum Medium Eagle  
150ml Penicillin-Streptomycin Stabilised 
150ml 100x MEM Non-Essential Amino Acid Solution 
150ml 100Mm Sodium Pyruvate 
33g Sodium Bicarbonate 
13ltr Distilled water 
0.2µm filter sterilised before aliquoting (30 x 500ml). Stored at 4 C. 
 
Heat – Inactiavtion Treatment of Donor Calf Serum (HIDCS) 
Donor calf serum was slowly defrosted on the benchtop or overnight at 4 C and then 
placed in 60 C waterbath for 30-40 minutes, to heat treat. 
The serum was then decanted into 75ml aliquots and stored at -20 C. 
 
Trypsin Solution (ET)  
980ml Distilled water 
5x PBS Tablets 
0.76g EGTA  
20ml 10x Trypsin Solution 
The PBS tablets were dissolved in the distilled water and then the solution was decanted 
into 2x 500ml bottles and autoclaved. After the solution was allowed to cool 10ml 
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Trypsin 10x solution was added to each bottle. After mixing, the solution was decanted 
into 100ml aliquots and stored at -20 C. 
  
Freeze Mix 
170ml 15%DCS, 1% l-Glutamine, MEM 
20ml HIDCS 
10ml Dimethyl Sulfoxide 
Reagents mixed together and then aliquoted into 20ml universals. Stored at -20 C. 
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Appendix 2.1b:  Supplier details for the cell culture reagents.                                                  
Abbreviation Full Name Company Prod. No. 
AA L-Ascorbic Acid GIBCO BRL/  
Invitrogen 
15240-096 
DCS Donor calf serum SLS/ Euroclone 
 
 
 
Thermo-Fisher, 
Perbio, Hyclone 
EC 50040L 
Lot No: 
EUS003855, 
EUS005475 
 
SH30072.03 
Lot No: 
APD21173, 
ANH19288 
DMEM Dublbecco’s MEM 
With glutamax-1, Na 
pyruvate, 100mg/ml 
glucose, pyridoxine 
GIBCO BRL/  
Invitrogen 
21885-025 
DMSO Dimethyl sulfoxide Sigma-Aldrich D-5879 
COLLAGEN  In house Prep --------- 
EGTA Ethylene Glycol-bis 
(b-aminomethyl ether)-
N,N,N’,N’-Tetreacetic 
Acid 
Sigma-Aldrich E-4378 
FCS Fetal Bovine Serum Sigma-Aldrich F-2442 
FUNGI’ZONE Antibiotic- Antimycotic 
100X 
Invitrogen 15240-096 
GELATIN Gelatine Powder Merck/ BDH/ 
VWR 
44045 
GLUT L-Glutamine 
200mM 
Sigma-Aldrich G-7513 
HBSS Hanks Balanced Salt 
Solution w/o calcium and 
magnesium 
Sigma-Aldrich H-4641 
MEM Minimum Essential 
Medium Eagle 10x 
Sigma-Aldrich M-0275 
MEM w/o 
phenol red 
Minimum Essential 
Medium 1x 
with Earle’s salts 
w/o L-glutamine 
w/o phenol red 
GIBCO/ 
Invitrogen 
51200-038 
MTT  Sigma-Aldrich  
MYCOPLASM
A  
REMOVAL 
AGENT 
50ug/ml ICN/ Invitrogen 30-500-44 
NEAA MEM Non-Essential 
Amino Acid Solution 
100X 
Sigma-Aldrich M-7145 
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PEN/ STREP Penicillin- Streptomycin 
Stabilised 
Sigma-Aldrich P-4333 
PBS Phosphate Buffered Saline Sigma-Aldrich P-4417 
PFHM11 (1X) Protein Free Hybridoma 
Medium 
GIBCO BRL/ 
Invitrogen 
12040-051 
NaHCO3 Sodium Bicarbonate Merck/ BDH/ 
VWR 
301515V 
Na BIC  
SOLUTION 
Sodium Bicarbonate 
Solution 
Sigma-Aldrich S-8761 
Na PYRUVATE Sodium Pyruvate  
100Mm Solution 
Sigma-Aldrich S-8636 
TRYPSIN Trypsin 10x Solution Sigma-Aldrich T-4549 
 
 
